dalteparin has been researched along with Hemorrhage in 754 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the rates of VTE recurrence and major bleeding and the relative efficacy and safety of 6-month treatment with oral apixaban or subcutaneous dalteparin in patients with different cancer sites randomized in the Caravaggio study." | 9.51 | Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A, 2022) |
| " We conducted a prospective, multicenter, open-label trial (NCT00952380) on dose-finding, safety, and efficacy (measured by 90-day risks of clinically relevant bleeding [CRB] and symptomatic recurrent VTE [srVTE]) of twice-daily subcutaneous dalteparin for acute VTE treatment in patients ≤18 years old." | 9.51 | A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. ( Goldenberg, NA; Hartman, LR; Jani, D; Nurmeev, I; Sherman, N; Svirin, P; Wolter, KD; Yan, JL, 2022) |
| "Of 138 randomized patients, 100 patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy were assigned to either oral apixaban therapy or subcutaneous low-molecular weight heparin (enoxaparin) through randomized clinical study in 1:1 ratio." | 9.41 | Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. ( Algaby, AZ; Hassan, A; Mokadem, ME, 2021) |
| " Major bleeding occurred in 22 of 576 patients on apixaban (3." | 9.41 | Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021) |
| "We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study." | 9.41 | Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021) |
| "Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications." | 9.34 | Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020) |
| "Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding." | 9.34 | Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020) |
| "Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin." | 9.30 | Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. ( Ageno, W; Cohen, AT; Gibson, CM; Goldhaber, SZ; Hernandez, A; Hull, RD; Lopes, RD; Yee, MK, 2019) |
| "To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively." | 9.30 | Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019) |
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 9.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding." | 9.27 | Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018) |
| "The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects." | 9.24 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017) |
| "The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the treatment of acute symptomatic venous thromboembolism." | 9.22 | Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. ( Ageno, W; Büller, HR; Di Nisio, M; Pap, AF; Rutjes, AW, 2016) |
| "Apixaban, a direct acting oral anticoagulant (DOAC), was found to be non-inferior to and safer as enoxaparin followed by warfarin for treatment of venous thromboembolism (VTE) in the AMPLIFY trial." | 9.22 | Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. ( Agnelli, G; Bleker, SM; Büller, HR; Cohen, AT; Curto, M; Gallus, AS; Middeldorp, S; Raskob, GE; Sisson, M; Weitz, JI, 2016) |
| "Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy." | 9.22 | Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016) |
| "In this French cohort of NSTEMI patients, predominantly managed invasively, there was no evidence that fondaparinux was superior to enoxaparin as regards bleeding events or 1-year mortality (FAST-MI 2010; NCT01237418)." | 9.20 | Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. ( Bonnefoy-Cudraz, E; Collet, JP; Coste, P; Danchin, N; Ennezat, PV; Puymirat, E; Richard, P; Roul, G; Schiele, F; Simon, T, 2015) |
| "To evaluate the effect of prestudy heparin on the efficacy and safety of rivaroxaban relative to enoxaparin/VKA, the 3-month incidence of recurrent VTE, and the 14-day incidence of major and nonmajor clinically relevant bleeding were compared in patients who did and did not receive prestudy heparin." | 9.20 | Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. ( Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC, 2015) |
| "The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)." | 9.20 | Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015) |
| "Major bleeding was less frequent during dalteparin therapy beyond 6 months." | 9.20 | Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 9.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding." | 9.19 | Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014) |
| "A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials." | 9.17 | Oral apixaban for the treatment of acute venous thromboembolism. ( Agnelli, G; Buller, HR; Cohen, A; Curto, M; Gallus, AS; Johnson, M; Masiukiewicz, U; Pak, R; Raskob, GE; Thompson, J; Weitz, JI, 2013) |
| "Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear." | 9.17 | Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ( Büller, HR; Décousus, H; Grosso, MA; Mercuri, M; Middeldorp, S; Prins, MH; Raskob, GE; Schellong, SM; Schwocho, L; Segers, A; Shi, M; Verhamme, P; Wells, P, 2013) |
| "To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA." | 9.17 | Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013) |
| "In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months." | 9.16 | Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. ( Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2012) |
| "Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding." | 9.16 | A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. ( Aston, CE; Rathbun, SW; Whitsett, TL, 2012) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 9.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%." | 9.14 | Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Flather, M; Fox, KA; Franzosi, MG; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Yusuf, S, 2009) |
| "Ambulatory treatment with enoxaparin plus warfarin seems to be effective in symptomatic healing and in clinical improvement by reducing thrombus formation and organization at all levels of lower extremity venous system with DVT, without a significant major bleeding risk." | 9.14 | Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. ( Akcalı, Y; Filizcan, U; Hasan, E; Karabay, O; Koksoy, C; Kurtoglu, M, 2010) |
| "Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation." | 9.14 | Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010) |
| "Compared with a heparin-based strategy, fondaparinux reduced mortality, ischemic events, and major bleeding across the full spectrum of acute coronary syndromes and was associated with a more favorable net clinical outcome in patients undergoing either an invasive or a conservative management strategy." | 9.13 | Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008) |
| "Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers." | 9.12 | Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006) |
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 9.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 9.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile." | 9.12 | Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007) |
| "The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness." | 9.12 | Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006) |
| "Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis." | 9.11 | Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. ( Büller, HR; Cariou, R; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Leeuwenkamp, O; Lensing, AW; Piovella, F; Prins, MH; Raskob, G; Segers, AE, 2004) |
| "In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)." | 9.11 | A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004) |
| "Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding." | 9.11 | Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004) |
| "Similar compliance, health status, deep venous thrombosis, and bleeding rates were found between dalteparin and enoxaparin." | 9.10 | Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. ( Chan, KT; Chiou-Tan, FY; Donovan, WH; Garza, H; Graves, DE; Holmes, SA; Parsons, KC; Rintala, DH; Robertson, CS, 2003) |
| "The FRISC II trial demonstrated that, for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach." | 9.10 | Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months." | 9.09 | Outpatient treatment of pulmonary embolism with dalteparin. ( Anderson, D; Gray, L; Kovacs, MJ; Morrow, B; Touchie, D; Wells, PS, 2000) |
| "To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty." | 9.08 | Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996) |
| "The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)." | 9.08 | Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 9.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| "In the EINSTEIN-Pulmonary Embolism (PE) trial, subjects randomized to rivaroxaban versus enoxaparin bridging to vitamin K antagonist (VKA) therapy experienced a reduced index hospital length of stay (LOS)." | 8.95 | Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. ( Ashton, V; Baugh, CW; Coleman, CI; Crivera, C; Fermann, GJ; Kohn, CG; Peacock, WF; Schein, JR; Wells, PS; Wildgoose, P, 2017) |
| "In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk." | 8.91 | Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015) |
| "Oral dabigatran was as effective as subcutaneous enoxaparin in reducing the risk of major VTE and VTE-related mortality after hip or knee arthroplasty and has a similar bleeding profile." | 8.86 | Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. ( Caprini, JA; Clemens, A; Dahl, OE; Eriksson, BI; Francis, CW; Friedman, RJ; Hantel, S; Kurth, AA; Rosencher, N; Schnee, JM, 2010) |
| "Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE)." | 8.85 | Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. ( Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE, 2009) |
| "A 70-year-old man on enoxaparin and warfarin sodium therapy due to pulmonary embolism was admitted for evaluation of a sudden, sharp pain in the left inguinal region." | 8.82 | Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature. ( Anadol, AZ; Gök, A; Topgül, K; Uzun, O, 2005) |
| "In 8246 patients included in the EINSTEIN-VTE studies for acute VTE, we evaluated the effect of polypharmacy on bleeding and on the relative differences between rivaroxaban and enoxaparin/vitamin K antagonist (VKA)." | 8.12 | Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. ( Bavalia, R; Bistervels, IM; Coppens, M; Gebel, M; Lensing, AWA; Middeldorp, S; Prins, MH, 2022) |
| "Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer." | 8.02 | Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021) |
| "In this study, although there were no significant differences in effectiveness or safety between the rivaroxaban and dalteparin groups, rivaroxaban use was associated with a higher rate of clinically relevant bleeding than dalteparin." | 7.96 | Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers. ( Huh, JW; Jo, KW; Lee, JH; Lee, JS; Oh, YM, 2020) |
| "Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy." | 7.88 | Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018) |
| " The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban." | 7.85 | Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017) |
| "Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction." | 7.83 | Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data. ( Bossa, AS; César, MC; Leal, TC; Okada, MY; Oliveira, MT; Pedroti, FC; Roque, EA; Silva, PG; Simões, SA; Soeiro, AM, 2016) |
| "We compared the incidence of clinically significant bleeding in patients with CKD receiving therapeutic doses of dalteparin to that of patients with CKD receiving therapeutic doses of UFH." | 7.83 | Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. ( Billett, HH; Calvo, M; Kushnir, M; Park, D; Sinnet, M; Solorzano, C; Southern, W, 2016) |
| "The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees." | 7.81 | The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| "The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012." | 7.81 | Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty. ( Charters, MA; Dobson, C; Frisch, NB; Les, CM; Silverton, CD; Wessell, NM, 2015) |
| " The primary analysis compared the temporal course of event rates and rate differences between rivaroxaban and enoxaparin prophylaxis for symptomatic venous thromboembolism plus all-cause mortality (efficacy events) versus nonfatal major bleeding (safety events)." | 7.80 | Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. ( Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z, 2014) |
| "Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented." | 7.80 | Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014) |
| "Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 7.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| "Oral dabigatran etexilate is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement or total hip replacement." | 7.76 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. ( Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2010) |
| "Rates of VTE and bleeding events did not differ significantly between dabigatran etexilate and enoxaparin." | 7.75 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. ( Beard, SM; Brenkel, IJ; Dolan, G; Maciver, F; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2009) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 7.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy." | 7.74 | Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007) |
| "In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin." | 7.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up." | 7.30 | Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023) |
| "Rivaroxaban is a novel oral anticoagulant with potent anti-Xa activity, which might be an attractive alternative drug to enoxaparin." | 7.11 | Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE. ( Fang, Z; Hu, X; Liu, Q; Tang, L; Xiao, Y; Zhou, S, 2022) |
| "Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2." | 7.11 | Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial ( Agnelli, G; Bauersachs, R; Becattini, C; Bertoletti, L; Brenner, B; Cohen, A; Connors, JM; Manfellotto, D; Maraziti, G; Sanchez, A, 2022) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 6.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| "Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7." | 6.84 | Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. ( Baran, A; Carrier, M; Francis, CW; Hobbs, S; Iyer, R; Kaproth-Joslin, K; Khorana, AA; Kuderer, NM; Lyman, GH; Ortel, TL; Peterson, D; Rubens, D; Wun, T, 2017) |
| "Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE)." | 6.82 | Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI, 2016) |
| "This double-blind, double-dummy, randomised, phase IIb study (NCT00902928) evaluated different dosing regimens of darexaban compared with enoxaparin (randomised 1:1:1:1:1 to 15 mg twice daily [bid], 30 mg once daily [qd], 30 mg bid or 60 mg qd or enoxaparin 40 mg qd) in patients undergoing elective total hip arthroplasty." | 6.79 | Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). ( Agnelli, G; Eriksson, BI; Gallus, AS; Kashiwa, M; Lassen, MR; Prins, MH; Renfurm, RW; Turpie, AG, 2014) |
| " There were no related serious adverse events, no clinically relevant bleeding events, and no symptomatic recurrent VTEs." | 6.79 | Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. ( Burr, S; Goldenberg, NA; Hamblin, F; Kulkarni, R; O'Brien, SH; Wallace, A, 2014) |
| "Apixaban is a potent, selective direct inhibitor of the coagulation factor Xa, recently approved in Europe for the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery." | 6.77 | Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. ( Gallerani, M; Imberti, D; Manfredini, R, 2012) |
| "Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b." | 6.71 | The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 6.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| " dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH." | 6.70 | Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002) |
| "Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio." | 6.61 | Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice. ( Brenner, MJ; Miller, KM, 2019) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 6.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Dalteparin was not stopped in any women." | 5.91 | Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023) |
| "Apixaban is a direct factor Xa inhibitor that may be intended as an ideal alternative for the management of HIT." | 5.72 | An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022) |
| "In this randomized, open-label, prospective superiority trial involving hospitalized patients with confirmed mild or moderate COVID-19 disease without known thromboembolism, we assigned 230 patients to receive either once-daily oral rivaroxaban (10mg or 15mg) or once-daily subcutaneous enoxaparin (40mg or 60mg) for a median duration of 8 days." | 5.51 | Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy. ( Chandralekha, S; Kaimaparambil, V; Kumar, D; Lalchandani, J, 2022) |
| " We evaluated the rates of VTE recurrence and major bleeding and the relative efficacy and safety of 6-month treatment with oral apixaban or subcutaneous dalteparin in patients with different cancer sites randomized in the Caravaggio study." | 5.51 | Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A, 2022) |
| "In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months." | 5.51 | Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. ( Aquilanti, S; Bertoletti, L; Brebion, N; Brisot, D; Bura-Rivière, A; Burnod, A; Charles-Nelson, A; Chatellier, G; Constans, J; Couturaud, F; Elias, A; Falvo, N; Girard, P; Grange, C; Laporte, S; Mahé, I; Meyer, G; Mismetti, P; Pernod, G; Planquette, B; Ray, V; Roy, PM; Sanchez, O; Sevestre, MA; Timar-David, M, 2022) |
| " We conducted a prospective, multicenter, open-label trial (NCT00952380) on dose-finding, safety, and efficacy (measured by 90-day risks of clinically relevant bleeding [CRB] and symptomatic recurrent VTE [srVTE]) of twice-daily subcutaneous dalteparin for acute VTE treatment in patients ≤18 years old." | 5.51 | A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. ( Goldenberg, NA; Hartman, LR; Jani, D; Nurmeev, I; Sherman, N; Svirin, P; Wolter, KD; Yan, JL, 2022) |
| "The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)." | 5.48 | Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 5.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "Apixaban is a new oral anticoagulant with the potential to overcome these limitations." | 5.43 | Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016) |
| " Of the eight papers comparing chemical prophylaxis medications in patients with hip or lower limb injuries, fondaparinux and enoxaparin were found to be significantly superior to placebo in respect of prevention of DVT, with no increased risk of bleeding." | 5.41 | The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis. ( Jin, J; MacCormick, AD; Peng, S; Zhang, M, 2023) |
| "Of 138 randomized patients, 100 patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy were assigned to either oral apixaban therapy or subcutaneous low-molecular weight heparin (enoxaparin) through randomized clinical study in 1:1 ratio." | 5.41 | Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. ( Algaby, AZ; Hassan, A; Mokadem, ME, 2021) |
| "In patients hospitalised with COVID-19 and elevated D-dimer concentration, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation." | 5.41 | Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. ( Alexander, JH; Armaganijan, L; Avezum, A; Azevedo, LCP; Barbosa, LM; Berwanger, O; Bronhara, B; Canesin, MF; Cavalcanti, AB; Conceição-Souza, GE; Damiani, LP; de Alcântara Chaud, MS; de Aquino Martins, P; de Aveiro Morata, J; de Barros E Silva, PGM; de Faria, LM; de Matos Soeiro, A; de Oliveira Twardowsky, A; de Oliveira, AL; de Souza Dantas, VC; Diaz, DRA; Dracoulakis, MDA; Feitosa-Filho, GS; Fernandes, ACS; Figueiredo, EL; Furtado, RHM; Gazzana, MB; Gebara, OCE; Guimarães, PO; Hernandes, ME; Lima, RGSD; Liporace, IL; Lopes, RD; Macedo, AVS; Machado, FR; Maia, LN; Melro, LMG; Neuenschwander, FC; Nunes, VS; Queiroz, DAR; Ramacciotti, E; Ritt, LEF; Rocha, AT; Rosa, RG; Santos, SV; Tramujas, L; Veiga, VC; Viana, LS, 2021) |
| " Major bleeding occurred in 22 of 576 patients on apixaban (3." | 5.41 | Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. ( Ageno, W; Agnelli, G; Bauersachs, R; Becattini, C; Cohen, A; Gussoni, G; Huisman, M; Vedovati, MC, 2021) |
| "We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study." | 5.41 | Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021) |
| "A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial." | 5.36 | Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. ( Feng, Y; Leil, TA; Mohan, P; Paccaly, A; Pfister, M; Zhang, L, 2010) |
| "In this international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patients undergoing lower-limb nonmajor orthopedic surgery who were considered to be at risk for venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or enoxaparin." | 5.34 | Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. ( Cucherat, M; Deygas, B; Duverger, D; Fisher, W; Girard, P; Laporte, S; Llau, J; Martínez-Martín, J; Mismetti, P; Mouret, P; Presles, E; Rosencher, N; Samama, CM, 2020) |
| "Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications." | 5.34 | Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020) |
| " However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation." | 5.34 | Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007) |
| "Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding." | 5.34 | Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020) |
| "Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin." | 5.30 | Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. ( Ageno, W; Cohen, AT; Gibson, CM; Goldhaber, SZ; Hernandez, A; Hull, RD; Lopes, RD; Yee, MK, 2019) |
| "To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively." | 5.30 | Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019) |
| "In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding." | 5.30 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019) |
| "Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding." | 5.27 | Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018) |
| "In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-associated VTE." | 5.27 | Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. ( Beyer-Westendorf, J; Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, M; Hernandez, CR; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, GE; Santamaria, A; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zhang, G; Zwicker, JI, 2018) |
| "Among hospitalized medically ill patients, extended-duration betrixaban demonstrated an ≈30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin." | 5.24 | Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. ( Arbetter, D; Chi, G; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, R; Jain, P; Korjian, S; Lopes, RD, 2017) |
| "The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects." | 5.24 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017) |
| "In patients with NSTE-ACS undergoing an early invasive strategy, treatment with bivalirudin alone significantly reduced major bleeding and improved net clinical outcomes during the upstream medical management phase with comparable rates of MACE." | 5.22 | Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial. ( Bernstein, D; Bertrand, ME; Cequier, AR; Deliargyris, EN; Desmet, W; Droppa, M; Gawaz, M; Geisler, T; Hoekstra, JW; Lincoff, AM; Mehran, R; Rasmussen, LH; Steinhubl, SR; Stone, GW, 2016) |
| "The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the treatment of acute symptomatic venous thromboembolism." | 5.22 | Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. ( Ageno, W; Büller, HR; Di Nisio, M; Pap, AF; Rutjes, AW, 2016) |
| "Apixaban, a direct acting oral anticoagulant (DOAC), was found to be non-inferior to and safer as enoxaparin followed by warfarin for treatment of venous thromboembolism (VTE) in the AMPLIFY trial." | 5.22 | Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. ( Agnelli, G; Bleker, SM; Büller, HR; Cohen, AT; Curto, M; Gallus, AS; Middeldorp, S; Raskob, GE; Sisson, M; Weitz, JI, 2016) |
| "Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy." | 5.22 | Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. ( Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S, 2016) |
| " Direct comparisons show that DOACs significantly decrease recurrent venous thromboembolism (VTE) events compared with dalteparin (odds ratio [OR], 0." | 5.22 | Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. ( Badgett, RG; Bryce, AH; Fuentes, HE; He, H; Liu, H; Marshall, AL; McBane, RD; Montori, V; Murad, MH; Naqvi, SAA; Padranos, L; Riaz, IB; Sipra, QR; Tafur, AJ; Vandvik, PO; Wysokinski, WE, 2022) |
| "In this French cohort of NSTEMI patients, predominantly managed invasively, there was no evidence that fondaparinux was superior to enoxaparin as regards bleeding events or 1-year mortality (FAST-MI 2010; NCT01237418)." | 5.20 | Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. ( Bonnefoy-Cudraz, E; Collet, JP; Coste, P; Danchin, N; Ennezat, PV; Puymirat, E; Richard, P; Roul, G; Schiele, F; Simon, T, 2015) |
| "To evaluate the effect of prestudy heparin on the efficacy and safety of rivaroxaban relative to enoxaparin/VKA, the 3-month incidence of recurrent VTE, and the 14-day incidence of major and nonmajor clinically relevant bleeding were compared in patients who did and did not receive prestudy heparin." | 5.20 | Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. ( Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC, 2015) |
| "The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)." | 5.20 | Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015) |
| "Major bleeding was less frequent during dalteparin therapy beyond 6 months." | 5.20 | Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 5.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "Rivaroxaban demonstrated superior efficacy and a similar safety profile to enoxaparin for the prevention of venous thromboembolism in the phase III RECORD programme in patients undergoing elective hip or knee replacement surgery." | 5.19 | A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. ( Haas, S; Holberg, G; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, LG; Pattanayak, CW; Schmidt, A; Turpie, AG; van Eickels, M, 2014) |
| "Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding." | 5.19 | Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014) |
| "A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials." | 5.17 | Oral apixaban for the treatment of acute venous thromboembolism. ( Agnelli, G; Buller, HR; Cohen, A; Curto, M; Gallus, AS; Johnson, M; Masiukiewicz, U; Pak, R; Raskob, GE; Thompson, J; Weitz, JI, 2013) |
| "Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear." | 5.17 | Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ( Büller, HR; Décousus, H; Grosso, MA; Mercuri, M; Middeldorp, S; Prins, MH; Raskob, GE; Schellong, SM; Schwocho, L; Segers, A; Shi, M; Verhamme, P; Wells, P, 2013) |
| "To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA." | 5.17 | Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013) |
| "Co-medication use with rivaroxaban or enoxaparin resulted in non-significant increases in bleeding events." | 5.16 | Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. ( Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N, 2012) |
| "In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months." | 5.16 | Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. ( Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2012) |
| "Edoxaban inhibited venous thrombosis comparably to warfarin and enoxaparin, and the attendant bleeding risk of edoxaban was lower than that of warfarin and enoxaparin in rats." | 5.16 | Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. ( Edo, N; Honda, Y; Kamisato, C; Kita, A; Morishima, Y; Shibano, T; Tsuji, N, 2012) |
| "Dalteparin is superior to the NSAID ibuprofen in preventing extension of superficial thrombophlebitis during the 14-day treatment period with similar relief of pain and no increase in bleeding." | 5.16 | A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. ( Aston, CE; Rathbun, SW; Whitsett, TL, 2012) |
| "To determine whether low molecular weight heparin (LMWH) plus low-dose aspirin (LDA) is comparable in efficacy and safety to unfractionated heparin (UFH) plus LDA in the management of pregnant women with a history of recurrent spontaneous abortion secondary to antiphospholipid syndrome (APS)." | 5.15 | Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. ( Abdou, AM; Fouda, IM; Fouda, UM; Ramadan, DI; Sayed, AM; Zaki, MM, 2011) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 5.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2." | 5.15 | Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. ( Goldhaber, SZ; Haas, SK; Kakkar, AK; Knabb, RM; Leizorovicz, A; Merli, G; Weitz, JI, 2011) |
| " We examined the incidence and outcomes after bleeding in 20 078 patients with acute coronary syndromes (ACS) enrolled in the OASIS-5 trial who were treated with fondaparinux or the low-molecular weight heparin, enoxaparin." | 5.14 | Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Fox, KA; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2009) |
| "The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%." | 5.14 | Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Flather, M; Fox, KA; Franzosi, MG; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Yusuf, S, 2009) |
| " Patients age > or =75 years treated with bivalirudin alone had similar ischemic outcomes, but significantly lower rates of bleeding compared with those treated with heparin and glycoprotein IIb/IIIa inhibitors overall and in the PCI subset." | 5.14 | Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Alexander, KP; Bertrand, ME; Feit, F; Gersh, BJ; Hoekstra, J; Lopes, RD; Manoukian, SV; Ohman, EM; Pollack, CV; Stone, GW; White, HD, 2009) |
| "Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agent in ST-elevation myocardial infarction (STEMI) patients receiving fibrinolytic therapy in ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction 25) trial." | 5.14 | Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. ( Antman, EM; Giraldez, RR; Giugliano, RP; Mohanavelu, S; Morrow, DA; Nicolau, JC; Wiviott, SD, 2009) |
| " Apixaban, a specific factor Xa inhibitor, may provide effective thromboprophylaxis with a low risk of bleeding and improved ease of use." | 5.14 | Apixaban or enoxaparin for thromboprophylaxis after knee replacement. ( Chen, D; Gallus, A; Lassen, MR; Pineo, G; Portman, RJ; Raskob, GE, 2009) |
| "In the OASIS-5 trial, fondaparinux reduced major bleeding with similar short-term efficacy as enoxaparin but lowered death and stroke during long-term follow-up." | 5.14 | Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. ( Afzal, R; Anderson, JA; Budaj, A; Eikelboom, JW; Fox, KA; Hirsh, J; Johnston, M; Mehta, SR; Yusuf, S, 2010) |
| "Ambulatory treatment with enoxaparin plus warfarin seems to be effective in symptomatic healing and in clinical improvement by reducing thrombus formation and organization at all levels of lower extremity venous system with DVT, without a significant major bleeding risk." | 5.14 | Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. ( Akcalı, Y; Filizcan, U; Hasan, E; Karabay, O; Koksoy, C; Kurtoglu, M, 2010) |
| "In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding." | 5.14 | Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. ( Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S, 2010) |
| "Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation." | 5.14 | Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010) |
| " Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use." | 5.14 | Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. ( Chen, D; Gallus, A; Lassen, MR; Pineo, G; Ramirez, LM; Raskob, GE, 2010) |
| "Compared with a heparin-based strategy, fondaparinux reduced mortality, ischemic events, and major bleeding across the full spectrum of acute coronary syndromes and was associated with a more favorable net clinical outcome in patients undergoing either an invasive or a conservative management strategy." | 5.13 | Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008) |
| "According to the available data, Apixaban, Edoxaban, and Darexaban are better than any anticoagulants in the prevention of VTE and bleeding during total knee or total hip arthroplasty." | 5.12 | Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis. ( Feng, W; Huang, D; Lu, A; Wang, X, 2021) |
| "In the THRIVE Treatment study, no patient suffered from a recurrent VTE, but 1 patient randomised to enoxaparin/warfarin experienced major bleeding." | 5.12 | Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. ( Harenberg, J; Jörg, I; Weiss, C, 2006) |
| "Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity." | 5.12 | Comparison of fondaparinux and enoxaparin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Fox, KA; Granger, CB; Joyner, C; Mehta, SR; Peters, RJ; Pogue, J; Wallentin, L; Yusuf, S, 2006) |
| "Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers." | 5.12 | Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006) |
| "In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin." | 5.12 | Bivalirudin for patients with acute coronary syndromes. ( Aylward, PE; Bertrand, ME; Cequier, AR; Colombo, A; Cox, DA; Darius, H; Desmet, W; Ebrahimi, R; Feit, F; Hamon, M; Hoekstra, J; Lincoff, AM; McLaurin, BT; Mehran, R; Moses, JW; Ohman, EM; Pocock, SJ; Rasmussen, LH; Rupprecht, HJ; Stone, GW; Ware, JH; White, HD, 2006) |
| "This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism." | 5.12 | Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism. ( Castro, DJ; Díaz, G; Escobar, C; García-Rull, S; Martí, D; Ortega, J; Picher, J; Sueiro, A, 2007) |
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 5.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 5.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "Heparins and warfarin are currently used as venous thromboembolism (VTE) prophylaxis in surgery." | 5.12 | The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. ( Ansell, J; Davidson, BL; Deitchman, D; Gallus, A; Lassen, MR; Pineo, G, 2007) |
| "Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile." | 5.12 | Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007) |
| "The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness." | 5.12 | Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006) |
| "Enoxaparin is noninferior to UFH+phenprocoumon for prevention of ischemic and embolic events, bleeding complications, and death in TEE-guided cardioversion of atrial fibrillation." | 5.11 | Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) ( Daniel, WG; Geller, C; Hanrath, P; Hofmann, T; Lehmacher, W; Mügge, A; Nixdorff, U; Schmidt-Lucke, C; Schmidt-Lucke, JA; Sehnert, W; Stellbrink, C, 2004) |
| "Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis." | 5.11 | Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. ( Büller, HR; Cariou, R; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Leeuwenkamp, O; Lensing, AW; Piovella, F; Prins, MH; Raskob, G; Segers, AE, 2004) |
| "In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)." | 5.11 | A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004) |
| "Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding." | 5.11 | Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004) |
| "Tirofiban combined with dalteparin was associated with relatively more bleeding complications in the short term, but was effective in reducing the incidence of MACE during long-term clinical follow-up in patients with ACS." | 5.11 | Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. ( Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH, 2005) |
| "Our objective was to provide estimates of the frequency of bleeding complications, as defined by means of the Thrombolysis In Myocardial Infarction(TIMI) group, and collect data on clinical efficacy of the combination of tirofiban with enoxaparin plus ASA." | 5.10 | Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and ( Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD, 2002) |
| "This study was designed to assess whether use of enoxaparin during percutaneous coronary intervention (PCI) increased bleeding compared with unfractionated heparin, in addition to background therapy with eptifibatide." | 5.10 | Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. ( Bhatt, DL; Breall, JA; Casterella, PJ; Cohen, M; Corrigan, VE; Eaton, GM; Lee, BI; Lincoff, AM; Moses, JW; Pulsipher, M; Rogers, M; Ryan, TJ; Sklar, MA, 2003) |
| "Similar compliance, health status, deep venous thrombosis, and bleeding rates were found between dalteparin and enoxaparin." | 5.10 | Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. ( Chan, KT; Chiou-Tan, FY; Donovan, WH; Garza, H; Graves, DE; Holmes, SA; Parsons, KC; Rintala, DH; Robertson, CS, 2003) |
| "The FRISC II trial demonstrated that, for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach." | 5.10 | Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002) |
| "In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding." | 5.10 | Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. ( Baker, RI; Bowden, C; Gent, M; Haley, S; Julian, JA; Kakkar, AK; Kovacs, MJ; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2003) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months." | 5.09 | Outpatient treatment of pulmonary embolism with dalteparin. ( Anderson, D; Gray, L; Kovacs, MJ; Morrow, B; Touchie, D; Wells, PS, 2000) |
| "To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted dose warfarin in preventing venous thromboembolism after knee arthroplasty." | 5.08 | Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. ( Cruickshank, M; Delorme, F; Demers, C; Desjardins, L; Geerts, WH; Kassis, J; L'Espérance, B; Laflamme, GH; Leclerc, JR; Whitman, L, 1996) |
| "Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase." | 5.08 | A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997) |
| "The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)." | 5.08 | Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997) |
| " with coumarin) is still the most widely used treatment for deep venous thromboembolism." | 5.07 | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. ( del Rio, L; Lafoz, E; Monreal, M; Olive, A; Vedia, C, 1994) |
| "Literature on the efficacy and safety of enoxaparin for thromboembolism and thromboprophylaxis remains scanty, and therefore efficacy was not assessed; in terms of safety, when including other indications for enoxaparin in pregnancy, we found that enoxaparin was associated with significantly lower complications than aspirin." | 5.05 | Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis. ( Jacobson, B; Leisegang, R; Naidoo, P; Paek, D; Rambiritch, V; Sayre, T; Shan, J, 2020) |
| " Initial studies of extended thromboprophylaxis in acutely ill medical patients with enoxaparin, rivaroxaban and apixaban showed little to no benefit towards VTE reduction that was consistently outweighed by increased bleeding." | 4.98 | Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis. ( Burnett, AE; Fletcher, ML; Mahan, CE; Spyropoulos, AC, 2018) |
| "In the EINSTEIN-Pulmonary Embolism (PE) trial, subjects randomized to rivaroxaban versus enoxaparin bridging to vitamin K antagonist (VKA) therapy experienced a reduced index hospital length of stay (LOS)." | 4.95 | Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. ( Ashton, V; Baugh, CW; Coleman, CI; Crivera, C; Fermann, GJ; Kohn, CG; Peacock, WF; Schein, JR; Wells, PS; Wildgoose, P, 2017) |
| " The RR of major/clinically relevant bleeding was lowest for apixaban 2." | 4.95 | Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. ( Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT, 2017) |
| " The cluster ranking of major outcomes indicated that FXI-ASO, ardeparin, aspirin, and apixaban were ideal for preventing all-cause VTE and avoiding all bleeding events." | 4.95 | Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. ( Chen, X; Jin, Y; Wang, Z; Xiang, Y; Zhao, Y; Zheng, J, 2017) |
| "In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk." | 4.91 | Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015) |
| "Studies reporting vein re-opening, inflammation expressed as Gadolinium enhancement and coagulation parameters were searched in the literature and pooled into a meta-analysis using an inverse variance with random effects." | 4.86 | P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. ( Deatrick, KB; Henke, PK; Londy, FJ; Myers, DD; Ramacciotti, E; Rectenwald, JE; Schaub, RG; Wakefield, TW; Wrobleski, SK, 2010) |
| "Primary efficacy (any VTE+all-cause mortality) and safety (major bleeding) outcomes in enoxaparin arms largely differed across similarly designed rivaroxaban and dabigatran trials (differences in venography adjudication and bleeding events definitions)." | 4.86 | Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. ( Kolundzic, R; Trkulja, V, 2010) |
| "Oral dabigatran was as effective as subcutaneous enoxaparin in reducing the risk of major VTE and VTE-related mortality after hip or knee arthroplasty and has a similar bleeding profile." | 4.86 | Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. ( Caprini, JA; Clemens, A; Dahl, OE; Eriksson, BI; Francis, CW; Friedman, RJ; Hantel, S; Kurth, AA; Rosencher, N; Schnee, JM, 2010) |
| " Newer agents, such as bivalirudin or fondaparinux, reduce bleeding complications, with no improvement in anti-ischemic efficacy." | 4.86 | Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. ( Aïssaoui, N; Danchin, N, 2010) |
| "Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE)." | 4.85 | Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. ( Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE, 2009) |
| " High-dose atorvastatin reduces recurrent stroke in patients with recent stroke, but probably slightly increases central nervous system hemorrhage (SPARCL)." | 4.84 | What's new in stroke? The top 10 studies of 2006-2008. Part II. ( Hart, RG, 2008) |
| " We explore the role of glycoprotein IIb-IIIa inhibitors and the direct thrombin inhibitor bivalirudin in ACS patients, and consider the difficulties involved in reducing ischemic events while limiting bleeding risks." | 4.84 | Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. ( Kwa, AT; Rogers, JH, 2008) |
| "A 70-year-old man on enoxaparin and warfarin sodium therapy due to pulmonary embolism was admitted for evaluation of a sudden, sharp pain in the left inguinal region." | 4.82 | Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature. ( Anadol, AZ; Gök, A; Topgül, K; Uzun, O, 2005) |
| "Rivaroxaban chemoprophylaxis following TKA and THA was associated with an increased risk of bleeding and prothrombotic complications compared to aspirin and enoxaparin." | 4.31 | Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty. ( Christ, AB; Heckmann, ND; Kang, HP; Lieberman, JR; Mayfield, CK; Mills, ES; Piple, AS; Wang, JC, 2023) |
| " Of the 7 readmissions in the enoxaparin group, one was due to bleeding requiring transfusion; there were no readmissions for bleeding in the apixaban group." | 4.31 | Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. ( Covens, A; Geerts, W; Gien, LT; Kupets, R; Lin, Y; Spénard, E; Vicus, D, 2023) |
| "In 8246 patients included in the EINSTEIN-VTE studies for acute VTE, we evaluated the effect of polypharmacy on bleeding and on the relative differences between rivaroxaban and enoxaparin/vitamin K antagonist (VKA)." | 4.12 | Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. ( Bavalia, R; Bistervels, IM; Coppens, M; Gebel, M; Lensing, AWA; Middeldorp, S; Prins, MH, 2022) |
| " The MAGELLAN (Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin) and MARINER (Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk) trials evaluated whether rivaroxaban compared with enoxaparin or placebo could prevent venous thromboembolism without increased bleeding." | 4.12 | Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. ( Ageno, W; Albers, GW; Barnathan, ES; Cohen, AT; Elliott, CG; Halperin, JL; Hiatt, WR; Lipardi, C; Lu, W; Maynard, G; Raskob, GE; Spiro, TE; Spyropoulos, AC; Steg, PG; Sugarmann, C; Weitz, JI, 2022) |
| "We evaluated the risks of VTE recurrence and treatment-related major bleeding according to the cancer stage in patients with VTE and solid cancer randomised to apixaban or dalteparin in the Caravaggio study." | 4.12 | Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. ( Agnelli, G; Becattini, C; Brenner, B; Cohen, AT; Connors, JM; Gussoni, G; Huisman, M; Munoz, A; Sanchez, O; Verso, M, 2022) |
| "Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer." | 4.02 | Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021) |
| " The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients." | 3.96 | Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. ( Agrusta, F; Amitrano, M; Bellizzi, A; Cardillo, G; Cavalli, A; Di Micco, P; Fontanella, A; Iannuzzo, M; Lodigiani, C; Mangiacapra, S; Russo, V; Sacco, C; Viggiano, GV, 2020) |
| "This study aims to validate the application of a multicriteria decision analysis in a real-world problem, the use of rivaroxaban and enoxaparin to prevent deep venous thrombosis." | 3.96 | Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study. ( Morais, QCD; Santos, MS, 2020) |
| "In this study, although there were no significant differences in effectiveness or safety between the rivaroxaban and dalteparin groups, rivaroxaban use was associated with a higher rate of clinically relevant bleeding than dalteparin." | 3.96 | Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers. ( Huh, JW; Jo, KW; Lee, JH; Lee, JS; Oh, YM, 2020) |
| "This study was a retrospective pilot analysis of adult patients with gynecologic malignancies who received either rivaroxaban, warfarin or low molecular weight heparin for treatment of venous thromboembolism at Augusta University Medical Center from 1 July 2013 to 30 June 2015." | 3.91 | Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study. ( Gandhi, AS; Signorelli, JR, 2019) |
| "Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy." | 3.88 | Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018) |
| " Objectives To estimate the incidence of VTE and bleeding outcomes, comparing prolonged prophylaxis with rivaroxaban 10 mg daily for 35 days with enoxaparin 40 mg daily for 10 days." | 3.88 | Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. ( Cohoon, KP; De Sanctis, Y; Haskell, L; McBane, RD; Spiro, TE, 2018) |
| "There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives." | 3.85 | Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017) |
| " The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban." | 3.85 | Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017) |
| "To evaluate the occurrence of bleeding and venous thromboembolic (VTE) events in patients receiving rivaroxaban, warfarin, or warfarin with the addition of enoxaparin during the immediate postoperative period following major orthopedic surgery." | 3.85 | Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital. ( Cieri, NE; Hassan, AK; Kusmierski, K; Lackie, C; Van Opdorp, A, 2017) |
| "Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction." | 3.83 | Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data. ( Bossa, AS; César, MC; Leal, TC; Okada, MY; Oliveira, MT; Pedroti, FC; Roque, EA; Silva, PG; Simões, SA; Soeiro, AM, 2016) |
| "We compared the incidence of clinically significant bleeding in patients with CKD receiving therapeutic doses of dalteparin to that of patients with CKD receiving therapeutic doses of UFH." | 3.83 | Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. ( Billett, HH; Calvo, M; Kushnir, M; Park, D; Sinnet, M; Solorzano, C; Southern, W, 2016) |
| "The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees." | 3.81 | The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| "The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012." | 3.81 | Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty. ( Charters, MA; Dobson, C; Frisch, NB; Les, CM; Silverton, CD; Wessell, NM, 2015) |
| " She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding." | 3.81 | Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher? ( Baquero-Salamanca, M; Calderon-Ospina, C; Téllez-Arévalo, AM, 2015) |
| " The primary analysis compared the temporal course of event rates and rate differences between rivaroxaban and enoxaparin prophylaxis for symptomatic venous thromboembolism plus all-cause mortality (efficacy events) versus nonfatal major bleeding (safety events)." | 3.80 | Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. ( Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z, 2014) |
| "Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented." | 3.80 | Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014) |
| "Our experience with rivaroxaban in elective hip and knee arthroplasty showed no significant difference in the incidence of VTE or major bleeding." | 3.79 | Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. ( Jeer, P; Rose, B; Saran, D; Shrivastava, R; Sindali, K; Soueid, H, 2013) |
| "To evaluate the consistency of the antithrombotic efficacy and bleeding risk of apixaban 2." | 3.79 | Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. ( Chen, D; Gallus, AS; Lassen, MR; Pineo, GF; Ramacciotti, E; Ramirez, LM; Raskob, GE; Wang, L, 2013) |
| " In this analysis of pooled data from four large, randomised, phase III clinical trials that compared the oral, direct Factor Xa inhibitor rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement (n = 12,729), the incidence of complications, including bleeding and adverse events related to surgery (such as wound infection, wound dehiscence and haemarthrosis) are reported." | 3.78 | The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. ( Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Turpie, AG, 2012) |
| "Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 3.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| "Oral dabigatran etexilate is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement or total hip replacement." | 3.76 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. ( Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2010) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, may worsen hypertension or congestive heart failure and obstruct access to the binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's mechanism of action in reducing death and recurrent myocardial infarction (MI)." | 3.75 | Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. ( Antman, EM; Aylward, PE; Bergovec, M; Buros, JL; Col, JJ; Gibson, CM; Goodman, SG; Gulba, D; Kunadian, V; Murphy, SA; Pride, YB; Zorkun, C, 2009) |
| "Rates of VTE and bleeding events did not differ significantly between dabigatran etexilate and enoxaparin." | 3.75 | Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. ( Beard, SM; Brenkel, IJ; Dolan, G; Maciver, F; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE, 2009) |
| "In the initial treatment of venous thromboembolism (VTE) fondaparinux, a pentasaccharide, is a good alternative to heparin." | 3.75 | Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; van Doormaal, FF, 2009) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 3.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy." | 3.74 | Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007) |
| "In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin." | 3.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "Over 2 million patients in North America are on warfarin anticoagulation therapy for prevention of thromboembolism." | 3.73 | Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. ( Ahmed, M; Bragg, L; Brotman, DJ; Jaffer, AK; Klein, A; Qadeer, MA; Seshadri, N, 2005) |
| "To determine the rate of bleeding and thromboembolic events within 1 month of outpatient dalteparin therapy in veterans with mechanical heart valves, to evaluate potential risk factors associated with these events, and to examine the prescribing patterns of dalteparin in this patient population." | 3.73 | Safety of outpatient dalteparin therapy in veterans with mechanical heart valves. ( Copeland, LA; Flanagan, PS; O'Neill, JL; Zaleon, CR, 2005) |
| "The safety outcome was any on-treatment bleeding event." | 3.30 | Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial. ( Bao, Y; Chen, C; Chen, L; Chen, Q; Jiang, C; Jiang, G; Li, J; Liu, X; She, Y; Shen, L; Xu, L; Yang, Y; Zhao, M, 2023) |
| "The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up." | 3.30 | Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023) |
| "Bleeding was predominantly intracranial (n=331 [69%]) or gastrointestinal (n=109 [23%])." | 3.30 | Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Cohen, AT; Connolly, SJ; Coppens, M; Crowther, M; Demchuk, A; Eikelboom, JW; Gibson, CM; Koch, B; Lopez-Sendon, J; Middeldorp, S; Milling, TJ; Schmidt, J; Shoamanesh, A; Verhamme, P; Xu, L, 2023) |
| "The study INHIXACOVID19 was registred on ClinicalTrials." | 3.30 | Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19. ( Bignami, EG; Brambilla, P; Castagna, A; Cosmi, B; Cristini, F; De Stefano, G; Di Perri, G; Drago, F; Fornaro, G; Frattima, S; Giannella, M; Grandone, E; Lupi, M; Mazzaferri, F; Montineri, A; Pan, A; Patacca, A; Romagnoli, A; Rozzini, R; Salvetti, M; Stella, A; Testa, S; Viale, P, 2023) |
| "No DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis." | 3.11 | Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. ( Agostinis, M; Antolini, L; Barberis, D; Birocchi, S; Bonacchini, L; Carioti, G; Cattaneo, M; Gazzaniga, G; Grazia Valsecchi, M; Massaini, G; Merli, M; Morici, N; Podda, G; Saverio Serino, F; Trezzi, M, 2022) |
| "This study aimed to compare initiating warfarin at the recommended dosing regimen versus empirically lowered doses intended to account for the variation in warfarin sensitivity." | 3.11 | Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial. ( Ahmed, MA; El Wakeel, LM; Sabry, S; Saleh, A, 2022) |
| "Rivaroxaban is a novel oral anticoagulant with potent anti-Xa activity, which might be an attractive alternative drug to enoxaparin." | 3.11 | Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE. ( Fang, Z; Hu, X; Liu, Q; Tang, L; Xiao, Y; Zhou, S, 2022) |
| "Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2." | 3.11 | Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial ( Agnelli, G; Bauersachs, R; Becattini, C; Bertoletti, L; Brenner, B; Cohen, A; Connors, JM; Manfellotto, D; Maraziti, G; Sanchez, A, 2022) |
| "Compared to cancer patients with symptomatic VTE, those with incidental VTE have different clinical features at presentation, with a numerically lower incidence of recurrent VTE and a numerically higher incidence of major bleeding." | 3.01 | Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. ( Agnelli, G; Bauersachs, R; Becattini, C; Cohen, AT; Connors, JM; Dentali, F; Falvo, N; Giustozzi, M; Huisman, M; Ruperez Blanco, AB; Szmit, S, 2021) |
| "Proximal deep vein thrombosis and/or pulmonary embolism occurred in seven patients (3·4 per cent) in the IPC group and one patient (0·5 per cent) in the IPC with enoxaparin group (P = 0·050)." | 2.94 | Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial. ( Amano, T; Funakoshi, T; Homma, S; Ichikawa, N; Kamachi, H; Kawamura, H; Maeda, Y; Ohno, Y; Takahashi, N; Taketomi, A; Yokota, R; Yoshida, T, 2020) |
| "Thromboprophylaxis dosing strategies using enoxaparin in elderly patients with renal disease are limited, while dose adjustments or monitoring of anti-Xa levels are recommended." | 2.90 | Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment. ( Chamoun, N; Dimassi, H; Ghanem, G; Ghanem, H; Hachem, A; Hariri, E; Lteif, C; Mansour, H; Zalloum, R, 2019) |
| "This study aimed to assess whether low-molecular-weight heparin (LMWH) is effective and safe in preventing postoperative venous thromboembolism (VTE) in patients undergoing esophageal cancer surgery." | 2.90 | Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study. ( Hirata, S; Matsuhashi, N; Sakuratani, T; Shimokawa, T; Tanaka, H; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K, 2019) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 2.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| "Essentials Cancer patients receiving anticoagulants for venous thromboembolism have an elevated bleeding risk." | 2.87 | Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018) |
| "RI in patients with cancer-associated thrombosis on anticoagulation was associated with a statistically significant increase in recurrent VTE and major bleeding, but no significant increase in CRB or mortality." | 2.87 | Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018) |
| "No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group." | 2.84 | Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017) |
| "Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7." | 2.84 | Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. ( Baran, A; Carrier, M; Francis, CW; Hobbs, S; Iyer, R; Kaproth-Joslin, K; Khorana, AA; Kuderer, NM; Lyman, GH; Ortel, TL; Peterson, D; Rubens, D; Wun, T, 2017) |
| "The results show that the treatment with heparin and nadroparin is safe and effective." | 2.82 | The safety and efficacy of Heparin and Nadroparin compared to placebo in acute ischemic stroke - pilot study. ( Dluha, J; Dusenka, R; Kalmarova, K; Kantorova, E; Kurca, E; Nosal, V; Sivak, S; Turcanova Koprusakova, M, 2016) |
| "Trauma patients are at high risk of developing venous thromboembolism (VTE), and standard dosing enoxaparin regimens may be inadequate for prophylaxis." | 2.82 | The efficacy of weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients: A systematic review and meta-analysis. ( Cole, E; Ebeid, A; Stallwood-Hall, C, 2022) |
| "To compare two enoxaparin dosing strategies at achieving prophylactic anti-Xa levels in women with a body mass index (BMI) ⩾35 (kg m(-2)) postcesarean delivery." | 2.82 | A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. ( Caballero, DC; McNulty, J; Neeper, JM; Serra, AE; Stephenson, ML, 2016) |
| "Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE)." | 2.82 | Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI, 2016) |
| "Bleeding was predominantly gastrointestinal or intracranial." | 2.82 | Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Bronson, MD; Cohen, AT; Conley, PB; Connolly, SJ; Crowther, M; Curnutte, JT; Eikelboom, JW; Gibson, CM; Gold, A; Goodman, S; Leeds, J; Lim, WT; Lopez-Sendon, J; Lu, G; Meeks, B; Middeldorp, S; Milling, TJ; Nakamya, J; Schmidt, J; Siegal, DM; Verhamme, P; Wiens, BL; Zotova, E, 2016) |
| "Prevention of deep venous thrombosis (DVT) and associated pulmonary embolism following major orthopedic surgeries is challenging, and there is an increased interest in developing new treatment strategies." | 2.80 | Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement. ( Altıntaş, F; Önal, A; Özler, T; Uluçay, Ç, 2015) |
| "The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer." | 2.80 | Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. ( Beyer-Westendorf, J; Bleker, SM; Boda, Z; Büller, HR; Carrier, M; Chlumsky, J; Décousus, H; Di Nisio, M; Garcia, D; Gibbs, H; Grosso, MA; Kakkar, A; Kamphuisen, PW; Mercuri, MF; Monreal, M; Ockelford, P; Pabinger, I; Raskob, GE; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Weitz, JI, 2015) |
| "We conclude that low-molecular-weight heparin either in a low-dose or high-dose regime during a peripheral EVR is safe concerning bleeding complications and acute reobstructions." | 2.79 | Safety and efficacy of periprocedural anticoagulation with enoxaparin in patients undergoing peripheral endovascular revascularization. ( Brodmann, M; Deutschmann, H; Dorr, A; Froehlich, H; Gary, T; Hafner, F; Kvas, E; Pilger, E, 2014) |
| "This double-blind, double-dummy, randomised, phase IIb study (NCT00902928) evaluated different dosing regimens of darexaban compared with enoxaparin (randomised 1:1:1:1:1 to 15 mg twice daily [bid], 30 mg once daily [qd], 30 mg bid or 60 mg qd or enoxaparin 40 mg qd) in patients undergoing elective total hip arthroplasty." | 2.79 | Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). ( Agnelli, G; Eriksson, BI; Gallus, AS; Kashiwa, M; Lassen, MR; Prins, MH; Renfurm, RW; Turpie, AG, 2014) |
| " There were no related serious adverse events, no clinically relevant bleeding events, and no symptomatic recurrent VTEs." | 2.79 | Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. ( Burr, S; Goldenberg, NA; Hamblin, F; Kulkarni, R; O'Brien, SH; Wallace, A, 2014) |
| "Apixaban is a potent, selective direct inhibitor of the coagulation factor Xa, recently approved in Europe for the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery." | 2.77 | Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. ( Gallerani, M; Imberti, D; Manfredini, R, 2012) |
| "Patients receiving chemotherapy for cancer are at increased risk for venous thromboembolism." | 2.77 | Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. ( Agnelli, G; Chaudhari, U; Fisher, W; George, DJ; Kakkar, AK; Lassen, MR; Lawson, F; Mismetti, P; Mouret, P; Turpie, AG, 2012) |
| "Traditionally, patients with pulmonary embolism (PE) are initially treated in the hospital with low molecular weight heparin (LMWH)." | 2.76 | Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. ( Creemers-Schild, D; de Vreede, MJ; Dekkers, OM; Dolsma, J; Eijsvogel, M; Faber, LM; Hofstee, HM; Hoogerbrugge, AD; Hovens, MM; Huisman, MV; Jonkers, GJ; Kruip, MJ; Mos, IC; van Kralingen, KW; Vlasveld, T; Zondag, W, 2011) |
| "Our purpose was to describe anti-Xa levels, dosage requirements, and complications associated with enoxaparin treatment doses in patients with morbid obesity." | 2.76 | Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. ( Deal, EN; Hollands, JM; Reichley, RM; Riney, JN; Skrupky, LP; Smith, JR, 2011) |
| "In selected low-risk patients with pulmonary embolism, outpatient care can safely and effectively be used in place of inpatient care." | 2.76 | Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. ( Aujesky, D; Beer, HJ; Cornuz, J; Egloff, M; Fine, MJ; Hugli, O; Legall, C; N'gako, A; Osterwalder, J; Perrier, A; Pugh, NA; Renaud, B; Righini, M; Roy, PM; Sanchez, O; Stone, RA; Verhamme, P; Verschuren, F; Yealy, DM, 2011) |
| "Major bleeding was comparable and minor bleedings (0." | 2.76 | Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. ( Abletshauser, C; Bauersachs, R; Bramlage, P; Gerlach, HE; Haas, S; Melzer, N; Riess, H; Schellong, SM; Sieder, C; Tebbe, U, 2011) |
| "Major bleeding was not significantly different between enoxaparin and placebo in either group." | 2.75 | Does ambulation modify venous thromboembolism risk in acutely ill medical patients? ( Amin, AN; Girard, F; Samama, MM, 2010) |
| "In acutely ill medical patients of at least 40 years of age, thromboprophylaxis with certoparin 3000 IU daily is effective and safe in comparison with 7500 IU twice daily UFH." | 2.75 | An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. ( Abletshauser, C; Bramlage, P; Greinacher, A; Haas, S; Riess, H; Schellong, SM; Schwanebeck, U; Sieder, C, 2010) |
| "Edoxaban is a new oral direct factor Xa inhibitor." | 2.75 | Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. ( Bocanegra, T; Cohen, AT; Eriksson, BI; Puskas, D; Raskob, G; Shi, M; Weitz, JI, 2010) |
| " The betrixaban dosage was blinded, but enoxaparin was not." | 2.74 | A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). ( Bauer, KA; Davidson, BL; Fisher, WD; Gent, M; Gretler, DD; Huo, MH; Sinha, U; Turpie, AG, 2009) |
| " Consecutive patients receiving enoxaparin at a dosage of 1 mg/kg body weight/12 hours for temporary interruption of phenprocoumon were prospectively enrolled to the study." | 2.74 | How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study. ( Hammerstingl, C; Omran, H; Poetzsch, B; Tripp, C, 2009) |
| " In the ABW dosing group, mean patient age was 76 years, mean weight 80 kg, mean serum creatinine 1." | 2.74 | Enoxaparin dosing in the elderly using adjusted body weight. ( Dzielak, E; Glavich, W; Guzek, J; Leri, F; Scialla, S; Smego, RA; Voyce, SJ, 2009) |
| "Data were obtained from a randomized controlled trial (n = 118) that compared conventional dosing of enoxaparin (product label) with an individualized dosing regimen." | 2.74 | Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. ( Atherton, JJ; Barras, MA; Duffull, SB; Green, B, 2009) |
| " We evaluated three dosage regimens of postoperative enoxaparin in Japanese patients undergoing elective total hip or knee arthroplasty." | 2.73 | Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. ( Fuji, T; Fujita, S; Niwa, S; Ochi, T, 2008) |
| "Bleeding is associated with adverse outcome in acute coronary syndromes." | 2.73 | Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial. ( DeYoung, P; Fitchett, DH; Goodman, SG; Huynh, T; Langer, A; Weeks, A; Yan, AT; Yan, RT, 2008) |
| "Major bleeding was observed in nine of 260 patients (3." | 2.73 | Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). ( Dunn, AS; Spyropoulos, AC; Turpie, AG, 2007) |
| "The aim of this study was to compare an individualized dosing regimen for enoxaparin to conventional dosing." | 2.73 | Individualized compared with conventional dosing of enoxaparin. ( Atherton, JJ; Barras, MA; Duffull, SB; Green, B, 2008) |
| "Minor bleeding was defined as hematoma that did not require intervention." | 2.73 | Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. ( Arruda, M; Barrett, C; Beheiry, S; Cummings, J; Di Biase, L; Fahmy, T; Hao, S; Kanj, M; Martin, DO; Natale, A; Patel, D; Saliba, W; Schweikert, R; Wazni, OM, 2007) |
| "In high risk critically ill patients citrate based anticoagulation for CVVH is safe in terms of bleeding complications and transfusion requirements." | 2.72 | Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin. ( Boerma, EC; Kingma, WP; Postma, SR; Van der Voort, PH; Van Roon, EN, 2006) |
| " The primary efficacy analysis did not demonstrate any significant trend in dose-response relationship for BAY 59-7939." | 2.72 | Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. ( Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F, 2006) |
| "Studies in cancer patients with venous thromboembolism suggested that low molecular weight heparin may prolong survival." | 2.71 | The effect of low molecular weight heparin on survival in patients with advanced malignancy. ( Bos, MM; Büller, HR; Klerk, CP; Lensing, AW; Otten, HM; Piovella, F; Prandoni, P; Prins, MH; Richel, DJ; Smorenburg, SM; van Tienhoven, G, 2005) |
| " This trial shows that bemiparin started postoperatively is as effective and safe as enoxaparin started preoperatively in the prevention of venous thromboembolism in patients undergoing total knee replacement." | 2.71 | Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. ( Castellet, E; Navarro-Quilis, A; Paz-Jiménez, J; Planès, A; Rocha, E, 2003) |
| "Minor bleeding was more frequent in the enoxaparin group (30." | 2.71 | Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. ( Armstrong, PW; Fitchett, D; Goodman, SG; Langer, A; Tan, M, 2003) |
| "Ximelagatran was to be initiated within the first two postoperative days." | 2.71 | Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. ( Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N, 2003) |
| " Three enoxaparin dosing strategies had been prescribed: therapeutic, prophylactic, or adjusted." | 2.71 | Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. ( Adamson, R; Khazan, M; Mathis, AS; Scheuering, S, 2003) |
| "We randomized 60 symptomatic pulmonary embolism patients in a 2:1 ratio to 90 days of enoxaparin as monotherapy without warfarin (N=40) or to intravenous unfractionated heparin as a "bridge" to warfarin, target INR 2." | 2.71 | Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. ( Beckman, JA; Dunn, K; Goldhaber, SZ; Sasahara, AA, 2003) |
| "The risk of venous thromboembolism is high after spinal cord injury (SCI)." | 2.71 | Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. ( , 2003) |
| "Incidences of recurrence of thromboembolism and of severe bleeding were assessed at the end of this period." | 2.71 | [Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism]. ( Baloira Villar, A; Golpe Gómez, R; Pajuelo Fernández, F; Pérez de Llano, LA; Veiga, F; Veres Racamonde, A, 2003) |
| " A population pharmacokinetic analysis was conducted and individual estimates of enoxaparin clearance and area under the curve were tested as prognostic factors for the occurrence of haemorrhagic episodes." | 2.71 | Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ( Antman, EM; Baille, P; Becker, R; Bruno, R; Retout, S; Sanderink, GJ; Veyrat-Follet, C; Vivier, N, 2003) |
| "Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b." | 2.71 | The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003) |
| " It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors." | 2.71 | Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. ( Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD, 2004) |
| "More bleeding was observed with enoxaparin, with a statistically significant increase in TIMI (Thrombolysis in Myocardial Infarction) major bleeding (9." | 2.71 | Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. ( Antman, EM; Armstrong, PW; Avezum, A; Aylward, P; Becker, RC; Biasucci, L; Borzak, S; Califf, RM; Cohen, M; Col, J; Ferguson, JJ; Frey, MJ; Fry, E; Goodman, S; Grines, CL; Gulba, DC; Guneri, S; Gurfinkel, E; Harrington, R; Hochman, JS; Kereiakes, DJ; Kleiman, NS; Langer, A; Leon, MB; Lopez-Sendon, JL; Mahaffey, KW; Nessel, CC; Pepine, CJ; Ruzyllo, W; Steinhubl, SR; Teirstein, PS; Toro-Figueroa, L; White, H, 2004) |
| " The primary efficacy endpoint was recurrent DVT (confirmed by venography or ultrasonography), and safety endpoints included bleeding and serious adverse events." | 2.71 | An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. ( Araújo, GR; Dietrich-Neto, F; Karaoglan de Moura, L; Lastoria, S; Maffei, FH; Michaelis, W; Ramacciotti, E; Sandri, JL, 2004) |
| "When there was a suspicion of pulmonary embolism (PE), patients were evaluated with spiral computed tomography." | 2.71 | Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin. ( Bilsel, Y; Buyukkurt, D; Granit, V; Guloglu, R; Kizilirmak, S; Kurtoglu, M; Yanar, H, 2004) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 2.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| " Dosage adjustments were made for patients developing renal failure." | 2.71 | Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. ( Couban, SH; Dorcas, VG; Forrest, DL; Pierce, R; Thompson, K, 2003) |
| "Venous thromboembolism is a frequent complication of total hip replacement." | 2.70 | A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. ( Gallus, AS; Hoek, JA; Turpie, AG, 2001) |
| "Patients with unstable angina pectoris (UAP) or non-ST-segment elevation acute myocardial infarction (AMI) are at risk of death or recurrent ischemic events, despite receiving aspirin and unfractionated heparin (UFH)." | 2.70 | Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. ( Berkowitz, SD; Bigonzi, F; Cohen, M; Fromell, GJ; Stinnett, S, 2001) |
| " The general use and correct dosage of low-molecular-weight heparin, however, are still under debate." | 2.70 | Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial. ( Eckmann, C; Kujath, P; Misselwitz, F, 2002) |
| "Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition." | 2.70 | Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. ( Breddin, HK; Hach-Wunderle, V; Kakkar, VV; Nakov, R, 2001) |
| " dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH." | 2.70 | Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002) |
| " SC weight-based dosing on off-dialysis days is a feasible regimen for further clinical thromboprophylaxis efficacy studies in hemodialysis patients." | 2.70 | Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ( Assaid, CA; Barrett, JS; Cox, DS; Fossler, MJ; Hainer, JW; Hua, TA; Pittenger, AL; Sherrard, DJ; Stephenson, CA; Swan, SK; Williams, RM, 2002) |
| "This pharmacodynamic study examined weight-based dosing of the low molecular weight heparin (LMWH), tinzaparin, in heavyweight/obese subjects." | 2.70 | Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. ( Assaid, CA; Barrett, JS; Cox, DS; Fossler, MJ; Hainer, JW; Leathers, T; Leese, PT, 2002) |
| "Bleedings were all minor, mostly during hospital stay." | 2.69 | Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. ( Barsotti, A; Belcaro, G; Cesarone, MR; Christopoulos, D; Corsi, M; De Sanctis, MT; Incandela, L; Laurora, G; Lennox, A; Malouf, M; Nicolaides, AN; Vasdekis, S, 1999) |
| "The incidence of deep vein thrombosis in group 1 was 14% (14 patients, 5 proximal vein thromboses and 9 distal vein thromboses) while in group 2, no patients developed deep vein thrombosis." | 2.69 | Use of low molecular weight heparin for prevention of deep vein thrombosis in total knee arthroplasty--a study of its efficacy in an Asian population. ( Fong, YK; Lee, BP; Lo, NN; Ng, SC; Ruban, P; Seow, KH; Yeo, SJ, 2000) |
| " However, body weight-adjusted dosage of low-molecular-weight heparin may be cumbersome and could lead possibly to incorrect dosing." | 2.69 | Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. ( Büller, HR; Harenberg, J; Huisman, MV; Koppenhagen, K; Schmidt, JA; Tolle, A, 2000) |
| "Dalteparin-treated patients received a commencement bolus of 20 units/kg and a maintenance infusion at 10 units/kg/hr." | 2.69 | A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. ( Cumming, AR; Gallagher, L; O'Brien, JL; Reeves, JH; Santamaria, JD, 1999) |
| " Therefore, tinzaparin administered in a dosage of 75 U anti-Xa/kg BW 12 hours before surgery is significantly more protective against proximal DVT and safer than the standard regimen of 50 U anti-Xa/kg BW started 2 hours before surgery in patients undergoing primary elective hip arthroplasty." | 2.69 | Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty. ( Andersen, BS; Borris, LC; Ejstrud, P; Jensen, HP; Lassen, MR; Poulsen, KA, 2000) |
| " This study was designed to test the hypothesis that 3 months of subcutaneous dosing of ardeparin would reduce angiographic restenosis after coronary balloon angioplasty." | 2.69 | Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty. ( Gimple, LW; Herrmann, HC; Mammen, E; Winniford, M, 1999) |
| "Bleeding was determined according to pre-defined objective criteria for major and minor episodes." | 2.68 | Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. ( Büller, HR; d'Azemar, P; Gent, M; Haley, S; Henkens, CM; Hoek, JA; Koopman, MM; Nurmohamed, MT; Que, GT; Sicurella, A; ten Cate, JW; Turpie, AG; van der Heul, C; van der Meer, J; van Riel, AM, 1996) |
| " This study showed that Enoxaparin administered postoperatively 30 mg every 12 hours is more effective and as safe as unfractionated heparin prophylaxis to prevent deep venous thrombosis in patients having elective total knee arthroplasty." | 2.68 | Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. ( Colwell, CW; Gardiner, GA; Ritter, MA; Spiro, TE; Stephens, JW; Trowbridge, AA, 1995) |
| " However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use." | 2.68 | A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. ( Anderson, D; Demers, C; Gent, M; Ginsberg, J; Hirsh, J; Kovacs, M; Leclerc, J; Levine, M; Turpie, AG; Weitz, J, 1996) |
| " Safety outcomes were defined as the occurrence of major and minor haemorrhage, other adverse events and changes in laboratory parameters." | 2.68 | Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. ( Bellaud, M; Compan, D; Darmon, JY; Fagola, M; Huet, Y; Planes, A; Saliba, E; Vochelle, N; Weisslinger, N, 1996) |
| "However, its application to pulmonary embolism or previous episodes of thromboembolism has not been studied." | 2.68 | Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. ( Baildon, R; Büller, HR; Gallus, AS; Gent, M; Ginsberg, J; Prins, MH, 1997) |
| "Bleeding was assessed on the basis of intraoperative blood loss, transfusion requirements, a decrease in hematocrit, and clinically identified bleeding complications." | 2.68 | Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. ( Ayers, DC; Boyd, AD; Francis, CW; Johanson, NA; Kessler, C; Liebert, KM; Marder, VJ; Pellegrini, VD; Rosenberg, A; Stulberg, BN; Totterman, S, 1997) |
| "Of these 14 late recurrences, just one occurred in patients with postoperative DVT." | 2.67 | Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. ( Aiello, S; Dettori, AG; Manotti, C; Pattacini, C; Pini, M; Poli, T; Quintavalla, R; Tagliaferri, A, 1994) |
| "The incidence of DVT and of pulmonary embolism was 4." | 2.67 | An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. ( Boneu, B, 1993) |
| "In THA patients, the rate of deep vein thrombosis (DVT) was lower with factor Xa inhibitors than LMWH." | 2.61 | Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( Cheng, K; Jia, J; Liang, Q; Sun, G; Wang, Q; Wang, Z; Wu, J, 2019) |
| "Betrixaban is a novel factor Xa inhibitor with unique pharmacokinetic properties, including low renal clearance, long half-life, and low peak-to-trough ratio." | 2.61 | Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice. ( Brenner, MJ; Miller, KM, 2019) |
| "No significant increase in major intracranial hemorrhage (p = 0." | 2.58 | Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis. ( Khan, NR; Lee, SL; Patel, PG; Sharpe, JP; Sorenson, J, 2018) |
| "Venous thromboembolism, specifically pulmonary embolism, is a rare complication following elective pediatric orthopedic surgery." | 2.58 | Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature. ( Bourget-Murray, J; Clarke, MA; Gorzitza, S; Phillips, LA, 2018) |
| "Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE." | 2.58 | Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. ( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018) |
| "Patients with cancer are at increased risk of recurrent venous thromboembolism (VTE) and bleeding." | 2.58 | Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis. ( Bauersachs, R; Martínez-Zapata, MJ; Mathioudakis, AG; Mousa, SA, 2018) |
| "We carried out a dose-response model-based meta-analysis to assess venous thromboembolism (VTE) and bleeding with factor Xa (FXa) inhibitors (apixaban, edoxaban, rivaroxaban) and a thrombin inhibitor (dabigatran) compared with European (EU) (40 mg q." | 2.55 | Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis. ( Boyd, RA; DiCarlo, L; Mandema, JW, 2017) |
| "To review the evidence regarding increased enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in the general trauma patient population." | 2.55 | Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients. ( Gales, MA; Horyna, TJ; Sandmann, EA; Walker, CK, 2017) |
| " With regard to dosage, for in-hospital treatment the higher dosage of 40 mg twice daily as opposed to 30 mg seems to significantly reduce the incidence of VTE without significantly affecting bleeding rate." | 2.52 | Enoxaparin venous thromboembolism prophylaxis in bariatric surgery: A best evidence topic. ( Khan, OA; Knight, WR; McGlone, ER; Parker, SG; Sufi, P, 2015) |
| "No major bleeding was observed in the patients treated with LMWH or warfarin and in less than 1% of those treated with aspirin." | 2.50 | Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. ( Di Nisio, M; Otten, HM; Porreca, E; Rutjes, AW, 2014) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 2.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Rivaroxaban is a newly developed oral medicine that direct inhibits factor Xa for the prevention and treatment of thromboembolic disorders." | 2.46 | Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. ( Cao, YB; Jiang, YY; Shen, H; Zhang, JD, 2010) |
| " Selection of the appropriate dosage is strongly recommended." | 2.45 | Safety evaluation of enoxaparin in currently approved indications. ( Meneveau, N, 2009) |
| " Furthermore, there is no difference according to liver enzymes elevation and cardio-vascular adverse events." | 2.44 | [Rivaroxaban (Xarelto): efficacy and safety]. ( Arnaout, L; Bellamy, L; Chabbouh, T; Rosencher, N, 2008) |
| "Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of venous thromboembolism (VTE)." | 2.44 | Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. ( Bauer, KA; Borris, L; Dahl, OE; Eriksson, BI; Fisher, WD; Gent, M; Haas, S; Homering, M; Huisman, MV; Kakkar, AK; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG, 2007) |
| "Fondaparinux has been shown to be as effective as enoxaparin in the prevention of thrombosis in patients undergoing orthopedic surgery and showed similar results compared to enoxaparin or UFH in patients with deep-vein-thrombosis or pulmonary embolism." | 2.44 | Factor Xa inactivation in acute coronary syndrome. ( Barantke, M; Bonnemeier, H, 2008) |
| " The dosage of LMWH was performed by body weight adjustment without dose-finding studies." | 2.42 | [Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage]. ( Harenberg, J, 2003) |
| " Future issues that need to be addressed include refinement of indications for administration and patient selection, comparison between existing agents, evaluation of newer agents, and optimization of dosing to maximize benefit and safety in the use of these powerful new classes of drugs." | 2.41 | Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. ( Vernon, SM, 2001) |
| " As prophylaxis, reviparin 1,750 anti-XaIU once daily was as effective as unfractionated heparin 5,000IU twice daily in 1,311 patients undergoing abdominal surgery and, in a once daily dosage of 4,200 anti-XaIU, was as effective as subcutaneous enoxaparin sodium 40 mg/day or acenocoumarol in patients undergoing hip replacement surgery." | 2.41 | Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. ( Jarvis, B; McClellan, K; Wellington, K, 2001) |
| " In comparative clinical trials, this dosage demonstrated either improved efficacy and a similar haemorrhagic profile, or a similar degree of efficacy with a lower rate of haemorrhagic events, compared with unfractionated heparin 5000IU 3 times daily." | 2.39 | Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. ( Goa, KL; Noble, S; Peters, DH, 1995) |
| " The enhanced bioavailability of these drugs, in conjunction with their prolonged half-life, makes subcutaneous therapy, in one to two daily doses, possible." | 2.39 | Low molecular weight heparins and their use in obstetrics and gynecology. ( Fejgin, MD; Lourwood, DL, 1994) |
| " This agent also showed sustained activity and better bioavailability characteristics than heparin." | 2.38 | Pharmacological profile of reviparin-sodium. ( Fareed, J; Hoppensteadt, D; Jeske, W, 1993) |
| " 27 patients (n = 68 samples) were evaluated and combined with published data (n = 319 samples from 35 patients) using population pharmacokinetic (popPK) modelling." | 1.91 | The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients. ( Hackeng, CM; Knibbe, CAJ; Mast, L; Peeters, MYM; Söhne, M; van den Broek, MPH, 2023) |
| "This single-center study suggests that DOACs are both safe and efficacious for the treatment of VTE in children with cancer." | 1.91 | Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients. ( Branchford, B; Liegl, M; Malec, L; Scheuermann, A; Simpson, P, 2023) |
| " capped (< 1 mg/kg) enoxaparin dosing regimen." | 1.91 | Management of venous thromboembolism in morbidly obese patients: a 10-year review. ( Donarelli, C; Ho, P; Khattak, Z; Kwok, A; Lai, J; Lim, HY; Lui, B; Wee, B, 2023) |
| " There is concern whether body mass index (BMI)-based enoxaparin dosing consistently achieves prophylactic targets in patients with severe obesity." | 1.91 | Effectiveness of Body Mass Index-Based Prophylactic Enoxaparin Dosing in Bariatric Surgery Patients. ( Chang, CK; Herrmann, DJ; Higgins, RM; Kindel, T; Peppard, WJ; Rein, L, 2023) |
| "Dalteparin was not stopped in any women." | 1.91 | Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023) |
| " After observing higher than expected VTE rates within our center's Trauma Quality Improvement Program data, we instituted a change in our VTE prophylaxis protocol, moving to enoxaparin dosing titrated by anti-Xa levels." | 1.72 | Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients. ( Collier, BR; Faulks, ER; Gates, RS; Gillen, JR; Lollar, DI; Smith, J, 2022) |
| "Anti-Xa-guided enoxaparin dosing for VTE prophylaxis in neurosurgical patients may help prevent major bleeding." | 1.72 | Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin. ( Cua, S; May, CC; Powers, CJ; Smetana, KS, 2022) |
| " Weight-based enoxaparin dosing was administered using a pharmacy-driven protocol, which later included a low molecular weight, anti-Xa level directed-dose adjustment strategy." | 1.72 | Outcomes of Prophylactic Enoxaparin Against Venous Thromboembolism in Hospitalized Children. ( Bennett, E; Delgado-Corcoran, C; Faustino, EV; Heyrend, C; Pannucci, CJ; Wilcox, R, 2022) |
| "Apixaban is a direct factor Xa inhibitor that may be intended as an ideal alternative for the management of HIT." | 1.72 | An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022) |
| " Standard trauma prophylaxis dosing with enoxaparin 30 mg twice daily may be inadequate to prevent VTEs." | 1.72 | Impact of Increased Enoxaparin Dosing on Anti-Xa Levels for Venous Thromboembolism Prophylaxis in Trauma Patients. ( Bellfi, LT; Boudreau, R; Greiffenstein, P; Hunt, JP; Marr, A; Mosier, W; Rueb, N; Schoen, J; Smith, A; Stuke, L; Zimmerman, SA, 2022) |
| "Risk of bleeding was assessed with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) scale, and risk of major bleeding in patients with NSTEMI was additionally assessed with the CRUSADE scale." | 1.72 | Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM. ( Boytsov, SA; Erlikh, AD; Gulyan, RG; Pevsner, DV; Shakhnovich, RM; Tereschenko, SN, 2022) |
| " There is no guideline regarding enoxaparin bridging in LVAD patients and a dosing strategy to ensure efficacy and safety is uncertain." | 1.72 | Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution. ( Alvarez, PA; Bernard, AM; Bream-Rouwenhorst, HR; Briasoulis, A; Czerniak, LC; Horner, KE, 2022) |
| "Central venous catheter (CVC) related venous thrombosis (VT) after pediatric cardiac surgery increases morbidity and mortality." | 1.72 | Enoxaparin Reduces Catheter-associated Venous Thrombosis After Infant Cardiac Surgery. ( Alfieris, GM; Cholette, JM; Hutchinson, DJ; Stauber, SD; Swartz, MF; Taillie, ER, 2022) |
| " The only registered antidote for ENX, protamine sulfate (PS), has 60% efficacy and can cause severe adverse side effects." | 1.62 | Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice. ( Kalaska, B; Miklosz, J; Mogielnicki, A; Pawlak, D; Swieton, J; Szczubialka, K; Yusa, SI, 2021) |
| " Enoxaparin dosing and corresponding anti-factor Xa levels were collected." | 1.62 | Evaluation of the Efficacy of Enoxaparin in the Neonatal Intensive Care Unit. ( Abdel-Rasoul, M; Magers, J; Prusakov, P; Song, D, 2021) |
| " Enoxaparin dosing was nearly double the recommended starting doses for secondary thromboprophylaxis." | 1.62 | Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort. ( Dobbie, LJ; Eskell, L; Lamb, A; Ramage, IJ; Reynolds, BC, 2021) |
| "Major bleeding was defined by INTERMACS criteria." | 1.62 | Comparison of Outcomes of Enoxaparin Bridge Therapy in HeartMate II versus HeartWare HVAD Recipients. ( Ahuja, T; Arnouk, S; Gidea, C; Lewis, TC; Moazami, N; Papadopoulos, J; Patel, M; Reyentovich, A; Smith, DE, 2021) |
| "The use of initial weight-based enoxaparin dosing in trauma patients routinely achieved the prespecified target anti-Xa goal." | 1.62 | Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients. ( Huang, E; Martinez-Quinones, P; Robinson, T; Taylor, A; Waller, J; White, C, 2021) |
| "Patients with oesophageal cancer undergoing neoadjuvant chemoradiotherapy and surgery are at substantial risk of thromboembolic and bleeding events throughout all stages of treatment." | 1.56 | Thromboembolic and bleeding complications in patients with oesophageal cancer. ( Büller, HR; Hovenkamp, A; Hulshof, MCCM; Kamphuisen, PW; Middeldorp, S; Mulder, FI; van Berge Henegouwen, MI; van Es, N; van Laarhoven, HWM, 2020) |
| " Various prophylaxis dosing strategies have been investigated." | 1.56 | Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients. ( Barber, A; Chen, SL; Jones, E; Mason, SW; Moll, S; Northam, K, 2020) |
| " Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-dose clopidogrel, or single-dose enoxaparin, consistent with clinically relevant dose regimens, was safe and well tolerated with no serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, bleeding-related TEAEs, and no significant changes in coagulation parameters." | 1.56 | Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. ( Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020) |
| " Given the favourable safety profile of NOACs (especially if a reduced dosage of Apixaban or Rivaroxaban is initiated after at least six months of therapeutic anticoagulation), extended oral anticoagulation of indefinite duration should be considered for all patients with intermediate risk of recurrence." | 1.56 | [Antithrombotic Treatment of Pulmonary Embolism]. ( Ebner, M; Lankeit, M, 2020) |
| "In patients with renal failure, enoxaparin 20 mg SC daily resulted in a 5." | 1.51 | Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment. ( Chamoun, N; Karaoui, LR; Salameh, P; Tawil, S, 2019) |
| "Geographic region, patient age, gender, deep vein thrombosis prophylaxis strategy, and complications were obtained." | 1.51 | Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. ( Gottschalk, MB; Pour, AE; Roberson, JR; Runner, RP; Staley, CA, 2019) |
| "Current treatment dose of enoxaparin is based on total body weight (TBW), however dosage in obesity remains unclear." | 1.51 | Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity. ( Barras, M; van Oosterom, N; Winckel, K, 2019) |
| " One patient required a switch to fondaparinux due to an adverse reaction." | 1.51 | Safety and Efficacy of Tinzaparin Anticoagulation during Nocturnal Hemodialysis. ( Akbari, A; Brown, PA; Bugeja, A; Harris, S; Krepelka, T; Liberty, C; McCormick, B; St-Cyr, G, 2019) |
| "The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)." | 1.48 | Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018) |
| " The risk of under dosing seems less predictable; therefore, anti-Xa assay may be useful in severe clinical situations that require higher anticoagulant activity." | 1.48 | Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure? ( Corrà, L; Di Francesco, V; Facchinetti, R; Fantin, F; Fontana, G; Pellizzari, L; Sepe, A; Zamboni, M, 2018) |
| "Adults with active cancer and an acute VTE were included." | 1.48 | Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients. ( Anselmo, L; Borrego, ME; Burnett, A; Fuller, K; Jakeman, B; Malecki, S, 2018) |
| "Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE)." | 1.48 | Anticoagulation prescribing patterns in patients with cancer. ( Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E, 2018) |
| "Dabigatran etexilate is an oral anticoagulant recognized as noninferior to LMWH." | 1.48 | Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada. ( Banica, A; Benoit, B; Delisle, J; Fernandes, JC; Laflamme, GY; Malo, M; Nguyen, H; Ranger, P; Senay, A; Trottier, M, 2018) |
| "Standard low-molecular-weight heparin dosing may be suboptimal for venous thromboembolism prophylaxis." | 1.48 | Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin. ( Clark, AT; Cripps, MW; Cunningham, HB; Eastman, AL; Huang, E; Imran, JB; Kacir, CD; Koshy, JP; Madni, TD; Minshall, CT; Rizk, P; Taveras, LR, 2018) |
| "Funded studies reported less pulmonary embolisms, fewer events of major bleeding, and significantly less 90-day mortality compared with nonfunded studies." | 1.48 | Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. ( Azboy, I; Groff, H; Parvizi, J, 2018) |
| ": Lupus anticoagulant hypoprothrombinemia syndrome (LAHS) is a rare disorder characterized by development of lupus anticoagulant and antiprothrombin antibodies." | 1.48 | Fatal pulmonary embolism and pulmonary hemorrhage in lupus anticoagulant hypoprothrombinemia syndrome: a case report and review of literature. ( Chen, X; Cunningham, MT; Nedved, D; Plapp, FV, 2018) |
| "Dalteparin is a safe and effective anticoagulant when used for paediatric home HD." | 1.48 | Dalteparin anticoagulation in paediatric home haemodialysis. ( Hothi, DK; Lutkin, M; Stronach, L; Yadav, P, 2018) |
| "In the Hokusai VTE Cancer study, 1050 patients with cancer and acute VTE were randomized to oral edoxaban or subcutaneous dalteparin for at least 6 months and up to 12 months." | 1.48 | [Treatment of cancer-associated venous thromboembolism]. ( Di Nisio, M, 2018) |
| " Once-daily dosing was associated with a lower bleeding risk as compared with twice-daily." | 1.46 | Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis. ( Biedermann, JS; Cannegieter, SC; Kruip, MJHA; Lijfering, WM; Reitsma, PH; van der Meer, FJM; van Rein, N; Vermaas, HW; Wiersma, N, 2017) |
| "The rate of VTE recurrences was similar in both subgroups." | 1.46 | Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. ( Bascuñana, J; Bergmann, JF; Bortoluzzi, C; Ferrazzi, P; Giorgi-Pierfranceschi, M; López-Reyes, R; López-Sáez, JB; Monreal, M; Suriñach, JM; Trujillo-Santos, J, 2017) |
| " The changes in anti-factor Xa activity due to plasmapheresis altered the final enoxaparin dosage required to remain in the therapeutic range of 0." | 1.46 | Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient. ( Higgins, KL; Noda, C; Rahawi, KW; Stultz, JS, 2017) |
| "In 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented the following guidelines in this setting: administer full dose enoxaparin for a platelet count > 50,000/mcL, half-dose enoxaparin for a platelet count of 25,000-50,000/mcL, and hold anticoagulation for a platelet count < 25,000/mcL." | 1.46 | Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. ( Mantha, S; Miao, Y; Parameswaran, R; Soff, GA; Wills, J, 2017) |
| "Adherence to FDA-approved dosing for the direct oral anticoagulants (DOACs) based on renal function, hepatic function, and concomitant medications in a real-world setting has not been evaluated." | 1.46 | Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment. ( Bohm, N; Duckett, A; Fisher, S; Tran, E, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 1.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "Apixaban is a new oral anticoagulant with the potential to overcome these limitations." | 1.43 | Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis. ( Dickison, DM; King, DA; Pow, RE; Vale, PR, 2016) |
| " Standard FDA-approved enoxaparin dosing in this population results in a high incidence of above-goal anti-Xa levels, but its association with bleeding remains unclear." | 1.43 | Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients. ( Bain, KB; Deal, EN; Hachem, RR; Iuppa, JA; Sofjan, AK; Witt, CA; Yusen, RD, 2016) |
| " The VTE rate when enoxaparin sodium is dosed by anti-factor Xa (anti-Xa) trough level is not well described." | 1.43 | Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. ( Barmparas, G; Chung, K; Dhillon, N; Gewertz, BL; Harada, MY; Ko, A; Ley, EJ; Margulies, DR; Mason, R; Yim, DA, 2016) |
| " The usage of enoxaparin for venous thromboembolism prophylaxis is safe for Japanese patients after gastrectomy." | 1.43 | Safety and Effectiveness of Enoxaparin as Venous Thromboembolism Prophylaxis after Gastric Cancer Surgery in Japanese Patients. ( Kusanagi, H; Yanagita, T, 2016) |
| "Early enoxaparin-based anticoagulation may be a safe option in trauma patients with blunt solid organ injury." | 1.42 | Early thromboembolic prophylaxis in patients with blunt solid abdominal organ injuries undergoing nonoperative management: is it safe? ( Friese, RS; Green, DJ; Gries, L; Harrison, C; Joseph, B; Kulvatunyou, N; Lubin, D; O'Keeffe, T; Pandit, V; Rhee, P; Tang, A; Zangbar, B, 2015) |
| "Active bleeding was documented by contrast enhanced-multidetector row computed tomography (CE-MDCT)." | 1.42 | Role of percutaneous transcatheter embolization (PTE) in the treatment of spontaneous bleeding associated with anticoagulant therapy. ( Carrafiello, G; Floridi, C; Golia, E; Grassi, R; Iadevito, I; Ierardi, AM; Pellegrino, C; Perillo, A; Petrillo, M; Pinto, A; Rotondo, A, 2015) |
| "Ninety-nine morbidly obese patients (body mass index [BMI] higher than 40 kg/m(2) or total body weight more than 150 kg) who received at least three doses of the standard treatment dosage of enoxaparin and had steady-state antifactor Xa peak levels between April 2009 and January 2014." | 1.42 | Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients. ( Ballew, A; Duong, HN; Lee, YR; Vega, JA, 2015) |
| "Intrahepatic bleeding is exceptional and only very few cases have been described." | 1.40 | Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty. ( Bonsignore, A; De Stefano, F; Palmiere, C; Pizzorno, E; Ventura, F, 2014) |
| "Obesity increases the risk for venous thromboembolism (VTE), but whether high-dose thromboprophylaxis is safe and effective in morbidly obese inpatients is unknown." | 1.40 | Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. ( Deal, EN; Gage, BF; Milligan, PE; Thoelke, MS; Wang, TF; Wong, CA, 2014) |
| "Age, critical illness, and timing of AT3 had no effect on time to therapeutic anti-Xa levels." | 1.40 | Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis. ( Corder, A; Held, K; Oschman, A, 2014) |
| "Dalteparin 5000 U/day was used in both groups." | 1.40 | The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment. ( Dzieciuchowicz, L; Krasińska, B; Krasiński, Z; Pawlaczyk, K; Staniszewski, R; Szpurek, D; Urbanek, T; Wójcicka, K, 2014) |
| "Venous thromboembolism and subsequent pulmonary embolism are frequent and sometimes fatal complications in patients after surgical interventions." | 1.39 | [Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study]. ( Guschmann, M; Kaiser, J; Rübenacker, S, 2013) |
| " In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens." | 1.39 | Use of enoxaparin in end-stage renal disease. ( Coppola, B; Lai, S, 2013) |
| "Enoxaparin dosing for patients with morbid obesity is uncertain, and therefore, an elevated incidence of bleeding may exist in this group." | 1.39 | Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese. ( Deal, EN; Hagopian, JC; Hollands, JM; Riney, JN, 2013) |
| " The aim of this retrospective study was to measure the therapeutic response to standard dosing with LMWH (using anti-Xa) in patients after ablative and reconstructive surgery for head and neck cancer, and to review the associated risk of bleeding." | 1.39 | Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications. ( Eley, KA; Parker, RJ; Watt-Smith, SR, 2013) |
| "As major bleeding has modifiable risk factors and is associated with in-hospital mortality, strategies to mitigate these factors should be evaluated in critically ill patients." | 1.39 | Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. ( Albert, M; Arnold, DM; Ashley, BJ; Cook, D; Crowther, M; Dodek, P; Finfer, S; Fowler, R; Heels-Ansdell, D; Karachi, T; Khwaja, K; Lauzier, F; Lopes, RD; McIntyre, L; Nates, JL; Ostermann, M; Rabbat, C; Skrobik, Y; Zarychanski, R; Zytaruk, N, 2013) |
| "However, bleeding was more prominent in the fondaparinux group compared with the enoxaparin group at an equipotent dose for anti-Xa activity." | 1.38 | Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. ( Aihara, K; Iba, T; Kayhanian, H; Ohike, T; Okamoto, K; Tajirika, T; Watanabe, S, 2012) |
| "Among patients with cancer-related VTE, 59." | 1.38 | Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. ( Blostein, M; Faucher, JP; Gamble, G; Game, M; Gordon, W; Kagoma, PK; Kahn, SR; Komari, N; Laverdière, D; Martineau, J; McLeod, A; Mills, A; Miron, MJ; Schulman, S; Springmann, V; Stewart, JA; Strulovitch, C, 2012) |
| " Inappropriate dosing of LMWH suggested by subtherapeutic and supratherapeutic antifactor Xa levels were very high in patients with different levels of kidney dysfunction." | 1.38 | Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5? ( Altun, B; Arici, M; Buyukasik, Y; Erdem, Y; Kocak, T; Yildirim, T; Yilmaz, R, 2012) |
| " The aim of this prospective study was to determine the lowest single bolus dose of low-molecular-weight heparin nadroparin for safe and effective HD in patients with a bleeding risk." | 1.37 | The individually optimized bolus dose of nadroparin is safe and effective in diabetic and nondiabetic patients with bleeding risk on hemodialysis. ( Jelicic, I; Kovacic, V; Ljutic, D; Radic, J; Sain, M, 2011) |
| "In short-term (up to 2 weeks) treatment, bleeding and VTE were more frequent than in long-term treatment." | 1.37 | Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation. ( Kienitz, C; Lang, A; Rollnik, JD; Wetzel, P, 2011) |
| "Primary end point was amount of valve thrombus at 30 days." | 1.37 | Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. ( Abel, S; Camp, CL; Ereth, MH; McKellar, SH; Schaff, HV; Suri, RM, 2011) |
| " Few standards exist for delineating the optimal dosing strategy for VTE prevention in obese patients, especially in the setting of major surgery or trauma." | 1.37 | Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. ( Barton, RG; Kimball, EJ; Ludwig, KP; Mone, M; Simons, HJ, 2011) |
| " Enoxaparin was dosed as 1 mg/kg regardless of body weight without maximum." | 1.36 | Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. ( Antman, EM; Aylward, PE; Becker, RC; Califf, RM; Col, JJ; Ducas, J; Ferguson, JJ; Gallo, R; Goodman, SG; Langer, A; Levine, GN; Mahaffey, KW; Spinler, SA; Tonev, ST; White, HD, 2010) |
| "Hospitalized cancer patients are at an increased risk for venous thromboembolism (VTE) and it is recommended they receive pharmacologic prophylaxis unless otherwise contraindicated." | 1.36 | Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population. ( Liu, CY; Reeves, D, 2010) |
| "A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial." | 1.36 | Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. ( Feng, Y; Leil, TA; Mohan, P; Paccaly, A; Pfister, M; Zhang, L, 2010) |
| "In patients receiving oral anticoagulant therapy with a target INR of 2,0-3,0 and at an intermediate risk of thromboembolic events who require interruption of oral anticoagulant therapy a half therapeutic dose of enoxaparin seems to be safe and effective for bridging." | 1.36 | Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy. ( Essers, E; Gottstein, S; Klamroth, R; Landgraf, H, 2010) |
| "Dalteparin was used as a reference compound." | 1.36 | Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. ( Elg, M; Johansson, K; Kjaer, M; Pehrsson, S, 2010) |
| " They analyzed rates of documented symptomatic venous thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) confirmed by objective methods, major bleeding, death, thrombocytopenia, and other adverse events." | 1.35 | Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice. ( Fontcuberta, J; Gómez-Outes, A; Martínez-González, J; Otero-Fernández, R; Rocha, E, 2008) |
| "Despite a lack of clear recommendations to guide decision-making, reductions in enoxaparin sodium dosage in the elderly and in patients with mild and moderate renal dysfunction are common in patients with acute coronary syndrome." | 1.35 | Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study. ( Beckerman, P; Ben-Artzi, M; Ben-Yehuda, A; Haber, G; Levin, A; Muszkat, M; Varon, D, 2009) |
| "The fibrinogen level was maintained at significantly better levels, and the elevation of alanine aminotransferase was significantly suppressed in enoxaparin group (P < 0." | 1.35 | Enoxaparin attenuates endothelial damage with less bleeding compared with unfractionated heparin in endotoxemic rats. ( Iba, T; Takayama, T, 2009) |
| " Therefore, we believe that intravenous enoxaparin is a safe alternative to unfractionated heparin in both settings." | 1.35 | Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention. ( Cheong, BY; Díez, JG; Ferguson, JJ; Medina, HM; O'Meallie, L, 2009) |
| "To evaluate how enoxaparin is dosed in contemporary clinical practice as a function of patients' total body weight (TBW) and body mass index (BMI), and to determine any association between dose and major bleeding." | 1.35 | Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. ( Alexander, KP; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT; Spinler, SA, 2009) |
| " While patients with renal impairment have a higher risk of bleeding and dosing of heparins is more difficult, there are no specific recommendations for bridging the latter patients." | 1.35 | Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures. ( Hammerstingl, C; Omran, H, 2009) |
| "But dabigatran was associated with surgical wound seepage in 7% of patients, versus 4." | 1.35 | Dabigatran: new drug. Continue to use heparin, a better-known option. ( , 2009) |
| "Major bleedings were reported as secondary endpoints in only two hospitalized patients." | 1.35 | [Prophylaxis of deep vein thrombosis with enoxaparin 40 mg in outpatients compared to hospitalized medically ill patients]. ( Kröger, K, 2009) |
| "Important CKD disagreements occur in approximately 20% of acute coronary syndrome patients, affecting dosing adjustments in those already susceptible to bleeding." | 1.35 | Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. ( Alexander, KP; Chen, AY; Gibler, WB; Harrington, RA; Melloni, C; Newby, LK; Ohman, EM; Peterson, ED; Roe, MT; Spinler, SA; Szczech, LA, 2008) |
| "Oral rivaroxaban (BAY 597939) is a new, highly selective and potent direct factor-Xa (FXa) inhibitor with a predictable pharmacodynamic and pharmacokinetic profile and could therefore be an attractive antithrombotic drug." | 1.34 | Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. ( Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E, 2007) |
| " However, further studies are needed to validate the dose-response relationship and further support the clinical utility of factor VIIa in this life-threatening situation." | 1.34 | Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. ( Al Askar, A; Al Shimemeri, A; Arabi, Y; Cherfan, A, 2007) |
| " In 35 patients (34%) with renal impairment (creatinine clearance <50 ml/min), LMWH dosage was halved." | 1.34 | Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. ( Hammerstingl, C; Omran, H; Schmidt, H; Tripp, C; von der Recke, G, 2007) |
| " The extent to which bleeding risk is attributable to excess dosing of enoxaparin is unclear." | 1.34 | Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. ( Alexander, KP; Chen, AY; Gibler, BW; LaPointe, NM; Lytle, BL; Ohman, ME; Peterson, ED; Pollack, CV; Roe, MT, 2007) |
| " An initial dosage of 1." | 1.34 | Enoxaparin use in the neonatal intensive care unit: experience over 8 years. ( Chan, AK; Knoppert, DC; Lee, DS; Malowany, JI; Pepelassis, D, 2007) |
| "Discontinuing LMWH more than 12 hours before delivery is safe in relation to maternal hemorrhagic complications." | 1.33 | The safety of low molecular weight heparin therapy during labor. ( Kupferminc, MJ; Landsberg, JA; Lessing, JB; Many, A; Maslovitz, S; Varon, D, 2005) |
| "Hemorrhage was documented in a total of 94 patients (17." | 1.33 | Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice. ( Elis, A; Ellis, MH; Hadari, R; Kovlenko, I; Kozmiakova, M; Shapira, S; Tchuvrero, N; Zissin, R, 2006) |
| "12 patients (2,6%) had pulmonary embolism and 8 of them (1,7%) had died." | 1.32 | [Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)]. ( Akar, U; Büyükkurt, CD; Dural, CA; Güloğlu, R; Kurtoğlu, M, 2003) |
| "To describe dosing practices and to identify risk factors for bleeding in patients with an acute coronary syndrome (ACS) who received treatment with enoxaparin." | 1.32 | Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. ( Douketis, JD; Forbes, L; Foster, GA; Macie, C, 2004) |
| "Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight heparin (LMWH) seems as safe and effective as inpatient treatment with unfractionated heparin (UFH)." | 1.31 | Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. ( Ferrer, R; Grau, E; Medrano, J; Pastor, E; Real, E; Selfa, S; Tenias, JM, 2001) |
| "Home treatment of deep vein thrombosis (DVT) has been shown to be safe and effective." | 1.31 | Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients. ( Beyer, J; Schellong, SM; Schmidt, B; Schröder, HE; Schwarz, T, 2001) |
| " Prospective studies need to be conducted to define the drug's role and dosage adjustments in these patients." | 1.31 | Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. ( Barnes, JF; Gerlach, AT; Pickworth, KK; Seth, SK; Tanna, SB, 2000) |
| "Major bleeding was defined as a postoperative drop of > or = 5 g/dL) of hemoglobin." | 1.31 | Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. ( Abdullah, H; Camblin, J; Fareed, J; Hakki, SI; Hamadeh, O; Hoppensteadt, DA; Nasseri, AF; Wright, T, 2000) |
| "The observed recurrence rate of 0." | 1.31 | Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study. ( Bonet, M; Büller, H; Fraile, M; Lensing, AW; Monreal, M; Muchart, J; Roncales, J, 2002) |
| "Three patients (0." | 1.30 | The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. ( Geerts, WH; Gent, M; Ginsberg, JS; Hirsh, J; Leclerc, JR, 1998) |
| " LMWH allows for consistent dosing in postoperative patients without the need for laboratory monitoring." | 1.30 | Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty. ( Houde, JP; Steinberg, G, 1999) |
| " This agent also showed sustained activity and better bioavailability characteristics than heparin." | 1.29 | Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). ( Ahsan, A; Fareed, J; Hoppensteadt, D; Jeske, W; Lojewski, B; Walenga, JM, 1993) |
| "During all low-dose treatments, marked thrombus formation occurred in the extracorporeal circuit, and in 2, the circuit clotted within the study period." | 1.29 | Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. ( Davison, AM; Douglas, JT; Jeffrey, RF; Khan, AA; Will, EJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 63 (8.36) | 18.2507 |
| 2000's | 285 (37.80) | 29.6817 |
| 2010's | 301 (39.92) | 24.3611 |
| 2020's | 105 (13.93) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, M | 1 |
| Bao, Y | 1 |
| Jiang, C | 1 |
| Chen, L | 1 |
| Xu, L | 2 |
| Liu, X | 1 |
| Li, J | 2 |
| Yang, Y | 1 |
| Jiang, G | 1 |
| She, Y | 1 |
| Chen, Q | 1 |
| Shen, L | 1 |
| Chen, C | 2 |
| Mast, L | 1 |
| Peeters, MYM | 1 |
| Söhne, M | 2 |
| Hackeng, CM | 1 |
| Knibbe, CAJ | 1 |
| van den Broek, MPH | 1 |
| Mulder, FI | 2 |
| Hovenkamp, A | 1 |
| van Laarhoven, HWM | 1 |
| Büller, HR | 29 |
| Kamphuisen, PW | 5 |
| Hulshof, MCCM | 1 |
| van Berge Henegouwen, MI | 1 |
| Middeldorp, S | 7 |
| van Es, N | 5 |
| Atamanova, EA | 1 |
| Andryukhin, MI | 1 |
| Vasilenko, IA | 1 |
| Makarov, OV | 1 |
| van Rein, N | 1 |
| Biedermann, JS | 1 |
| van der Meer, FJM | 1 |
| Cannegieter, SC | 1 |
| Wiersma, N | 1 |
| Vermaas, HW | 1 |
| Reitsma, PH | 1 |
| Kruip, MJHA | 1 |
| Lijfering, WM | 1 |
| Ventura, F | 1 |
| Bonsignore, A | 1 |
| De Stefano, F | 1 |
| Pizzorno, E | 1 |
| Palmiere, C | 1 |
| Duzhyĭ, ID | 1 |
| Kravets', OV | 1 |
| Hres'ko, IIa | 1 |
| Iurchenko, AV | 1 |
| Dluha, J | 1 |
| Sivak, S | 1 |
| Kurca, E | 1 |
| Dusenka, R | 1 |
| Kalmarova, K | 1 |
| Turcanova Koprusakova, M | 1 |
| Kantorova, E | 1 |
| Nosal, V | 1 |
| Righini, M | 2 |
| Galanaud, JP | 1 |
| Guenneguez, H | 1 |
| Brisot, D | 2 |
| Diard, A | 1 |
| Faisse, P | 1 |
| Barrellier, MT | 1 |
| Hamel-Desnos, C | 1 |
| Jurus, C | 1 |
| Pichot, O | 1 |
| Martin, M | 1 |
| Mazzolai, L | 1 |
| Choquenet, C | 1 |
| Accassat, S | 1 |
| Robert-Ebadi, H | 1 |
| Carrier, M | 10 |
| Le Gal, G | 2 |
| Mermilllod, B | 1 |
| Laroche, JP | 1 |
| Bounameaux, H | 4 |
| Perrier, A | 2 |
| Kahn, SR | 4 |
| Quere, I | 1 |
| Ofosu, FA | 1 |
| Kistler, U | 1 |
| Kramers-de Quervain, I | 1 |
| Munzinger, U | 1 |
| Kucher, N | 1 |
| Oudemans-van Straaten, HM | 1 |
| Bosman, RJ | 1 |
| Koopmans, M | 1 |
| van der Voort, PH | 3 |
| Wester, JP | 1 |
| van der Spoel, JI | 1 |
| Dijksman, LM | 1 |
| Zandstra, DF | 1 |
| Camporese, G | 3 |
| Bernardi, E | 1 |
| Noventa, F | 1 |
| Sain, M | 1 |
| Ljutic, D | 1 |
| Kovacic, V | 1 |
| Radic, J | 1 |
| Jelicic, I | 1 |
| van Doormaal, FF | 2 |
| Di Nisio, M | 8 |
| Otten, HM | 3 |
| Richel, DJ | 2 |
| Prins, M | 2 |
| Zondag, W | 1 |
| Mos, IC | 1 |
| Creemers-Schild, D | 1 |
| Hoogerbrugge, AD | 1 |
| Dekkers, OM | 1 |
| Dolsma, J | 1 |
| Eijsvogel, M | 1 |
| Faber, LM | 1 |
| Hofstee, HM | 1 |
| Hovens, MM | 1 |
| Jonkers, GJ | 1 |
| van Kralingen, KW | 1 |
| Kruip, MJ | 1 |
| Vlasveld, T | 1 |
| de Vreede, MJ | 1 |
| Huisman, MV | 10 |
| Zhang, W | 1 |
| Chen, X | 3 |
| Chen, Y | 3 |
| Chen, N | 1 |
| Bassand, JP | 9 |
| Berthe, C | 1 |
| Bethencourt, A | 1 |
| Bolognese, L | 1 |
| Wójcik, J | 1 |
| Gerlach, R | 1 |
| Raabe, A | 1 |
| Beck, J | 1 |
| Woszczyk, A | 1 |
| Seifert, V | 1 |
| Klerk, CP | 1 |
| Smorenburg, SM | 1 |
| Lensing, AW | 10 |
| Prins, MH | 14 |
| Piovella, F | 6 |
| Prandoni, P | 6 |
| Bos, MM | 1 |
| van Tienhoven, G | 1 |
| Postma, SR | 2 |
| Kingma, WP | 2 |
| Boerma, EC | 2 |
| Van Roon, EN | 1 |
| Biemond, BJ | 1 |
| Perzborn, E | 1 |
| Friederich, PW | 1 |
| Levi, M | 2 |
| Buetehorn, U | 1 |
| Wong, KS | 2 |
| Ng, PW | 1 |
| Tsoi, TH | 1 |
| Li, HL | 1 |
| Fong, WC | 1 |
| Yeung, J | 1 |
| Wong, CK | 2 |
| Yip, KK | 1 |
| Gao, H | 1 |
| Wong, HB | 1 |
| de Heide, LJ | 1 |
| Bakker, AJ | 1 |
| Forette, B | 1 |
| Wolmark, Y | 1 |
| Peyrou, V | 1 |
| Lormeau, JC | 1 |
| Caranobe, C | 1 |
| Gabaig, AM | 1 |
| Crepon, B | 1 |
| Saivin, S | 1 |
| Houin, G | 1 |
| Sié, P | 2 |
| Boneu, B | 3 |
| Pistorius, MA | 1 |
| Said, L | 1 |
| Planchon, B | 1 |
| Koopman, MM | 2 |
| Ockelford, PA | 1 |
| Brandjes, DP | 1 |
| van der Meer, J | 2 |
| Gallus, AS | 11 |
| Simonneau, G | 3 |
| Chesterman, CH | 1 |
| Cyrkowicz, A | 1 |
| Rytwińska, E | 1 |
| Nytko, J | 1 |
| Słowińska-Zabówka, M | 1 |
| Nurmohamed, MT | 1 |
| van Riel, AM | 1 |
| Henkens, CM | 1 |
| Que, GT | 1 |
| d'Azemar, P | 2 |
| ten Cate, JW | 1 |
| Hoek, JA | 2 |
| van der Heul, C | 1 |
| Turpie, AG | 26 |
| Haley, S | 2 |
| Sicurella, A | 1 |
| Gent, M | 14 |
| Hirsh, J | 7 |
| Lablanche, JM | 2 |
| McFadden, EP | 1 |
| Meneveau, N | 2 |
| Lusson, JR | 1 |
| Bertrand, B | 1 |
| Metzger, JP | 1 |
| Legrand, V | 1 |
| Grollier, G | 1 |
| Macaya, C | 3 |
| de Bruyne, B | 1 |
| Vahanian, A | 2 |
| Grentzinger, A | 1 |
| Masquet, C | 1 |
| Wolf, JE | 1 |
| Tobelem, G | 1 |
| Fontecave, S | 1 |
| Vacheron, A | 1 |
| Bertrand, ME | 5 |
| Martineau, P | 1 |
| Tawil, N | 1 |
| Martyin, T | 1 |
| Jakucs, J | 1 |
| Iványi, J | 1 |
| Kis, E | 1 |
| Varga, I | 1 |
| Mellár, E | 1 |
| Tam, WH | 1 |
| Yuen, PM | 1 |
| Leung, TN | 1 |
| Li, CY | 1 |
| Zed, PJ | 1 |
| Tisdale, JE | 1 |
| Borzak, S | 3 |
| Belcaro, G | 1 |
| Nicolaides, AN | 1 |
| Cesarone, MR | 1 |
| Laurora, G | 1 |
| De Sanctis, MT | 1 |
| Incandela, L | 1 |
| Barsotti, A | 1 |
| Corsi, M | 1 |
| Vasdekis, S | 1 |
| Christopoulos, D | 1 |
| Lennox, A | 1 |
| Malouf, M | 1 |
| Breddin, HK | 3 |
| Fong, YK | 1 |
| Ruban, P | 1 |
| Yeo, SJ | 1 |
| Lee, BP | 1 |
| Lo, NN | 1 |
| Seow, KH | 1 |
| Ng, SC | 1 |
| López-Beret , P | 1 |
| Orgaz, A | 1 |
| Fontcuberta, J | 2 |
| Doblas, M | 1 |
| Martinez, A | 1 |
| Lozano, G | 1 |
| Romero, A | 1 |
| Grau, E | 1 |
| Tenias, JM | 1 |
| Real, E | 1 |
| Medrano, J | 1 |
| Ferrer, R | 1 |
| Pastor, E | 1 |
| Selfa, S | 1 |
| Vernon, SM | 1 |
| Couturaud, F | 3 |
| Julian, JA | 2 |
| Kearon, C | 2 |
| Schwarz, T | 1 |
| Schmidt, B | 1 |
| Beyer, J | 1 |
| Schröder, HE | 1 |
| Schellong, SM | 8 |
| Bugamelli, S | 1 |
| Zangheri, E | 1 |
| Montebugnoli, M | 1 |
| Guerra, L | 1 |
| Ageno, W | 6 |
| Cattaneo, R | 1 |
| Manfredi, E | 1 |
| Chelazzi, P | 1 |
| Venco, L | 1 |
| Ghirarduzzi, A | 2 |
| Cimino, L | 1 |
| Filippucci, E | 1 |
| Ricci, AL | 1 |
| Romanelli, D | 1 |
| Incorvaia, C | 1 |
| D'Angelo, S | 1 |
| Campana, F | 1 |
| Molfino, F | 1 |
| Scannapieco, G | 1 |
| Rubbi, F | 1 |
| Imberti, D | 3 |
| Cosmi, B | 2 |
| Filippini, M | 1 |
| Tonti, D | 1 |
| Avruscio, G | 1 |
| Bucherini, E | 1 |
| Palareti, G | 2 |
| Wang, XK | 1 |
| Zhang, Y | 2 |
| Yang, CM | 1 |
| Wang, Y | 1 |
| Liu, GY | 1 |
| Galeano-Valle, F | 1 |
| Pérez-Rus, G | 1 |
| Demelo-Rodríguez, P | 1 |
| Ordieres-Ortega, L | 1 |
| Ortega-Morán, L | 1 |
| Muñoz-Martín, AJ | 1 |
| Medina-Molina, S | 1 |
| Alvarez-Sala-Walther, LA | 1 |
| Del-Toro-Cervera, J | 1 |
| Lecumberri, R | 1 |
| López Vivanco, G | 1 |
| Font, A | 1 |
| González Billalabeitia, E | 1 |
| Gúrpide, A | 1 |
| Gómez Codina, J | 1 |
| Isla, D | 1 |
| Galán, A | 1 |
| Bover, I | 1 |
| Domine, M | 1 |
| Vicente, V | 1 |
| Rosell, R | 1 |
| Rocha, E | 3 |
| Rodríguez-Mañas, L | 1 |
| Gómez-Huelgas, R | 1 |
| Veiga-Fernández, F | 1 |
| Ruiz, GM | 1 |
| González, JM | 1 |
| Del Peso, G | 1 |
| Bajo, MA | 1 |
| Fontán, MP | 1 |
| Martínez, J | 1 |
| Marrón, B | 1 |
| Selgas, R | 1 |
| Navarro-Quilis, A | 1 |
| Castellet, E | 1 |
| Paz-Jiménez, J | 1 |
| Planès, A | 5 |
| Otero-Fernández, R | 1 |
| Gómez-Outes, A | 2 |
| Martínez-González, J | 1 |
| Oldham, M | 1 |
| Palkimas, S | 1 |
| Hedrick, A | 1 |
| Gates, RS | 1 |
| Lollar, DI | 1 |
| Collier, BR | 1 |
| Smith, J | 1 |
| Faulks, ER | 1 |
| Gillen, JR | 1 |
| May, CC | 1 |
| Cua, S | 1 |
| Smetana, KS | 1 |
| Powers, CJ | 1 |
| Swieton, J | 1 |
| Miklosz, J | 1 |
| Yusa, SI | 1 |
| Szczubialka, K | 1 |
| Pawlak, D | 1 |
| Mogielnicki, A | 1 |
| Kalaska, B | 1 |
| Raskob, GE | 21 |
| Spyropoulos, AC | 11 |
| Spiro, TE | 12 |
| Lu, W | 3 |
| Yuan, Z | 2 |
| Levitan, B | 2 |
| Suh, E | 2 |
| Barnathan, ES | 3 |
| Morici, N | 1 |
| Podda, G | 1 |
| Birocchi, S | 1 |
| Bonacchini, L | 1 |
| Merli, M | 1 |
| Trezzi, M | 1 |
| Massaini, G | 1 |
| Agostinis, M | 1 |
| Carioti, G | 1 |
| Saverio Serino, F | 1 |
| Gazzaniga, G | 1 |
| Barberis, D | 1 |
| Antolini, L | 1 |
| Grazia Valsecchi, M | 1 |
| Cattaneo, M | 1 |
| Di Micco, P | 2 |
| Imbalzano, E | 1 |
| Russo, V | 2 |
| Attena, E | 1 |
| Mandaliti, V | 1 |
| Orlando, L | 1 |
| Lombardi, M | 1 |
| Di Micco, G | 1 |
| Annunziata, S | 1 |
| Piccinocchi, G | 1 |
| Pacelli, W | 1 |
| Del Guercio, M | 1 |
| Baumann Kreuziger, L | 1 |
| Feng, M | 1 |
| Bartosic, A | 1 |
| Simpson, P | 2 |
| Wang, TF | 6 |
| Bistervels, IM | 1 |
| Bavalia, R | 1 |
| Gebel, M | 3 |
| Lensing, AWA | 1 |
| Coppens, M | 2 |
| Sabry, S | 1 |
| El Wakeel, LM | 1 |
| Saleh, A | 1 |
| Ahmed, MA | 1 |
| Bouget, J | 1 |
| Balusson, F | 1 |
| Kerbrat, S | 1 |
| Roy, PM | 3 |
| Viglino, D | 1 |
| Lacut, K | 1 |
| Pavageau, L | 1 |
| Oger, E | 1 |
| Cohen, AT | 22 |
| Weitz, JI | 16 |
| Lipardi, C | 2 |
| Albers, GW | 1 |
| Elliott, CG | 2 |
| Halperin, JL | 1 |
| Hiatt, WR | 1 |
| Maynard, G | 1 |
| Steg, PG | 6 |
| Sugarmann, C | 1 |
| Kumar, D | 1 |
| Kaimaparambil, V | 1 |
| Chandralekha, S | 1 |
| Lalchandani, J | 1 |
| Sochet, AA | 1 |
| Morrison, JM | 1 |
| Jaffray, J | 1 |
| Godiwala, N | 1 |
| Wilson, HP | 1 |
| Thornburg, CD | 1 |
| Bhat, RV | 1 |
| Zia, A | 1 |
| Lawrence, C | 1 |
| Kudchadkar, SR | 1 |
| Hamblin, F | 2 |
| Russell, CJ | 1 |
| Streiff, MB | 2 |
| Amankwah, EK | 1 |
| Goldenberg, NA | 3 |
| Bennett, E | 1 |
| Delgado-Corcoran, C | 1 |
| Pannucci, CJ | 2 |
| Wilcox, R | 1 |
| Heyrend, C | 1 |
| Faustino, EV | 1 |
| Ebeid, A | 1 |
| Cole, E | 1 |
| Stallwood-Hall, C | 1 |
| Farasatinasab, M | 1 |
| Balouchzehi, S | 1 |
| Moghaddam, OM | 1 |
| Ansarinejad, N | 1 |
| Mohammadi, M | 1 |
| Nasiripour, S | 1 |
| Cools, F | 1 |
| Virdone, S | 1 |
| Sawhney, J | 1 |
| Lopes, RD | 8 |
| Jacobson, B | 2 |
| Arcelus, JI | 1 |
| Hobbs, FDR | 1 |
| Gibbs, H | 2 |
| Himmelreich, JCL | 1 |
| MacCallum, P | 1 |
| Schellong, S | 5 |
| Haas, S | 11 |
| Turpie, AGG | 2 |
| Rocha, AT | 2 |
| Kayani, G | 1 |
| Pieper, K | 1 |
| Kakkar, AK | 11 |
| Stitzel, HJ | 1 |
| Hue, JJ | 1 |
| Elshami, M | 1 |
| McCaulley, L | 1 |
| Hoehn, RS | 1 |
| Rothermel, LD | 1 |
| Ammori, JB | 1 |
| Hardacre, JM | 1 |
| Winter, JM | 1 |
| Ocuin, LM | 1 |
| Abatzis-Papadopoulos, M | 1 |
| Tigkiropoulos, K | 1 |
| Nikas, S | 1 |
| Papoutsis, I | 1 |
| Kostopoulou, O | 1 |
| Stavridis, K | 1 |
| Karamanos, D | 1 |
| Lazaridis, I | 1 |
| Saratzis, N | 1 |
| Bellfi, LT | 1 |
| Zimmerman, SA | 1 |
| Boudreau, R | 1 |
| Mosier, W | 1 |
| Smith, A | 1 |
| Rueb, N | 1 |
| Hunt, JP | 1 |
| Stuke, L | 1 |
| Greiffenstein, P | 1 |
| Schoen, J | 1 |
| Marr, A | 1 |
| Scheuermann, A | 1 |
| Liegl, M | 1 |
| Branchford, B | 1 |
| Malec, L | 1 |
| Kandula, V | 1 |
| Shah, PV | 1 |
| Thirunavu, VM | 1 |
| Yerneni, K | 1 |
| Karras, C | 1 |
| Abecassis, ZA | 1 |
| Hopkins, B | 1 |
| Bloch, O | 1 |
| Potts, MB | 1 |
| Jahromi, BS | 1 |
| Tate, MC | 1 |
| Boytsov, SA | 3 |
| Shakhnovich, RM | 3 |
| Tereschenko, SN | 3 |
| Erlikh, AD | 3 |
| Pevsner, DV | 3 |
| Gulyan, RG | 3 |
| Albisinni, R | 2 |
| Vitrone, M | 2 |
| Ursi, MP | 2 |
| Spiezia, S | 2 |
| Salemme, A | 2 |
| Florio, LL | 2 |
| Boccia, F | 2 |
| Iossa, D | 2 |
| Zampino, R | 2 |
| Atripaldi, L | 2 |
| Squillante, F | 2 |
| Maturo, N | 2 |
| Fraganza, F | 2 |
| Severino, S | 2 |
| Punzi, R | 2 |
| Fiorentino, G | 2 |
| Verhoeff, K | 2 |
| Connell, M | 2 |
| Shapiro, AJ | 2 |
| Strickland, M | 2 |
| Bigam, DL | 2 |
| Anantha, RV | 2 |
| Wee, B | 2 |
| Lui, B | 2 |
| Lai, J | 2 |
| Khattak, Z | 2 |
| Kwok, A | 2 |
| Donarelli, C | 2 |
| Ho, P | 2 |
| Lim, HY | 2 |
| Elmi, G | 1 |
| Allegri, D | 1 |
| Aluigi, L | 1 |
| Antignani, PL | 1 |
| Aspide, R | 1 |
| Camaggi, V | 1 |
| DI Giulio, R | 1 |
| Domanico, A | 1 |
| Rinaldi, ER | 1 |
| Martignani, A | 1 |
| Zhou, S | 2 |
| Xiao, Y | 2 |
| Zhou, C | 1 |
| Zheng, Z | 1 |
| Jiang, W | 1 |
| Shen, Q | 1 |
| Zhu, C | 1 |
| Pan, H | 1 |
| Liu, C | 1 |
| Zeng, G | 1 |
| Ge, L | 1 |
| Ouyang, Z | 1 |
| Fu, G | 1 |
| Pan, G | 1 |
| Chen, F | 1 |
| Huang, L | 1 |
| Liu, Q | 2 |
| Milling, TJ | 2 |
| Koch, B | 1 |
| Demchuk, A | 1 |
| Eikelboom, JW | 10 |
| Verhamme, P | 13 |
| Beyer-Westendorf, J | 5 |
| Gibson, CM | 10 |
| Lopez-Sendon, J | 2 |
| Crowther, M | 6 |
| Shoamanesh, A | 1 |
| Schmidt, J | 2 |
| Albaladejo, P | 3 |
| Connolly, SJ | 2 |
| Piple, AS | 1 |
| Wang, JC | 1 |
| Kang, HP | 1 |
| Mills, ES | 1 |
| Mayfield, CK | 1 |
| Lieberman, JR | 2 |
| Christ, AB | 1 |
| Heckmann, ND | 1 |
| Spénard, E | 1 |
| Geerts, W | 3 |
| Lin, Y | 1 |
| Gien, LT | 1 |
| Kupets, R | 1 |
| Covens, A | 1 |
| Vicus, D | 1 |
| Chang, CK | 1 |
| Higgins, RM | 1 |
| Rein, L | 1 |
| Peppard, WJ | 1 |
| Herrmann, DJ | 1 |
| Kindel, T | 1 |
| Durila, M | 1 |
| Berousek, J | 1 |
| Vlasakova, V | 1 |
| Vymazal, T | 1 |
| Weerasaksanti, A | 1 |
| Siwamogsatham, S | 1 |
| Kunlamas, Y | 1 |
| Bunditanukul, K | 1 |
| Grubic, N | 1 |
| Canney, M | 1 |
| Delluc, A | 1 |
| Hundemer, GL | 1 |
| Knoll, G | 1 |
| Lazo-Langner, A | 1 |
| Massicotte-Azarniouch, D | 1 |
| Tanuseputro, P | 1 |
| Sood, MM | 1 |
| Rajput, RV | 1 |
| Sharron, MP | 1 |
| Pavuluri, P | 1 |
| Hansen, H | 1 |
| Ansusinha, E | 1 |
| DeBiasi, R | 1 |
| Majumdar, S | 1 |
| Diab, Y | 1 |
| Alexander, M | 1 |
| Harris, S | 2 |
| Underhill, C | 1 |
| Torres, J | 1 |
| Sharma, S | 1 |
| Lee, N | 1 |
| Wong, H | 1 |
| Eek, R | 1 |
| Michael, M | 1 |
| Tie, J | 1 |
| Rogers, J | 1 |
| Heriot, AG | 1 |
| Ball, D | 1 |
| MacManus, M | 1 |
| Wolfe, R | 1 |
| Solomon, BJ | 1 |
| Burbury, K | 1 |
| Peng, S | 1 |
| Zhang, M | 2 |
| Jin, J | 2 |
| MacCormick, AD | 1 |
| Giannella, M | 1 |
| Fornaro, G | 1 |
| Cristini, F | 1 |
| Patacca, A | 1 |
| Castagna, A | 1 |
| Mazzaferri, F | 1 |
| Testa, S | 1 |
| Pan, A | 1 |
| Lupi, M | 1 |
| Brambilla, P | 1 |
| Montineri, A | 1 |
| Frattima, S | 1 |
| Bignami, EG | 1 |
| Salvetti, M | 1 |
| De Stefano, G | 1 |
| Grandone, E | 1 |
| Di Perri, G | 1 |
| Rozzini, R | 1 |
| Stella, A | 1 |
| Romagnoli, A | 1 |
| Drago, F | 1 |
| Viale, P | 1 |
| Yee, MK | 3 |
| Hernandez, A | 1 |
| Hull, RD | 7 |
| Goldhaber, SZ | 13 |
| Lobo, Y | 1 |
| Robertson, I | 1 |
| Stewart, A | 1 |
| Rowe, C | 1 |
| Song, D | 1 |
| Magers, J | 1 |
| Abdel-Rasoul, M | 1 |
| Prusakov, P | 1 |
| Rambiritch, V | 1 |
| Paek, D | 1 |
| Sayre, T | 1 |
| Naidoo, P | 1 |
| Shan, J | 1 |
| Leisegang, R | 1 |
| Gersch, K | 1 |
| Spencer, TR | 1 |
| Torres-Navarro, I | 1 |
| de Unamuno-Bustos, B | 1 |
| Pujol-Marco, C | 1 |
| Mason, SW | 1 |
| Barber, A | 1 |
| Jones, E | 1 |
| Chen, SL | 1 |
| Moll, S | 1 |
| Northam, K | 1 |
| Roy, SF | 1 |
| Watson, P | 1 |
| Bouffard, D | 1 |
| Bauersachs, R | 15 |
| Becker, B | 1 |
| Berkowitz, SD | 8 |
| Freitas, MCS | 1 |
| Lassen, MR | 16 |
| Metzig, C | 1 |
| De Sanctis, Y | 3 |
| Xu, J | 1 |
| Argenti, D | 1 |
| Yang, H | 1 |
| Albanese, J | 1 |
| Limsakun, T | 1 |
| Dishy, V | 1 |
| Mendell, J | 1 |
| Pizzagalli, F | 1 |
| Pav, J | 1 |
| Kochan, J | 1 |
| Vandell, AG | 1 |
| Rambaran, C | 1 |
| Kobayashi, F | 1 |
| Orihashi, Y | 1 |
| Warren, V | 1 |
| McPhillips, P | 1 |
| Zhou, J | 1 |
| Samama, CM | 2 |
| Laporte, S | 4 |
| Rosencher, N | 9 |
| Girard, P | 4 |
| Llau, J | 1 |
| Mouret, P | 5 |
| Fisher, W | 5 |
| Martínez-Martín, J | 1 |
| Duverger, D | 1 |
| Deygas, B | 1 |
| Presles, E | 1 |
| Cucherat, M | 1 |
| Mismetti, P | 5 |
| Kubicek, P | 1 |
| Boughalem, E | 1 |
| Frere, C | 1 |
| Kamachi, H | 1 |
| Homma, S | 1 |
| Kawamura, H | 1 |
| Yoshida, T | 1 |
| Ohno, Y | 1 |
| Ichikawa, N | 1 |
| Yokota, R | 1 |
| Funakoshi, T | 1 |
| Maeda, Y | 1 |
| Takahashi, N | 1 |
| Amano, T | 1 |
| Taketomi, A | 1 |
| Haac, BE | 1 |
| O'Hara, NN | 1 |
| Manson, TT | 1 |
| Slobogean, GP | 1 |
| Castillo, RC | 1 |
| O'Toole, RV | 1 |
| Stein, DM | 1 |
| Chen, PF | 1 |
| Yi, JL | 1 |
| Pei, JY | 1 |
| Tang, L | 2 |
| Fang, ZF | 1 |
| Zhou, SH | 1 |
| Hu, XQ | 1 |
| Hu, X | 1 |
| Fang, Z | 1 |
| Cattelan, AM | 1 |
| Carrozzi, L | 1 |
| Leone, L | 1 |
| Filippi, L | 1 |
| De Gaudenzi, E | 1 |
| Villalta, S | 1 |
| Pesavento, R | 1 |
| Cardillo, G | 1 |
| Viggiano, GV | 1 |
| Mangiacapra, S | 1 |
| Cavalli, A | 1 |
| Fontanella, A | 2 |
| Agrusta, F | 1 |
| Bellizzi, A | 1 |
| Amitrano, M | 1 |
| Iannuzzo, M | 1 |
| Sacco, C | 1 |
| Lodigiani, C | 1 |
| Oh, TH | 1 |
| Jung, H | 1 |
| Lee, Y | 1 |
| Dobbie, LJ | 1 |
| Lamb, A | 1 |
| Eskell, L | 1 |
| Ramage, IJ | 1 |
| Reynolds, BC | 1 |
| Mokadem, ME | 1 |
| Hassan, A | 1 |
| Algaby, AZ | 1 |
| Morais, QCD | 1 |
| Santos, MS | 1 |
| Veeranki, SP | 1 |
| Xiao, Z | 1 |
| Levorsen, A | 1 |
| Sinha, M | 1 |
| Shah, BR | 1 |
| Feng, W | 1 |
| Wang, X | 1 |
| Huang, D | 1 |
| Lu, A | 1 |
| Rentsch, CT | 1 |
| Beckman, JA | 2 |
| Tomlinson, L | 1 |
| Gellad, WF | 1 |
| Alcorn, C | 1 |
| Kidwai-Khan, F | 1 |
| Skanderson, M | 1 |
| Brittain, E | 1 |
| King, JT | 1 |
| Ho, YL | 1 |
| Eden, S | 1 |
| Kundu, S | 1 |
| Lann, MF | 1 |
| Greevy, RA | 1 |
| Ho, PM | 2 |
| Heidenreich, PA | 1 |
| Jacobson, DA | 1 |
| Douglas, IJ | 1 |
| Tate, JP | 1 |
| Evans, SJW | 1 |
| Atkins, D | 1 |
| Justice, AC | 1 |
| Freiberg, MS | 1 |
| Snoga, JL | 1 |
| Benitez, RM | 1 |
| Kim, S | 1 |
| Creager, O | 1 |
| Lusk, KA | 1 |
| Stillson, JE | 1 |
| Bunch, CM | 1 |
| Gillespie, L | 1 |
| Khan, R | 1 |
| Wierman, M | 1 |
| Pulvirenti, J | 1 |
| Phyu, H | 1 |
| Anderson, S | 1 |
| Al-Fadhl, M | 1 |
| Thomas, AV | 1 |
| Kwaan, HC | 2 |
| Moore, E | 1 |
| Moore, H | 1 |
| Walsh, MM | 1 |
| Lv, Y | 1 |
| Bai, W | 1 |
| Li, K | 1 |
| Wang, Z | 3 |
| Guo, W | 1 |
| Luo, B | 1 |
| Wang, J | 1 |
| Wang, Q | 2 |
| Wang, E | 1 |
| Xia, D | 1 |
| Li, X | 1 |
| Yuan, J | 1 |
| Han, N | 1 |
| Niu, J | 1 |
| Yin, Z | 1 |
| Fan, D | 1 |
| Han, G | 1 |
| DeBiase, C | 1 |
| Giuliano, CA | 1 |
| Doshi, M | 1 |
| Ganoff, M | 1 |
| Alexander Paxton, R | 1 |
| Bernard, AM | 1 |
| Alvarez, PA | 1 |
| Bream-Rouwenhorst, HR | 1 |
| Horner, KE | 1 |
| Briasoulis, A | 1 |
| Czerniak, LC | 1 |
| Sadeghipour, P | 4 |
| Talasaz, AH | 2 |
| Rashidi, F | 2 |
| Sharif-Kashani, B | 2 |
| Beigmohammadi, MT | 2 |
| Farrokhpour, M | 2 |
| Sezavar, SH | 2 |
| Payandemehr, P | 2 |
| Dabbagh, A | 2 |
| Moghadam, KG | 2 |
| Jamalkhani, S | 2 |
| Khalili, H | 2 |
| Yadollahzadeh, M | 2 |
| Riahi, T | 2 |
| Rezaeifar, P | 2 |
| Tahamtan, O | 2 |
| Matin, S | 2 |
| Abedini, A | 2 |
| Lookzadeh, S | 2 |
| Rahmani, H | 2 |
| Zoghi, E | 2 |
| Mohammadi, K | 2 |
| Abri, H | 2 |
| Tabrizi, S | 2 |
| Mousavian, SM | 2 |
| Shahmirzaei, S | 2 |
| Bakhshandeh, H | 2 |
| Amin, A | 2 |
| Rafiee, F | 2 |
| Baghizadeh, E | 2 |
| Mohebbi, B | 2 |
| Parhizgar, SE | 2 |
| Aliannejad, R | 2 |
| Eslami, V | 2 |
| Kashefizadeh, A | 2 |
| Kakavand, H | 2 |
| Hosseini, SH | 2 |
| Shafaghi, S | 2 |
| Ghazi, SF | 2 |
| Najafi, A | 2 |
| Jimenez, D | 2 |
| Gupta, A | 2 |
| Madhavan, MV | 2 |
| Sethi, SS | 2 |
| Parikh, SA | 2 |
| Monreal, M | 9 |
| Hadavand, N | 2 |
| Hajighasemi, A | 2 |
| Maleki, M | 2 |
| Sadeghian, S | 2 |
| Piazza, G | 2 |
| Kirtane, AJ | 2 |
| Van Tassell, BW | 2 |
| Dobesh, PP | 2 |
| Stone, GW | 6 |
| Lip, GYH | 2 |
| Krumholz, HM | 2 |
| Bikdeli, B | 2 |
| Patel, M | 1 |
| Ahuja, T | 2 |
| Arnouk, S | 1 |
| Gidea, C | 1 |
| Reyentovich, A | 1 |
| Smith, DE | 1 |
| Moazami, N | 1 |
| Papadopoulos, J | 2 |
| Lewis, TC | 1 |
| Taylor, A | 1 |
| Huang, E | 2 |
| Waller, J | 1 |
| White, C | 1 |
| Martinez-Quinones, P | 1 |
| Robinson, T | 1 |
| de Barros E Silva, PGM | 2 |
| Furtado, RHM | 2 |
| Macedo, AVS | 2 |
| Ramacciotti, E | 7 |
| Damini, LP | 1 |
| Bronhara, B | 2 |
| Cavalcanti, AB | 2 |
| Rosa, RG | 2 |
| Azevedo, LCP | 2 |
| Veiga, VC | 2 |
| Machado, FR | 2 |
| Ritt, LE | 1 |
| Martins, PA | 1 |
| Alexander, JH | 3 |
| Avezum, A | 4 |
| Berwanger, O | 3 |
| Rodríguez-Villa Lario, A | 1 |
| Piteiro-Bermejo, AB | 1 |
| Bèa-Ardébol, S | 1 |
| Swartz, MF | 1 |
| Hutchinson, DJ | 1 |
| Stauber, SD | 1 |
| Taillie, ER | 1 |
| Alfieris, GM | 1 |
| Cholette, JM | 1 |
| Damiani, LP | 1 |
| Barbosa, LM | 1 |
| de Aveiro Morata, J | 1 |
| de Aquino Martins, P | 1 |
| de Oliveira, AL | 1 |
| Nunes, VS | 1 |
| Ritt, LEF | 1 |
| Tramujas, L | 1 |
| Santos, SV | 1 |
| Diaz, DRA | 1 |
| Viana, LS | 1 |
| Melro, LMG | 1 |
| de Alcântara Chaud, MS | 1 |
| Figueiredo, EL | 1 |
| Neuenschwander, FC | 1 |
| Dracoulakis, MDA | 1 |
| Lima, RGSD | 1 |
| de Souza Dantas, VC | 1 |
| Fernandes, ACS | 1 |
| Gebara, OCE | 1 |
| Hernandes, ME | 1 |
| Queiroz, DAR | 1 |
| Canesin, MF | 1 |
| de Faria, LM | 1 |
| Feitosa-Filho, GS | 1 |
| Gazzana, MB | 1 |
| Liporace, IL | 1 |
| de Oliveira Twardowsky, A | 1 |
| Maia, LN | 1 |
| de Matos Soeiro, A | 1 |
| Conceição-Souza, GE | 1 |
| Armaganijan, L | 1 |
| Guimarães, PO | 1 |
| Ortiz, RM | 1 |
| Golijanin, B | 1 |
| O'Rourke, TK | 1 |
| Sobel, DW | 1 |
| Pillsbury, L | 1 |
| T Tucci, C | 1 |
| Caffery, P | 1 |
| Golijanin, D | 1 |
| Yi, BA | 1 |
| Segers, A | 9 |
| Salter, J | 1 |
| Bloomfield, D | 1 |
| Houghton, DE | 2 |
| Vlazny, DT | 2 |
| Casanegra, AI | 2 |
| Brunton, N | 1 |
| Froehling, DA | 2 |
| Meverden, RA | 1 |
| Hodge, DO | 2 |
| Peterson, LG | 2 |
| McBane, RD | 4 |
| Wysokinski, WE | 4 |
| Boyd, RA | 1 |
| DiCarlo, L | 1 |
| Mandema, JW | 1 |
| Shavadia, J | 1 |
| Welsh, R | 1 |
| Gershlick, A | 1 |
| Zheng, Y | 1 |
| Huber, K | 3 |
| Halvorsen, S | 1 |
| Van de Werf, F | 5 |
| Armstrong, PW | 5 |
| Tang, Y | 1 |
| Wang, K | 1 |
| Shi, Z | 1 |
| Yang, P | 1 |
| Dang, X | 1 |
| Cafri, G | 1 |
| Paxton, EW | 1 |
| Cheetham, CT | 1 |
| Gould, MK | 1 |
| Sluggett, J | 1 |
| Bini, SA | 1 |
| Khatod, M | 1 |
| Kohn, CG | 1 |
| Fermann, GJ | 1 |
| Peacock, WF | 1 |
| Wells, PS | 3 |
| Baugh, CW | 1 |
| Ashton, V | 1 |
| Crivera, C | 1 |
| Schein, JR | 1 |
| Wildgoose, P | 1 |
| Coleman, CI | 1 |
| Korjian, S | 2 |
| Chi, G | 3 |
| Daaboul, Y | 2 |
| Jain, P | 1 |
| Arbetter, D | 1 |
| Hull, R | 5 |
| Hernandez, AF | 3 |
| Gold, A | 4 |
| Harrington, RA | 12 |
| Alzghari, SK | 1 |
| Seago, SE | 1 |
| Garza, JE | 1 |
| Hashimie, YF | 1 |
| Baty, KA | 1 |
| Evans, MF | 1 |
| Shaver, C | 1 |
| Herrington, JD | 1 |
| Cimminiello, C | 2 |
| Agnelli, G | 19 |
| Di Minno, G | 1 |
| Polo Friz, H | 1 |
| Scaglione, F | 1 |
| Boracchi, P | 1 |
| Marano, G | 1 |
| Harenberg, J | 10 |
| Kittelson, JM | 1 |
| Curnutte, JT | 2 |
| De la Torre Hernández, JM | 1 |
| Sadaba Sagredo, M | 1 |
| Telleria Arrieta, M | 1 |
| Gimeno de Carlos, F | 1 |
| Sanchez Lacuesta, E | 1 |
| Bullones Ramírez, JA | 1 |
| Pineda Rocamora, J | 1 |
| Martin Yuste, V | 1 |
| Garcia Camarero, T | 1 |
| Larman, M | 1 |
| Rumoroso, JR | 1 |
| Pellizzari, L | 1 |
| Facchinetti, R | 1 |
| Corrà, L | 1 |
| Sepe, A | 1 |
| Fantin, F | 1 |
| Fontana, G | 1 |
| Zamboni, M | 1 |
| Di Francesco, V | 1 |
| Nam, KW | 1 |
| Kim, CK | 1 |
| Kim, TJ | 1 |
| An, SJ | 1 |
| Oh, K | 1 |
| Ko, SB | 1 |
| Yoon, BW | 1 |
| Fuller, K | 1 |
| Malecki, S | 1 |
| Anselmo, L | 1 |
| Borrego, ME | 1 |
| Jakeman, B | 1 |
| Burnett, A | 1 |
| Xiang, E | 1 |
| Raco, V | 1 |
| Cirrone, F | 1 |
| Green, D | 1 |
| Hamilton, CE | 1 |
| King, BA | 1 |
| Cowper, SE | 1 |
| Hochster, H | 1 |
| Leventhal, JS | 1 |
| Ek, L | 1 |
| Gezelius, E | 1 |
| Bergman, B | 1 |
| Bendahl, PO | 1 |
| Anderson, H | 1 |
| Sundberg, J | 1 |
| Wallberg, M | 1 |
| Falkmer, U | 1 |
| Verma, S | 1 |
| Belting, M | 1 |
| Signorelli, JR | 1 |
| Gandhi, AS | 1 |
| Mahan, CE | 1 |
| Burnett, AE | 1 |
| Fletcher, ML | 1 |
| Khan, NR | 1 |
| Patel, PG | 1 |
| Sharpe, JP | 1 |
| Lee, SL | 1 |
| Sorenson, J | 1 |
| Nicklaus, MD | 1 |
| Ludwig, SL | 1 |
| Kettle, JK | 1 |
| Yang, LS | 1 |
| Alukaidey, S | 1 |
| Croucher, K | 1 |
| Dowling, D | 1 |
| Peetermans, M | 1 |
| Liesenborghs, L | 1 |
| Peerlinck, K | 1 |
| Wijngaerden, EV | 1 |
| Gheysens, O | 1 |
| Goffin, KE | 1 |
| Hoylaerts, MF | 1 |
| Jacquemin, M | 1 |
| Verhaegen, J | 1 |
| Peetermans, WE | 1 |
| Vanassche, T | 1 |
| Cohoon, KP | 1 |
| Haskell, L | 4 |
| Gill-Schuster, D | 1 |
| Bergold, M | 1 |
| Holzer, L | 1 |
| Senay, A | 1 |
| Trottier, M | 1 |
| Delisle, J | 1 |
| Banica, A | 1 |
| Benoit, B | 1 |
| Laflamme, GY | 1 |
| Malo, M | 1 |
| Nguyen, H | 1 |
| Ranger, P | 1 |
| Fernandes, JC | 1 |
| Bourget-Murray, J | 1 |
| Clarke, MA | 1 |
| Gorzitza, S | 1 |
| Phillips, LA | 1 |
| Imran, JB | 1 |
| Madni, TD | 1 |
| Clark, AT | 1 |
| Rizk, P | 1 |
| Minshall, CT | 1 |
| Taveras, LR | 1 |
| Cunningham, HB | 1 |
| Eastman, AL | 1 |
| Koshy, JP | 1 |
| Kacir, CD | 1 |
| Cripps, MW | 1 |
| Groff, H | 1 |
| Azboy, I | 1 |
| Parvizi, J | 1 |
| Karaoui, LR | 1 |
| Tawil, S | 1 |
| Salameh, P | 1 |
| Chamoun, N | 2 |
| Levin, G | 1 |
| Badrieh, A | 1 |
| Attari, R | 1 |
| Sabag, L | 1 |
| Safrai, M | 1 |
| Rottenstreich, A | 1 |
| Nafee, T | 1 |
| Alkhalfan, F | 1 |
| Travis, R | 1 |
| Mir, M | 1 |
| Kalayci, A | 1 |
| Jafarizade, M | 1 |
| Ganti, A | 1 |
| Kazmi, SH | 1 |
| Ghaffarpasand, E | 1 |
| Pitliya, A | 1 |
| Datta, S | 1 |
| Sharfaei, S | 1 |
| Alihashemi, M | 1 |
| Elsaiey, A | 1 |
| Qamar, I | 1 |
| Jahansouz, M | 1 |
| Talib, U | 1 |
| Kahe, F | 1 |
| Habibi, S | 1 |
| Abdelwahed, M | 1 |
| Tariq, F | 1 |
| Kaur, M | 1 |
| Younes, A | 1 |
| Walia, SS | 1 |
| Singh, A | 1 |
| Dildar, SM | 1 |
| Afzal, MK | 1 |
| Kerneis, M | 2 |
| Nedved, D | 1 |
| Plapp, FV | 1 |
| Cunningham, MT | 1 |
| Yu, Z | 1 |
| Shan, P | 1 |
| Yang, X | 1 |
| Lou, XJ | 1 |
| Runner, RP | 1 |
| Gottschalk, MB | 1 |
| Staley, CA | 1 |
| Pour, AE | 1 |
| Roberson, JR | 1 |
| Sun, G | 2 |
| Wu, J | 1 |
| Liang, Q | 1 |
| Jia, J | 1 |
| Cheng, K | 1 |
| Miller, KM | 1 |
| Brenner, MJ | 1 |
| Amos, LE | 1 |
| Silvey, M | 1 |
| Hall, M | 1 |
| Witmer, CM | 1 |
| Carpenter, SL | 1 |
| Yoo, HH | 1 |
| Nunes-Nogueira, VS | 1 |
| Fortes Villas Boas, PJ | 1 |
| Broderick, C | 1 |
| van Oosterom, N | 1 |
| Winckel, K | 1 |
| Barras, M | 1 |
| Ghanem, H | 1 |
| Hachem, A | 1 |
| Hariri, E | 1 |
| Lteif, C | 1 |
| Mansour, H | 1 |
| Dimassi, H | 1 |
| Zalloum, R | 1 |
| Ghanem, G | 1 |
| Tanaka, Y | 1 |
| Yamada, A | 1 |
| Hirata, S | 1 |
| Tanaka, H | 1 |
| Sakuratani, T | 1 |
| Matsuhashi, N | 1 |
| Yamaguchi, K | 1 |
| Shimokawa, T | 1 |
| Yoshida, K | 1 |
| Stepien, K | 1 |
| Nowak, K | 1 |
| Zalewski, J | 1 |
| Pac, A | 1 |
| Undas, A | 1 |
| Wilsey, HA | 1 |
| Pandya, K | 1 |
| Beavers, C | 1 |
| Xiaoshu, L | 1 |
| Ather, A | 1 |
| Bott-Kitslaar, DM | 1 |
| Rübenacker, S | 1 |
| Kaiser, J | 1 |
| Guschmann, M | 1 |
| Sindali, K | 1 |
| Rose, B | 1 |
| Soueid, H | 1 |
| Jeer, P | 1 |
| Saran, D | 1 |
| Shrivastava, R | 1 |
| Lu, G | 2 |
| DeGuzman, FR | 1 |
| Hollenbach, SJ | 1 |
| Karbarz, MJ | 1 |
| Abe, K | 1 |
| Lee, G | 1 |
| Luan, P | 1 |
| Hutchaleelaha, A | 1 |
| Inagaki, M | 1 |
| Conley, PB | 2 |
| Phillips, DR | 1 |
| Sinha, U | 2 |
| Zeidan, AM | 1 |
| Lau, BD | 1 |
| Ahmed, SR | 1 |
| Kraus, PS | 1 |
| Hobson, DB | 1 |
| Carolan, H | 1 |
| Lambrianidi, C | 1 |
| Horn, PB | 1 |
| Shermock, KM | 1 |
| Tinoco, G | 1 |
| Siddiqui, S | 1 |
| Haut, ER | 2 |
| Alameddine, R | 1 |
| Husari, A | 1 |
| Derksen, RJ | 1 |
| Mulder, WM | 1 |
| Mulder, JW | 1 |
| Vink, R | 1 |
| Peña, ZG | 1 |
| Suszko, JW | 1 |
| Morrison, LH | 1 |
| Chan, KE | 1 |
| Thadhani, RI | 1 |
| Maddux, FW | 1 |
| Brodmann, M | 1 |
| Dorr, A | 1 |
| Hafner, F | 1 |
| Gary, T | 1 |
| Froehlich, H | 1 |
| Kvas, E | 1 |
| Deutschmann, H | 1 |
| Pilger, E | 1 |
| Cohen, A | 7 |
| Curto, M | 2 |
| Johnson, M | 1 |
| Masiukiewicz, U | 1 |
| Pak, R | 2 |
| Thompson, J | 1 |
| Vavalle, JP | 1 |
| Clare, R | 1 |
| Chiswell, K | 2 |
| Rao, SV | 2 |
| Petersen, JL | 4 |
| Kleiman, NS | 6 |
| Mahaffey, KW | 12 |
| Wang, TY | 1 |
| Lucania, G | 1 |
| Camiolo, E | 1 |
| Carmina, MG | 1 |
| Fiandaca, T | 1 |
| Indovina, A | 1 |
| Malato, A | 1 |
| Messina, R | 1 |
| Fabbiano, F | 1 |
| Marcenò, R | 1 |
| Lai, S | 1 |
| Coppola, B | 1 |
| Décousus, H | 8 |
| Grosso, MA | 4 |
| Mercuri, M | 1 |
| Schwocho, L | 3 |
| Shi, M | 3 |
| Wells, P | 4 |
| Yusen, RD | 4 |
| Tapson, VF | 4 |
| Samama, MM | 4 |
| Chen, M | 1 |
| Deslandes, B | 1 |
| Pelzer, U | 1 |
| Sinn, M | 1 |
| Stieler, J | 1 |
| Riess, H | 7 |
| Ginsberg, JS | 3 |
| Chan, N | 1 |
| Guyatt, G | 3 |
| Milligan, PE | 1 |
| Wong, CA | 1 |
| Deal, EN | 4 |
| Thoelke, MS | 1 |
| Gage, BF | 2 |
| Eriksson, BI | 16 |
| Renfurm, RW | 1 |
| Kashiwa, M | 1 |
| Kreutz, R | 1 |
| Mantovani, LG | 1 |
| Pattanayak, CW | 1 |
| Holberg, G | 1 |
| Jamal, W | 1 |
| Schmidt, A | 1 |
| van Eickels, M | 1 |
| Hagopian, JC | 1 |
| Riney, JN | 2 |
| Hollands, JM | 2 |
| Corder, A | 1 |
| Held, K | 1 |
| Oschman, A | 1 |
| Desanctis, YH | 1 |
| Homering, M | 5 |
| Hu, D | 3 |
| Mebazaa, A | 3 |
| Merli, G | 5 |
| Burton, P | 1 |
| Loidi Pascual, L | 1 |
| Valcayo Peñalba, A | 1 |
| Yerani Ruiz de Azúa Ciria, A | 1 |
| Yanguas Bayona, I | 1 |
| Hayashi, H | 1 |
| Morikawa, T | 1 |
| Yoshida, H | 1 |
| Motoi, F | 1 |
| Okada, T | 1 |
| Nakagawa, K | 1 |
| Mizuma, M | 1 |
| Naitoh, T | 1 |
| Katayose, Y | 1 |
| Unno, M | 1 |
| Friedman, RJ | 4 |
| Berlin, JA | 1 |
| Weinstein, RB | 1 |
| DiBattiste, PM | 2 |
| Davidson, BL | 11 |
| Verheijen, S | 1 |
| Brighton, TA | 2 |
| Lyons, RM | 1 |
| Rehm, J | 1 |
| Yeung, V | 1 |
| Formal, C | 1 |
| Robinson, S | 2 |
| Zincuk, A | 1 |
| Larsen, UL | 1 |
| Ekstrøm, C | 1 |
| Toft, P | 1 |
| Joseph, B | 1 |
| Pandit, V | 1 |
| Harrison, C | 1 |
| Lubin, D | 1 |
| Kulvatunyou, N | 1 |
| Zangbar, B | 1 |
| Tang, A | 1 |
| O'Keeffe, T | 1 |
| Green, DJ | 1 |
| Gries, L | 1 |
| Friese, RS | 1 |
| Rhee, P | 1 |
| Jinatongthai, P | 1 |
| Khaisombut, N | 1 |
| Likittanasombat, K | 1 |
| Chaiyakunapruk, N | 1 |
| Watcharathanakij, S | 1 |
| Nathisuwan, S | 1 |
| Schellong, SW | 1 |
| Figueiró-Filho, EA | 1 |
| Aydos, RD | 1 |
| Senefonte, FR | 1 |
| Ferreira, CM | 1 |
| Pereira, EF | 1 |
| Oliveira, VM | 1 |
| Menezes, GP | 1 |
| Bósio, MA | 1 |
| Puymirat, E | 1 |
| Schiele, F | 1 |
| Ennezat, PV | 1 |
| Coste, P | 1 |
| Collet, JP | 7 |
| Bonnefoy-Cudraz, E | 1 |
| Roul, G | 1 |
| Richard, P | 1 |
| Simon, T | 1 |
| Danchin, N | 2 |
| Saheb Sharif-Askari, F | 1 |
| Syed Sulaiman, SA | 1 |
| Saheb Sharif-Askari, N | 1 |
| Al Sayed Hussain, A | 1 |
| Railey, MJ | 1 |
| Oliveira, SN | 2 |
| Santos, GR | 1 |
| Glauser, BF | 3 |
| Capillé, NV | 1 |
| Queiroz, IN | 1 |
| Pereira, MS | 3 |
| Pomin, VH | 1 |
| Mourão, PA | 3 |
| Bahl, V | 1 |
| Shuman, AG | 1 |
| Hu, HM | 1 |
| Jackson, CR | 1 |
| Alaniz, C | 1 |
| Chepeha, DB | 1 |
| Bradford, CR | 1 |
| Revigliono, JI | 1 |
| Cornavaca, T | 1 |
| Becerra, F | 1 |
| Albertini, R | 1 |
| Contreras, AE | 1 |
| Tabares, A | 1 |
| Ierardi, AM | 1 |
| Floridi, C | 1 |
| Pellegrino, C | 1 |
| Petrillo, M | 1 |
| Pinto, A | 1 |
| Iadevito, I | 1 |
| Golia, E | 1 |
| Perillo, A | 1 |
| Grassi, R | 1 |
| Rotondo, A | 1 |
| Carrafiello, G | 1 |
| Bethune, C | 1 |
| Bhanot, S | 1 |
| Gailani, D | 2 |
| Monia, BP | 2 |
| Concha-Garzon, M | 1 |
| Sotomayor-Lopez, E | 1 |
| Solano-Lopez, G | 1 |
| Fraga, J | 1 |
| De Argila, D | 1 |
| Patel, AA | 1 |
| Ogden, K | 1 |
| Mody, SH | 1 |
| Bookhart, B | 1 |
| Müller, K | 1 |
| Pap, ÁF | 2 |
| Tewes, MC | 1 |
| Charters, MA | 1 |
| Frisch, NB | 1 |
| Wessell, NM | 1 |
| Dobson, C | 1 |
| Les, CM | 1 |
| Silverton, CD | 1 |
| Ma, G | 1 |
| Zhang, R | 1 |
| Wu, X | 1 |
| Wang, D | 1 |
| Ying, K | 1 |
| Vazquez, FJ | 1 |
| Paulin, P | 1 |
| Rodriguez, P | 1 |
| Lubertino, M | 1 |
| Gándara, E | 1 |
| Aydin, U | 1 |
| Asik, MB | 1 |
| Gokgoz, MC | 1 |
| Karakoc, O | 1 |
| Cui, SB | 1 |
| Shu, RH | 1 |
| Yan, SP | 1 |
| Wu, H | 1 |
| Wang, L | 2 |
| Zhu, Q | 1 |
| Baquero-Salamanca, M | 1 |
| Téllez-Arévalo, AM | 1 |
| Calderon-Ospina, C | 1 |
| Gouveia, AI | 1 |
| Lopes, L | 1 |
| Soares-Almeida, L | 1 |
| Filipe, P | 1 |
| Dang, JD | 1 |
| Davis, LE | 1 |
| Kathmann, W | 1 |
| Gulati, A | 1 |
| Faed, JM | 1 |
| Isbister, GK | 1 |
| Duffull, SB | 3 |
| Ong, WL | 1 |
| Koh, TL | 1 |
| Fletcher, J | 1 |
| Gruen, R | 1 |
| Royce, P | 1 |
| Özler, T | 1 |
| Uluçay, Ç | 1 |
| Önal, A | 1 |
| Altıntaş, F | 1 |
| Kooistra, HA | 1 |
| Sahin, K | 1 |
| Meijer, K | 1 |
| Geisler, T | 1 |
| Droppa, M | 1 |
| Gawaz, M | 1 |
| Steinhubl, SR | 6 |
| Lincoff, AM | 3 |
| Cequier, AR | 2 |
| Desmet, W | 2 |
| Rasmussen, LH | 4 |
| Hoekstra, JW | 1 |
| Bernstein, D | 1 |
| Deliargyris, EN | 1 |
| Mehran, R | 3 |
| Parker, SG | 1 |
| McGlone, ER | 1 |
| Knight, WR | 1 |
| Sufi, P | 1 |
| Khan, OA | 1 |
| Lee, TC | 1 |
| Yamabe, T | 1 |
| Triscott, J | 1 |
| Mercer, S | 1 |
| Tian, PG | 1 |
| Dobbs, B | 1 |
| Rutjes, AW | 2 |
| Lee, YR | 1 |
| Vega, JA | 1 |
| Duong, HN | 1 |
| Ballew, A | 1 |
| Adams, CB | 1 |
| Vollman, KE | 1 |
| Leventhal, EL | 1 |
| Acquisto, NM | 1 |
| Stephenson, ML | 1 |
| Serra, AE | 1 |
| Neeper, JM | 1 |
| Caballero, DC | 1 |
| McNulty, J | 1 |
| Sanders, P | 1 |
| Thompson, JR | 1 |
| Ross Terres, JA | 1 |
| Lozano-Ortega, G | 1 |
| Kendall, R | 1 |
| Sculpher, MJ | 1 |
| Rostagno, C | 1 |
| Mehta, AY | 1 |
| Mohammed, BM | 1 |
| Martin, EJ | 1 |
| Brophy, DF | 2 |
| Desai, UR | 1 |
| Quon, P | 1 |
| Le, HH | 1 |
| Raymond, V | 1 |
| Mtibaa, M | 1 |
| Moshyk, A | 1 |
| Sharfman, ZT | 2 |
| Campbell, JC | 2 |
| Mirocha, JM | 1 |
| Spitzer, AI | 2 |
| Kim, SM | 1 |
| Moon, YW | 1 |
| Lim, SJ | 1 |
| Kim, DW | 1 |
| Park, YS | 1 |
| Campbell, PM | 1 |
| Ippoliti, C | 1 |
| Parmar, S | 1 |
| Liu, Z | 1 |
| Silvain, J | 4 |
| Barthélémy, O | 3 |
| Payot, L | 2 |
| Choussat, R | 5 |
| Sabouret, P | 1 |
| Cohen, M | 19 |
| Pollack, CV | 4 |
| Goldstein, P | 3 |
| Zeymer, U | 6 |
| Vicaut, E | 3 |
| Montalescot, G | 12 |
| Ning, GZ | 1 |
| Kan, SL | 1 |
| Chen, LX | 1 |
| Shangguan, L | 1 |
| Feng, SQ | 1 |
| Zhou, Y | 1 |
| Desai, A | 2 |
| Calixte, R | 1 |
| Aparnath, M | 1 |
| Hindenburg, A | 1 |
| Salzman, S | 1 |
| Mathew, JP | 1 |
| King, DA | 1 |
| Pow, RE | 1 |
| Dickison, DM | 1 |
| Vale, PR | 1 |
| Krueger, K | 1 |
| Schmutz, A | 1 |
| Zieger, B | 1 |
| Kalbhenn, J | 1 |
| Sofjan, AK | 1 |
| Iuppa, JA | 1 |
| Bain, KB | 1 |
| Witt, CA | 1 |
| Hachem, RR | 1 |
| Ko, A | 1 |
| Harada, MY | 1 |
| Barmparas, G | 1 |
| Chung, K | 1 |
| Mason, R | 1 |
| Yim, DA | 1 |
| Dhillon, N | 1 |
| Margulies, DR | 1 |
| Gewertz, BL | 1 |
| Ley, EJ | 1 |
| Bonilla, GA | 1 |
| Gutierrez, C | 1 |
| Bautista, MP | 1 |
| Llinas, AM | 1 |
| Monsalvo, DJ | 1 |
| Bronson, MD | 1 |
| Goodman, S | 3 |
| Leeds, J | 1 |
| Wiens, BL | 1 |
| Siegal, DM | 2 |
| Zotova, E | 1 |
| Meeks, B | 1 |
| Nakamya, J | 1 |
| Lim, WT | 1 |
| Soeiro, AM | 1 |
| Silva, PG | 1 |
| Roque, EA | 1 |
| Bossa, AS | 1 |
| César, MC | 1 |
| Simões, SA | 1 |
| Okada, MY | 1 |
| Leal, TC | 1 |
| Pedroti, FC | 1 |
| Oliveira, MT | 1 |
| Bleker, SM | 2 |
| Sisson, M | 1 |
| Goette, A | 2 |
| Merino, JL | 1 |
| Ezekowitz, MD | 1 |
| Zamoryakhin, D | 1 |
| Melino, M | 1 |
| Mercuri, MF | 4 |
| Fernandez, V | 1 |
| Al-Saady, N | 1 |
| Pelekh, N | 1 |
| Merkely, B | 1 |
| Zenin, S | 1 |
| Kushnir, M | 2 |
| Spinar, J | 1 |
| Batushkin, V | 1 |
| de Groot, JR | 1 |
| Lip, GY | 2 |
| Greig, SL | 1 |
| Garnock-Jones, KP | 1 |
| Venker, BT | 1 |
| Ganti, BR | 1 |
| Lin, H | 1 |
| Lee, ED | 1 |
| Nunley, RM | 1 |
| Samuel, NG | 1 |
| Seifert, CF | 1 |
| Tao, DL | 1 |
| Bien, JY | 1 |
| DeLoughery, TG | 1 |
| Shatzel, JJ | 1 |
| Pignataro, BS | 1 |
| Nishinari, K | 1 |
| Cavalcante, RN | 1 |
| Centofanti, G | 1 |
| Yazbek, G | 1 |
| Krutman, M | 1 |
| Bomfim, GAZ | 1 |
| Fonseca, IYI | 1 |
| Teivelis, MP | 1 |
| Wolosker, N | 1 |
| Sanches, SM | 1 |
| Cieri, NE | 1 |
| Kusmierski, K | 1 |
| Lackie, C | 1 |
| Van Opdorp, A | 1 |
| Hassan, AK | 1 |
| Trujillo-Santos, J | 1 |
| Bergmann, JF | 2 |
| Bortoluzzi, C | 1 |
| López-Reyes, R | 1 |
| Giorgi-Pierfranceschi, M | 1 |
| López-Sáez, JB | 1 |
| Ferrazzi, P | 1 |
| Bascuñana, J | 1 |
| Suriñach, JM | 1 |
| Rahawi, KW | 1 |
| Higgins, KL | 1 |
| Noda, C | 1 |
| Stultz, JS | 1 |
| Xie, J | 1 |
| Ma, J | 1 |
| Huang, Q | 1 |
| Yue, C | 1 |
| Pei, F | 1 |
| Mantha, S | 1 |
| Miao, Y | 1 |
| Wills, J | 1 |
| Parameswaran, R | 1 |
| Soff, GA | 1 |
| Walker, CK | 1 |
| Sandmann, EA | 1 |
| Horyna, TJ | 1 |
| Gales, MA | 1 |
| Yanagita, T | 1 |
| Kusanagi, H | 1 |
| Halaby, R | 1 |
| Arbetter, DF | 1 |
| Lu, SP | 1 |
| Bandman, O | 1 |
| Leeds, JM | 1 |
| Tran, E | 1 |
| Duckett, A | 1 |
| Fisher, S | 1 |
| Bohm, N | 1 |
| Alexander, KP | 6 |
| Marcucci, G | 1 |
| White, HD | 19 |
| Spinler, S | 1 |
| Col, J | 2 |
| Aylward, PE | 9 |
| Califf, RM | 11 |
| Khoobiar, S | 1 |
| Mejevoi, N | 1 |
| Kaid, K | 1 |
| Boiangiu, C | 1 |
| Setty, S | 1 |
| Tanwir, A | 1 |
| Khalid, K | 1 |
| Pride, YB | 1 |
| Col, JJ | 3 |
| Goodman, SG | 8 |
| Gulba, D | 1 |
| Bergovec, M | 1 |
| Kunadian, V | 1 |
| Zorkun, C | 1 |
| Buros, JL | 1 |
| Murphy, SA | 7 |
| Antman, EM | 19 |
| Budaj, A | 8 |
| Mehta, SR | 8 |
| Afzal, R | 7 |
| Chrolavicius, S | 6 |
| Fox, KA | 12 |
| Wallentin, L | 7 |
| Peters, RJ | 3 |
| Granger, CB | 6 |
| Joyner, CD | 3 |
| Yusuf, S | 8 |
| Díez, JG | 2 |
| Fuji, T | 1 |
| Ochi, T | 1 |
| Niwa, S | 1 |
| Fujita, S | 1 |
| Yan, AT | 1 |
| Yan, RT | 1 |
| Huynh, T | 1 |
| DeYoung, P | 1 |
| Weeks, A | 1 |
| Fitchett, DH | 1 |
| Langer, A | 8 |
| Boden, WE | 1 |
| Flather, M | 2 |
| Piegas, LS | 2 |
| Faxon, DP | 1 |
| Widimsky, P | 1 |
| Rupprecht, HJ | 3 |
| Jolly, S | 1 |
| Deitelzweig, SB | 1 |
| Becker, R | 2 |
| Lin, J | 2 |
| Benner, J | 1 |
| Lotke, PA | 3 |
| Tonev, ST | 1 |
| Spinler, SA | 3 |
| Levine, GN | 1 |
| Gallo, R | 6 |
| Ducas, J | 2 |
| Becker, RC | 2 |
| Ferguson, JJ | 11 |
| Al-Sallami, H | 1 |
| Ferguson, R | 1 |
| Wilkins, G | 1 |
| Gray, A | 1 |
| Medlicott, NJ | 1 |
| Bode, C | 3 |
| Steinhubl, S | 1 |
| Heer, T | 3 |
| Juenger, C | 1 |
| Gitt, AK | 1 |
| Bauer, T | 3 |
| Towae, F | 1 |
| Zahn, R | 3 |
| Senges, J | 3 |
| Levin, A | 1 |
| Ben-Artzi, M | 1 |
| Beckerman, P | 1 |
| Haber, G | 1 |
| Varon, D | 2 |
| Ben-Yehuda, A | 1 |
| Muszkat, M | 1 |
| Eikelboom, JE | 1 |
| Bauer, KA | 6 |
| Fisher, WD | 4 |
| Huo, MH | 2 |
| Gretler, DD | 1 |
| Wolowacz, SE | 3 |
| Roskell, NS | 3 |
| Plumb, JM | 3 |
| Caprini, JA | 2 |
| Heidenreich, C | 1 |
| Hohmann, V | 1 |
| Bramlage, P | 6 |
| Hacobian, M | 1 |
| Shetty, R | 1 |
| Niles, CM | 1 |
| Gerhard-Herman, M | 1 |
| Vallurupalli, N | 1 |
| Baroletti, S | 1 |
| McKean, SC | 1 |
| Sonis, J | 1 |
| Parasuraman, S | 1 |
| Kosowsky, JM | 1 |
| Arnaout, L | 1 |
| Chabbouh, T | 1 |
| Bellamy, L | 1 |
| Hammerstingl, C | 6 |
| Omran, H | 6 |
| Tripp, C | 2 |
| Poetzsch, B | 1 |
| Arellano-Rodrigo, E | 2 |
| Gironella, M | 1 |
| Nicolau, I | 3 |
| Vila, M | 1 |
| Hart, RG | 1 |
| Maciver, F | 1 |
| Beard, SM | 1 |
| Robinson, PA | 2 |
| Dolan, G | 2 |
| Brenkel, IJ | 2 |
| Brener, SJ | 2 |
| Bhatt, DL | 2 |
| Franzosi, MG | 1 |
| Leri, F | 1 |
| Voyce, SJ | 1 |
| Scialla, S | 1 |
| Glavich, W | 1 |
| Dzielak, E | 1 |
| Smego, RA | 1 |
| Guzek, J | 1 |
| Gitt, A | 2 |
| Jünger, C | 2 |
| Koeth, O | 2 |
| Iba, T | 2 |
| Takayama, T | 1 |
| Karthikeyan, G | 2 |
| Manoukian, SV | 2 |
| Feit, F | 2 |
| Hoekstra, J | 2 |
| Gersh, BJ | 2 |
| Ohman, EM | 4 |
| Gallus, A | 6 |
| Miesbach, W | 1 |
| Galanakis, D | 1 |
| Scharrer, I | 1 |
| Reeves, D | 1 |
| Liu, CY | 1 |
| Kwong, LM | 3 |
| Cushner, FD | 1 |
| Bandel, TJ | 1 |
| Benson, A | 1 |
| Misselwitz, F | 7 |
| Medina, HM | 1 |
| Cheong, BY | 1 |
| O'Meallie, L | 1 |
| Ou, FS | 1 |
| Roe, MT | 5 |
| Gibler, WB | 2 |
| Peterson, ED | 4 |
| Hamon, M | 3 |
| Cequier, A | 1 |
| Lincoff, MA | 1 |
| Mann, T | 1 |
| Kuczka, K | 1 |
| Baum, K | 1 |
| Picard-Willems, B | 1 |
| Harder, S | 1 |
| Giraldez, RR | 2 |
| Wiviott, SD | 2 |
| Nicolau, JC | 2 |
| Mohanavelu, S | 3 |
| Morrow, DA | 6 |
| Giugliano, RP | 2 |
| Pineo, G | 3 |
| Chen, D | 3 |
| Portman, RJ | 1 |
| Kosar, A | 1 |
| Cipil, HS | 1 |
| Kaya, A | 1 |
| Uz, B | 1 |
| Haznedaroglu, IC | 1 |
| Goker, H | 1 |
| Ozdemir, O | 1 |
| Ercetin, S | 1 |
| Kirazli, S | 1 |
| Firat, HC | 1 |
| Kröger, K | 1 |
| Suárez-Gea, ML | 1 |
| Blázquez-Pérez, A | 1 |
| Pozo-Hernández, C | 1 |
| Vargas-Castrillón, E | 1 |
| Famularo, G | 1 |
| Gasbarrone, L | 1 |
| Minisola, G | 1 |
| De Simone, C | 1 |
| Eikelboom, J | 1 |
| Peters, R | 1 |
| Mehta, S | 1 |
| De, A | 1 |
| Roy, P | 1 |
| Garg, VK | 1 |
| Pandey, NK | 1 |
| Bui, HT | 1 |
| Krisnaswami, A | 1 |
| Le, CU | 1 |
| Chan, J | 1 |
| Shenoy, BN | 1 |
| Dobrev, D | 1 |
| Ravens, U | 1 |
| Schmitz, A | 1 |
| Fimmers, R | 1 |
| Barras, MA | 2 |
| Atherton, JJ | 2 |
| Green, B | 2 |
| Sakon, M | 1 |
| Kobayashi, T | 1 |
| Shimazui, T | 1 |
| Chiariello, M | 2 |
| King, SB | 2 |
| Desmet, WJ | 2 |
| Amin, AN | 2 |
| Johnson, BH | 1 |
| Schulman, KL | 1 |
| Anderson, JA | 1 |
| Johnston, M | 1 |
| Myers, DD | 1 |
| Wrobleski, SK | 1 |
| Deatrick, KB | 1 |
| Londy, FJ | 1 |
| Rectenwald, JE | 1 |
| Henke, PK | 2 |
| Schaub, RG | 1 |
| Wakefield, TW | 1 |
| Tsai, TT | 1 |
| Maddox, TM | 1 |
| Dai, D | 1 |
| Messenger, JC | 1 |
| Nallamothu, BK | 1 |
| Rumsfeld, JS | 1 |
| Rajamanickam, A | 1 |
| Patel, P | 1 |
| Anbazhagan, P | 1 |
| Harte, B | 1 |
| Clemens, A | 2 |
| Noack, H | 1 |
| Raja, Y | 1 |
| Lo, TS | 1 |
| Townend, JN | 1 |
| Motte, S | 1 |
| Claes, N | 1 |
| Verhaeghe, R | 2 |
| Hermans, C | 1 |
| Giugliano, R | 1 |
| McCabe, CH | 4 |
| Braunwald, E | 10 |
| Trkulja, V | 1 |
| Kolundzic, R | 1 |
| Dahl, OE | 12 |
| Kurth, AA | 4 |
| Francis, CW | 5 |
| Hantel, S | 4 |
| Schnee, JM | 2 |
| Sinnaeve, P | 1 |
| Liang, J | 1 |
| Brant, R | 1 |
| Lang, A | 1 |
| Kienitz, C | 1 |
| Wetzel, P | 1 |
| Rollnik, JD | 1 |
| Brieger, D | 1 |
| Landivier, A | 1 |
| Beygui, F | 4 |
| Bellemain-Appaix, A | 1 |
| Mercadier, A | 1 |
| Vignolles, N | 3 |
| Costagliola, D | 1 |
| Quinlan, DJ | 2 |
| Bergqvist, D | 2 |
| Nicol, P | 1 |
| Leil, TA | 1 |
| Feng, Y | 1 |
| Zhang, L | 1 |
| Paccaly, A | 1 |
| Mohan, P | 1 |
| Pfister, M | 1 |
| Aïssaoui, N | 1 |
| Kurtoglu, M | 4 |
| Koksoy, C | 1 |
| Hasan, E | 1 |
| Akcalı, Y | 1 |
| Karabay, O | 1 |
| Filizcan, U | 1 |
| Klamroth, R | 1 |
| Gottstein, S | 1 |
| Essers, E | 1 |
| Landgraf, H | 2 |
| Tsiatis, AA | 1 |
| Davidian, M | 1 |
| Pieper, KS | 3 |
| Zhang, H | 1 |
| Löwenberg, EC | 1 |
| Crosby, JR | 1 |
| MacLeod, AR | 1 |
| Zhao, C | 1 |
| Gao, D | 1 |
| Black, C | 1 |
| Revenko, AS | 1 |
| Meijers, JC | 1 |
| Stroes, ES | 1 |
| Cao, YB | 1 |
| Zhang, JD | 1 |
| Shen, H | 1 |
| Jiang, YY | 1 |
| Girard, F | 1 |
| Cao, C | 1 |
| Kupfer, S | 1 |
| Raskob, G | 5 |
| Spaeder, J | 1 |
| Zufferey, PJ | 1 |
| Schulman, S | 2 |
| Huang, J | 1 |
| Cao, Y | 1 |
| Liao, C | 1 |
| Wu, L | 1 |
| Gao, F | 1 |
| Bottaro, FJ | 1 |
| Ceresetto, JM | 1 |
| Dentali, F | 3 |
| Gianni, M | 1 |
| Squizzato, A | 1 |
| Carson, MP | 1 |
| Kuo, YH | 1 |
| Brenner, B | 6 |
| Ramirez, LM | 2 |
| Loke, YK | 1 |
| Kwok, CS | 1 |
| Hermansson, K | 1 |
| Liotier, J | 1 |
| Bertoletti, L | 3 |
| Kleber, FX | 2 |
| Pineo, GF | 3 |
| Chapelle, C | 1 |
| Moulin, N | 1 |
| Fouda, UM | 1 |
| Sayed, AM | 1 |
| Abdou, AM | 1 |
| Ramadan, DI | 1 |
| Fouda, IM | 1 |
| Zaki, MM | 1 |
| Palumbo, A | 1 |
| Cavo, M | 1 |
| Bringhen, S | 1 |
| Zamagni, E | 1 |
| Romano, A | 1 |
| Patriarca, F | 1 |
| Rossi, D | 1 |
| Gentilini, F | 1 |
| Crippa, C | 1 |
| Galli, M | 1 |
| Nozzoli, C | 1 |
| Ria, R | 1 |
| Marasca, R | 1 |
| Montefusco, V | 1 |
| Baldini, L | 1 |
| Elice, F | 1 |
| Callea, V | 1 |
| Pulini, S | 1 |
| Carella, AM | 1 |
| Zambello, R | 1 |
| Benevolo, G | 1 |
| Magarotto, V | 1 |
| Tacchetti, P | 1 |
| Pescosta, N | 1 |
| Cellini, C | 1 |
| Polloni, C | 1 |
| Evangelista, A | 1 |
| Caravita, T | 1 |
| Morabito, F | 1 |
| Offidani, M | 1 |
| Tosi, P | 1 |
| Boccadoro, M | 1 |
| Moliterno, DJ | 1 |
| Lokhnygina, Y | 3 |
| Hochman, JS | 2 |
| Jameson, SS | 1 |
| Sanders, RD | 1 |
| Reed, MR | 1 |
| Landman, GW | 1 |
| Gans, RO | 1 |
| McKellar, SH | 1 |
| Abel, S | 1 |
| Camp, CL | 1 |
| Suri, RM | 1 |
| Ereth, MH | 1 |
| Schaff, HV | 1 |
| Skrupky, LP | 1 |
| Smith, JR | 1 |
| Reichley, RM | 1 |
| Vairo, BC | 2 |
| Oliveira, CP | 1 |
| Cinelli, LP | 2 |
| Stark, JE | 1 |
| Smith, WJ | 1 |
| Rosenberger, LH | 1 |
| Smith, PW | 1 |
| Sawyer, RG | 1 |
| Quirke, M | 1 |
| O'Donnell, JJ | 1 |
| Aujesky, D | 1 |
| Verschuren, F | 1 |
| Osterwalder, J | 1 |
| Egloff, M | 1 |
| Renaud, B | 1 |
| Stone, RA | 1 |
| Legall, C | 1 |
| Sanchez, O | 4 |
| Pugh, NA | 1 |
| N'gako, A | 1 |
| Cornuz, J | 1 |
| Hugli, O | 1 |
| Beer, HJ | 1 |
| Fine, MJ | 1 |
| Yealy, DM | 1 |
| Rahman, MS | 1 |
| Soo, L | 1 |
| Qasim, A | 1 |
| Montero Ruiz, E | 1 |
| Baldominos Utrilla, G | 1 |
| López Álvarez, J | 1 |
| Santolaya Perrin, R | 1 |
| Duschek, N | 1 |
| Vafaie, M | 1 |
| Skrinjar, E | 1 |
| Hirsch, K | 1 |
| Waldhör, T | 1 |
| Hübl, W | 1 |
| Bergmayr, W | 1 |
| Knoebl, P | 1 |
| Assadian, A | 1 |
| Ludwig, KP | 1 |
| Simons, HJ | 1 |
| Mone, M | 1 |
| Barton, RG | 1 |
| Kimball, EJ | 1 |
| Leizorovicz, A | 3 |
| Haas, SK | 1 |
| Knabb, RM | 1 |
| Hoffmann, P | 1 |
| Keller, F | 2 |
| Parakh, R | 1 |
| Wang, C | 1 |
| Pollack, C | 1 |
| Cayla, G | 1 |
| Okamoto, K | 1 |
| Ohike, T | 1 |
| Tajirika, T | 1 |
| Aihara, K | 1 |
| Watanabe, S | 1 |
| Kayhanian, H | 1 |
| Villanueva, CA | 1 |
| Nájera, L | 1 |
| Espinosa, P | 1 |
| Borbujo, J | 1 |
| Elsaid, KA | 1 |
| Collins, CM | 1 |
| Nieto, JA | 1 |
| Espada, NG | 1 |
| Merino, RG | 1 |
| González, TC | 1 |
| George, D | 1 |
| Kakkar, A | 2 |
| Lensin, AW | 1 |
| Jacobson, BF | 1 |
| Minar, E | 1 |
| Chlumsky, J | 2 |
| Gallerani, M | 1 |
| Manfredini, R | 1 |
| Morishima, Y | 1 |
| Honda, Y | 1 |
| Kamisato, C | 1 |
| Tsuji, N | 1 |
| Kita, A | 1 |
| Edo, N | 1 |
| Shibano, T | 1 |
| Springmann, V | 1 |
| Martineau, J | 1 |
| Stewart, JA | 1 |
| Komari, N | 1 |
| McLeod, A | 2 |
| Strulovitch, C | 1 |
| Blostein, M | 1 |
| Faucher, JP | 1 |
| Gamble, G | 1 |
| Gordon, W | 1 |
| Kagoma, PK | 1 |
| Miron, MJ | 1 |
| Laverdière, D | 1 |
| Game, M | 1 |
| Mills, A | 1 |
| Dufour, B | 1 |
| Toussaint-Hacquard, M | 1 |
| Kearney-Schwartz, A | 1 |
| Manckoundia, MD | 1 |
| Laurain, MC | 1 |
| Joly, L | 1 |
| Deibener, J | 1 |
| Wahl, D | 1 |
| Lecompte, T | 2 |
| Benetos, A | 1 |
| Perret-Guillaume, C | 1 |
| Albertsen, IE | 1 |
| Larsen, TB | 1 |
| Overvad, TF | 1 |
| Marx, S | 1 |
| Marder, VJ | 3 |
| Schulze, A | 1 |
| Wehling, M | 1 |
| Weiss, C | 2 |
| Yildirim, T | 1 |
| Kocak, T | 1 |
| Buyukasik, Y | 1 |
| Yilmaz, R | 1 |
| Altun, B | 1 |
| Erdem, Y | 1 |
| Arici, M | 1 |
| Byrne, M | 1 |
| Zumberg, M | 1 |
| Gómez Arrayas, I | 1 |
| Suárez Fernández, C | 1 |
| Gómez Cerezo, JF | 1 |
| Betegón Nicolás, L | 1 |
| de Salas-Cansado, M | 1 |
| Rubio-Terrés, C | 1 |
| Yoshida, Rde A | 1 |
| Yoshida, WB | 1 |
| Maffei, FH | 2 |
| El Dib, R | 1 |
| Nunes, R | 1 |
| Rollo, HA | 1 |
| Tapson, V | 1 |
| Bigonzi, F | 5 |
| Théroux, P | 3 |
| Frey, MJ | 2 |
| Van Mieghem, W | 1 |
| Senatore, F | 1 |
| Lis, J | 1 |
| Mukherjee, R | 1 |
| Harris, K | 1 |
| Morris, E | 1 |
| Vormfelde, SV | 1 |
| Hughes, SJ | 1 |
| Fitchett, D | 1 |
| Tan, M | 1 |
| Fine, E | 1 |
| Golmard, JL | 2 |
| Dalby, M | 1 |
| Ankri, A | 3 |
| Dumaine, R | 2 |
| Lesty, C | 1 |
| Thomas, D | 3 |
| Lee, BI | 1 |
| Casterella, PJ | 1 |
| Pulsipher, M | 1 |
| Rogers, M | 1 |
| Corrigan, VE | 1 |
| Ryan, TJ | 1 |
| Breall, JA | 1 |
| Moses, JW | 2 |
| Eaton, GM | 1 |
| Sklar, MA | 1 |
| Eskilson, C | 2 |
| Nylander, I | 1 |
| Frison, L | 1 |
| Ogren, M | 1 |
| Cestac, P | 1 |
| Bagheri, H | 1 |
| Lapeyre-Mestre, M | 1 |
| Fouladi, A | 1 |
| Maupas, E | 1 |
| Léger, P | 1 |
| Fontan, B | 1 |
| Massip, P | 1 |
| Montastruc, JL | 1 |
| Büyükkurt, CD | 1 |
| Dural, CA | 1 |
| Güloğlu, R | 2 |
| Akar, U | 1 |
| Alikhan, R | 1 |
| Witt, C | 1 |
| Vogel, G | 1 |
| Koppenhagen, K | 4 |
| Schomaker, U | 1 |
| Flosbach, CW | 2 |
| Ferreira, I | 1 |
| Dos, L | 1 |
| Tornos, P | 2 |
| Permanyer-Miralda, G | 2 |
| Soler-Soler, J | 2 |
| Khazan, M | 1 |
| Scheuering, S | 1 |
| Adamson, R | 1 |
| Mathis, AS | 1 |
| Pless, T | 1 |
| Loertzer, H | 1 |
| Brandt, S | 1 |
| Radke, J | 1 |
| Fornara, P | 1 |
| Soukup, J | 1 |
| Dunn, K | 1 |
| Sasahara, AA | 1 |
| Adgey, AA | 1 |
| Arntz, HR | 1 |
| Bogaerts, K | 1 |
| Danays, T | 1 |
| Lindahl, B | 2 |
| Mäkijärvi, M | 1 |
| Verheugt, F | 1 |
| Pérez de Llano, LA | 1 |
| Baloira Villar, A | 1 |
| Veres Racamonde, A | 1 |
| Veiga, F | 2 |
| Golpe Gómez, R | 1 |
| Pajuelo Fernández, F | 1 |
| Carroll, DN | 1 |
| Hudson, EB | 1 |
| Streif, W | 1 |
| Goebel, G | 1 |
| Chan, AK | 2 |
| Massicotte, MP | 1 |
| Gómez de la Torre, R | 1 |
| Milla Crespo, A | 1 |
| Cadenas, F | 1 |
| Fernández Bustamante, J | 1 |
| Vázquez Castañón, M | 1 |
| Chiou-Tan, FY | 1 |
| Garza, H | 1 |
| Chan, KT | 1 |
| Parsons, KC | 1 |
| Donovan, WH | 1 |
| Robertson, CS | 1 |
| Holmes, SA | 1 |
| Graves, DE | 1 |
| Rintala, DH | 1 |
| Bruno, R | 1 |
| Baille, P | 1 |
| Retout, S | 1 |
| Vivier, N | 1 |
| Veyrat-Follet, C | 1 |
| Sanderink, GJ | 1 |
| Colwell, CW | 3 |
| Neubauer, J | 1 |
| McElhattan, JL | 1 |
| Peters, GR | 1 |
| Nader, F | 1 |
| Bates, ER | 1 |
| Every, NR | 1 |
| Pepine, CJ | 2 |
| Kälebo, P | 5 |
| Panfilov, S | 1 |
| Andersson, M | 1 |
| Freij, A | 1 |
| Stellbrink, C | 1 |
| Nixdorff, U | 1 |
| Hofmann, T | 1 |
| Lehmacher, W | 1 |
| Daniel, WG | 1 |
| Hanrath, P | 1 |
| Geller, C | 1 |
| Mügge, A | 1 |
| Sehnert, W | 1 |
| Schmidt-Lucke, C | 1 |
| Schmidt-Lucke, JA | 1 |
| Thorevska, N | 1 |
| Amoateng-Adjepong, Y | 1 |
| Sabahi, R | 1 |
| Schiopescu, I | 1 |
| Salloum, A | 1 |
| Muralidharan, V | 1 |
| Manthous, CA | 1 |
| Woessner, R | 1 |
| Grauer, M | 1 |
| Bianchi, O | 1 |
| Mueller, M | 1 |
| Moersdorf, S | 1 |
| Berlit, P | 1 |
| Goertler, M | 1 |
| Grotemeyer, KH | 1 |
| Sliwka, U | 1 |
| Stoll, M | 1 |
| Treib, J | 1 |
| Kavanagh, D | 1 |
| Hill, AD | 1 |
| Martin, S | 1 |
| Power, C | 1 |
| McDermott, EW | 1 |
| O'Higgins, N | 1 |
| Murphy, K | 2 |
| Tanguy, ML | 2 |
| Drobinski, G | 1 |
| Ellis, SG | 1 |
| Armstrong, P | 2 |
| Betriu, A | 1 |
| Brodie, B | 1 |
| Herrmann, H | 1 |
| Neumann, FJ | 1 |
| Smith, JJ | 1 |
| Topol, E | 1 |
| Macie, C | 1 |
| Forbes, L | 1 |
| Foster, GA | 1 |
| Douketis, JD | 2 |
| Segers, AE | 2 |
| Cariou, R | 1 |
| Leeuwenkamp, O | 1 |
| Hu, Q | 1 |
| Brady, JO | 1 |
| Simoons, ML | 2 |
| Bobbink, IW | 1 |
| Boland, J | 1 |
| Gardien, M | 1 |
| Klootwijk, P | 1 |
| Ruzyllo, W | 2 |
| Umans, VA | 1 |
| Blazing, MA | 2 |
| de Lemos, JA | 2 |
| Verheugt, FW | 1 |
| Ardissino, D | 1 |
| Palmisano, J | 1 |
| Bilheimer, DW | 1 |
| Snapinn, SM | 1 |
| Ramsey, KE | 1 |
| Gardner, LH | 1 |
| Hasselblad, V | 3 |
| Pfeffer, MA | 1 |
| Lewis, EF | 1 |
| Grines, CL | 1 |
| Kereiakes, DJ | 1 |
| Nessel, CC | 3 |
| Aylward, P | 1 |
| Biasucci, L | 1 |
| Fry, E | 1 |
| Gulba, DC | 3 |
| Guneri, S | 3 |
| Gurfinkel, E | 1 |
| Harrington, R | 1 |
| Leon, MB | 1 |
| Lopez-Sendon, JL | 2 |
| Teirstein, PS | 1 |
| Toro-Figueroa, L | 1 |
| White, H | 1 |
| Le-Moigne-Amrani, A | 1 |
| Gallois, V | 1 |
| Araújo, GR | 1 |
| Lastoria, S | 1 |
| Karaoglan de Moura, L | 1 |
| Michaelis, W | 1 |
| Sandri, JL | 1 |
| Dietrich-Neto, F | 1 |
| Michaels, LA | 1 |
| Gurian, M | 1 |
| Hegyi, T | 1 |
| Drachtman, RA | 1 |
| Herishanu, Y | 1 |
| Misgav, M | 1 |
| Kirgner, I | 1 |
| Ben-Tal, O | 1 |
| Eldor, A | 2 |
| Naparstek, E | 1 |
| Yanar, H | 1 |
| Bilsel, Y | 1 |
| Kizilirmak, S | 1 |
| Buyukkurt, D | 1 |
| Granit, V | 1 |
| Lynd, LD | 2 |
| O'brien, BJ | 2 |
| Hoffman, R | 1 |
| Carp, H | 1 |
| Dulitsky, M | 1 |
| Younis, J | 1 |
| Davutoglu, V | 1 |
| Kervancioglu, S | 1 |
| Sezen, Y | 1 |
| Topgül, K | 1 |
| Uzun, O | 1 |
| Anadol, AZ | 1 |
| Gök, A | 1 |
| Quiles, J | 1 |
| Avanzas, P | 1 |
| Bueno, H | 1 |
| Maslovitz, S | 1 |
| Many, A | 2 |
| Landsberg, JA | 1 |
| Lessing, JB | 1 |
| Kupferminc, MJ | 1 |
| Ibrahim, RB | 1 |
| Peres, E | 1 |
| Dansey, R | 1 |
| Abidi, MH | 1 |
| Abella, EM | 1 |
| Gumma, MM | 1 |
| Milan, N | 1 |
| Smith, DW | 1 |
| Heilbrun, LK | 1 |
| Klein, J | 1 |
| Huxtable, LM | 1 |
| Tafreshi, MJ | 1 |
| Ondreyco, SM | 1 |
| Nessel, CO | 1 |
| Enyart, JJ | 1 |
| Jones, RJ | 1 |
| Siddiqui, MA | 1 |
| Wagstaff, AJ | 1 |
| Weinsheimer, RL | 1 |
| Libby, E | 1 |
| Howdieshell, TR | 1 |
| Chong, BH | 1 |
| Baker, RI | 2 |
| Thurlow, P | 1 |
| Lee, CH | 1 |
| Jaffer, AK | 1 |
| Ahmed, M | 1 |
| Brotman, DJ | 1 |
| Bragg, L | 1 |
| Seshadri, N | 1 |
| Qadeer, MA | 1 |
| Klein, A | 1 |
| Irwin, MW | 1 |
| Borris, L | 2 |
| Jörg, I | 1 |
| Zalc, S | 1 |
| Lemos, PA | 1 |
| Esteves, A | 1 |
| Ribeiro, EE | 1 |
| Horta, P | 1 |
| Ramires, JA | 1 |
| Martinez, EE | 1 |
| Pogue, J | 1 |
| Joyner, C | 1 |
| Gibbons, RJ | 1 |
| Fuster, V | 1 |
| Ruda, M | 2 |
| Sadowski, Z | 1 |
| Jiang, F | 1 |
| Lim, W | 1 |
| Crowther, MA | 6 |
| Ellis, MH | 1 |
| Hadari, R | 1 |
| Tchuvrero, N | 1 |
| Shapira, S | 1 |
| Kovlenko, I | 1 |
| Kozmiakova, M | 1 |
| Zissin, R | 1 |
| Elis, A | 1 |
| Schädlich, PK | 1 |
| Kentsch, M | 1 |
| Weber, M | 1 |
| Kämmerer, W | 1 |
| Brecht, JG | 1 |
| Nadipelli, V | 1 |
| Huppertz, E | 1 |
| Majure, DT | 1 |
| Aberegg, SK | 1 |
| DeCarolis, DD | 1 |
| Sleight, P | 1 |
| Waksman, R | 1 |
| Wolfram, RM | 1 |
| Torguson, RL | 1 |
| Okubagzi, P | 1 |
| Xue, Z | 1 |
| Suddath, WO | 1 |
| Satler, LF | 1 |
| Kent, KM | 1 |
| O'Neill, WW | 1 |
| Bickler, P | 1 |
| Brandes, J | 1 |
| Lee, M | 1 |
| Bozic, K | 1 |
| Chesbro, B | 1 |
| Claassen, J | 1 |
| Klein, AL | 1 |
| Jasper, SE | 1 |
| Katz, WE | 1 |
| Malouf, JF | 1 |
| Pape, LA | 1 |
| Stoddard, MF | 1 |
| Apperson-Hansen, C | 1 |
| Lieber, EA | 1 |
| Dharmarajan, TS | 1 |
| Sohagia, A | 1 |
| McLaurin, BT | 1 |
| Cox, DA | 1 |
| Pocock, SJ | 1 |
| Ware, JH | 1 |
| Colombo, A | 1 |
| Darius, H | 1 |
| Ebrahimi, R | 1 |
| Shorr, AF | 1 |
| Jackson, WL | 1 |
| Moores, LK | 1 |
| Warkentin, TE | 2 |
| Frezza, EE | 1 |
| Wachtel, MS | 1 |
| Cantor, WJ | 1 |
| Huang, Z | 1 |
| Das, P | 1 |
| Glezer, S | 1 |
| Chisholm, RJ | 1 |
| Schobess, R | 1 |
| Düring, C | 1 |
| Bidlingmaier, C | 1 |
| Heinecke, A | 1 |
| Merkel, N | 1 |
| Nowak-Göttl, U | 1 |
| Chew, DP | 1 |
| Berdan, LG | 2 |
| Bhala, N | 1 |
| Schuler, J | 1 |
| Altenberger, J | 1 |
| Heigert, M | 1 |
| Pasceri, V | 1 |
| Riddell, JW | 1 |
| Gardner, MJ | 1 |
| Flik, KR | 1 |
| Dreese, JC | 1 |
| Athanasian, EA | 1 |
| Lyden, JP | 1 |
| O'Donnell, MJ | 1 |
| Johnson, J | 1 |
| Robinson, M | 1 |
| Zondag, M | 1 |
| Turpie, I | 1 |
| Castro, DJ | 1 |
| Díaz, G | 1 |
| Martí, D | 1 |
| Escobar, C | 1 |
| Ortega, J | 1 |
| García-Rull, S | 1 |
| Picher, J | 1 |
| Sueiro, A | 1 |
| Crooke, B | 1 |
| Callaway, LK | 1 |
| Ben-David, B | 1 |
| Chelly, JE | 1 |
| Bleckner, LL | 1 |
| Buckenmaier, CC | 1 |
| Jacob, AJ | 2 |
| Gotcheva, N | 1 |
| Polonetsky, L | 1 |
| Cherfan, A | 1 |
| Arabi, Y | 1 |
| Al Askar, A | 1 |
| Al Shimemeri, A | 1 |
| Rivas-Gándara, N | 1 |
| Ferreira-González, I | 1 |
| Torrents, A | 1 |
| Vallejo, N | 1 |
| Igual, A | 1 |
| Kamal, MK | 1 |
| Reilly, PM | 1 |
| Stavropoulos, SW | 1 |
| Schmidt, H | 1 |
| von der Recke, G | 1 |
| Marlovits, S | 1 |
| Striessnig, G | 1 |
| Schuster, R | 1 |
| Stocker, R | 1 |
| Luxl, M | 1 |
| Trattnig, S | 1 |
| Vécsei, V | 1 |
| LaPointe, NM | 1 |
| Chen, AY | 2 |
| Lytle, BL | 1 |
| Ohman, ME | 1 |
| Gibler, BW | 1 |
| Goeree, R | 1 |
| Dunn, AS | 1 |
| Malowany, JI | 1 |
| Knoppert, DC | 1 |
| Pepelassis, D | 1 |
| Lee, DS | 1 |
| Despotovic, N | 2 |
| Erceg, P | 1 |
| Nikolic-Despotovic, M | 2 |
| Milosevic, DP | 1 |
| Davidovic, M | 1 |
| van Dijk, CN | 2 |
| Frostick, SP | 2 |
| Christiansen, AV | 1 |
| Hettiarachchi, R | 2 |
| Schnee, J | 2 |
| Valentin, V | 1 |
| Moccetti, T | 1 |
| Ansell, J | 1 |
| Deitchman, D | 1 |
| Paar, WD | 1 |
| Sica, DA | 1 |
| Ruff, CT | 1 |
| Wazni, OM | 1 |
| Beheiry, S | 1 |
| Fahmy, T | 1 |
| Barrett, C | 1 |
| Hao, S | 1 |
| Patel, D | 1 |
| Di Biase, L | 1 |
| Martin, DO | 1 |
| Kanj, M | 1 |
| Arruda, M | 1 |
| Cummings, J | 1 |
| Schweikert, R | 1 |
| Saliba, W | 1 |
| Natale, A | 1 |
| Tricoci, P | 1 |
| Newby, LK | 2 |
| Qin, J | 1 |
| Loncar, G | 1 |
| Ilicć, M | 1 |
| Dimković, S | 1 |
| Dixon, D | 1 |
| Peek, B | 1 |
| Reeve, R | 1 |
| Normand, SL | 1 |
| Rubboli, A | 1 |
| Capecchi, A | 1 |
| Di Pasquale, G | 1 |
| Wienbergen, H | 1 |
| Kwa, AT | 1 |
| Rogers, JH | 1 |
| Melloni, C | 1 |
| Szczech, LA | 1 |
| Barantke, M | 1 |
| Bonnemeier, H | 1 |
| Trowbridge, AA | 5 |
| Stephens, JW | 1 |
| Gardiner, GA | 2 |
| Ritter, MA | 1 |
| Bang, CJ | 1 |
| Talstad, I | 1 |
| Berstad, A | 1 |
| Noble, S | 2 |
| Peters, DH | 1 |
| Goa, KL | 1 |
| Pini, M | 1 |
| Aiello, S | 1 |
| Manotti, C | 1 |
| Pattacini, C | 1 |
| Quintavalla, R | 1 |
| Poli, T | 1 |
| Tagliaferri, A | 1 |
| Dettori, AG | 1 |
| Fejgin, MD | 1 |
| Lourwood, DL | 1 |
| Morris, BA | 1 |
| Blaha, JD | 1 |
| Comerota, AJ | 1 |
| Skoutakis, VA | 1 |
| Levine, M | 1 |
| Leclerc, J | 1 |
| Anderson, D | 2 |
| Weitz, J | 3 |
| Ginsberg, J | 2 |
| Demers, C | 4 |
| Kovacs, M | 2 |
| Leclerc, JR | 2 |
| Geerts, WH | 2 |
| Desjardins, L | 1 |
| Laflamme, GH | 1 |
| L'Espérance, B | 1 |
| Kassis, J | 1 |
| Cruickshank, M | 1 |
| Whitman, L | 1 |
| Delorme, F | 1 |
| Vochelle, N | 2 |
| Darmon, JY | 1 |
| Fagola, M | 2 |
| Bellaud, M | 2 |
| Compan, D | 1 |
| Saliba, E | 1 |
| Weisslinger, N | 1 |
| Huet, Y | 2 |
| Borris, LC | 2 |
| Nelson-Piercy, C | 1 |
| Letsky, EA | 1 |
| de Swiet, M | 1 |
| Gurfinkel, EP | 2 |
| Fromell, GJ | 2 |
| Premmereur, J | 2 |
| Manktelow, AR | 1 |
| Haddad, FS | 1 |
| Powles, DP | 1 |
| Leadley, RJ | 1 |
| Kasiewski, CJ | 1 |
| Bostwick, JS | 1 |
| Bentley, R | 1 |
| McVey, MJ | 1 |
| White, FJ | 1 |
| Perrone, MH | 1 |
| Dunwiddie, CT | 1 |
| Parent, F | 1 |
| Page, Y | 2 |
| Tardy, B | 1 |
| Faivre, R | 1 |
| Charbonnier, B | 2 |
| Barral, FG | 1 |
| Connolly, ES | 1 |
| Mocco, J | 1 |
| Andreassen, G | 1 |
| Houde, JP | 1 |
| Steinberg, G | 1 |
| Bernink, PJ | 1 |
| Salein, D | 1 |
| Bayes De Luna, A | 1 |
| Fox, K | 1 |
| Radley, D | 1 |
| Saltissi, D | 1 |
| Morgan, C | 1 |
| Westhuyzen, J | 1 |
| Healy, H | 1 |
| Sosis, MB | 1 |
| Calderon, EJ | 1 |
| Varela, JM | 1 |
| Gonzalez de la Puente, MA | 1 |
| Dolenska, S | 1 |
| Gerlach, AT | 1 |
| Pickworth, KK | 1 |
| Seth, SK | 1 |
| Tanna, SB | 1 |
| Barnes, JF | 1 |
| Lindqvist, PG | 1 |
| Dahlbäck, B | 1 |
| Hakki, SI | 1 |
| Fareed, J | 3 |
| Hoppensteadt, DA | 1 |
| Abdullah, H | 1 |
| Camblin, J | 1 |
| Nasseri, AF | 1 |
| Hamadeh, O | 1 |
| Wright, T | 1 |
| Escribá, A | 1 |
| Maluenda, MP | 1 |
| López Rubio, M | 1 |
| Margalet, I | 1 |
| Lezana, A | 1 |
| Gallego, J | 1 |
| Ribera, JM | 1 |
| Olsson, CG | 2 |
| Abildgaard, U | 2 |
| Elias, D | 1 |
| Grigg, A | 1 |
| Musset, D | 1 |
| Rodgers, GM | 2 |
| Zawilska, K | 1 |
| Busby, LT | 1 |
| Weyman, A | 1 |
| Fitzgerald, RH | 1 |
| Whitsett, TL | 3 |
| O'Connell, MB | 1 |
| Ohar, JA | 1 |
| Young, TR | 1 |
| Lile, J | 1 |
| Stinnett, S | 1 |
| Cook, C | 1 |
| Callaway, M | 1 |
| Pauzner, R | 1 |
| Dulitzki, M | 1 |
| Langevitz, P | 1 |
| Livneh, A | 1 |
| Kenett, R | 1 |
| Stepinska, J | 1 |
| Banaszewski, M | 1 |
| Konopka, A | 1 |
| Szajewski, T | 1 |
| Louwerenburg, HW | 1 |
| Baars, HF | 1 |
| Wesdorp, JC | 1 |
| Hamer, B | 1 |
| Pisapia, G | 1 |
| Heidbuchel, H | 1 |
| Baird, SH | 1 |
| Menown, IB | 1 |
| Mcbride, SJ | 1 |
| Trouton, TG | 1 |
| Wilson, C | 1 |
| Sarasin, FP | 1 |
| Hillbom, M | 1 |
| Erilä, T | 1 |
| Sotaniemi, K | 1 |
| Tatlisumak, T | 1 |
| Sarna, S | 1 |
| Kaste, M | 1 |
| Kujath, P | 1 |
| Eckmann, C | 1 |
| Xie, C | 1 |
| Ahmed, RJ | 1 |
| Xavier, D | 1 |
| Pais, P | 1 |
| Zhu, J | 1 |
| Liu, L | 1 |
| De Giorgi, A | 1 |
| Giannarelli, C | 1 |
| De Negri, F | 1 |
| Carmassi, F | 1 |
| Hoppensteadt, D | 2 |
| Jeske, W | 2 |
| Andrassy, K | 1 |
| Lojewski, B | 1 |
| Walenga, JM | 1 |
| Ahsan, A | 1 |
| Baumbach, A | 1 |
| Oberhoff, M | 1 |
| Rübsamen, K | 1 |
| Jochims, K | 1 |
| Herdeg, C | 1 |
| Kranzhöfer, A | 1 |
| Safer, A | 1 |
| Karsch, KR | 2 |
| Preisack, MB | 1 |
| Baildon, R | 2 |
| Eschenfelder, V | 1 |
| Foley, D | 1 |
| Garcia, EJ | 1 |
| Kaltenbach, M | 1 |
| Meisner, C | 1 |
| Selbmann, HK | 1 |
| Serruys, PW | 1 |
| Shiu, MF | 1 |
| Sujatta, M | 1 |
| Bonan, R | 1 |
| Kakkar, VV | 2 |
| Boeckl, O | 1 |
| Bordenave, L | 1 |
| Brehm, OA | 1 |
| Brücke, P | 1 |
| Coccheri, S | 1 |
| Galland, F | 1 |
| Jarrige, J | 1 |
| LeQuerrec, A | 1 |
| Parraguette, E | 1 |
| Roder, JD | 1 |
| Roos, M | 1 |
| Rüschemeyer, C | 1 |
| Siewert, JR | 1 |
| Vinazzer, H | 1 |
| Wenzel, E | 1 |
| Hach-Wunderle, V | 1 |
| Nakov, R | 1 |
| Wellington, K | 1 |
| McClellan, K | 1 |
| Jarvis, B | 1 |
| Greinacher, A | 1 |
| Schwanebeck, U | 1 |
| Sieder, C | 5 |
| Abletshauser, C | 4 |
| Tebbe, U | 3 |
| Gerlach, HE | 3 |
| Melzer, N | 4 |
| Dorsch, O | 1 |
| Krieter, DH | 1 |
| Lemke, HD | 1 |
| Fischer, S | 1 |
| Tolle, A | 2 |
| Kemkes-Matthes, B | 2 |
| Gräve, M | 2 |
| Patek, F | 1 |
| Drexler, M | 1 |
| Siemens, HJ | 1 |
| Weidinger, G | 3 |
| Brom, J | 3 |
| Diener, HC | 2 |
| Schmidt, JA | 1 |
| Ringelstein, EB | 1 |
| von Kummer, R | 1 |
| Langohr, HD | 1 |
| Bewermeyer, H | 1 |
| Hennerici, M | 1 |
| Welzel, D | 1 |
| Tolle, AR | 1 |
| Kirchmaier, CM | 1 |
| Muñoz, A | 4 |
| Franco, L | 1 |
| Mahé, I | 3 |
| Connors, JM | 5 |
| Gussoni, G | 4 |
| Hamulyak, EN | 1 |
| Lambert, C | 2 |
| Suero, MR | 1 |
| Torbicki, A | 2 |
| Becattini, C | 7 |
| Planquette, B | 1 |
| Charles-Nelson, A | 1 |
| Grange, C | 1 |
| Pernod, G | 1 |
| Elias, A | 1 |
| Falvo, N | 2 |
| Sevestre, MA | 1 |
| Ray, V | 1 |
| Burnod, A | 1 |
| Brebion, N | 1 |
| Timar-David, M | 1 |
| Aquilanti, S | 1 |
| Constans, J | 1 |
| Bura-Rivière, A | 1 |
| Chatellier, G | 2 |
| Meyer, G | 9 |
| Lu, C | 1 |
| Mithoowani, S | 1 |
| Verso, M | 3 |
| Huisman, M | 3 |
| Hartman, LR | 1 |
| Nurmeev, I | 1 |
| Svirin, P | 1 |
| Wolter, KD | 1 |
| Yan, JL | 1 |
| Jani, D | 1 |
| Sherman, N | 1 |
| Novak, P | 1 |
| Novak, A | 1 |
| Šabović, M | 1 |
| Kozak, M | 1 |
| Arce-Huamani, MA | 1 |
| Barboza, JJ | 1 |
| Martínez-Herrera, JF | 1 |
| Torres-Roman, JS | 1 |
| Maguiña, JL | 1 |
| Lee, JH | 2 |
| Jo, KW | 1 |
| Huh, JW | 1 |
| Oh, YM | 1 |
| Lee, JS | 1 |
| Sueiro, MR | 1 |
| Campanini, M | 1 |
| Vescovo, G | 2 |
| Ebner, M | 1 |
| Lankeit, M | 1 |
| Miranda, S | 1 |
| Levesque, H | 1 |
| Li Fraine, S | 1 |
| Coman, D | 1 |
| Vallée Guignard, V | 1 |
| Costa, JP | 1 |
| Riaz, IB | 2 |
| Marshall, AL | 2 |
| Badgett, RG | 2 |
| Vedovati, MC | 1 |
| Mandalà, M | 1 |
| Fuentes, HE | 1 |
| Naqvi, SAA | 1 |
| He, H | 1 |
| Sipra, QR | 1 |
| Tafur, AJ | 1 |
| Padranos, L | 1 |
| Vandvik, PO | 1 |
| Montori, V | 1 |
| Bryce, AH | 1 |
| Liu, H | 1 |
| Murad, MH | 1 |
| Giustozzi, M | 1 |
| Ruperez Blanco, AB | 1 |
| Szmit, S | 1 |
| Maraziti, G | 1 |
| Manfellotto, D | 1 |
| Sanchez, A | 1 |
| McBane Ii, R | 1 |
| Loprinzi, CL | 1 |
| Ashrani, A | 1 |
| Perez-Botero, J | 1 |
| Leon Ferre, RA | 1 |
| Henkin, S | 1 |
| Lenz, CJ | 1 |
| Le-Rademacher, JG | 1 |
| Garcia, D | 4 |
| Kovacs, MJ | 6 |
| Yeo, E | 1 |
| Zhang, G | 3 |
| Zwicker, JI | 2 |
| Hakoum, MB | 1 |
| Kahale, LA | 1 |
| Tsolakian, IG | 1 |
| Matar, CF | 1 |
| Yosuico, VE | 1 |
| Terrenato, I | 1 |
| Sperati, F | 1 |
| Barba, M | 1 |
| Schünemann, H | 1 |
| Akl, EA | 1 |
| Khorana, AA | 5 |
| Lee, AYY | 5 |
| Soff, G | 1 |
| O'Connell, C | 1 |
| Kraaijpoel, N | 1 |
| Grosso, M | 1 |
| Hernandez, CR | 1 |
| Santamaria, A | 1 |
| Lutkin, M | 1 |
| Stronach, L | 1 |
| Yadav, P | 1 |
| Hothi, DK | 1 |
| Woodruff, S | 1 |
| Feugère, G | 1 |
| Abreu, P | 1 |
| Heissler, J | 1 |
| Buller, H | 2 |
| Eley, KA | 1 |
| Parker, RJ | 1 |
| Watt-Smith, SR | 1 |
| Anderson, DR | 1 |
| Dunbar, MJ | 1 |
| Bohm, ER | 1 |
| Belzile, E | 1 |
| Zukor, D | 1 |
| Gofton, W | 1 |
| Gross, P | 1 |
| Pelet, S | 1 |
| MacDonald, S | 1 |
| Kim, P | 1 |
| Pleasance, S | 1 |
| Davis, N | 1 |
| Andreou, P | 1 |
| Rodger, MA | 2 |
| Ramsay, T | 1 |
| Vendittoli, PA | 1 |
| Lauzier, F | 1 |
| Arnold, DM | 1 |
| Rabbat, C | 2 |
| Heels-Ansdell, D | 3 |
| Zarychanski, R | 1 |
| Dodek, P | 1 |
| Ashley, BJ | 1 |
| Albert, M | 2 |
| Khwaja, K | 1 |
| Ostermann, M | 1 |
| Skrobik, Y | 2 |
| Fowler, R | 2 |
| McIntyre, L | 1 |
| Nates, JL | 1 |
| Karachi, T | 2 |
| Zytaruk, N | 3 |
| Finfer, S | 1 |
| Cook, D | 3 |
| Cui, W | 1 |
| Li, Y | 1 |
| Gao, X | 1 |
| Wei, Q | 1 |
| Cao, X | 1 |
| Xiao, W | 1 |
| Jiang, P | 1 |
| Lyu, X | 1 |
| Liu, F | 1 |
| Gu, G | 1 |
| Liu, J | 1 |
| Krasiński, Z | 1 |
| Szpurek, D | 1 |
| Staniszewski, R | 1 |
| Dzieciuchowicz, L | 1 |
| Pawlaczyk, K | 1 |
| Krasińska, B | 1 |
| Wójcicka, K | 1 |
| Urbanek, T | 1 |
| Hague, WM | 1 |
| Kingdom, J | 1 |
| Karovitch, A | 1 |
| Sermer, M | 1 |
| Clement, AM | 1 |
| Coat, S | 1 |
| Chan, WS | 1 |
| Said, J | 1 |
| Rey, E | 1 |
| Khurana, R | 1 |
| Solymoss, S | 2 |
| Hinshaw, K | 1 |
| Dwyer, J | 1 |
| Smith, G | 1 |
| McDonald, S | 1 |
| Newstead-Angel, J | 1 |
| Khandelwal, M | 1 |
| Silver, RM | 1 |
| Greer, IA | 1 |
| Keely, E | 1 |
| Rosene-Montella, K | 1 |
| Walker, M | 1 |
| O'Brien, SH | 1 |
| Kulkarni, R | 1 |
| Wallace, A | 1 |
| Burr, S | 1 |
| Kessler, CM | 1 |
| Ortel, TL | 2 |
| Pabinger, I | 2 |
| Park, D | 1 |
| Southern, W | 1 |
| Calvo, M | 1 |
| Solorzano, C | 1 |
| Sinnet, M | 1 |
| Billett, HH | 1 |
| Boda, Z | 1 |
| Ockelford, P | 1 |
| Kuderer, NM | 1 |
| Wun, T | 1 |
| Rubens, D | 1 |
| Hobbs, S | 1 |
| Iyer, R | 1 |
| Peterson, D | 1 |
| Baran, A | 1 |
| Kaproth-Joslin, K | 1 |
| Lyman, GH | 1 |
| McMahon, GS | 1 |
| Webster, SE | 1 |
| Hayes, PD | 1 |
| Jones, CI | 1 |
| Goodall, AH | 1 |
| Naylor, AR | 1 |
| Puskas, D | 1 |
| Bocanegra, T | 1 |
| Pehrsson, S | 1 |
| Johansson, K | 1 |
| Kjaer, M | 1 |
| Elg, M | 1 |
| Meade, M | 2 |
| Walter, S | 1 |
| Cooper, DJ | 1 |
| Vallance, S | 1 |
| Qushmaq, I | 1 |
| Rocha, M | 1 |
| Vlahakis, NE | 1 |
| Rathbun, SW | 2 |
| Stoner, JA | 1 |
| Aston, CE | 1 |
| Husted, SE | 1 |
| Lagerqvist, B | 1 |
| Kontny, F | 3 |
| Ståhle, E | 2 |
| Swahn, E | 1 |
| Ulander, VM | 1 |
| Stenqvist, P | 1 |
| Kaaja, R | 2 |
| James, S | 1 |
| Califf, R | 1 |
| Husted, S | 1 |
| Niemminen, M | 1 |
| Pfisterer, M | 1 |
| Bonet, M | 1 |
| Roncales, J | 1 |
| Muchart, J | 1 |
| Fraile, M | 1 |
| Mah, AF | 2 |
| Forrest, DL | 1 |
| Thompson, K | 1 |
| Dorcas, VG | 1 |
| Couban, SH | 1 |
| Pierce, R | 1 |
| Lee, AY | 1 |
| Levine, MN | 2 |
| Bowden, C | 1 |
| Rickles, FR | 1 |
| Vaitkus, PT | 1 |
| Kim, JH | 1 |
| Jeong, MH | 1 |
| Rhew, JY | 1 |
| Lim, JH | 1 |
| Yun, KH | 1 |
| Kim, KH | 1 |
| Kang, DK | 1 |
| Hong, SN | 1 |
| Lim, SY | 1 |
| Lee, SH | 1 |
| Lee, YS | 1 |
| Hong, YJ | 1 |
| Park, HW | 1 |
| Kim, W | 1 |
| Ahn, YK | 1 |
| Moon, Y | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| O'Neill, JL | 1 |
| Flanagan, PS | 1 |
| Zaleon, CR | 1 |
| Copeland, LA | 1 |
| Rabbat, CG | 1 |
| Cook, DJ | 1 |
| McDonald, E | 1 |
| Clarke, F | 1 |
| Meade, MO | 1 |
| Lee, KA | 1 |
| Cook, RJ | 1 |
| Tincani, E | 1 |
| Mannucci, C | 1 |
| Casolari, B | 1 |
| Turrini, F | 1 |
| Prisco, D | 1 |
| Cenci, AM | 1 |
| Bondi, M | 1 |
| Krafft, A | 1 |
| Bauersachs, RM | 1 |
| Dudenhausen, J | 1 |
| Faridi, A | 1 |
| Fischer, T | 1 |
| Fung, S | 1 |
| Geisen, U | 1 |
| Herchenhan, E | 1 |
| Schinzel, H | 1 |
| Spannagl, M | 1 |
| Thaler, CJ | 1 |
| Douketis, J | 1 |
| Granton, J | 1 |
| Hebert, P | 1 |
| Pagliarello, G | 1 |
| Friedrich, J | 1 |
| Freitag, A | 1 |
| Sakuragawa, N | 1 |
| Hasegawa, H | 1 |
| Maki, M | 1 |
| Nakagawa, M | 1 |
| Nakashima, M | 1 |
| Lafoz, E | 1 |
| Olive, A | 1 |
| del Rio, L | 1 |
| Vedia, C | 1 |
| Jeffrey, RF | 1 |
| Khan, AA | 1 |
| Douglas, JT | 1 |
| Will, EJ | 1 |
| Davison, AM | 1 |
| Pellegrini, VD | 1 |
| Totterman, S | 1 |
| Boyd, AD | 1 |
| Liebert, KM | 1 |
| Stulberg, BN | 1 |
| Ayers, DC | 1 |
| Rosenberg, A | 1 |
| Kessler, C | 1 |
| Johanson, NA | 1 |
| Dale, J | 1 |
| Pedersen, TR | 1 |
| Pan, M | 1 |
| Suárez de Lezo, J | 1 |
| Medina, A | 1 |
| Romero, M | 1 |
| Hernández, E | 1 |
| Segura, J | 1 |
| Melian, F | 1 |
| Wangüemert, F | 1 |
| Landin, M | 1 |
| Benítez, F | 1 |
| Amat, M | 1 |
| Velasco, F | 1 |
| Torres, A | 1 |
| Reeves, JH | 1 |
| Cumming, AR | 1 |
| Gallagher, L | 1 |
| O'Brien, JL | 1 |
| Santamaria, JD | 1 |
| Pettilä, V | 1 |
| Leinonen, P | 1 |
| Ekblad, U | 1 |
| Kataja, M | 1 |
| Ikkala, E | 1 |
| Massel, D | 1 |
| Morrow, B | 1 |
| Gray, L | 1 |
| Touchie, D | 1 |
| Carrascosa Porras, M | 1 |
| del Riego Martín, M | 1 |
| González Ruiz, M | 1 |
| Tinmouth, AH | 1 |
| Morrow, BH | 1 |
| Cruickshank, MK | 1 |
| Moore, PM | 1 |
| Cho, JH | 1 |
| Yun, CH | 1 |
| Seo, HS | 1 |
| Koga, T | 1 |
| Dan, T | 1 |
| Koo, BA | 1 |
| Kim, HY | 1 |
| Bugeja, A | 1 |
| McCormick, B | 1 |
| Brown, PA | 1 |
| Liberty, C | 1 |
| Krepelka, T | 1 |
| St-Cyr, G | 1 |
| Akbari, A | 1 |
| Helfer, H | 1 |
| Siguret, V | 2 |
| Dimakakos, EP | 1 |
| Vathiotis, I | 1 |
| Syrigos, K | 1 |
| Janas, MS | 3 |
| Jarner, MF | 3 |
| Novo-Veleiro, I | 1 |
| Alvela-Suárez, L | 1 |
| Costa-Grille, A | 1 |
| Suárez-Dono, J | 1 |
| Ferrón-Vidan, F | 1 |
| Pose-Reino, A | 1 |
| Wu, IQ | 1 |
| Tan, CW | 1 |
| Wong, WH | 1 |
| Ng, HJ | 1 |
| Tseng, EK | 1 |
| Kolesar, E | 1 |
| Handa, P | 1 |
| Anvari, M | 1 |
| Tiboni, M | 1 |
| Khalifeh, A | 1 |
| Grantham, J | 1 |
| Byrne, J | 1 |
| McAuliffe, F | 1 |
| Byrne, B | 1 |
| Noel-Savina, E | 1 |
| Descourt, R | 2 |
| André, M | 1 |
| Leroyer, C | 1 |
| Martínez-Zapata, MJ | 1 |
| Mathioudakis, AG | 1 |
| Mousa, SA | 2 |
| Kakkar, R | 1 |
| Ellis, M | 1 |
| Fearon, PV | 1 |
| Besse, B | 1 |
| Friard, S | 1 |
| Corbi, P | 1 |
| Azarian, R | 2 |
| Monnet, I | 1 |
| Alifano, M | 1 |
| Chouaid, C | 1 |
| Dennewald, G | 1 |
| Taillade, L | 1 |
| De Luca, K | 1 |
| Giraud, F | 1 |
| Pichon, E | 1 |
| Stegmayr, BG | 1 |
| Jonsson, P | 1 |
| Mahmood, D | 1 |
| Hainer, JW | 2 |
| Sherrard, DJ | 1 |
| Swan, SK | 1 |
| Barrett, JS | 2 |
| Assaid, CA | 2 |
| Fossler, MJ | 2 |
| Cox, DS | 2 |
| Williams, RM | 1 |
| Pittenger, AL | 1 |
| Stephenson, CA | 1 |
| Hua, TA | 1 |
| de Maistre, E | 1 |
| Allart, C | 1 |
| Bollaert, PE | 1 |
| Chan, S | 1 |
| Kong, M | 1 |
| Minning, DM | 1 |
| Hedner, U | 2 |
| Brant, RF | 1 |
| Burke, N | 1 |
| Dear, R | 1 |
| Wong, T | 1 |
| Cook, R | 1 |
| Poon, MC | 1 |
| Daskalopoulos, ME | 1 |
| Daskalopoulou, SS | 1 |
| Liapis, CD | 1 |
| Qari, MH | 1 |
| Aljaouni, SK | 1 |
| Alardawi, MS | 1 |
| Fatani, H | 1 |
| Alsayes, FM | 1 |
| Zografos, P | 1 |
| Alsaigh, M | 1 |
| Alalfi, A | 1 |
| Alamin, M | 1 |
| Gadi, A | 1 |
| Lauritzen, B | 1 |
| Johansen, PB | 1 |
| Tranholm, M | 1 |
| Ezban, M | 1 |
| Sors, H | 1 |
| Laaban, JP | 1 |
| Laurent, M | 2 |
| Hirsch, JL | 1 |
| Ferrari, E | 1 |
| Bosson, JL | 1 |
| Mottier, D | 1 |
| Beau, B | 1 |
| Jensen, HP | 1 |
| Poulsen, KA | 1 |
| Ejstrud, P | 1 |
| Andersen, BS | 1 |
| Pautas, E | 1 |
| Février, M | 1 |
| Wipff, C | 1 |
| Durand-Gasselin, B | 1 |
| Andreux, JP | 1 |
| d'Urso, M | 1 |
| Gaussem, P | 1 |
| Rose, P | 1 |
| Bell, D | 1 |
| Green, ES | 1 |
| Davenport, A | 1 |
| Fegan, C | 1 |
| Grech, H | 1 |
| O'Shaughnessy, D | 1 |
| Voke, J | 1 |
| Leathers, T | 1 |
| Leese, PT | 1 |
| Zheng, J | 1 |
| Zhao, Y | 1 |
| Xiang, Y | 1 |
| Jin, Y | 1 |
| Powers, P | 1 |
| Neemeh, J | 1 |
| Willan, A | 1 |
| Skingley, P | 1 |
| Morrison, RB | 1 |
| Diran, LL | 1 |
| Creager, MA | 1 |
| Lee, TH | 1 |
| Gimple, LW | 1 |
| Herrmann, HC | 1 |
| Winniford, M | 1 |
| Mammen, E | 1 |
| Heit, JA | 1 |
| Morrey, BF | 1 |
| Heller, S | 1 |
| Krause, M | 1 |
| Porreca, E | 1 |
| George, DJ | 1 |
| Chaudhari, U | 1 |
| Lawson, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke[NCT01862978] | Phase 4 | 150 participants (Anticipated) | Interventional | 2013-05-31 | Recruiting | ||
| Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography[NCT00421538] | Phase 3 | 260 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin[NCT00286273] | Phase 4 | 215 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study[NCT03976440] | 30 participants (Anticipated) | Observational | 2019-06-01 | Active, not recruiting | |||
| A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate[NCT00312013] | Phase 3 | 503 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Criteria for Hospitalization or Outpatient Management of Patients With Pulmonary Embolism, Hestia Rule Versus Simplified PESI Score : an Open-label Controlled Randomized International Trial (HOME-PE)[NCT02811237] | 1,975 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study)[NCT00203580] | Phase 4 | 910 participants | Interventional | 1994-12-31 | Completed | ||
| LITE Study, Appendix A (HOME-LITE), Amendment 6[NCT00203658] | Phase 4 | 400 participants | Interventional | 1997-04-30 | Completed | ||
| Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism[NCT02355548] | 200 participants (Anticipated) | Observational | 2012-12-31 | Completed | |||
| Parnaparin Versus Aspirin in the Treatment of Retinal Vein Occlusion. A Randomized, Double Blind, Controlled Study[NCT00732927] | Phase 3 | 67 participants (Actual) | Interventional | 2002-07-31 | Terminated (stopped due to slow recruitment rate) | ||
| Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer[NCT00324558] | Phase 2 | 39 participants (Actual) | Interventional | 2005-06-30 | Terminated (stopped due to Sponsor stopped due to difficulties to recruit 130 patients required by protocol) | ||
| Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients[NCT02795065] | 100 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study[NCT00571649] | Phase 3 | 8,101 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk[NCT02111564] | Phase 3 | 12,024 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| Evaluation of Warfarin Initiation at 3mg Versus 5mg for Anticoagulation of Mechanical Mitral Valve Replacement Patients[NCT04235569] | Phase 4 | 50 participants (Actual) | Interventional | 2018-03-01 | Completed | ||
| Major Bleeding Risk Associated With Antithrombotics : The SACHA (Surveillance Des Accidents Hémorragiques Graves Sous Antithrombotiques) Study[NCT02886533] | 6,484 participants (Actual) | Observational | 2013-01-01 | Completed | |||
| COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial[NCT04354155] | Phase 2 | 40 participants (Actual) | Interventional | 2020-06-02 | Completed | ||
| Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients[NCT04492254] | Phase 3 | 219 participants (Actual) | Interventional | 2020-10-27 | Terminated (stopped due to Average event rate (end point) was much lower than expected. A larger sample size would have been required to maintain same statistical power, which was not achievable in a feasible time scale. No safety concerns were identified with bleeding.) | ||
| A Randomized, Active-comparator-controlled, Multicenter Study to Assess the Safety and Efficacy of Different Doses of BAY1213790 for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Total Knee Arthroplasty, Open-label to Tr[NCT03276143] | Phase 2 | 813 participants (Actual) | Interventional | 2017-09-21 | Completed | ||
| A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects[NCT02560688] | Phase 1 | 22 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS[NCT02071004] | Phase 1 | 18 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery[NCT02401594] | Phase 3 | 3,608 participants (Actual) | Interventional | 2015-12-08 | Terminated (stopped due to Remaining outdated treatments and additional costs too high for new manufacturing) | ||
| Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial[NCT03363035] | Phase 4 | 2,055 participants (Actual) | Interventional | 2018-01-15 | Completed | ||
| Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.[NCT04462003] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-07-03 | Recruiting | ||
| Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508] | Phase 3 | 600 participants (Actual) | Interventional | 2020-07-30 | Completed | ||
| Evaluation of the Effect of Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients[NCT04847375] | 60 participants (Anticipated) | Interventional | 2021-04-20 | Not yet recruiting | |||
| Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial[NCT04394377] | Phase 4 | 615 participants (Actual) | Interventional | 2020-06-21 | Completed | ||
| Standardized, Guidelines Directed But Patients Oriented Clinical Practice Prospectively Registered[NCT03504007] | 10,000 participants (Anticipated) | Observational | 2013-03-01 | Recruiting | |||
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| (Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218] | Phase 3 | 7,513 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization[NCT00077753] | Phase 4 | 4,726 participants | Interventional | 2002-02-28 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.[NCT00457002] | Phase 3 | 6,758 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer[NCT00717938] | Phase 3 | 390 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Evaluation of Non-Surgical Venous Thromboembolism Prophylaxis Dosing Strategies: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function[NCT03158792] | Phase 4 | 32 participants (Actual) | Interventional | 2015-10-24 | Completed | ||
| Title: EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients[NCT03243708] | 90,537 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism[NCT00643201] | Phase 3 | 5,614 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism[NCT03988842] | Phase 4 | 4 participants (Actual) | Interventional | 2019-07-25 | Terminated (stopped due to COVID-19 pandemic) | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women[NCT02829957] | Phase 2/Phase 3 | 19 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)[NCT02942576] | Phase 3 | 632 participants (Actual) | Interventional | 2017-03-21 | Completed | ||
| Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism (VTE) in Korea and Taiwan[NCT02952599] | 352 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)[NCT03977363] | 25 participants (Actual) | Observational [Patient Registry] | 2020-01-27 | Terminated (stopped due to Halted Prematurely) | |||
| Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe[NCT02943993] | 2,809 participants (Actual) | Observational | 2016-04-06 | Completed | |||
| A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From B[NCT02798471] | Phase 3 | 290 participants (Actual) | Interventional | 2017-03-27 | Completed | ||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism ([NCT00986154] | Phase 3 | 8,292 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 Bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery[NCT00902928] | Phase 2/Phase 3 | 1,992 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery of Hip or Knee[NCT00831714] | 19,076 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| Diagnostic and Prognostic Value of Cardiac Biomarkers and Echocardiography for Patients Hospitalized Due to Acute Dyspnea: Prospective Observational Multicenter Cohort Study[NCT03048032] | 1,566 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010[NCT01237418] | 3,700 participants (Anticipated) | Observational | 2010-10-31 | Active, not recruiting | |||
| An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patients Undergoing Total Knee Arthroplasty[NCT01713361] | Phase 2 | 315 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily[NCT02070237] | Phase 1 | 90 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Strategies for Anticoagulation During Venovenous ECMO: The SAFE-ECMO Pilot Trial[NCT04997265] | 30 participants (Anticipated) | Interventional | 2022-05-12 | Recruiting | |||
| Anticoagulation-free VV ECMO for Acute Respiratory Failure: A Pilot Safety and Feasibility Randomized Clinical Trial[NCT04273607] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | ||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)[NCT02329327] | Phase 3 | 479 participants (Actual) | Interventional | 2015-04-10 | Completed | ||
| A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial F[NCT02072434] | Phase 3 | 2,199 participants (Actual) | Interventional | 2014-03-25 | Completed | ||
| The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Per[NCT00077844] | Phase 2/Phase 3 | 3,532 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158] | Phase 3 | 13,800 participants | Interventional | 2003-08-31 | Completed | ||
| An Efficacy and Safety Study of Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression Treated With Stent Implantation (PLICTS)：A Prospective Randomized Controlled Trial[NCT04067505] | Phase 3 | 224 participants (Anticipated) | Interventional | 2020-05-18 | Recruiting | ||
| RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled, Double-blind, Randomized Study of BAY59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement[NCT00362232] | Phase 3 | 3,148 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | ||
| Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty[NCT02453802] | Phase 4 | 90 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| A Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery[NCT00371683] | Phase 3 | 3,608 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes[NCT00139815] | Phase 3 | 20,078 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Influence of the Compression Method After Transradial Catheterization in Radial Artery[NCT02697526] | 274 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis[NCT02506985] | Phase 4 | 10 participants (Actual) | Interventional | 2015-07-31 | Terminated | ||
| A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolyt[NCT00077792] | Phase 3 | 20,506 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome[NCT04420312] | 1,024 participants (Actual) | Observational | 2020-03-01 | Completed | |||
| A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement[NCT00641732] | Phase 2 | 1,045 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00440193] | Phase 3 | 3,449 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study[NCT00439725] | Phase 3 | 1,197 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis[NCT03191305] | 50 participants (Anticipated) | Interventional | 2017-08-31 | Not yet recruiting | |||
| A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Antic[NCT00423319] | Phase 3 | 5,407 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp[NCT00657150] | Phase 3 | 2,055 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778] | Phase 2 | 60 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)[NCT00043784] | Phase 3 | 8,000 participants | Interventional | 2001-08-31 | Completed | ||
| Outpatient Treatment of Low-risk Patients With Pulmonary Embolism: a Randomized-controlled Trial[NCT00425542] | Phase 3 | 343 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings[NCT00622648] | Phase 4 | 8,329 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386] | Phase 3 | 60 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery[NCT00697099] | Phase 3 | 2,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery[NCT00721760] | Phase 3 | 1,003 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of Semuloparin (AVE5026) With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery[NCT00718224] | Phase 3 | 1,150 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion[NCT03630055] | Phase 3 | 1,800 participants (Anticipated) | Interventional | 2018-10-03 | Recruiting | ||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00439777] | Phase 3 | 4,833 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Multi-center、Randomize、Open、Non-inferiority Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD[NCT03277001] | 438 participants (Anticipated) | Interventional | 2017-10-01 | Not yet recruiting | |||
| Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Focus on Cost-effective Analysis and Safety Comparison Between Rivaroxaban and Enoxaparin[NCT03299296] | Phase 3 | 100 participants (Actual) | Interventional | 2017-01-01 | Enrolling by invitation | ||
| A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)[NCT00452530] | Phase 3 | 3,221 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Once Daily Enoxaparin for Outpatient Treatment of Acute Deep Venous Thrombosis and/or Pulmonary Embolism[NCT00413374] | 40 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Multicenter Open Label Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actilyse) in Patients With Acute Ischemic Stroke[NCT03151993] | Phase 3 | 336 participants (Actual) | Interventional | 2017-03-18 | Completed | ||
| Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients[NCT02301910] | Phase 3 | 392 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Pharmacodynamics Study of Enoxalow, Produced by Blau Farmacêutica S/A, Compared to Clexane, Produced by Sanofi-Aventis Farmacêutica Ltda, in Healthy Subjects After Intravenous Administration.[NCT01692171] | Phase 1 | 32 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention [NCT00046228] | Phase 3 | 2,461 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Fondaparinux as Monotherapy for Deep Vein Thrombosis and/or Pulmonary Embolism (Pilot Study)[NCT00413504] | 30 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| Trousseau Studie, Mortaliteit Door Maligniteit Bij patiënten Met Idiopatische Veneuze Tromboembolie[NCT01088334] | 630 participants (Actual) | Observational | 2002-12-31 | Terminated (stopped due to Terminated because of futility to continue, after planned interim analysis.) | |||
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism[NCT02977013] | 42 participants (Actual) | Observational | 2013-08-31 | Completed | |||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| The Safety and Efficacy of Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism in Medical Patients With Renal Insufficiency[NCT00927602] | Phase 4 | 206 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to study was stopped after enrolment of about 200 patients for slow recruitment) | ||
| Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study[NCT03303794] | Phase 3 | 25 participants (Actual) | Interventional | 2017-10-25 | Terminated (stopped due to Interim Analysis showed no significance) | ||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 [NCT00168818] | Phase 3 | 3,494 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices[NCT02345642] | 20 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study[NCT00457158] | Phase 4 | 399 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Retrievable Inferior Vena Cava Filter for Primary Pulmonary Embolism Prophylaxis in At-Risk Trauma Patients: RIPT Feasibility Trial[NCT03070834] | 42 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients[NCT00311753] | Phase 3 | 342 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients[NCT00451412] | Phase 3 | 3,254 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose)in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients [NCT01179620] | Phase 3 | 109 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.[NCT02746185] | Phase 3 | 159 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES[NCT00952380] | Phase 2 | 38 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study[NCT03045406] | Phase 3 | 1,168 participants (Actual) | Interventional | 2017-04-13 | Active, not recruiting | ||
| CONKO_011/ AIO-SUP-0115/Ass.: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients - a Randomized Phase III Study[NCT02583191] | Phase 3 | 246 participants (Actual) | Interventional | 2016-03-23 | Terminated (stopped due to Recruitment was not as expected.) | ||
| Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)[NCT02744092] | 811 participants (Actual) | Interventional | 2016-12-13 | Completed | |||
| A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancrea[NCT03139487] | Phase 2 | 176 participants (Anticipated) | Interventional | 2017-08-07 | Recruiting | ||
| A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism[NCT02585713] | Phase 3 | 300 participants (Actual) | Interventional | 2015-11-20 | Completed | ||
| Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy[NCT04508855] | 240 participants (Anticipated) | Observational | 2020-08-01 | Recruiting | |||
| A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer[NCT02073682] | Phase 3 | 1,046 participants (Actual) | Interventional | 2015-07-16 | Completed | ||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143] | Phase 3 | 3,659 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.[NCT00967382] | Phase 3 | 292 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients[NCT00876915] | Phase 3 | 218 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to slow enrollment and lack of continuing funds) | ||
| Management of Superficial Thrombophlebitis[NCT00264381] | Phase 4 | 72 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445] | 700 participants (Anticipated) | Observational | 2012-07-31 | Completed | |||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism[NCT02898051] | 370 participants (Actual) | Observational | 2011-08-31 | Active, not recruiting | |||
| Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism[NCT01164046] | Phase 3 | 56 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Due to slow inclusion of patients) | ||
| Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients[NCT01602432] | 0 participants (Actual) | Observational | 2012-11-30 | Withdrawn (stopped due to Project did not meet criteria of a research study and was confirmed as a Quality Initiative Project) | |||
| Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients[NCT01916707] | Phase 4 | 1,200 participants (Anticipated) | Interventional | 2013-07-31 | Active, not recruiting | ||
| Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928] | 70 participants (Actual) | Observational | 2012-12-03 | Completed | |||
| Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)[NCT00138099] | 140 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT[NCT01130025] | Phase 3 | 900 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Prospective, Randomized, Double-blind, Placebo Controlled, Multi-national Study of Therapeutic Anticoagulation Strategy for Acute Chest Syndrome in Adults[NCT02580773] | Phase 3 | 200 participants (Anticipated) | Interventional | 2016-12-16 | Recruiting | ||
| EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial[NCT01853202] | 40 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study[NCT02025894] | 3,032 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy[NCT00694382] | Phase 3 | 3,212 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.4 |
| Enoxaparin | 5.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 8.6 |
| Enoxaparin | 9.2 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.7 |
| Enoxaparin | 2.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.0 |
| Enoxaparin | 3.1 |
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.5 |
| Enoxaparin | 3.9 |
Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events. (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 9.4 |
| Enoxaparin | 7.8 |
Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin or transfusion of >=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.8 |
| Enoxaparin | 1.2 |
Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin; or transfusion of >= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.1 |
| Enoxaparin | 1.7 |
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.8 |
| Enoxaparin | 4.5 |
All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths. (NCT00571649)
Timeframe: Up to Day 90 + 7 days
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Any event | Death (cardiovascular) | Death (other) | VTE related death | |
| Enoxaparin | 6.2 | 1.4 | 3.7 | 1.1 |
| Rivaroxaban (Xarelto, BAY59-7939) | 6.7 | 1.4 | 4.3 | 1.0 |
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Symptomatic non-fatal PE | Symptomatic DVT in lower extremity | Asymptomatic proximal DVT in lower extremity | VTE related death | |
| Enoxaparin | 0.1 | 0.2 | 2.4 | 0.2 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 | 0.2 | 2.4 | 0.1 |
The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Symptomatic non-fatal PE | Symptomatic DVT in lower extremity | Asymptomatic proximal DVT in lower extremity | VTE related death | |
| Enoxaparin | 0.5 | 0.5 | 4.4 | 1.0 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 | 0.4 | 3.5 | 0.6 |
Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category. (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any event-Day 10 | Ischemic stroke-Day 10 | Acute MI-Day 10 | Death (cardiovascular)-Day 10 | Any event-Day 35 | Ischemic stroke-Day 35 | Acute MI-Day 35 | Death (cardiovascular)-Day 35 | Any event-Day 90 | Ischemic stroke-Day 90 | Acute MI-Day 90 | Death (cardiovascular)-Day 90 | |
| Enoxaparin | 1.0 | 0.3 | 0.4 | 0.4 | 1.6 | 0.5 | 0.5 | 0.8 | 2.8 | 1.1 | 0.7 | 1.4 |
| Rivaroxaban (Xarelto, BAY59-7939) | 1.0 | 0.3 | 0.5 | 0.4 | 1.8 | 0.5 | 0.6 | 0.9 | 2.8 | 0.8 | 0.9 | 1.4 |
Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90 (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| symptomatic VTE (incl. VTE-related death)-Day 10 | symptomatic VTE (non fatal)-Day 10 | symptomatic VTE (incl. VTE-related death)-Day 35 | symptomatic VTE (non fatal)-Day 35 | symptomatic VTE (incl. VTE-related death)-Day 90 | symptomatic VTE (non fatal)-Day 90 | |
| Enoxaparin | 0.6 | 0.3 | 1.4 | 0.7 | 1.9 | 0.9 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 | 0.5 | 1.0 | 0.6 | 1.7 | 0.7 |
Event rate based on time from randomization to first occurrence of ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 1.19 |
| Placebo | 1.49 |
Event rate based on time from randomization to first occurrence of VTE-related death (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.72 |
| Placebo | 0.77 |
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE and ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 1.31 |
| Placebo | 1.80 |
Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke, and CV death (death due to a known CV cause and death in which a CV cause cannot be ruled out; by this definition, a VTE-related death was considered a CV death) as adjudicated by CEC was reported. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 1.58 |
| Placebo | 2.03 |
Event rate based on time from randomization to the first occurrence of a symptomatic VTE (adjudicated by CEC) was assessed. Symptomatic VTE included lower extremity DVT and non-fatal PE. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.19 |
| Placebo | 0.42 |
A major bleeding event was defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria. A major bleeding event was defined as overt bleeding that was associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or a critical site defined as intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or a fatal outcome. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or last dose + 2 days. (NCT02111564)
Timeframe: From randomization to 2 days after the last dose (Day 45)
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.28 |
| Placebo | 0.15 |
Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45
| Intervention | Events per 100 participants in 45 days (Number) |
|---|---|
| Rivaroxaban 10 mg or 7.5 mg | 0.84 |
| Placebo | 1.11 |
To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by number of participants with confirmed HA-VTE. (NCT04354155)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Thromboprophylaxis | 2 |
"The safety of in-hospital thromboprophylaxis with twice-daily low-dose enoxaparin thromboprophylaxis will be measured by cumulative incidence (number of participants) of ISTH-defined clinically-relevant bleeding events during hospitalization. Clinically relevant bleeding episodes may include any of the following:~fatal bleeding;~clinically overt bleeding associated with a decline in hemoglobin of ≥2g/dL in a 24h period;~retroperitoneal, pulmonary, or central nervous system bleeding;~bleeding requiring surgical intervention in an operating suite;~bleeding for which a blood product is administered (blood product administration not directly attributable to the patient's underlying condition);~bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating suite." (NCT04354155)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Thromboprophylaxis | 0 |
The median twice-daily enoxaparin dose, as measured in mg/kg, required to achieve a 4-hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL in children hospitalized with COVID-19, and to compare dose-requirements by age group (<12 and those >12 years of age). (NCT04354155)
Timeframe: 4 hours post initial dose
| Intervention | mg/kg (Median) | |
|---|---|---|
| Children 12 years or older | Children less than 12 years | |
| Thromboprophylaxis | 0.5 | 0.52 |
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.30 |
| Enoxaparin | 1.90 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.03 |
| Enoxaparin | 1.45 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.70 |
| Enoxaparin | 6.02 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.94 |
| Enoxaparin | 1.45 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.43 |
| Enoxaparin | 5.99 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 5.70 |
| Enoxaparin | 7.18 |
Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.67 |
| Enoxaparin | 0.57 |
A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.36 |
| Enoxaparin 40 mg | 2.12 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.22 |
| Enoxaparin 40 mg | 0.24 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. PE: non-fatal or fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.22 |
| Enoxaparin 40 mg | 0.24 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.40 |
| Enoxaparin 40 mg | 2.50 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 6.44 |
| Enoxaparin 40 mg | 6.50 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.71 |
| Enoxaparin 40 mg | 2.93 |
Events were adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.00 |
| Enoxaparin 40 mg | 0.15 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.15 |
| Enoxaparin 40 mg | 0.49 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.15 |
| Enoxaparin 40 mg | 0.37 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 3.11 |
| Enoxaparin 40 mg | 3.46 |
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Key Secondary Efficacy population: all who received at least 1 dose of parenteral study drug and: (those without suspected VTE events during Parenteral Treatment) had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or (those with suspected VTE events during Parenteral Treatment) had those suspected VTE events adjudicated as non-events, and had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or had an adjudicated total VTE during Parenteral Treatment; or had an adjudicated VTE-related death during Parenteral Treatment. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day
| Intervention | Event rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 1.73 |
| Enoxaparin 40 mg | 1.61 |
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Secondary Efficacy Evaluable includes those who had an adjudicated, evaluable ultrasound at end of parenteral treatment and for those with a suspected symptomatic event, the result of the adjudication for the symptomatic event was not inadequate; or those with an adjudicated event that was part of the composite endpoint.. Event rate (%): n/N*100 (n=number with observation; N=total secondary efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1 to last dose of parenteral study drug plus 1 day
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 1.66 |
| Enoxaparin 40 mg | 1.51 |
Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal (N-F) PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. All-Cause Death (A-C Death). Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 6.44 |
| Enoxaparin 40 mg | 6.63 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.06 |
| Enoxaparin 40 mg | 0.09 |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs, for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of drug to last dose of drug plus 2 days
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 7.73 |
| Enoxaparin 40 mg | 6.81 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 7.16 |
| Enoxaparin 40 mg | 6.83 |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis, if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for bleeding endpoints. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days
| Intervention | Event Rate (%): (Number) |
|---|---|
| Apixaban 2.5 mg | 2.26 |
| Enoxaparin 40 mg | 1.90 |
VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. All efficacy events were adjudicated by the Independent Central Adjudication Committee (ICAC). Event rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.71 |
| Enoxaparin 40 mg | 3.06 |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Major bleeding: acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or bleeding in a critical site or bleeding which is fatal. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage; rectal blood loss. Treatment Period=onset from first dose of study drug through 2 days after last dose of study drugs. Incidence: Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 2.67 |
| Enoxaparin 40 mg | 2.08 |
Major bleeding was adjudicated by an ICAC using criteria from the International Society on Thrombosis and Hemostasis (ISTH) and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or bleeding in a critical site or bleeding which is fatal. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.47 |
| Enoxaparin 40 mg | 0.19 |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). (NCT00457002)
Timeframe: Intended Treatment Period
| Intervention | Event Rate (%) (Number) |
|---|---|
| Apixaban 2.5 mg | 0.40 |
| Enoxaparin 40 mg | 0.80 |
Events of Special Interest include: adjudicated thrombocytopenia, adjudicated myocardial infarction (MI), adjudicated stroke, and adjudicated MI or stroke. Incidence determined by Event Rate (%): n/N*100 (n=number with observation; N=total efficacy evaluable participants). Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | Event Rate (%) (Number) | |||
|---|---|---|---|---|
| MI or stoke (N=3183, 3216) | MI (N=3184, 3217) | Stroke (N=3183, 3216) | Thrombocytopenia (N=3184, 3217) | |
| Apixaban 2.5 mg | 0.38 | 0.22 | 0.16 | 0.19 |
| Enoxaparin 40 mg | 0.37 | 0.12 | 0.25 | 0.09 |
Diastolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken with the participant either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | mmHg (Mean) | |
|---|---|---|
| Day of Discharge from Hospital (N=1607, 1625) | Day 30 of Treatment + 2 (N=2227,2301) | |
| Apixaban 2.5 mg | -1.0 | 0.0 |
| Enoxaparin 40 mg | -0.4 | -0.5 |
Heart Rate was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Heart rate was measured in beats per minute (bpm) and could have been taken with participants either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | bpm (Mean) | |
|---|---|---|
| Hospital Discharge (N=1606,1622) | Day 30 of treatment (N=2225,2299) | |
| Apixaban 2.5 mg | -5.4 | -4.0 |
| Enoxaparin 40 mg | -5.1 | -4.3 |
Systolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken either sitting, standing, or supine. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | mmHg (Mean) | |
|---|---|---|
| Discharge from Hospital (N=1607, 1625) | Day 30 of Treatment + 2 (N=2227, 2301) | |
| Apixaban 2.5 mg | -3.0 | -2.3 |
| Enoxaparin 40 mg | -2.4 | -2.9 |
Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for AEs, and 30 days after last dose of study drugs for SAEs and deaths. (NCT00457002)
Timeframe: Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AEs | SAEs | Bleeding AEs | Discontinuations Due to AE | Deaths | |
| Apixaban 2.5 mg | 1871 | 611 | 244 | 290 | 131 |
| Enoxaparin 40 mg | 1910 | 601 | 221 | 262 | 133 |
Special interest include: liver function test increases, AEs related to liver function, and neurologic AEs. Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drug when summarizing AEs and through 30 days after the last dose when summarizing SAEs. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days (AEs) and plus 30 days (SAEs)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Neurologic AEs | Neurologic SAEs | Liver-related AEs | Liver-related SAEs | |
| Apixaban 2.5 mg | 45 | 5 | 127 | 9 |
| Enoxaparin 40 mg | 42 | 1 | 142 | 12 |
Liver function tests: Alanine aminotransferase (ALT) U/L; Aspartate aminotransferase (AST) U/L; Alkaline phosphatase U/L; Total Bilirubin (TBili) mg/dL. Elevations consist of >3*Upper Limit of Normal (ULN) for ALT and AST and elevation of >2*ULN for Bilirubin. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST Elevation >3*ULN (N=2831, 2863) | ALT Elevation >3*ULN (N=2827, 2861) | AST + ALT >3*ULN on same date (N= 2827, 2861) | TBili >2*ULN (N= 2853, 2884) | ALT or AST >3*ULN + TBili >2*ULN (N=2818,2855) | ALT>3*ULN + TBili >2*ULN (N=2817, 2853) | |
| Apixaban 2.5 mg | 23 | 22 | 14 | 13 | 2 | 0 |
| Enoxaparin 40 mg | 28 | 32 | 13 | 14 | 2 | 2 |
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if PreRx < LLN then use < 0.75* PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if PreRx < LLN then use < 0.75*PreRx or > ULN if PreRx > ULN then use > 1.25*PreRx or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if PreRx < LLN then use < 0.9*PreRx or > ULN if PreRx > ULN then use > 1.1*PreRx or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if PreRx < LLN then use < 0.95*PreRx or > ULN if PreRx > ULN then use > 1.05*PreRx or < LLN. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Calcium < 0.8*LLN (N=2861, 2893) | Calcium > 1.2*ULN (N=2861, 2893) | Chloride < 0.9*LLN (N=2861, 2886) | Chloride > 1.1*ULN (N=2861, 2886) | Bicarbonate < 0.75*LLN (N=2831, 2855) | Bicarbonate > 1.25*ULN (N=2831, 2855) | Potassium < 0.9*LLN (N=2851, 2878) | Potassium > 1.1*ULN (N=2851, 2878) | Sodium < 0.95*LLN (N=2862, 2888) | Sodium > 1.05*ULN (N=2862, 2888) | |
| Apixaban 2.5 mg | 6 | 3 | 25 | 5 | 5 | 6 | 61 | 140 | 23 | 9 |
| Enoxaparin 40 mg | 8 | 3 | 25 | 1 | 6 | 4 | 58 | 137 | 25 | 6 |
Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if PreRx < LLN then use 0.9* PreRx or > ULN if PreRx > ULN then use 1.1 *PreRx or
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Glucose Fasting <0.9*LLN (N=284,287) | Glucose Fasting > 1.5*ULN (N=284,287) | Total Protein < 0.9 *LLN (N=2864, 2890) | Total Protein > 1.1*ULN (N=2864, 2890) | Creatine kinase >5*ULN U/L(N=2856, 2888) | Uric acid > 1.5* ULN (N=2862, 2889) | |
| Apixaban 2.5 mg | 5 | 39 | 78 | 16 | 8 | 47 |
| Enoxaparin 40 mg | 3 | 30 | 51 | 8 | 10 | 44 |
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). Absolute (Abs). Hemoglobin: >2 g/dL decrease compared to PreRx value or value <=8 g/dL; Hematocrit: <0.75*PreRx; Erythrocytes: <0.75*PreRx c/µL; Leukocytes: <0.75*LLN or > 1.25*ULN, if PreRx
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin >2 g/dL decrease (N=2835, 2871) | Hematocrit <0.75*PreRx (N=2688, 2722) | Platelet Count < 100*10^9 c/L (N=2761, 2799) | Erythrocytes <0.75*PreRx c/µL (N=2697, 2730) | Leukocytes <0.75*LLN (N= 2835, 2869) | Leukocytes > 1.25*ULN (N=2835, 2869) | Abs Eosinophils > 0.75*10^3 c/µL (N=20, 24) | Abs Lymphocytes < 0.750*10*3 c/ µL (N=20, 24) | Abs Monocytes > 2000/MM^3 (N= 19, 25) | |
| Apixaban 2.5 mg | 133 | 23 | 9 | 28 | 64 | 331 | 1 | 4 | 1 |
| Enoxaparin 40 mg | 98 | 17 | 7 | 16 | 55 | 283 | 1 | 2 | 0 |
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. Samples for laboratories obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. (NCT00457002)
Timeframe: Day 1 to last dose of study drug plus 2 days
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Alkaline phosphatase U/L > 2*ULN(N=2866, 2895) | ALT U/L > 3*ULN (N=2827, 2861) | AST U/L > 3*ULN (N=2831, 2863) | Bilirubin Direct mg/dL > 1.5*ULN (N=2782, 2821) | Bilirubin Total mg/dL > 2*ULN (N=2853, 2884) | BUN mg/dL > 1.5*ULN (N=2864, 2891) | Creatinine mg/dL > 1.5*ULN (N=2862, 2892) | |
| Apixaban 2.5 mg | 35 | 23 | 24 | 123 | 17 | 194 | 150 |
| Enoxaparin 40 mg | 47 | 33 | 29 | 106 | 15 | 188 | 156 |
Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0385 |
| Enoxaparin + Warfarin | 0.0800 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0322 |
| Enoxaparin + Warfarin | 0.0395 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0234 |
| Enoxaparin + Warfarin | 0.0292 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0280 |
| Enoxaparin + Warfarin | 0.0448 |
VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0699 |
| Enoxaparin + Warfarin | 0.1261 |
VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0226 |
| Enoxaparin + Warfarin | 0.0269 |
All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0056 |
| Enoxaparin + Warfarin | 0.0182 |
Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0430 |
| Enoxaparin + Warfarin | 0.0971 |
Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.1170 |
| Enoxaparin + Warfarin | 0.1878 |
DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0084 |
| Enoxaparin + Warfarin | 0.0133 |
PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0104 |
| Enoxaparin + Warfarin | 0.0095 |
Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.1502 |
| Enoxaparin + Warfarin | 0.2514 |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0046 |
| Enoxaparin + Warfarin | 0.0061 |
Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0157 |
| Enoxaparin + Warfarin | 0.0198 |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0058 |
| Enoxaparin + Warfarin | 0.0087 |
Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00643201)
Timeframe: First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AE | SAE | Bleeding AE or SAE | Discontinued Due to AE or SAE | Death | |
| Apixaban | 1795 | 417 | 415 | 162 | 37 |
| Enoxaparin + Warfarin | 1923 | 410 | 695 | 199 | 44 |
Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if pre-dose < LLN then use 0.9* pre-dose or > ULN if pre-dose > ULN then use 1.1 *pre-dose or
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Creatine Kinase High (N=2601, 2596) | Uric Acid High (N=2601, 2596) | Total Protein Low (N=2601, 2596) | Total Protein High (N=2601, 2596) | |
| Apixaban | 20 | 6 | 15 | 0 |
| Enoxaparin + Warfarin | 24 | 3 | 16 | 0 |
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*pre-dose or > ULN if pre-dose > ULN then use > 1.05*pre-dose or < LLN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bicarbonate Low (N=2600,2593) | Bicarbonate High (N=2600,2593) | Total Calcium Low (N=2601,2596) | Total Calcium High (N=2601,2596) | Chloride Low Total Calcium Low (N=2601,2596) | Chloride Low Total Calcium High (N=2601,2596) | Potassium Low (N=2601,2596) | Potassium High (N=2601,2596) | Sodium Low (N=2601,2596) | ||
| Apixaban | 44 | 17 | 3 | 12 | 5 | 0 | 26 | 19 | 10 | 4 |
| Enoxaparin + Warfarin | 31 | 11 | 10 | 11 | 3 | 1 | 22 | 22 | 6 | 4 |
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: < 0.75*LLN, > 1.25*ULN; Hemoglobin: <= 11.5 g/dL (males), <= 9.5 g/dL (females); Hematocrit: <= 37% (males), <= 32% (females); Erythrocytes: <0.75*10^6 c/µL*PreRx; Platelet count: < 75*10^9 c/L, > 700*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.750*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes> 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL, > 7.5*10^3 c/ µL. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erthrocytes Low (N=2599, 2593) | Hematocrit Low (N=2588, 2587) | Hemoglobin Low (N=2599, 2593) | Platelet Count Low (N=2594, 2589) | Leukocytes Low (N=2528, 2519) | Leukocytes High (N=2528, 2519) | Absolute Basophils High (N=2594,2589) | Absolute Eosinophils High (N=2594,2589) | Absolute Lyphocytes Low (N=2594,2589) | Absolute Lyphocytes High (N=2594,2589) | Absolute Monocytes High (N=2594,2589) | Absolute Neutrophils Low (N=2594,2589) | |
| Apixaban | 23 | 26 | 96 | 23 | 41 | 26 | 1 | 84 | 94 | 4 | 1 | 9 |
| Enoxaparin + Warfarin | 17 | 20 | 101 | 13 | 41 | 15 | 2 | 79 | 76 | 3 | 2 | 20 |
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| BUN High (N=517, 523) | Creatinine High (N=2601, 2596) | ALT High (N=2601, 2598) | ALP High (N=2601, 2598) | AST High (N=2601, 2598) | Direct Bilirubin High (N=2601, 2593) | Total Bilirubin High (N=2601, 2597) | |
| Apixaban | 2 | 47 | 52 | 35 | 40 | 28 | 8 |
| Enoxaparin + Warfarin | 7 | 37 | 145 | 27 | 40 | 21 | 7 |
All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Blood in Urine High (N=2289, 2273) | Glucose in Urine High (N=2289, 2273) | Leukocyte Esterase in Urine High (N=2289, 2273) | Protein in Urine High (N=2289, 2273) | RBC + WBC in Urine High (N=1685, 1719) | RBC in Urine High (N=1293, 1389) | WBC in Urine High (N=1354, 1361) | |
| Apixaban | 85 | 46 | 105 | 41 | 359 | 111 | 274 |
| Enoxaparin + Warfarin | 127 | 31 | 102 | 50 | 361 | 140 | 263 |
Measure Description: Normal hemoglobin range for adult women - 12 - 16 g/dL. Lower levels indicate worse outcomes. (NCT02829957)
Timeframe: 3 months
| Intervention | g/dl (Median) |
|---|---|
| Rivaroxaban | 12.8 |
| Apixaban | 13.25 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 1 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 4 |
| Apixaban | 2 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 1, 2, and 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
"Measure Description: A PBAC Score of < 100 indicates a normal menstrual cycle. The lowest possible score would be zero. Higher values indicate worse outcomes. The higher theoretical range value cannot be calculated. The scoring mechanism is as follows;~Towels~1 point for each lightly stained towel~5 points or each moderately soiled towel~20 points if the towel is completely saturated with blood~Tampons~1 point for each lightly stained tampon~5 points for each moderately soiled tampon~10 points if the tampon is completely saturated with blood~Clots~1 point for small clots~5 points for large clots" (NCT02829957)
Timeframe: 3 months
| Intervention | score on a scale (Median) |
|---|---|
| Rivaroxaban | 292 |
| Apixaban | 146 |
The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. (NCT02829957)
Timeframe: 3 months
| Intervention | Score (Median) |
|---|---|
| Rivaroxaban | 55.5 |
| Apixaban | 45.6 |
Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability. (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 10 |
| VKA-based Regimen | 3 |
"An alternative definition characterized stroke (ischemic, hemorrhagic, or undetermined) as an abrupt onset, over minutes to hours, of a focal neurological deficit in the distribution of a single brain artery that was not due to an identifiable nonvascular cause (ie, brain tumor or trauma), and that either lasted at least 24 hours or resulted in death within 24 hours of onset.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 1 |
| VKA-based Regimen | 2 |
"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~Major bleeding was defined by the International Society on Thrombosis and Hemostasis (ISTH) as fatal bleeding and/or bleeding that is symptomatic and occurs in a critical area or organ and/or extrasurgical site bleeding causing a fall in hemoglobin level of >2 g/dL or leads to blood transfusion, surgical site bleeding that requires a second intervention, causes hemarthrosis that delays mobilization or wound healing, or causes hemodynamic instability." (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 1 |
| VKA-based Regimen | 2 |
"Stroke (ischemic, hemorrhagic, or undetermined) was defined by Valve Academic Research Consortium-2 (VARC-2) as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury following hemorrhage or infarction. A stroke event was based on any of the following: duration of neurological dysfunction >24 hours (h), duration of neurological dysfunction <24 h in case of imaging-documented new hemorrhage or infarction, and a neurological dysfunction resulting in death.~SEE was defined as an arterial embolism resulting in clinical ischemia, excluding the central nervous system, coronary, and pulmonary arterial circulation.~CV mortality was defined as cardiac or vascular death according to Academic Research Consortium." (NCT02942576)
Timeframe: Day 1 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban-based Regimen | 1 |
| VKA-based Regimen | 0 |
Descriptive statistics were used to report the number of participants with at least 1 symptomatic VTE recurrence. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| ETNA-VTE | 100 |
Descriptive statistics were used to report the duration of edoxaban treatment. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Month 1 ongoing | Month 3 ongoing | Month 6 ongoing | Month 12 ongoing | Month 18 ongoing | Participants off edoxaban treatment at 18 months | |
| ETNA-VTE | 2527 | 2346 | 1842 | 1272 | 713 | 1910 |
Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | days (Median) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 11.0 | 9.5 | 0 | 15.0 |
Descriptive statistics were used to assess the duration of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | days (Median) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 18.0 | 44.5 | 8.0 | 16.0 |
Descriptive statistics were used to report the number of participants experiencing recurrent VTE and at least 1 real world safety event. VTE recurrence data were reported by recurrent deep vein thrombosis (DVT), recurrent pulmonary embolism (PE) with DVT, and recurrent PE only. Recurrent VTE events were based on adjudicated events. Real world safety events included all-cause death, cardiovascular (CV)-related death, VTE-related death, stroke, systemic embolic event, and hospitalization related to CV. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Recurrent DVT only | Recurrent PE with DVT | Recurrent PE only | All-cause death | Cardiovascular-related death | Venous thromboembolism-related death | Stroke | Systemic embolic event | Hospitalization related to CV | |
| ETNA-VTE | 61 | 7 | 31 | 95 | 23 | 1 | 26 | 2 | 253 |
Adverse drug reactions were reported and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observational period (18 months)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Haemorrhage | Gastrointestinal haemorrhage | Menorrhagia | Epistaxis | Fatigue | Nausea | Dizziness | Rash | Headache | Pruritus | |
| ETNA-VTE | 35 | 12 | 12 | 11 | 8 | 8 | 7 | 7 | 5 | 5 |
Descriptive statistics were used to report the number of participants with overall symptomatic VTE recurrence. VTE recurrence data were further reported by recurrent deep venous thrombosis (DVT), recurrent pulmonary embolism (PE) with deep venous thrombosis (DVT), and recurrent PE only. Recurrent VTE events were based on adjudicated events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Recurrent VTE | Recurrent DVT only | Recurrent PE with DVT | Recurrent PE only | All-cause death | CV-related death | VTE-related death | Stroke | Systemic embolic event | Hospitalization-related to cardiovascular | |
| ETNA-VTE | 37 | 27 | 1 | 9 | 50 | 11 | 1 | 15 | 1 | 167 |
Descriptive statistics were used to report the number of participants with bleeding events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with any bleeding events | At least 1 major bleeding event | Clinically relevant non-major bleeding event | Minor | Gastrointestinal bleeding event | Epidural or subdural haematoma bleeding event | Intra-ocular bleeding event | Intra-articular bleeding event | Pleural bleeding event | Other bleeding event | Spontaneous bleeding | Provoked bleeding | Unknown bleeding | |
| ETNA-VTE | 304 | 38 | 82 | 300 | 77 | 4 | 5 | 3 | 1 | 319 | 287 | 115 | 18 |
Descriptive statistics were used to report the number of participants with pre-defined adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Stroke | Bleeding events | Systemic embolic events | Non-valvular atrial fibrillation | Malignancy | Others | |
| ETNA-VTE | 2 | 75 | 0 | 0 | 0 | 4 |
Descriptive statistics were used to assess the number of participants with risk factors for thromboembolic events. (NCT02943993)
Timeframe: at Baseline
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Puerperium | Prolonged immobilisation | >5 days in bed | History of major surgery trauma | Known thrombophilic conditions | |
| ETNA-VTE | 9 | 401 | 218 | 359 | 111 |
Descriptive statistics were used to report the number of stroke events. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | events (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall treatment: Total number of stroke events | Overall treatment: Ischemic events | Overall treatment: Haemorrhagic events | Overall treatment: Unknown events | On treatment: Total number of stroke events | On treatment: Ischemic events | On treatment: Haemorrhagic events | On treatment: Unknown events | |
| ETNA-VTE | 27 | 17 | 5 | 5 | 16 | 12 | 3 | 1 |
Descriptive statistics were used to report the number of systemic embolic events (SEE). (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Systemic embolic events (Number) | |
|---|---|---|
| Upper/lower extremity | Renal | |
| ETNA-VTE | 1 | 1 |
Descriptive statistics were used to report an overview of participants with adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Death due to ADR | Participants with at least 1 ADR | Participants with at least 1 serious ADR | Study discontinuation due to ADR | |
| ETNA-VTE | 2 | 142 | 59 | 0 |
Descriptive statistics were used to assess the number of recurrent VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | VTE recurrences (Number) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 39 | 28 | 1 | 9 |
Descriptive statistics were used to describe the number of VTE events reported by the patient. (NCT02943993)
Timeframe: Baseline up to end of observation period (18 months)
| Intervention | VTE recurrences (Number) | |||
|---|---|---|---|---|
| Total number of VTE recurrences | Deep vein thrombosis (DVT) only | Pulmonary embolism with DVT | Pulmonary embolism only | |
| ETNA-VTE | 105 | 64 | 7 | 32 |
All bleeding events included major bleeding defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells (RBCs), clinically relevant non-major bleeding defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug), nuisance bleeding, or a combination of bleeding events. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 25 |
| Standard of Care | 24 |
Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 3 |
| Standard of Care | 5 |
Any bleeding event defined as major and clinically relevant non-major bleeding (CRNM) events was reported. Major bleeding was defined as defined as a composite of any of the following: fatal bleeding; and/or symptomatic bleeding in critical area or organ such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, pulmonary, or pericardial, or intramuscular with compartment syndrome; and/or bleeding that causes a decrease in hemoglobin of at least 2 g/dL or more, or leading to transfusion of the equivalent of two or more units of whole blood or red blood cells. CRNM was defined as acute or sub-acute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of the following: a hospital admission for bleeding; a physician-guided medical or surgical treatment for bleeding or a change in antithrombotic therapy (including interruption or discontinuation of study drug). (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 8 |
| Standard of Care | 5 |
No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus at baseline and at Month 3. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 21 |
| Standard of Care | 29 |
No change or extension of thrombotic burden as assessed by quantitative diagnostic imaging of the index qualifying VTE thrombus. Imaging criteria for VTE included: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 35 |
| Standard of Care | 47 |
Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 5 |
| Standard of Care | 2 |
Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban | 7 |
| Standard of Care | 2 |
All-cause mortality is defined as death due to any cause. Adjudicated data are reported for overall all-cause mortality, all-cause mortality by the primary cause of death, and primary cause of death further described by additional specifications. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Participants with adjudicated all-cause mortality | Venous thromboembolism (VTE)-related death | Venous thromboembolism (VTE)-related death: Unexplained death which VTE cannot be ruled out | Other known causes of death | Other known causes of death: Cancer | Other known causes of death: Infectious disease | Other known causes of death: Other | |
| Edoxaban | 2 | 1 | 1 | 1 | 0 | 0 | 1 |
| Standard of Care | 3 | 1 | 1 | 2 | 1 | 1 | 0 |
Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Pulmonary embolism (PE) with or without deep vein thrombosis (DVT) | Fatal PE | Non-fatal PE | Deep vein thrombosis (DVT) only | Fatal DVT | Non-fatal DVT | Unexplained death which VTE cannot be ruled out | |
| Edoxaban | 0 | 0 | 0 | 5 | 0 | 4 | 1 |
| Standard of Care | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Death as a result of VTE | Unexplained death which VTE cannot be ruled out | |
| Edoxaban | 1 | 1 |
| Standard of Care | 1 | 1 |
Death from venous thromboembolism (VTE) is based on objective diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Pulmonary embolism (PE) with or without deep vein thrombosis (DVT) | Fatal PE | Non-fatal PE | Deep vein thrombosis (DVT) only | Fatal DVT | Non-fatal DVT | Unexplained death which VTE cannot be ruled out | |
| Edoxaban | 1 | 0 | 1 | 6 | 0 | 5 | 1 |
| Standard of Care | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
Diagnosis of recurrent VTE requires the confirmation imaging and ≥1 symptom of VTE. Death from VTE is based on diagnostic testing, autopsy or death which cannot be attributed to documented cause for which VTE cannot be ruled out. No change or extension of thrombotic burden (quantitative diagnostic imaging) of the index qualifying VTE thrombus. Imaging criteria for VTE: - Abnormal compression ultrasonography where compression had been normal or, if non-compressible during screening, an increase in diameter of the thrombus during full compression; - An extension of the echogenic intra-luminal thrombus or absence of flow in the central venous system on Doppler ultrasonography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect, or an extension of non-visualization of veins in the presence of a sudden cut-off on venography. - An extension of an intraluminal filling defect, or a new intraluminal filling defect on computed tomography angiogram (CTA). (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Symptomatic recurrent VTE | PE with or without DVT | DVT only | Death as a result of VTE | Unexplained death which VTE cannot be ruled out | No change or extension of thrombotic burden | |
| Edoxaban | 4 | 0 | 4 | 1 | 1 | 21 |
| Standard of Care | 1 | 1 | 0 | 1 | 1 | 29 |
Deep vein thrombosis was assessed by ultrasonography or magnetic resonance venography (MRV), catheter-related thrombosis was assessed by ultrasonography or echocardiography, sino-venous thrombosis was assessed by brain MRI, and pulmonary embolism was assessed by nuclear ventilation/perfusion (V/Q) scanning. (NCT02798471)
Timeframe: From randomization up to Month 12
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Main Treatment: Participants with DVT only | Main Treatment: Participants with catheter-related thrombosis | Main Treatment: Participants with cerebral sino-venous DVT thrombosis | Main Treatment: Participants with PE with or without DVT | Extension Treatment: Participants with DVT | Extension Treatment: Participants with catheter-related thrombosis | Extension Treatment: Participants with sino-venous DVT thrombosis | Extension Treatment: Participants with PE | Overall Treatment: Participants with DVT | Overall Treatment: Participants with catheter-related thrombosis | Overall Treatment: Participants with sino-venous DVT thrombosis | Overall Treatment: Participants with PE | |
| Edoxaban | 4 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 5 | 1 | 1 | 1 |
| Standard of Care | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Diagnosis of recurrent venous thromboembolism (VTE) requires the confirmation by diagnostic imaging and at least one of the symptoms of VTE from such areas as lower or upper extremity, catheter related thrombosis, pulmonary embolism, or sinovenous thrombosis. (NCT02798471)
Timeframe: Randomization to Month 3
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Symptomatic VTE | Pulmonary embolism (PE) with or without deep vein thrombosis (DVT) | Deep vein thrombosis (DVT) only | |
| Edoxaban | 4 | 0 | 4 |
| Standard of Care | 1 | 1 | 0 |
Clinically relevant bleeding (i.e., major or clinically relevant non-major bleeding) occurring during treatment plus 3 days after their last dose for that time period. (NCT00986154)
Timeframe: 12 months from time of randomization
| Intervention | participants with an event (Number) |
|---|---|
| Heparin/Edoxaban Tosylate | 349 |
| Heparin/Warfarin | 423 |
"Symptomatic recurrent Venous Thromboembolism (VTE), i.e., the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE occurring during the Overall Study Period.~Overall Study Period defined as The time from the reference date (randomization date/initial dose of study drug date) to the last study follow-up visit." (NCT00986154)
Timeframe: 12 months from time of randomization
| Intervention | number or participants with an event (Number) |
|---|---|
| Heparin/Edoxaban Tosylate | 130 |
| Heparin/Warfarin | 146 |
(NCT00986154)
Timeframe: 12 months from time of randomization
| Intervention | number of participants with event (Number) |
|---|---|
| Heparin/Edoxaban Tosylate | 228 |
| Heparin/Warfarin | 228 |
Our primary outcome will be to assess the Anti Xa level drawn 3.5-4 hours after the third dose of Lovenox (enoxaparin) to assess if this is in the prophylactic range. (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | IU/mL (Mean) |
|---|---|
| Enoxaparin Once Daily | 0.14 |
| Enoxaparin Twice Daily | 0.30 |
We will assess if any of the subjects has an Anti Xa level that is in the supraprophylactic range (treatment range). (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | participants (Number) |
|---|---|
| Enoxaparin Once Daily | 0 |
| Enoxaparin Twice Daily | 0 |
Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) |
|---|---|
| FXa Inhibitor: Apixaban | -93.3 |
| FXa Inhibitor: Rivaroxaban | -94.1 |
| FXa Inhibitor: Edoxaban | -71.3 |
| FXa Inhibitor: Enoxaparin | -75.41 |
| FXa Inhibitor: Rivaroxaban - Additional Participants | -96.3 |
Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy. (NCT02329327)
Timeframe: 12 Hours (post infusion)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Excellent/Good | Poor/None | |
| Andexanet: High Dose | 54 | 17 |
| Andexanet: High Dose - Additional Participant | 1 | 0 |
| Andexanet: Low Dose | 218 | 51 |
| Andexanet: Low Dose - Additional Participant | 1 | 0 |
| Bleed Type: Gastrointestinal | 61 | 13 |
| Bleed Type: Intracranial Hemorrhage | 193 | 51 |
| Bleed Type: Intracranial Hemorrhage - Additional Participants | 2 | 0 |
| Bleed Type: Other | 18 | 4 |
| FXa Inhibitor: Apixaban | 134 | 35 |
| FXa Inhibitor: Edoxaban | 22 | 6 |
| FXa Inhibitor: Enoxaparin | 14 | 2 |
| FXa Inhibitor: Rivaroxaban | 102 | 25 |
| FXa Inhibitor: Rivaroxaban - Additional Participants | 2 | 0 |
| Overall | 272 | 68 |
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) |
|---|---|
| Excellent/Good | |
| FXa Inhibitor: Rivaroxaban - Additional Participants | -96.3 |
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) | |
|---|---|---|
| Excellent/Good | Poor/None | |
| FXa Inhibitor: Apixaban | -93.4 | -93.3 |
| FXa Inhibitor: Edoxaban | -75.8 | -65.2 |
| FXa Inhibitor: Enoxaparin | -75.20 | -78.44 |
| FXa Inhibitor: Rivaroxaban | -94.6 | -92.4 |
(NCT02072434)
Timeframe: Randomization to end of follow-up (within 2 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Edoxaban | 0.5 |
| Warfarin | 1 |
(NCT02072434)
Timeframe: During treatment period (within 2 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Edoxaban | 1.5 |
| Warfarin | 1 |
(NCT02072434)
Timeframe: From randomization to the end of follow-up (within 2 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Edoxaban | 0.7 |
| Warfarin | 1.4 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.71 |
| Enoxaparin 30 mg Twice a Day (Bid) | 9.34 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.94 |
| Enoxaparin 30 mg Twice a Day (Bid) | 10.11 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.32 |
| Enoxaparin 30 mg Twice a Day (Bid) | 8.97 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.37 |
| Enoxaparin 30 mg Twice a Day (Bid) | 8.66 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.14 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.88 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.04 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.48 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 47 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 0.31 |
| Enoxaparin 30 mg Twice a Day (Bid) | 0.21 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 47 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 0.35 |
| Enoxaparin 30 mg Twice a Day (Bid) | 0.11 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.16 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.98 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.09 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.47 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.25 |
| Enoxaparin 30 mg Twice a Day (Bid) | 2.25 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.09 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.67 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.84 |
| Enoxaparin 30 mg Twice a Day (Bid) | 9.80 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.71 |
| Enoxaparin 30 mg Twice a Day (Bid) | 9.11 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, anesthesia and surgery reports, number of transfusions (NCT00362232)
Timeframe: Up to 47 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 2.04 |
| Enoxaparin 30 mg Twice a Day (Bid) | 2.33 |
Blinded, adjudicated assessments of all available information (eg, anesthesia and surgery reports, laboratory results, number of transfusions, autopsy report) (NCT00362232)
Timeframe: from start of double-blind study medication to last dose of double-blind study medication plus two days. The average duration of double-blind treatment was 12 days in each treatment group (safety population).
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 0.66 |
| Enoxaparin 30 mg Twice a Day (Bid) | 0.27 |
Event rate was number of participants with all-cause death divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 0.19 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.19 |
An ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 1.97 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.40 |
ICAC adjudicated suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 1.25 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.00 |
ICAC adjudicated suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 1.19 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.81 |
ICAC adjudicated cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 0.13 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.00 |
ICAC adjudicated VTE, acute clinically overt bleeding events, suspected thrombocytopenia, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 9.90 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 10.60 |
ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 2.13 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.97 |
ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. VTE includes DVT and PE. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 2.05 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.73 |
VTE / VTE-related death was defined as the combination of fatal or non-fatal PE, and symptomatic or asymptomatic DVT. A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. An ICAC adjudicated all venograms, suspected symptomatic DVT and PE, and cause of death. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 8.91 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 8.61 |
A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. An ICAC adjudicated all venograms, suspected proximal DVT and non-fatal PE, and all-cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed and reported as percentage (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 2.05 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.64 |
An Independent Central Adjudication Committee (ICAC) adjudicated all venograms, suspected symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed and reported as percentage (%). Surgery=Day 1; Randomization/Treatment started on Day of Surgery or the next day (Day 1 or Day 2). A mandatory bilateral ascending contrast venogram was performed on all participants after 12 days (±2 days) of study treatment. Intended Treatment Period=starts on the day of randomization; for treated participants, the period ends at the latter of 2 days after last dose of study drug or 14 days after the first dose of study drug; for randomized participants who were not treated, the period ends 14 days after randomization. (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Apixaban 2.5mg BID | 8.99 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 8.85 |
ICAC adjudicated acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From first dose to last dose, plus 2 days (12 days, plus 2)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| MI/Stroke | MI | Stroke | Thrombocytopenia | |
| Apixaban 2.5mg BID | 0.06 | 0.06 | 0.00 | 0.00 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.31 | 0.25 | 0.13 | 0.13 |
ICAC adjudicated acute clinically overt bleeding events as per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). Follow up Period was from the end of the treatment period (last dose) up to 60 days post last dose, Day 72. (NCT00371683)
Timeframe: Last dose of study drug to Day 72 (60 days)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Major Bleeding (n=1563, 1553) | CR N-M Bleeding (n=1563, 1553) | Major or CR N-M Bleeding (n=1563, 1553) | Any Bleeding (n=1563, 1553) | |
| Apixaban 2.5mg BID | 0.13 | 0.26 | 0.38 | 0.90 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.13 | 0.45 | 0.58 | 1.29 |
ICAC adjudicated acute clinically overt bleeding events as per International Society on Thrombosis and Hemostasis (ISTH) guidelines modified for surgical patients. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). Clinically relevant (CR); Non-Major (N-M) Bleeding. Day 1=Day of surgery. Treatment started (first dose) day of surgery or next day. Treatment continued for 12 days. (NCT00371683)
Timeframe: First dose of study drug to last dose, plus 2 days post last dose
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Major Bleeding (n=1596, 1588) | CR N-M Bleeding (n=1596, 1588) | Major or CR N-M Bleeding(n=1596, 1588) | Any Bleeding (n=1596, 1588) | |
| Apixaban 2.5mg BID | 0.69 | 2.19 | 2.88 | 5.33 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 1.39 | 2.96 | 4.28 | 6.80 |
An ICAC adjudicated all venograms, suspected symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke, and cause of death. Event rate was number of participants with the composite endpoint divided by the number of participants analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| PE (Fatal or Non-Fatal) (n=1599, 1596) | Non-Fatal PE (n=1599, 1596) | All DVT n=1142, 1122 | Symptomatic DVT (n=1599, 1596) | Asymptomatic DVT (n=1139,1115) | Symptomatic Proximal DVT (n=1599,1596) | Symptomatic Distal DVT (n=1599,1596) | |
| Apixaban 2.5mg BID | 1.00 | 0.88 | 7.79 | 0.19 | 7.55 | 0.13 | 0.06 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.44 | 0.44 | 8.20 | 0.44 | 7.62 | 0.19 | 0.38 |
ICAC adjudicated all venograms and suspected symptomatic DVT. Event rate was number of participants with the endpoint divided by the number of participant's analyzed (%). (NCT00371683)
Timeframe: From Day 1 or Day 2 to last dose, plus 2 days or 14 days post randomization
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Proximal DVT (n=1254, 1207) | Distal DVT (n=1146, 1133) | Asymptomatic Proximal DVT (n=1252, 1204) | Asymptomatic Distal DVT (n=1145, 1127) | |
| Apixaban 2.5mg BID | 0.72 | 7.24 | 0.56 | 7.16 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.91 | 8.03 | 0.66 | 7.54 |
A 60-day follow-up period started after the last dose of study drug and continued until the End of Study Visit on Day 72 (60 days ± 3 days, after the last dose of study drug). Event rate was number of participants with the endpoint divided by the number of participants analyzed (%). ICAC adjudicated acute clinically overt bleeding events, suspected thrombocytopenia, suspected acute MI, suspected acute stroke per ISTH guidelines modified for surgical patients. (NCT00371683)
Timeframe: Post last dose of study drug to Day 72 (60 days)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| MI/Stroke | MI | Stroke | Thrombocytopenia | |
| Apixaban 2.5mg BID | 0.06 | 0.06 | 0.00 | 0.00 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 0.06 | 0.06 | 0.00 | 0.00 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug (12 + 2 days). Baseline=measurement prior to first dose of study drug. Heart rate was measured during screening (pre-operative, post-operative) and in the treatment period on Days 1 (day of first dose), 2, 3, 4,12 (end of treatment). Heart rate was measured in beats per minute (bpm). (NCT00371683)
Timeframe: Baseline to last dose of study drug, plus 2 days
| Intervention | bpm (Mean) | ||||
|---|---|---|---|---|---|
| Heart Rate Day 1 (n=240,237) | Heart Rate Day 2 (n=1575,1574) | Heart Rate Day 3 (n=1490,1498) | Heart Rate Day 4 (n=127,134) | Heart Rate Day 12 (n=1495, 1462) | |
| Apixaban 2.5mg BID | 2.3 | 4.6 | 4.5 | 7.6 | -0.3 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 2.7 | 4.5 | 5.0 | 9.4 | -0.1 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug (12 + 2 days). Baseline=measurement prior to first dose of study drug. Blood pressures (BP) were measured during screening (pre-operative, post-operative) and in the treatment period on Days 1 (day of first dose), 2, 3, 4,12 (end of treatment). Systolic and diastolic pressures were measured in millimeters of mercury (mmHg). (NCT00371683)
Timeframe: Baseline to last dose of study drug, plus 2 days
| Intervention | mmHg (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diastolic BP Day 1 (n=240, 237) | Diastolic BP Day 2 (n=1577, 1574) | Diastolic BP Day 3 (n=1489,1498) | Diastolic BP Day 4 (n=127,134) | Diastolic BP Day 12 (n=1495,1463) | Systolic BP Day 1 (n=240,237) | Systolic BP Day 2 (n=1577,1574) | Systolic BP Day 3 (n=1489,1498) | Systolic BP Day 4 (n=127,134) | Systolic BP Day 12 (n=1495,1463) | |
| Apixaban 2.5mg BID | -0.4 | 1.7 | 2.3 | 0.6 | 7.3 | 1.5 | 5.4 | 4.7 | 2.8 | 9.1 |
| Enoxaparin 30 mg SC Injection q 12 Hours | -0.9 | 1.5 | 2.1 | 0.3 | 7.5 | -0.7 | 4.2 | 4.3 | 1.4 | 8.9 |
Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Potassium: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*predose or > ULN if pre-dose > ULN then use > 1.1*predose or < LLN. Calcium: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*predose or > ULN If pre-dose > ULN then use > 1.25*predose or < LLN. Chloride: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*predose or > ULN if pre-dose > ULN then use > 1.1*predose or < LLN. Sodium: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*predose or >ULN if pre-dose > ULN then use > 1.05*predose or < LLN. Bicarbonate: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*predose or > ULN if pre-dose > ULN then use > 1.25*predose or < LLN. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Calcium low (n=1569,1562) | Calcium high (n=1569,1562) | Chloride low (n=1568,1562) | Chloride high (n=1568,1562) | Bicarbonate low (n=1568,1561) | Potassium low(n=1568,1559) | Potassium high(n=1568,1559) | Sodium low (n=1568,1562) | Sodium high (n=1568,1562) | |
| Apixaban 2.5mg BID | 1 | 0 | 11 | 0 | 11 | 54 | 26 | 23 | 2 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 5 | 1 | 17 | 1 | 13 | 56 | 20 | 39 | 0 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Hematology profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 2, 3, 4, 12 (end of treatment). Upper limit of normal (ULN); lower limit of normal (LLN). Platelet Count low: < 100,000/mm^3 (or < 100*109 cells/L). Erythrocytes low: < 0.75 *pre-dose. Hemoglobin low: > 2 g/dL decrease compared to pre-dose or Value ≤ 8 g/dL. Hematocrit low: < 0.75*pre-dose . Leukocytes: < 0.75*LLN or > 1.25* ULN, or if pre-dose < LLN then use < 0.8*predose or > ULN if pre-dose > ULN then use > 1.2*predose or < LLN. Lymphocytes (absolute): < 0.750*10^3 cells/µL or > 7.50*10^3 cells/ µL. Eosinophils (absolute) high: > 0.750*10^3 cells/µL. Basophils(absolute) high: > 400/mm^3 (or > 0.4*103 cells/µL). Monocytes (absolute) high: > 2000/mm^3 (or > 2*103 cells/µL). Neutrophils(absolute) high: < 1.0*103 cells/µL. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin low (n=1561,1549) | Hematocrit low (n=1558,1547) | Platelet count low (n=1556,1543) | Erythrocytes low (n=1557,1547) | Leukocytes low(n=1583,1572) | Leukocytes high(n=1583,1572) | Basophils high (n=1577, 1564) | Eosinophils high (n=1577, 1564) | Lymphocytes low (n=1577,1564) | Lymphocytes high (n=1577,1564) | Monocytes high (n=1577,1564) | Neutrophils low (n=1577,1564) | |
| Apixaban 2.5mg BID | 386 | 135 | 6 | 130 | 8 | 214 | 0 | 32 | 125 | 2 | 4 | 4 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 392 | 157 | 9 | 149 | 11 | 210 | 2 | 13 | 117 | 4 | 4 | 5 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Bilirubin (direct) high: > 1.5*ULN. Total bilirubin: : > 2*ULN, Alanine Aminotransferase (ALT) high: > 3*ULN. Alkaline Phosphatase (ALP): > 2*ULN. Aspartate Aminotransferase (AST): > 3*ULN. Creatinine: > 1.5*ULN. (NCT00371683)
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| ALP high (n=1573,1563) | ALT high (n=1573,1562) | AST high (n=1573,1562) | Bilirubin direct high (n=1563,1553) | Bilirubin total high(n=1572,1562) | Creatinine high (n=1569,1562) | |
| Apixaban 2.5mg BID | 42 | 33 | 29 | 63 | 2 | 17 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 55 | 45 | 40 | 54 | 8 | 28 |
Treatment Period=the period from first dose of study drug through 2 days after discontinuation of study drug. Laboratory Chemistry profile was measured during screening (pre-operative, post-operative) and in the Treatment Period on Days 4, and 12 (end of treatment). Fasting Glucose: if pre-dose < LLN then use < 0.8*predose; or > ULN if pre-dose > ULN then use > 2.0*predose or
Timeframe: First dose to last dose of study drug (12 days), plus 2 days
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Fasting Glucose low (n=611, 579) | Fasting Glucose high (n=611, 579) | Total Protein low (n=1568,1562) | CK high (n=1573,1563) | Uric Acid high (n=1567,1562) | |
| Apixaban 2.5mg BID | 8 | 54 | 527 | 52 | 22 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 5 | 28 | 513 | 45 | 12 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00371683)
Timeframe: First dose to last dose, plus 2 days for AEs (12 + 2 days) or plus 30 days for SAEs (12 + 30 days)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| SAE | Bleeding AE | AEs leading to discontinuation | Deaths | |
| Apixaban 2.5mg BID | 123 | 110 | 60 | 3 |
| Enoxaparin 30 mg SC Injection q 12 Hours | 123 | 144 | 58 | 5 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.1 |
| Enoxaparin/VKA | 1.1 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.9 |
| Enoxaparin/VKA | 4.2 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding, cardiovascular death, myocardial infarctions, stroke, or non CNS systemic embolism. Major bleeding was associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography ( PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.3 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death, cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events confirmed by independent committee blinded to treatment, based on compression ultrasound, venography, spiral CT scan, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy, results/films/images of confirmatory testing and/or case summaries (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.6 |
| Enoxaparin/VKA | 4.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 8.1 |
| Enoxaparin/VKA | 8.1 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.6 |
| Enoxaparin/VKA | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 1.6 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.8 |
| Enoxaparin/VKA | 0.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 3.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.2 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 5.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 3.0 | 1.1 | 1.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.4 | 1.0 | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.07 | 0 | 0.1 | 0.3 | 0.1 | 0.3 | 0.8 | 0.6 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0 | 0.07 | 0 | 0.3 | 0.6 | 0.07 | 0.07 | 1.3 | 0.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.3 | 0 | 1.0 | 1.6 | 0.3 | 0.2 | 2.0 | 1.3 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.06 | 0.2 | 0.06 | 1.2 | 0.8 | 0.06 | 0.1 | 1.8 | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 |
| Placebo | 0.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.0 |
| Placebo | 0.2 |
Events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral CT scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.0 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound or venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Placebo | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.8 |
| Placebo | 5.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Placebo | 0.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Placebo | 2.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. For definition of DVT/PE, kindly refer to the link in the Protocol section. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.3 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 1.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), or lung scintigraphy (for PE), and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.3 |
| Placebo | 7.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.4 |
| Placebo | 1.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Placebo | 7.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. Treatment-emergent events and all events post randomization were reported. Treatment-emergent: after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days) (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 0.2 | 0.3 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 | 0.2 |
All events adjudicated/confirmed by CIAC blinded to treatment. Clinically relevant bleeding included major bleeding (definition: see outcome 7) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of daily life activities. Treatment-emergent events (after intake of 1st study medication tablet as randomized up to 2 days after stop of study medication ['time window: 2 days']) and all events post randomization were reported (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 1.2 | 1.9 |
| Rivaroxaban (Xarelto, BAY59-7939) | 6.0 | 6.0 |
All events were adjudicated and confirmed by a central independent adjudication committee (CIAC) blinded to treatment. Major bleeding event was overt bleeding associated with a 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Treatment-emergent [after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days)] events and all events post randomization were reported. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 0.0 | 0.2 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 | 0.7 |
All pre-defined vascular events (acute coronary syndromes, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism and vascular death) were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on results/films/images of confirmatory testing, and/or case summaries. On treatment events and all events post randomization were reported. On treatment: after intake of first tablet of study medication as randomized but not more than 1 day after stop of study medication (referred to as time window: 1 day) (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| On treatment (time window: 1 day) | All post-randomization | |
| Placebo | 0.7 | 0.7 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.5 | 0.8 |
Event rate=Number of events divided by the number of patients evaluated. Each patient was categorized as having no proximal DVT, having proximal DVT, being nonevaluable for proximal DVT, having no distal DVT, having distal DVT, or being nonevaluable for distal DVT. Adjudication criteria were: Normal=All deep veins were visualized, and there was no intraluminal filling defect (ILFD). ILFD=An area of reduced, or absent filling, at least partially surrounded with contrast medium in ≥ 2 projections or a lack of filling in a vessel in which there was a cut-off that had the configuration of a thrombus. Indeterminate=A lack of filling of a region of the deep vein system, proximal or distal, without the presence of an ILFD elsewhere in the same region. Not Done=A venography was not performed. Proximal DVT was found if any of the proximal veins had an ILFD. Pulmonary embolism was radiographically (angiography, V/Q scan, computed tomography) determined. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID Plus Placebo | 0.45 |
| Enoxaparin, 40 mg QD Plus Placebo | 1.14 |
Event rate=Number of events divided by the number of patients evaluated. A mandatory bilateral ascending contrast venogram was to be obtained on Day 35 (± 3). Patients with confirmed symptomatic DVT at any time, or asymptomatic DVT upon venography, were to receive treatment for DVT according to the investigator's standard of care. Signs and symptoms suggestive of VTE included, but were not limited to: 1) lower extremity DVT: erythema, warmth, pain, swelling, tenderness; and 2) PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia. Intended Treatment Period started on day of randomization and, for patients who received treatment, ended at the later of 2 days after last dose of study drug or 38 days after the first dose (presurgery) of study drug. For randomized patients who did not receive study drug, the period ended 38 days after randomization. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID Plus Placebo | 1.39 |
| Enoxaparin, 40 mg QD Plus Placebo | 3.86 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Postprocedural hematoma | Operative hemorrhage | Incision site hematoma | Incision site hemorrhage | Postprocedural hemorrhagic | Hematuria traumatic | Periorbital hematoma | Subcutaneous hematoma | Traumatic hematoma | Hematoma | Wound hemorrhage | Hemorrhage | Hematuria | Hemorrhage urinary tract | Urethral hemorrhage | Epistaxis | Hemoptysis | |
| Apixaban, 2.5 mg BID Plus Placebo | 20 | 19 | 14 | 13 | 4 | 1 | 1 | 1 | 0 | 34 | 18 | 13 | 41 | 1 | 0 | 33 | 3 |
| Enoxaparin, 40 mg QD Plus Placebo | 23 | 14 | 10 | 19 | 7 | 1 | 0 | 0 | 1 | 38 | 15 | 13 | 39 | 1 | 2 | 25 | 1 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic anemia | Ecchymosis | Petechiae | Hemorrhage subcutaneous | Increased tendency to bruise | Vaginal hemorrhage | Menorrhagia | Uterine hemorrhage | Conjunctival hemorrhage | Hematoma infection | Spinal hematoma | |
| Apixiban, 2.5 mg BID Plus Placebo | 20 | 5 | 2 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 0 |
| Enoxaparin, 40 mg QD Plus Placebo | 15 | 9 | 2 | 0 | 5 | 0 | 0 | 1 | 0 | 0 | 1 |
All suspected bleeding events were to be reported by the investigator as either an adverse event or serious adverse event or and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. All acute clinically overt bleeding events were adjudicated by the ICAC as a major bleeding event or a clinically relevant nonmajor bleeding event; suspected minor bleeding events were not sent for adjudication. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bloody discharge | Catheter site hemorrhage | Injection site hemorrhage | Injection site hematoma | Infusion site hematoma | Vessel puncture site hematoma | Hematocrit decreased | Red blood cell count decreased | Blood urine present | Blood urine | Occult blood positive | Fibrin D dimer increased | Hematochezia | Mallory-Weiss Syndrome | Hematemesis | Melaena | Rectal hemorrhage | Gingival bleeding | Anal hemorrhage | Diarrhea hemorrhagic | Diverticulum intestinal hemorrhagic | Gastrointestinal hemorrhage | Intra-abdominal hematoma | Duodenal ulcer hemorrhage | Hemorrhoidal hemorrhage | Mouth hemorrhage | |
| Apixaban, 2.5 mg BID Plus Placebo | 16 | 6 | 4 | 3 | 1 | 1 | 18 | 14 | 8 | 1 | 1 | 0 | 6 | 4 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Enoxaparin, 40 mg QD Plus Placebo | 13 | 5 | 10 | 28 | 0 | 0 | 21 | 20 | 6 | 1 | 0 | 1 | 2 | 0 | 2 | 1 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
Treatment guidelines were provided for jaundice and elevated results of liver function tests. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 30 days after the last dose of study drug
| Intervention | Participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspartate aminotransferase increased | Alanine aminotransferase increased | Gamma-glutamyltransferase increased | Blood bilirubin increased | Bilirubin conjugated increased | Hepatic enzyme increased | Liver function test results abnormal | Transaminases increased | Cholelithiasis | Hepatitis toxic | Cholecystitis acute | Cholestasis | Hyperbilirubinemia | Postcholecystectomy syndrome | Cholecystitis | Hepatic pain | Hepatitis | Hepatomegaly | Jaundice cholestatic | Hypoalbuminemia | Hypoproteinemia | Yellow skin | |
| Apixaban, 2.5 mg BID Plus Placebo | 48 | 40 | 27 | 17 | 11 | 9 | 4 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Enoxaparin, 40 mg QD Plus Placebo | 67 | 61 | 54 | 7 | 12 | 16 | 9 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. MA criteria: Hemoglobin: >2 g/dL decrease from preRx or value ≤ 8 g/dL; hematocrit (%): <0.75*preRx; platelet count (*10^9 cells/L): <100,000/mm^3; erythrocytes (*10^6 cells/μL): <0.75*preRx level; leukocytes (*10^3 cells/μL): < 0.75*LLN or >1.25*ULN, or if preRx LLN use < 0.8*preRx or >ULN if preRx >ULN use >1.2*preRx or
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=2605, 2587) | Hematocrit, low (n=2554, 2536) | Platelet count, low (n=2597, 2576) | Erythrocytes, low (n=2558, 2540) | Leukocytes, low (n=2632, 2617) | Leukocytes, high (n=2632, 2617) | Basophils (absolute), high (n=2629, 2613) | Eosinophils (absolute), high (n=2629, 2613) | Lymphocytes (absolute), low (n=2629, 2613) | Lymphocytes (absolute), high (n=2629, 2613) | Monocytes (absolute), high (n=2629, 2613) | Neutrophils (absolute), low (n=2629, 2613) | |
| Apixaban, 2.5 mg BID Plus Placebo | 2189 | 1274 | 6 | 1310 | 54 | 385 | 1 | 75 | 383 | 3 | 9 | 5 |
| Enoxaparin, 40 mg QD Plus Placebo | 2218 | 1350 | 9 | 1377 | 54 | 360 | 3 | 70 | 382 | 3 | 11 | 4 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Alanine aminotransferase (ALT) (U/L): >3 *ULN: alkaline phosphatase (ALP) (U/L): >2* ULN; aspartate aminotransferase (ASP) (U/L): >3 *ULN; bilirubin, direct (mg/dL): >2*ULN; bilirubin, total (mg/dL): >2*ULN; BUN (mg/dL): >2*ULN; creatinine (mg/dL): >1.5*ULN; calcium (mg/dL): < 0.8*LLN or >1.2 *ULN, or if preRx
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline phosphatase, high (n=2631, 2618) | Alanine aminotransferase, high (n=2629, 2616) | Aspartate aminotransferase, high (n=2629, 2616) | Bilirubin, direct, high (n=2622, 2604) | Bilirubin, total, high (n=2630, 2617) | Blood urea nitrogen (BUN), high (n=2618, 2598) | Creatinine, high (n=2618, 2598) | Calcium, total, low (n=2618, 2598) | Calcium, total, high (n=2618, 2598) | Chloride, serum, low (n=2615, 2594) | Bicarbonate, low (n=2615, 2595) | Potassium, serum, low (n=2614, 2594) | Potassium, serum, high (n=2614, 2594) | Sodium, serum, low (n=2615, 2594) | Sodium, serum, high (n=2615, 2594) | |
| Apixaban, 2.5 mg BID Plus Placebo | 55 | 50 | 73 | 145 | 24 | 19 | 21 | 7 | 0 | 6 | 8 | 73 | 61 | 29 | 5 |
| Enoxaparin, 40 mg QD Plus Placebo | 57 | 83 | 73 | 139 | 12 | 17 | 25 | 18 | 1 | 6 | 8 | 73 | 47 | 23 | 4 |
preRx=predose; LLN=lower limit of normal; ULN=upper limit of normal. Glucose, fasting (mg/dL): <.8*LLN or >1.5*ULN, or if preRx
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, fasting serum, high (n=14, 17) | Protein, total, low (n=2618, 2596) | Protein, total, high (n=2618, 2596) | Creatine kinase, high (n=2630, 2616) | Uric acid, high (n=2618, 2597) | Blood, urine, high (n=2588, 2568) | Glucose, urine, high (n=2588, 2568) | Leukocyte esterase, urine, high (n=21, 41) | Protein, urine (n=2588, 2568) | Red blood cells (RBC), urine, high (n=1310, 1230) | White blood cells (WBC),urine, high (n=1311, 1228) | |
| Apixaban, 2.5 mg BID Plus Placebo | 0 | 747 | 3 | 615 | 2 | 275 | 68 | 0 | 169 | 216 | 217 |
| Enoxaparin, 40 mg QD Plus Placebo | 1 | 752 | 1 | 642 | 3 | 234 | 76 | 4 | 168 | 173 | 229 |
Neurologic events were based on Medical Dictionary for Regulatory Activities search categories.For new or worsening events that were not related to the site of surgery, additional information was collected on a specific form. In addition, neurology consultation was to be obtained for these patients. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paraesthesia | Hypoaesthesia | Burning sensation | Peroneal nerve palsy | Hypotonia | Dysarthria | Paresis | Cervicobrachial syndrome | Coordination abnormal | Hypertonia | Neuropathy peripheral | Peripheral nerve lesion | Radiculitis | Paralysis | Muscular weakness | Nerve injury | Femoral nerve injury | Sciatic nerve injury | Peroneal nerve injury | Diplopia | Gait disturbance | |
| Apixaban, 2.5 mg BID Plus Placebo | 32 | 29 | 7 | 5 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 | 2 | 1 | 1 | 0 | 1 | 1 |
| Enoxaparin, 40 mg QD Plus Placebo | 19 | 35 | 5 | 6 | 4 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 1 | 11 | 1 | 0 | 0 | 1 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All suspected bleeding events were to be reported by the investigator as either an AE or SAE and adjudicated by the Independent Central Adjudication Committee (ICAC). Definitions of bleeding outcomes: Acute clinically overt bleeding =new onset, visible bleeding, or signs or symptoms suggestive of bleeding with confirmatory imaging techniques that could detect the presence of blood. (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 30 days after the last dose of study drug
| Intervention | Participants (Number) | ||
|---|---|---|---|
| SAEs | Bleeding AEs | Death | |
| Apixaban, 2.5 mg BID Plus Placebo | 18 | 15 | 2 |
| Enoxaparin, 40 mg QD Plus Placebo | 18 | 21 | 0 |
Event rate=Number of events divided by the number of patients evaluated. Major bleeding event defined as a bleeding event that was 1) Acute clinically overt bleeding accompanied by at least 1 of the following: decrease in hemoglobin of ≥ 2 g/dL over a 24-hour period, transfusion of ≥2 units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intra-spinal, intraocular, pericardial, an operated joint and requires reoperation or intervention, intramuscular with compartment syndrome, or retroperitoneal; 2) Fatal. CRNM was defined as acute clinically overt bleeding that did not satisfy the criteria for a major bleeding event and met at least 1 of the following: epistaxis, gastrointestinal bleed, hematuria, bruising/ecchymosis, or hemoptysis. Minor bleeding was defined as an acute clinically overt bleeding event that did not meet the criteria for major bleeding or a CRNM. Fatal bleeding event was defined as bleeding that was the primary (NCT00423319)
Timeframe: First dose of study drug (presurgery) through 2 days after the last dose of study drug
| Intervention | Percentage of events/patients evaluted (Number) | |||
|---|---|---|---|---|
| Major bleeding | CRNM | Major or CRNM | Any bleeding | |
| Apixaban, 2.5 mg BID Plus Placebo | 0.82 | 4.08 | 4.83 | 11.71 |
| Enoxaparin, 40 mg QD Plus Placebo | 0.68 | 4.51 | 5.04 | 12.56 |
VTE=venous thromboembolic event; VTE-related death=combination of fatal or nonfatal PE and symptomatic or asymptomatic DVT. Event rate=Number of events divided by the number of patients evaluated. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percentage of events/patients evaluated (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All-cause death | VTE-related death | PE (fatal or nonfatal) | Nonfatal PE | All DVT (n=1944, 1911) | Symptomatic DVT | Asymptomatic DVT (n=1943, 1907) | Proximal DVT (n=2196, 2190) | Distal DVT (1951, 1908) | Symptomatic proximal DVT | Asymptomatic proximal DVT (n=2195, 2187) | Symptomatic distal DVT | Asymptomatic distal DVT (n=1950, 1907) | |
| Apixaban, 2.5 mg BID Plus Placebo | 0.11 | 0.04 | 0.11 | 0.07 | 1.13 | 0.04 | 1.08 | 0.32 | 1.03 | 0.04 | 0.27 | 0.04 | 0.97 |
| Enoxaparin, 40 mg QD Plus Placebo | 0.04 | 0.00 | 0.19 | 0.19 | 3.56 | 0.19 | 3.30 | 0.91 | 2.99 | 0.15 | 0.73 | 0.04 | 2.94 |
Event rate=Number of events divided by the number of patients evaluated. All suspected events were reported by investigator. Acute MI=the presence of a clinical situation (eg, abnormal history, physical examination, new electrocardiogram changes) suggestive of an MI and at least 1 of the following: elevated creatine kinase (CK)-MB or troponin T or troponin I ≥2*upper limit of normal (ULN); if CK-MB or troponin values not available, total CK ≥2*ULN; or new significant (≥0.04 sec) Q waves in ≥2 contiguous leads. Stroke=a new focal neurologic deficit of sudden onset lasting at least 24 hours that was not due to a readily identifiable nonvascular cause. Adjudication classified each reported stroke as primary hemorrhagic, nonhemorrhagic, infarction with hemorrhagic conversion, or unknown type. Thrombocytopenia=after 3 days as drop in platelet count to <100,000/mm^3 for patients with a baseline value >150,000/mm^3 or a >50% decline, if the baseline value was ≤150,000/mm^3. (NCT00423319)
Timeframe: Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose
| Intervention | Percent of events/patients evaluated (Number) | |||
|---|---|---|---|---|
| MI/stroke | MI | Stroke | Thrombocytopenia | |
| Apixaban, 2.5 mg BID Plus Placebo | 0.22 | 0.19 | 0.04 | 0.07 |
| Enoxaparin, 40 mg QD Plus Placebo | 0.26 | 0.11 | 0.15 | 0.11 |
All cause death, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 1 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 18 |
| Enoxaparin | 33 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 17 |
| Enoxaparin | 31 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 1 |
| Enoxaparin | 2 |
Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 4 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 60 |
| Enoxaparin | 67 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 61 |
| Enoxaparin | 69 |
Volume of blood loss for treated and operated patients during surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 404.9 |
| Enoxaparin | 411.0 |
Number of treated and operated patients with required blood transfusion on day of surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Transfusions required | Missing | |
| Dabigatran 220mg | 246 | 4 |
| Enoxaparin | 237 | 7 |
Frequency of patients with possible clinically significant abnormalities. (NCT00657150)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(964;962) | AST decrease N=(964;962) | ALT increase N=(966;962) | ALT decrease N=(966;962) | Bilirubin increase N=(966;962) | Bilirubin decrease N=(966;962) | |
| Dabigatran 220mg | 28 | 0 | 34 | 0 | 3 | 0 |
| Enoxaparin | 44 | 0 | 67 | 0 | 1 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major bleeding events | Major and clinically relevant bleeding events | Any bleeding events | |
| Dabigatran 220mg | 14 | 37 | 98 |
| Enoxaparin | 9 | 29 | 83 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00657150)
Timeframe: 3 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptomatic Deep Vein Thrombosis | symptomatic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 220mg | 2 | 0 | 1 | 1 | 0 |
| Enoxaparin | 4 | 1 | 0 | 2 | 1 |
Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation
| Intervention | Percentage of pregnancies (Number) |
|---|---|
| Enoxaparin 40 mg /Day Plus Low Dose Aspirin | 24 |
| Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin | 20 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.2 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.4 |
| Enoxaparin/VKA | 4.0 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.4 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.5 |
| Enoxaparin/VKA | 4.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 10.3 |
| Enoxaparin/VKA | 11.4 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Enoxaparin/VKA | 0.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.4 |
| Enoxaparin/VKA | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 3.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 2.1 | 0.8 | 1.1 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.6 | 1.2 | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.05 | 0 | 0.5 | 0.1 | 0.09 | 0.05 | 0.7 | 0.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.09 | 0 | 0.09 | 0.5 | 0.2 | 0.09 | 0.3 | 0.8 | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0.04 | 0.2 | 0.1 | 0.8 | 0.7 | 0.2 | 0.1 | 1.5 | 2.4 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.1 | 0.3 | 0.0 | 1.0 | 0.7 | 0.2 | 0.4 | 1.3 | 1.4 |
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization; for randomized patients who did not receive study drug, the period ends 14 days after randomization. Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause. (NCT00452530)
Timeframe: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID + Placebo | 1.09 |
| Enoxaparin, 40 mg QD + Placebo | 2.17 |
Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization.Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause. (NCT00452530)
Timeframe: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study drug
| Intervention | Percentage of events/patients evaluated (Number) |
|---|---|
| Apixaban, 2.5 mg BID | 15.06 |
| Enoxaparin, 40 mg QD | 24.37 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Bleeding AEs=all serious or nonserious bleeding-related AEs. (NCT00452530)
Timeframe: Days 1 through 12 + 2 days (nonserious AEs, bleeding AES) or 30 days (SAES, deaths) after last dose of study drug
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| SAE | Bleeding AE | Discontinuations due to AEs | Deaths | |
| Apixaban, 2.5 mg BID + Placebo | 72 | 90 | 40 | 2 |
| Enoxaparin, 40 mg QD + Placebo | 88 | 112 | 44 | 0 |
Event rate=Number of events divided by number of patients evaluated. Adjusted difference of event rates takes into consideration type of surgery as a stratification factor. Bleeding Criteria: Major bleeding=an event consisting of clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. CRNM bleeding= clinically overt bleeding; that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event; that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding; or a change in antithrombic treatment. (NCT00452530)
Timeframe: Days 1 to 12
| Intervention | Percentage of events/patients evaluated (Number) | |||
|---|---|---|---|---|
| Major bleeding (n=9, 14) | CRNM (n=44, 58) | Major bleeding or CRNM (n=53, 72) | Any bleeding | |
| Apixaban, 2.5 mg BID + Placebo | 0.60 | 2.93 | 3.53 | 6.93 |
| Enoxaparin, 40 mg QD + Placebo | 0.93 | 3.85 | 4.77 | 8.36 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Calcium, total (mg/dL): <0.8*LLN or >1.2*ULN, or if preRx
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calcium, total (low) (n=1447, 1457) | Chloride, serum (low)(n=1442, 1454) | Bicarbonate (low) (n=1435, 1447) | Potassium, serum (low) (n=1438, 1453) | Potassium, serum (high)(n=1438, 1453) | Sodium, serum (low) (n=1442, 1454) | Sodium, serum (high) (n=1442, 1454) | Glucose, fasting serum (low) (n=715, 713) | Glucose, fasting serum (high) (n=715, 713) | Protein, total (low) (n=1447, 1457 | Creatine kinase (CK) (high) (n=1463, 1476) | Uric acid (high) (n=1446, 1458) | |
| Apixaban, 2.5 mg BID + Placebo | 5 | 1 | 0 | 38 | 34 | 5 | 1 | 8 | 46 | 223 | 66 | 1 |
| Enoxaparin, 40 mg QD + Placebo | 9 | 0 | 3 | 41 | 40 | 10 | 0 | 1 | 25 | 243 | 65 | 2 |
preRX=pretreatment. Blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; glucose, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; protein, urine: If missing preRx use ≥ 2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; Red blood cells , urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; white blood cells, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4. (NCT00452530)
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (± 5 days) of follow-up
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Blood, urine (high) (n=1421, 1430) | Glucose, urine (high) (n=1421, 1429) | Protein, urine (high) (n=1421, 1430) | Red blood cells, urine (high) (n=441, 385) | White blood cells, urine (high)(n=441, 386) | |
| Apixaban, 2.5 mg BID + Placebo | 169 | 160 | 60 | 133 | 101 |
| Enoxaparin, 40 mg QD + Placebo | 113 | 154 | 89 | 116 | 102 |
preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal; abs=absolute. Hemoglobin (g/dL): >2 decrease from preRx value or value <=8; hematocrit (%): <0.75*preRx; platelets: <100*10^9 cells/L; erythrocytes (*10^6 cells/μL): <0.75*preRx; leukocytes: <0.75*LLN or >1.25*ULN, or if preRx
Timeframe: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up
| Intervention | Participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=1424, 1442) | Hematocrit, low n=(1369, 1396) | Platelet count, low (n=1413, 1425) | Erythrocytes, low (n=1368, 1396) | Leukocytes, low (n=1457, 1471) | Leukocytes, high (n=1457, 1471) | Basophils (absolute), high (n=1448, 1465) | Eosinophils (absolute), high (n=1448, 1465) | Lymphocytes (absolute), low (n=1448, 1465) | Lymphocytes (absolute), high (n=1448, 1465) | Monocytes (absolute), high (n=1448, 1465) | Neutrophils (absolute), low (n=1448, 1465) | Alkaline phosphatase (ALP), high (n=1465, 1476) | Alanine aminotransferase (ALT), high (n=1459,1472) | Aspartate aminotransferase (AST) , high (n=1459,14 | Bilirubin, direct (high) (n=1447,1457) | Bilirubin, total (high) (n=1461,1476) | Blood urea nitrogen (BUN) (high)(n=1447,1458) | Creatinine (high) (n=1447,1458) | |
| Apixaban, 2.5 mg BID + Placebo | 1127 | 668 | 7 | 690 | 27 | 193 | 2 | 43 | 203 | 1 | 5 | 5 | 15 | 32 | 34 | 87 | 15 | 15 | 17 |
| Enoxaparin, 40 mg QD + Placebo | 1178 | 723 | 5 | 735 | 26 | 213 | 4 | 60 | 215 | 0 | 2 | 2 | 31 | 26 | 26 | 76 | 9 | 17 | 23 |
All-cause mortality (NCT00413374)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Enoxaparin 1.5 mg/kg Once Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 0 |
Major bleeding complication as defined as spinal, retroperitoneal, or intracranial bleeding; drop in hemoglobin ≥2g/dl or transfusion ≥2U or surgical or medical intervention, death related to bleeding. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
Major clotting complication (recurrent VTE) as defined as recurrent acute pulmonary embolism confirmed on chest CT or recurrent deep vein thrombosis in the contralateral extremity confirmed with venous ultrasound or CT scan while on once daily enoxaparin therapy. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 1 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
All-cause mortality through 1 year from randomization. (NCT00046228)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 56 |
| Abciximab Facilitated PCI Group | 60 |
| Reteplase/Abciximab Facilitated PCI Group | 52 |
All cause mortality occurred through 90 days from randomization. (NCT00046228)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 36 |
| Abciximab Facilitated PCI Group | 45 |
| Reteplase/Abciximab Facilitated PCI Group | 43 |
The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization. (NCT00046228)
Timeframe: 90 Days
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 72 |
| Abciximab Facilitated PCI Group | 61 |
| Reteplase/Abciximab Facilitated PCI Group | 61 |
(NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 139 |
| Abciximab Facilitated PCI Group | 178 |
| Reteplase/Abciximab Facilitated PCI Group | 271 |
All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee). (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 1 |
| Abciximab Facilitated PCI Group | 0 |
| Reteplase/Abciximab Facilitated PCI Group | 5 |
Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined. (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participant (Number) |
|---|---|
| Primary PCI Group | 55 |
| Abciximab Facilitated PCI Group | 81 |
| Reteplase/Abciximab Facilitated PCI Group | 118 |
Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion. (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 128 |
| Abciximab Facilitated PCI Group | 122 |
| Reteplase/Abciximab Facilitated PCI Group | 120 |
Severe thrombocytopenia is defined as platelet count < 50,000 cells/μL. (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 11 |
| Abciximab Facilitated PCI Group | 16 |
| Reteplase/Abciximab Facilitated PCI Group | 16 |
(NCT00046228)
Timeframe: 60 to 90 minutes
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 75 |
| Abciximab Facilitated PCI Group | 85 |
| Reteplase/Abciximab Facilitated PCI Group | 108 |
Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization). (NCT00046228)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 86 |
| Abciximab Facilitated PCI Group | 86 |
| Reteplase/Abciximab Facilitated PCI Group | 81 |
AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge. (NCT03303794)
Timeframe: Post-Operation Day 1
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 23 |
| Bupivicaine + Exparel | 23 |
Monitor how much opioid patient consumes (NCT03303794)
Timeframe: During the first 48 hours after surgery
| Intervention | milligram (Mean) |
|---|---|
| Bupivicaine | 90 |
| Bupivicaine + Exparel | 76 |
Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain. (NCT03303794)
Timeframe: 48 hours postoperatively
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 4 |
| Bupivicaine + Exparel | 4 |
All cause death, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 3 |
| Dabigatran 150mg | 3 |
| Enoxaparin | 0 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 28 |
| Dabigatran 150mg | 38 |
| Enoxaparin | 36 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 23 |
| Dabigatran 150mg | 35 |
| Enoxaparin | 33 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 5 |
| Dabigatran 150mg | 1 |
| Enoxaparin | 3 |
Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 6 |
| Dabigatran 150mg | 9 |
| Enoxaparin | 1 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 46 |
| Dabigatran 150mg | 72 |
| Enoxaparin | 57 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 53 |
| Dabigatran 150mg | 75 |
| Enoxaparin | 60 |
Volume of blood loss for treated and operated patients during surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 457 |
| Dabigatran 150mg | 435 |
| Enoxaparin | 463 |
Blood transfusion for treated and operated patients on Day of surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Patients with >=1 transfusions | Patients with >=1 non-autologous transfusions | |
| Dabigatran 150mg | 531 | 266 |
| Dabigatran 220mg | 517 | 259 |
| Enoxaparin | 542 | 286 |
Frequency of patients with possible clinically significant abnormalities. (NCT00168818)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(1103;1097;1103) | AST decrease N=(1103;1097;1103) | ALT increase N=(1103;1098;1103) | ALT decrease N=(1103;1098;1103) | Bilirubin increase N=(1102;1094;1102) | Bilirubin decrease N=(1102;1094;1102) | |
| Dabigatran 150mg | 16 | 0 | 29 | 0 | 24 | 0 |
| Dabigatran 220mg | 11 | 0 | 28 | 0 | 25 | 0 |
| Enoxaparin | 29 | 0 | 59 | 0 | 34 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma greater than or equal to 25 cm²~wound hematoma greater than or equal to 100 cm²~spontaneous nose bleed lasting longer than 5 min~macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention~spontaneous rectal bleeding (more than a spot on toilet paper)~gingival bleeding lasting longer than 5 min~any other bleeding event considered clinically relevant by the investigator~Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major | Clinical relevant | Minor | None | |
| Dabigatran 150mg | 15 | 55 | 72 | 1021 |
| Dabigatran 220mg | 23 | 48 | 70 | 1005 |
| Enoxaparin | 18 | 40 | 74 | 1022 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00168818)
Timeframe: end of treatment to day 91±7
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptotic Deep Vein Thrombosis | symptotic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 150mg | 4 | 1 | 1 | 0 | 2 |
| Dabigatran 220mg | 1 | 0 | 1 | 0 | 0 |
| Enoxaparin | 5 | 3 | 0 | 1 | 1 |
Ultrasound of the venous system just below the saphenofemoral junction to assess the venous velocity will be taken before and after application the VenaFlow and the ActiveCare+S.F.T pneumatic compression devices. Change from Baseline in Peak Venous Velocity 30 minutes after Device is applied is recorded. (NCT02345642)
Timeframe: Change from Baseline in Peak Venous Velocity 30 minutes after Device is Applied
| Intervention | cm/s (Mean) | |||
|---|---|---|---|---|
| Delta PVV from before to after Venaflow (Standing) | Delta PVV from before to after Venaflow (Supine) | delta PVV from before to after Activeca (Standing) | delta PVV from before to after Activecare (supine) | |
| 10 Healthy Patients Without THA | 127.9 | 87.1 | 32.6 | 40.5 |
| 10 Patients With THA on Post-Op Day 2 | 155.7 | 86.8 | 41.9 | 37.8 |
Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury
| Intervention | participants (Number) |
|---|---|
| Fondaparinux Sodium | 0 |
Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3
| Intervention | Participants (Number) | |
|---|---|---|
| Trough values outside normative range | Peak values outside normative range | |
| Fondaparinux Sodium | 0 | 0 |
Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury
| Intervention | participants (Number) | ||
|---|---|---|---|
| DVT | DVT after fondaparinux | PE | |
| Fondaparinux Sodium | 2 | 1 | 0 |
| No Fondaparinux | 2 | NA | 0 |
Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data for day 1 to 7 has been reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase
| Intervention | IU/kg (Mean) |
|---|---|
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 207.50 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 141.85 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 132.40 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 115.06 |
Prespecified therapeutic anti-factor Xa level was 0.5-1.0 international unit per milliliter (IU/mL). Cumulative data of Day 1 to 7 has been reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase
| Intervention | IU/mL (Median) |
|---|---|
| Dalteparin Sodium: All Participants (>= 0 to < 19 Years) | 125 |
During dose adjustment phase, doses were adjusted according to prespecified therapeutic anti-Xa levels in order to achieve target prespecified therapeutic anti-factor Xa levels (0.5 to 1.0 IU/mL). Number of dose adjustments which were done within the specified time window of up to 4 hours post dose on all days (1 to 7) to achieve the prespecified therapeutic anti-Xa levels are reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase
| Intervention | dose adjustment (Median) |
|---|---|
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 3.5 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0.5 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 0.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 0.0 |
Criteria:hematology:hemoglobin, hematocrit, erythrocytes less than(<)0.8*lower limit of normal(LLN), platelets <0.5*LLN >1.75*upper limit of normal (ULN),leukocytes <0.6* LLN >1.5* ULN, lymphocytes, lymphocytes/Leukocytes, neutrophils, neutrophils/leukocytes <0.8* LLN >1.2* ULN, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes monocytes monocytes/leukocytes >1.2*ULN, activated partial thromboplastin time, prothrombin time, prothrombin international normalized ratio >1.1* ULN. Clinical chemistry: bilirubin >1.5*ULN, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase >3.0*ULN, protein, albumin <0.8* LLN >1.2* ULN, blood urea nitrogen, creatinine >1.3* ULN, sodium <0.95*LLN >1.05*ULN, potassium, chloride, calcium, magnesium <0.9* LLN >1.1* ULN, phosphate <0.8* LLN >1.2* ULN, glucose <0.6*LLN >1.5*ULN, estimated(est) creatinine clearance, est GFR modified and bedside schwartz, >1.0* ULN. Urinalysis: creatinine >1.0*ULN. (NCT00952380)
Timeframe: Baseline up to 104 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 1 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 2 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 8 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 5 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 19 |
Symptomatic VTE defined as new or progressive signs and symptoms as judged by the investigator including but not limited to: objective swelling, pain or tenderness, pitting edema, erythema or cyanosis. Progression of VTE: Progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | Participants (Count of Participants) |
|---|---|
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 1 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 0 |
Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Percentage of participants who achieved the prespecified level during the dose adjustment phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 1 to 7 in dose adjustment phase
| Intervention | percentage of participants (Number) |
|---|---|
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 0 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 100.0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 100.0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 100.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 85.0 |
Time to achieve the target range (prespecified therapeutic anti- factor Xa levels) was defined as the number of days from the first dose of study drug to the final dose that achieves the target anti-factor Xa level. Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data of Day 1 to 7 is reported. (NCT00952380)
Timeframe: Day 1 to 7 in dose adjustment phase
| Intervention | days (Median) |
|---|---|
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 4.5 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 3.0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 2.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 2.0 |
Time to first occurrence of major bleeding event was defined as the time interval (in days) between date of first study treatment and date of documentation of first major bleeding event. A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter, overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration, bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal or intraspinal). (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | days (Median) |
|---|---|
| Dalteparin Sodium: All Participants (>= 0 to < 19 Years) | NA |
It was defined as the time interval (in days) between date of first study treatment and date of documentation of first VTE. VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes PE. When a blood clot breaks, loose and travels in the blood, this is called VTE. VTE was confirmed by at least one radiographic test and was defined as any new or progressive VTE whose signs and symptoms (identified by the investigator) included: objective swelling or tenderness, pitting edema, erythema or cyanosis. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | days (Median) |
|---|---|
| Dalteparin Sodium: All Participants (>= 0 to < 19 Years) | NA |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeter (Median) | ||||
|---|---|---|---|---|---|
| Baseline | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 100 | 104.75 | 100 | 103 | 97.75 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeter (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 54 | 54 | 56 | 60 | 63 | 64 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 55 | 55 | 55.30 | 56.60 | 60 | 61 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 172 | 135 | 135 | 135 | 135 | 151.75 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | degree celsius (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 36.60 | 36.70 | 36.90 | 36.50 | 36.60 | 36.70 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 36.70 | 36.85 | 36.40 | 36.50 | 36.70 | 37.15 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 36.50 | 36.80 | 36.70 | 36.60 | 36.80 | 36.75 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 37.00 | 36.70 | 36.70 | 36.50 | 36.60 | 36.90 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 36.80 | 36.80 | 36.70 | 36.70 | 36.60 | 36.80 |
Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | beats per minute (bpm) (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR: Baseline | HR: Day 1 | HR: Day 2 | HR: Day 30 | HR: Day 60 | HR: Day 90 | PR: Baseline | PR: Day 1 | PR: Day 2 | PR: Day 30 | PR: Day 60 | PR: Day 90 | |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 115.00 | 112.00 | 114.00 | 120.50 | 120.00 | 107.00 | 96.50 | 121.00 | 117.00 | 88.00 | 88.00 | 114.00 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 70.00 | 85.00 | 75.00 | 87.50 | 94.50 | 80.00 | 73.00 | 94.50 | 93.00 | 102.00 | 95.00 | 92.00 |
Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | beats per minute (bpm) (Median) | |||||
|---|---|---|---|---|---|---|
| HR: Baseline | HR: Day 1 | HR: Day 2 | HR: Day 30 | HR: Day 60 | HR: Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 148.00 | 146.00 | 136.00 | 138.00 | 132.00 | 122.00 |
Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | beats per minute (bpm) (Median) | |||||
|---|---|---|---|---|---|---|
| PR: Baseline | PR: Day 1 | PR: Day 2 | PR: Day 30 | PR: Day 60 | PR: Day 90 | |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 114.00 | 87.00 | 98.00 | 101.00 | 93.00 | 96.00 |
Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | beats per minute (bpm) (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| HR: Baseline | HR: Day 1 | HR: Day 2 | HR: Day 30 | HR: Day 60 | HR: Day 90 | PR: Day 1 | PR: Day 90 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 146.00 | 142.00 | 130.00 | 130.00 | 184.00 | 134.00 | 108.00 | 140.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeters (cm) (Median) | |||
|---|---|---|---|---|
| Baseline | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 55.00 | 56.60 | 60.00 | 61.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeters (cm) (Median) | ||||
|---|---|---|---|---|---|
| Baseline | Day 1 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 54.00 | 54.00 | 60.00 | 63.00 | 64.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | centimeters (cm) (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 110.00 | 115.80 | 107.90 | 115.10 | 115.00 | 109.50 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 133.00 | 134.00 | 142.00 | 140.30 | 139.70 | 140.70 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 166.00 | 166.00 | 166.90 | 167.75 | 168.50 | 166.65 |
Respiratory rate was defined as the number of breaths per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | breaths per minute (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 35.00 | 34.00 | 34.00 | 34.00 | 30.00 | 24.00 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 25.00 | 36.00 | 34.00 | 36.00 | 36.00 | 34.00 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 24.00 | 21.00 | 20.00 | 22.00 | 20.00 | 22.00 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 20.00 | 18.00 | 20.00 | 22.00 | 20.00 | 20.00 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 20.00 | 18.00 | 18.00 | 18.00 | 20.00 | 18.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | millimeters of mercury (mmHg) (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP: Baseline | SBP: Day 1 | SBP: Day 2 | SBP: Day 30 | SBP: Day 60 | SBP: Day 90 | DSBP: Baseline | DSBP: Day 1 | DSBP: Day 2 | DSBP: Day 30 | DSBP: Day 60 | DSBP: Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 101.00 | 97.00 | 94.00 | 77.0 | 74.00 | 76.00 | 60.00 | 61.00 | 48.00 | 53.00 | 51.00 | 53.00 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 50.00 | 105.50 | 75.00 | 77.00 | 102.00 | 105.00 | 41.00 | 57.00 | 53.00 | 61.00 | 57.00 | 55.50 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 110.50 | 112.0 | 107.00 | 112.00 | 101.00 | 97.50 | 66.00 | 65.50 | 60.50 | 64.00 | 60.00 | 60.50 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 96.00 | 111.00 | 112.00 | 109.00 | 118.00 | 116.00 | 67.00 | 66.50 | 70.00 | 68.00 | 67.00 | 67.00 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 117.50 | 113.00 | 119.50 | 118.00 | 117.50 | 116.00 | 65.00 | 64.00 | 65.00 | 69.00 | 67.00 | 69.00 |
(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90
| Intervention | kilograms (Median) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 2 | Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 4.05 | 4.17 | 4.50 | 6.30 | 7.15 | 7.70 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 3.93 | 4.04 | 4.15 | 4.56 | 4.60 | 4.70 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 18.78 | 17.23 | 14.95 | 15.50 | 16.60 | 21.50 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 36.60 | 37.00 | 39.35 | 39.20 | 38.30 | 39.30 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 60.00 | 63.40 | 58.00 | 63.80 | 65.80 | 59.60 |
Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdomen: Screening | Abdomen: Visit 3 | Abdomen: Visit 4 | Abdomen: Visit 5 | Abdomen: Visit 6 | Abdomen: Visit 7 | Chest: Screening | Chest: Visit 3 | Chest: Visit 4 | Chest: Visit 5 | Chest: Visit 6 | Chest: Visit 7 | Extremities: Screening | Extremities: Visit 3 | Extremities: Visit 4 | Extremities: Visit 5 | Extremities: Visit 6 | Extremities: Visit 7 | Eyes, ears, nose, throat:Screening | Eyes, ears, nose, throat: Visit 3 | Eyes, ears, nose, throat: Visit 4 | Eyes, ears, nose, throat: Visit 5 | Eyes, ears, nose, throat: Visit 6 | Eyes, ears, nose, throat: Visit 7 | General appearance: Screening | General appearance: Visit 3 | General appearance: Visit 4 | General appearance: Visit 5 | General appearance: Visit 6 | General appearance: Visit 7 | Head: Screening | Head: Visit 3 | Head: Visit 4 | Head: Visit 5 | Head: Visit 6 | Head: Visit 7 | Heart: Screening | Heart: Visit 3 | Heart: Visit 4 | Heart: Visit 7 | Lungs: Screening | Lungs: Visit 4 | Lungs: Visit 6 | Lungs: Visit 7 | Neck: Screening | Neck: Visit 4 | Neurological: Screening | Neurological: Visit 3 | Neurological: Visit 4 | Neurological: Visit 5 | Neurological: Visit 7 | Skin: Screening | Skin: Visit 3 | Skin: Visit 4 | Skin: Visit 5 | Skin: Visit 6 | Skin: Visit 7 | |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 4 | 3 | 4 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 2 | 2 | 3 |
Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdomen: Screening | Abdomen: Visit 2 | Abdomen: Visit 3 | Abdomen: Visit 4 | Abdomen: Visit 5 | Abdomen: Visit 6 | Abdomen: Visit 7 | Chest: Screening | Chest: Visit 2 | Chest: Visit 3 | Chest: Visit 4 | Chest: Visit 5 | Chest: Visit 6 | Chest: Visit 7 | Extremities: Screening | Extremities: Visit 2 | Extremities: Visit 3 | Extremities: Visit 4 | Extremities: Visit 5 | Extremities: Visit 6 | Extremities: Visit 7 | Eyes: Screening | Eyes: Visit 2 | Eyes: Visit 3 | Eyes: Visit 4 | Eyes: Visit 5 | Eyes: Visit 6 | Eyes: Visit 7 | Eyes, ears, nose, throat:Screening | General appearance: Screening | General appearance: Visit 2 | General appearance: Visit 3 | General appearance: Visit 4 | General appearance: Visit 5 | General appearance: Visit 6 | General appearance: Visit 7 | Head: Screening | Head: Visit 3 | Head: Visit 4 | Head: Visit 5 | Head: Visit 6 | Head: Visit 7 | Heart: Screening | Heart: Visit 3 | Heart: Visit 4 | Heart: Visit 7 | Lungs: Screening | Lungs: Visit 4 | Lungs: Visit 6 | Lungs: Visit 7 | Neck: Screening | Neck: Visit 4 | Neurological: Screening | Neurological: Visit 2 | Neurological: Visit 3 | Neurological: Visit 4 | Neurological: Visit 5 | Neurological: Visit 7 | Nose: Screening | Nose: Visit 2 | Skin: Screening | Skin: Visit 2 | Skin: Visit 3 | Skin: Visit 4 | Skin: Visit 5 | Skin: Visit 6 | Skin: Visit 7 | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdomen: Screening | Abdomen: Visit 2 | Abdomen: Visit 3 | Abdomen: Visit 4 | Abdomen: Visit 5 | Abdomen: Visit 6 | Abdomen: Visit 7 | Chest: Screening | Chest: Visit 2 | Chest: Visit 3 | Chest: Visit 4 | Chest: Visit 5 | Chest: Visit 6 | Chest: Visit 7 | Extremities: Screening | Extremities: Visit 2 | Extremities: Visit 3 | Extremities: Visit 4 | Extremities: Visit 5 | Extremities: Visit 6 | Extremities: Visit 7 | Eyes: Screening | Eyes: Visit 2 | Eyes: Visit 3 | Eyes: Visit 4 | Eyes: Visit 5 | Eyes: Visit 6 | Eyes: Visit 7 | Eyes, ears, nose, throat:Screening | Eyes, ears, nose, throat: Visit 3 | Eyes, ears, nose, throat: Visit 4 | Eyes, ears, nose, throat: Visit 7 | General appearance: Screening | General appearance: Visit 2 | General appearance: Visit 3 | General appearance: Visit 4 | General appearance: Visit 5 | General appearance: Visit 6 | General appearance: Visit 7 | Head: Screening | Head: Visit 3 | Head: Visit 4 | Head: Visit 5 | Head: Visit 6 | Head: Visit 7 | Heart: Screening | Heart: Visit 3 | Heart: Visit 4 | Heart: Visit 7 | Lungs: Screening | Lungs: Visit 4 | Lungs: Visit 6 | Lungs: Visit 7 | Neck: Screening | Neck: Visit 4 | Neurological: Screening | Neurological: Visit 2 | Neurological: Visit 3 | Neurological: Visit 4 | Neurological: Visit 5 | Neurological: Visit 7 | Nose: Screening | Nose: Visit 2 | Skin: Screening | Skin: Visit 2 | Skin: Visit 3 | Skin: Visit 4 | Skin: Visit 5 | Skin: Visit 6 | Skin: Visit 7 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdomen: Screening | Abdomen: Visit 2 | Abdomen: Visit 3 | Abdomen: Visit 4 | Abdomen: Visit 5 | Abdomen: Visit 6 | Abdomen: Visit 7 | Chest: Screening | Chest: Visit 2 | Chest: Visit 3 | Chest: Visit 4 | Chest: Visit 5 | Chest: Visit 6 | Chest: Visit 7 | Extremities: Screening | Extremities: Visit 2 | Extremities: Visit 3 | Extremities: Visit 4 | Extremities: Visit 5 | Extremities: Visit 6 | Extremities: Visit 7 | Eyes: Screening | Eyes: Visit 2 | Eyes: Visit 3 | Eyes: Visit 4 | Eyes: Visit 5 | Eyes: Visit 6 | Eyes: Visit 7 | Eyes, ears, nose, throat:Screening | Eyes, ears, nose, throat: Visit 3 | Eyes, ears, nose, throat: Visit 4 | Eyes, ears, nose, throat: Visit 5 | Eyes, ears, nose, throat: Visit 6 | Eyes, ears, nose, throat: Visit 7 | General appearance: Screening | General appearance: Visit 2 | General appearance: Visit 3 | General appearance: Visit 4 | General appearance: Visit 5 | General appearance: Visit 6 | General appearance: Visit 7 | Head: Screening | Head: Visit 3 | Head: Visit 4 | Head: Visit 5 | Head: Visit 6 | Head: Visit 7 | Heart: Screening | Heart: Visit 3 | Heart: Visit 4 | Heart: Visit 7 | Lungs: Screening | Lungs: Visit 4 | Lungs: Visit 6 | Lungs: Visit 7 | Neck: Screening | Neck: Visit 4 | Neurological: Screening | Neurological: Visit 2 | Neurological: Visit 3 | Neurological: Visit 4 | Neurological: Visit 5 | Neurological: Visit 7 | Nose: Screening | Nose: Visit 2 | Skin: Screening | Skin: Visit 2 | Skin: Visit 3 | Skin: Visit 4 | Skin: Visit 5 | Skin: Visit 6 | Skin: Visit 7 | |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 0 | 1 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 2 | 0 | 2 | 3 | 4 | 1 | 3 | 2 | 0 | 0 | 1 | 0 | 0 | 3 | 10 | 1 | 3 | 8 | 3 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 1 | 2 | 3 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 2 | 5 | 4 | 3 | 5 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 5 | 1 | 3 | 6 | 7 | 5 | 4 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after the last dose of study drug (up to Day 132) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AEs | SAEs | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 1 | 0 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 2 | 2 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 7 | 3 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 7 | 3 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 19 | 13 |
Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. The percentage of participants who had anti factor-Xa levels within the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 30, Day 60, Day 90 in follow up phase
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 100.0 | 100.0 | 100.0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 100.0 | 100.0 | 100.0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 33.3 | 75.0 | 50.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 93.3 | 81.8 | 72.7 |
Prespecified therapeutic anti-factor Xa range was 0.5-1.0 IU/mL. The percentage of participants who had anti-factor Xa levels outside the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 30, Day 60, Day 90 in follow-up phase
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 30 | Day 60 | Day 90 | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 0 | 0 | 0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0 | 0 | 0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 66.7 | 25.0 | 50.0 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 6.7 | 18.2 | 27.3 |
VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. PE is a blood clot in the lungs. Clinical response of progression was defined as progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis. Clinical response of regression: Regressed clot burden utilizing the same imaging modality as the screening visit. Clinical response of resolution: Thrombus resolution of the qualifying event measured by repeat imaging at the end of study (EOS) visit. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Progression | Regression | Resolution | No Change | |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 0 | 0 | 100.0 | 0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0 | 12.5 | 62.5 | 0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 0 | 14.3 | 57.1 | 14.3 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 0 | 29.4 | 58.8 | 5.9 |
A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter 24 hours, Overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, Overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration or bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal). A bleeding event was considered as minor if it was clinically overt but not meeting the criteria for major or clinically relevant no major bleeding (bleeding resulting in any medical or surgical interventions but which did not meet the criteria for major bleeding). (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Major Bleeding | Minor Bleeding | |
| Dalteparin Sodium: Group 1 (>=0 to <8 Weeks) | 0 | 0 |
| Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years) | 50.0 | 0 |
| Dalteparin Sodium: Group 3 (>=2 Years to <8 Years) | 0 | 50.0 |
| Dalteparin Sodium: Group 4 (>=8 Years to <12 Years) | 0 | 57.1 |
| Dalteparin Sodium: Group 5 (>=12 Years to <19 Years) | 0 | 40.0 |
To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 3-months
| Intervention | score on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 11.2 |
| Randomized Arm 2 (LMWH) | 10.7 |
| Preference Cohort 1 (DOACs) | 10.3 |
| Preference Cohort 2 (LMWH) | 10.5 |
To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 6-months
| Intervention | score on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 11.6 |
| Randomized Arm 2 (LMWH) | 11.3 |
| Preference Cohort 1 (DOACs) | 11.5 |
| Preference Cohort 2 (LMWH) | 10.1 |
To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 3 months
| Intervention | score on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 56.7 |
| Randomized Arm 2 (LMWH) | 53.3 |
| Preference Cohort 1 (DOACs) | 55.8 |
| Preference Cohort 2 (LMWH) | 54.9 |
To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 6 months
| Intervention | score on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 56.5 |
| Randomized Arm 2 (LMWH) | 54.1 |
| Preference Cohort 1 (DOACs) | 54.9 |
| Preference Cohort 2 (LMWH) | 53.1 |
To compare the effectiveness of anticoagulation with a DOAC (intervention) with LMWH/warfarin (comparator) for preventing VTE recurrence in patients with cancer based on cumulative VTE recurrence reported by patients or clinicians at 6 months. Only VTEs that were nonfatal were considered because of the challenges of attributing cause of death in cancer patients to tumor progression vs. VTE. (NCT02744092)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Randomized Arm 1 (DOACs) | 6.1 |
| Randomized Arm 2 (LMWH) | 8.8 |
| Preference Cohort 1 (DOACs) | 7.5 |
| Preference Cohort 2 (LMWH) | 4.1 |
To compare the harms of DOAC vs. LMWH/warfarin therapy for cancer patients with VTE based on the cumulative rate of major bleeding at 6 months. d. Major bleeding was defined as Grade >=3 on the Common Terminology Criteria for Adverse Events from the National Cancer Institute (NCI CTCAE) criteria version 5.0 (i.e., severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living). (NCT02744092)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Randomized Arm 1 (DOACs) | 5.2 |
| Randomized Arm 2 (LMWH) | 5.6 |
| Preference Cohort 1 (DOACs) | 11.5 |
| Preference Cohort 2 (LMWH) | 7.6 |
Change in mental health at 3 months from baseline. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The scores indicate change in score from baseline. (NCT02744092)
Timeframe: 3-months
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | -0.3 |
| Randomized Arm 2 (LMWH) | 0.7 |
| Preference Cohort 1 (DOACs) | 0.3 |
| Preference Cohort 2 (LMWH) | 0.4 |
Change in mental health at 6 months from baseline. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The scores indicate change in score from baseline. (NCT02744092)
Timeframe: 6-months
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 0.3 |
| Randomized Arm 2 (LMWH) | 0.9 |
| Preference Cohort 1 (DOACs) | 1.1 |
| Preference Cohort 2 (LMWH) | -1.9 |
Change in physical health at 3 months. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The presented scores in this results section indicate the change (difference) in mean scores between the baseline and 3-month follow-up assessment. (NCT02744092)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 1.8 |
| Randomized Arm 2 (LMWH) | 0.7 |
| Preference Cohort 1 (DOACs) | 3.4 |
| Preference Cohort 2 (LMWH) | -0.3 |
Change in physical health at 6 months. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The presented scores in this results section indicate the change (difference) in mean scores between the baseline and 6-month follow-up assessment. (NCT02744092)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Arm 1 (DOACs) | 2.4 |
| Randomized Arm 2 (LMWH) | 0.7 |
| Preference Cohort 1 (DOACs) | 2.1 |
| Preference Cohort 2 (LMWH) | -2.8 |
To compare the impact of DOAC vs. LMWH/warfarin therapy on mortality in cancer patients with VTE based on survival at 6 months. Mortality was reported by participants' surrogates (via study-specific questionnaire) or clinicians (via study-specific case report form) (NCT02744092)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Randomized Arm 1 (DOACs) | 21.5 |
| Randomized Arm 2 (LMWH) | 18.4 |
| Preference Cohort 1 (DOACs) | 16.3 |
| Preference Cohort 2 (LMWH) | 23.8 |
The rate (percentage) of patients experiencing major bleeding at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Apixaban) | 0 |
| Arm B (Dalteparin) | 2.1 |
A similar analysis as described for the primary safety analysis will be used. The rate (percentage) of patients experiencing major bleeding or a clinically relevant non-major bleed at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Apixaban) | 7.0 |
| Arm B (Dalteparin) | 8.1 |
Analyzed using the same methods described above for the primary endpoint.Time to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE) is defined as the time from randomization to the date the patient experienced the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE). (NCT02585713)
Timeframe: Up to 3 months post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A (Apixaban) | NA |
| Arm B (Dalteparin) | NA |
The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug). (NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 32 |
| Dalteparin Group | 16 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 67 |
| Dalteparin Group | 71 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 19 |
| Dalteparin Group | 35 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 21 |
| Dalteparin Group | 24 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 41 |
| Dalteparin Group | 59 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 235 |
| Dalteparin Group | 228 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 6 |
| Dalteparin Group | 4 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
The percentage of patients who experienced a clinically significant bleeding event were recorded (including major and clinically significant non-major bleeding) over 13 weeks (12 weeks of study and an additional week of observation). Major bleeding was defined as being clinically overt and satisfying one of the following: decrease in hemoglobin of 2.0 g/dL, leading to transfusion of 2 or more units of blood or packed red cells, occurring in a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial) or leading to death. Clinically significant non-major bleeding was defined as clinically overt, not meeting criteria for major bleeding and with one of the following characteristics: multiple-source, spontaneous hematoma > 25 cm², epistaxis > 5 mins, macroscopic hematuria not related to instrumentation, spontaneous rectal bleeding, gingival bleeding > 5 mins, hemoptysis, hematemesis or prolonged bleeding (> 5 minutes) after venipuncture. (NCT00876915)
Timeframe: 13 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Dalteparin Injection | 14 |
| No Therapy | 2 |
The percentage of patients who developed a Venous thromboembolism were recorded within 12 weeks following randomization including all adjudicated occurrences of symptomatic DVT, PE and upper extremity thrombus as well as all asymptomatic DVT and PE detected by lower extremity ultrasonography and chest CT. (NCT00876915)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Dalteparin Injection | 12 |
| No Therapy | 21 |
Blood samples were obtained to measure the value of D-Dimer at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of D-Dimer
| Intervention | ug/mL (Mean) |
|---|---|
| High Risk | 2.99 |
| Low Risk | 1.87 |
Blood samples were obtained to measure the value of FVIIa at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of FVIIa
| Intervention | pM (Mean) |
|---|---|
| High Risk | 151.2 |
| Low Risk | 148.6 |
Blood samples were obtained to measure the value of Human F12 at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of Human F12
| Intervention | ng/mL (Mean) |
|---|---|
| High Risk | 484.7 |
| Low Risk | 306.3 |
Blood samples were obtained to measure the value of TAT at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of TAT
| Intervention | ug/L (Mean) |
|---|---|
| High Risk | 9.89 |
| Low Risk | 12.44 |
Blood samples were obtained to measure the value of Tissue Factor at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients. (NCT00876915)
Timeframe: baseline value of tissue factor
| Intervention | pg/mL (Mean) |
|---|---|
| High Risk | 0.669 |
| Low Risk | 0.187 |
Blood samples were obtained to measure the value of TFPI at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of TFPI
| Intervention | pg/mL (Mean) |
|---|---|
| High Risk | 813.6 |
| Low Risk | 738.2 |
Change in pain at day 14 as measured by 11-point Box Pain Scale, 0 being the least amount of pain, and 10 the most amount of pain (NCT00264381)
Timeframe: Day 1, Day 14
| Intervention | units on a scale (Mean) |
|---|---|
| Ibuprofen 800 mg Tid | -2.28 |
| Dalteparin 200 U/kg Then 10,000 U Daily | -2.23 |
Number of participants with bleeding events related to treatment (NCT00264381)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Ibuprofen 800 mg Tid | 0 |
| Dalteparin 200 U/kg Then 10,000 U Daily | 0 |
Thrombosis progression and deep vein thrombosis at day 14 by ultrasound testing (NCT00264381)
Timeframe: Day 14
| Intervention | participants (Number) | |
|---|---|---|
| Thrombosis progression | VTE | |
| Dalteparin 200 U/kg Then 10,000 U Daily | 0 | 0 |
| Ibuprofen 800 mg Tid | 4 | 0 |
Symptomatic thrombosis extension (DVT) or pulmonary embolism at 3 months documented by radiologic testing. (NCT00264381)
Timeframe: 3 months
| Intervention | participants (Number) | |
|---|---|---|
| Thrombosis progression | VTE | |
| Dalteparin 200 U/kg Then 10,000 U Daily | 4 | 1 |
| Ibuprofen 800 mg Tid | 6 | 0 |
90 reviews available for dalteparin and Hemorrhage
| Article | Year |
|---|---|
[Prevention of deep venous thrombosis after knee arthroscopy. Recent advances].
Topics: Anticoagulants; Arthroscopy; Combined Modality Therapy; Follow-Up Studies; Hemorrhage; Humans; Incid | 2009 |
Clinical experience with nadroparin in patients undergoing dialysis for renal impairment.
Topics: Acute Kidney Injury; Anticoagulants; Female; Hemorrhage; Humans; Male; Nadroparin; Practice Guidelin | 2011 |
Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin; He | 1996 |
Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Topics: Blood Platelets; Capillary Permeability; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage; He | 1998 |
[Preventive treatment in internal medicine by low-molecular-weight heparin (nadroparine calcium)].
Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Internal Medicine; Nadropari | 1998 |
Low-molecular-weight heparins in the management of acute coronary syndromes.
Topics: Angina, Unstable; Canada; Coronary Disease; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage; | 1999 |
Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery.
Topics: Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Surgical Procedures, Oper | 1999 |
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin; | 2001 |
Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hep | 2001 |
Clinical use of parnaparin in major and minor orthopedic surgery: a review.
Topics: Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans | 2008 |
Heparin and SARS-CoV-2: Multiple Pathophysiological Links.
Topics: Anticoagulants; COVID-19; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Molecular-Weig | 2021 |
The efficacy of weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients: A systematic review and meta-analysis.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Drug Administration Schedule; Enoxaparin; Hemorrhage | 2022 |
The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Random | 2023 |
The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis.
Topics: Adult; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Multiple Trauma; Network Meta-A | 2023 |
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications; | 2020 |
Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridine | 2021 |
A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism | 2021 |
Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Hemorrhage; Huma | 2017 |
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies.
Topics: Anticoagulants; Enoxaparin; Health Care Costs; Hemorrhage; Humans; Length of Stay; Pulmonary Embolis | 2017 |
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Drug-Related Side Effects | 2017 |
Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Topics: Age Factors; Anticoagulants; Benzamides; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hospi | 2018 |
Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis.
Topics: Anticoagulants; Enoxaparin; Evidence-Based Medicine; Hemorrhage; Heparin, Low-Molecular-Weight; Intr | 2018 |
Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature.
Topics: Adolescent; Anterior Cruciate Ligament Reconstruction; Anticoagulants; Arthroscopy; Elective Surgica | 2018 |
Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
Topics: Anticoagulants; Benzamides; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Fa | 2018 |
Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis.
Topics: Anticoagulants; Arthroplasty; Enoxaparin; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Ra | 2018 |
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enox | 2019 |
Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Topics: Anticoagulants; Benzamides; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; | 2019 |
Outpatient versus inpatient treatment for acute pulmonary embolism.
Topics: Acute Disease; Adult; Ambulatory Care; Anticoagulants; Confidence Intervals; Enoxaparin; Hemorrhage; | 2019 |
Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides.
Topics: Anticoagulants; Cardiology; Clinical Trials as Topic; Contrast Media; Enoxaparin; Fibrinolytic Agent | 2014 |
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Human | 2015 |
The outcome of pulmonary vein thrombosis in non-surgical patients. A systematic review and case report.
Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Male; Middle | 2015 |
Enoxaparin venous thromboembolism prophylaxis in bariatric surgery: A best evidence topic.
Topics: Anticoagulants; Bariatric Surgery; Clinical Protocols; Cohort Studies; Enoxaparin; Female; Hemorrhag | 2015 |
Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease.
Topics: Aged, 80 and over; Anticoagulants; Aspirin; Enoxaparin; Erythrocyte Transfusion; Female; Hematoma; H | 2015 |
New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low | 2016 |
Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Factor | 2016 |
Apixaban: A Review in Venous Thromboembolism.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Enoxaparin; Hemorrhage; H | 2016 |
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; H | 2017 |
Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Randomized Controlled Trials a | 2017 |
Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
Topics: Anticoagulants; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxapa | 2017 |
Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Infusions, | 2008 |
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2009 |
[Rivaroxaban (Xarelto): efficacy and safety].
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III | 2008 |
What's new in stroke? The top 10 studies of 2006-2008. Part II.
Topics: Anticoagulants; Atorvastatin; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrin | 2008 |
Safety evaluation of enoxaparin in currently approved indications.
Topics: Adult; Animals; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Myocardial Infarction; Posto | 2009 |
P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.
Topics: Animals; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Enoxaparin; Fibrin Fibrinogen | 2010 |
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dab | 2010 |
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimi | 2010 |
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cardiology; Clinica | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopido | 2010 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method | 2010 |
Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Evidence-Based Medicine; Female; | 2011 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib | 2011 |
Antithrombotic therapy in ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Electrocardiography; Enoxaparin | 2011 |
Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.
Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; France; Hemorrhage; Heparin; Humans; | 2011 |
Standard or extended-duration prophylaxis in medical patients? A review of the evidence.
Topics: Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Pulmonary Embolism; Randomized Control | 2011 |
Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis.
Topics: Anticoagulants; Cardiovascular Diseases; Enoxaparin; Glomerular Filtration Rate; Hemorrhage; Humans; | 2012 |
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Hep | 2012 |
Bullous hemorrhagic dermatosis at distant sites: a report of 2 new cases due to enoxaparin injection and a review of the literature.
Topics: Aged; Anticoagulants; Drug Eruptions; Enoxaparin; Hemorrhage; Humans; Male; Skin Diseases, Vesiculob | 2012 |
Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; F | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, R | 2012 |
Apixaban. After hip or knee replacement: LMWH remains the standard treatment.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Interact | 2012 |
Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
Topics: Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Elective Surgical Procedures; Enoxaparin; | 2013 |
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
Topics: Angina Pectoris; Angina, Unstable; Cause of Death; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Hepa | 2004 |
Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Centra | 2004 |
Surgical management of enoxaparin- and/or warfarin-induced massive retroperitoneal bleeding: report of a case and review of the literature.
Topics: Aged; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Laparotomy; Male; Pulmonary Embolism; Retroper | 2005 |
Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.
Topics: Acute Disease; Anticoagulants; Antithrombins; Blood Coagulation; Enoxaparin; Hemorrhage; Humans; Thr | 2005 |
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma | 2006 |
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma | 2006 |
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma | 2006 |
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Topics: Anticoagulants; Autoantibodies; Creatinine; Drug Monitoring; Enoxaparin; Factor Xa; Hemorrhage; Huma | 2006 |
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dos | 2007 |
Use of enoxaparin in patients with chronic kidney disease: safety considerations.
Topics: Animals; Anticoagulants; Clinical Trials as Topic; Enoxaparin; Hemorrhage; Humans; Kidney Failure, C | 2007 |
Utilizing enoxaparin in the management of STEMI.
Topics: Clinical Trials as Topic; Enoxaparin; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi | 2007 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Factor Xa inactivation in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Fondapa | 2008 |
Prevention of postoperative thromboembolism in general surgery with enoxaparin.
Topics: Adult; Aged; Blood Loss, Surgical; Enoxaparin; Hematologic Tests; Hemorrhage; Heparin; Humans; Middl | 1994 |
Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.
Topics: Biological Availability; Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Female; He | 1995 |
Low molecular weight heparins and their use in obstetrics and gynecology.
Topics: Clinical Trials as Topic; Enoxaparin; Female; Fetus; Gynecology; Hemorrhage; Heparin, Low-Molecular- | 1994 |
Neuroaxial blocks and LMWH thromboprophylaxis.
Topics: Anesthesia, Epidural; Contraindications; Enoxaparin; Fibrinolytic Agents; Hematoma, Epidural, Crania | 1998 |
The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Electroca | 2001 |
Overview of the clinical results of pentasaccharide in major orthopedic surgery.
Topics: Clinical Trials, Phase III as Topic; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Huma | 2001 |
Pharmacological profile of reviparin-sodium.
Topics: Animals; Biological Availability; Blood Coagulation; Carbohydrate Sequence; Factor Xa Inhibitors; He | 1993 |
Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Topics: Biocompatible Materials; Blood Coagulation Tests; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Mol | 1993 |
Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
Topics: Adult; Anticoagulants; Catheterization, Central Venous; Child; Female; Hemorrhage; Heparin, Low-Mole | 2001 |
[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage].
Topics: Adult; Aged; Anticoagulants; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Hemorrha | 2003 |
Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Venous Thromboembolism | 2023 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Mol | 2018 |
Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications.
Topics: Fibrinolytic Agents; Hemorrhage; Humans; Renal Elimination; Renal Insufficiency, Chronic; Risk Adjus | 2020 |
The Role of Tinzaparin in Oncology.
Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Tinzaparin; Treat | 2018 |
Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis.
Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Randomized Contro | 2018 |
Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis.
Topics: Anticoagulants; Aspirin; Databases, Factual; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Join | 2017 |
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Topics: Adult; Ambulatory Care; Anticoagulants; Antineoplastic Agents; Antithrombins; Child; Hemorrhage; Hep | 2014 |
291 trials available for dalteparin and Hemorrhage
| Article | Year |
|---|---|
Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial.
Topics: Anticoagulants; Hemorrhage; Humans; Lung Neoplasms; Nadroparin; Rivaroxaban; Thoracic Surgery; Venou | 2023 |
The safety and efficacy of Heparin and Nadroparin compared to placebo in acute ischemic stroke - pilot study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Double-Blind Met | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2011 |
Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study.
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Anticoagulants; Female; Hemorrhage; Humans; Male; Middl | 2011 |
Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Female; Fibrinolytic Agents; Hemorrhage; Hum | 2003 |
The effect of low molecular weight heparin on survival in patients with advanced malignancy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Humans; Inj | 2005 |
Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin.
Topics: Anticoagulants; Citric Acid; Cohort Studies; Critical Illness; Erythrocyte Transfusion; Hemofiltrati | 2006 |
Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; A | 2007 |
An observational study on the effects of nadroparin-based and citrate-based continuous venovenous hemofiltration on calcium metabolism.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Calcium Citrate; Chelating Agents; Citrates; Cri | 2007 |
[Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance].
Topics: Aged; Aged, 80 and over; Female; Hemorrhage; Heparin; Humans; Injections, Subcutaneous; Male; Nadrop | 1995 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions, | 1996 |
[Preparation for delivery in patients with missed labor considering low-dose heparin and prostaglandins].
Topics: Adult; Anticoagulants; Delivery, Obstetric; Dinoprostone; Female; Hemorrhage; Humans; Labor, Induced | 1996 |
Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
Topics: Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Hemorrhage; Humans; Nadrop | 1996 |
Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coron | 1997 |
Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Topics: Ambulatory Care; Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Health Care Costs; | 1999 |
Use of low molecular weight heparin for prevention of deep vein thrombosis in total knee arthroplasty--a study of its efficacy in an Asian population.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee | 2000 |
Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis.
Topics: Acenocoumarol; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Blo | 2001 |
Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study.
Topics: Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female | 2010 |
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum).
Topics: Aged; Analysis of Variance; Anticoagulants; Chi-Square Distribution; Dose-Response Relationship, Dru | 2012 |
Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Coagulation; Drug Administration Schedule; Drug Therapy, Combination; Electroca | 2006 |
Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; | 2013 |
Effect of self-administered intraperitoneal bemiparin on peritoneal transport and ultrafiltration capacity in peritoneal dialysis patients with membrane dysfunction. A randomized, multi-centre open clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; H | 2012 |
Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Fibrinolytic Agents; Hemoglobins; Hemorrh | 2003 |
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk | 2021 |
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk | 2021 |
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk | 2021 |
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Hospitalization; Humans; Patient Discharge; Risk | 2021 |
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial.
Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism | 2022 |
Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial.
Topics: Anticoagulants; Drug Resistance; Enoxaparin; Hemorrhage; Humans; International Normalized Ratio; Met | 2022 |
Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy.
Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Humans; Prospective Studies; Rivaroxaban; Thromboe | 2022 |
Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial.
Topics: Anticoagulants; Child; COVID-19; Enoxaparin; Hemorrhage; Humans; Prospective Studies; Systemic Infla | 2022 |
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.
Topics: COVID-19; COVID-19 Vaccines; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Male; Platelet Aggre | 2023 |
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Topics: Aged; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhag | 2023 |
Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.
Topics: Anticoagulants; COVID-19; Enoxaparin; Hemorrhage; Heparin; Humans; Prospective Studies; Treatment Ou | 2023 |
Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzamides; Blood Coagulation; | 2019 |
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Respo | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In | 2020 |
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
Topics: Administration, Oral; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hu | 2020 |
Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial.
Topics: Aged; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Female; Hemorrhage; Humans; Intermittent Pne | 2020 |
Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.
Topics: Adult; Aged; Anticoagulants; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Fractures, Bone; Hemo | 2020 |
Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE.
Topics: Acute Coronary Syndrome; Anticoagulants; Asian People; Dose-Response Relationship, Drug; Enoxaparin; | 2022 |
Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis.
Topics: Administration, Oral; Aged; Anticoagulants; Egypt; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrh | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
Topics: Aged; Anticoagulants; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Critical Care; Dose-Respons | 2022 |
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
Topics: Administration, Oral; Anticoagulants; Brazil; COVID-19; Drug Administration Schedule; Enoxaparin; Fi | 2021 |
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Brazil; COVID-19; COVID-19 Drug Treatment; Endpoint | 2021 |
Abelacimab for Prevention of Venous Thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Rep | 2021 |
A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
Topics: Aged; Aged, 80 and over; China; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Sche | 2017 |
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Benzamides; Cardiovascular Diseases; Double-Blind Method | 2017 |
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Enoxaparin; Female; Hemorrhage | 2018 |
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithro | 2018 |
Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Male; Re | 2019 |
Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study.
Topics: Aged; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Hemorrhage; Heparin, Low-Molecular-We | 2019 |
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Human | 2019 |
Safety and efficacy of periprocedural anticoagulation with enoxaparin in patients undergoing peripheral endovascular revascularization.
Topics: Aged; Anticoagulants; Endovascular Procedures; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle | 2014 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Oral apixaban for the treatment of acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; F | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrh | 2013 |
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.
Topics: Age Factors; Aged; Anticoagulants; Canada; Enoxaparin; Europe; Female; Follow-Up Studies; Hemorrhage | 2013 |
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Australia; Azepines; Benzamides; Brazil; Canad | 2014 |
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Produc | 2014 |
A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Anticoagulants; Critical Illness; Double-Blind Met | 2014 |
Use of the CRUSADE bleeding risk score in the prediction of major bleeding for patients with acute coronary syndrome receiving enoxaparin in Thailand.
Topics: Acute Coronary Syndrome; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle A | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fema | 2014 |
Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; France; Heart Conduction System; Hemorrhage; | 2015 |
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Clinical Protocols; | 2015 |
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Mor | 2015 |
Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B.
Topics: Adult; China; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Hep | 2015 |
Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2015 |
Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Fe | 2015 |
Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Coronary Artery Bypass; Drug Therapy, | 2016 |
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Topics: Aged; Anticoagulants; Chi-Square Distribution; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors | 2015 |
Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Black or Africa | 2016 |
A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
Topics: Adult; Blood Coagulation; Body Mass Index; Chemoprevention; Dose-Response Relationship, Drug; Drug A | 2016 |
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial.
Topics: Adult; Aged; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles | 2016 |
Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Factor Xa Inhibitors; Female; Hemo | 2016 |
Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Hepari | 2017 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridones; Venous Thromboembolism; Warfar | 2016 |
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Enoxaparin; Factor Xa Inhibitors; | 2016 |
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa | 2017 |
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzamides; Double-Blind Method; Enoxaparin; Factor Xa Inhi | 2017 |
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anticoagulants; Coronary Angiography; Cross-Over Studies | 2008 |
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Humans; | 2009 |
Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind | 2008 |
Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Electrocardiography, Ambulatory; Enoxaparin; Eptifiba | 2008 |
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Double-Blind Method; | 2008 |
The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Elective Surgical Procedures; Enoxaparin; Fema | 2009 |
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Topics: Administration, Oral; Adult; Aged; Arthroplasty, Replacement, Knee; Canada; Dose-Response Relationsh | 2009 |
[Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
Topics: Adult; Aged; Ambulatory Care; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxap | 2009 |
How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Drug Monitoring; Enoxa | 2009 |
Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Inject | 2009 |
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Polysaccharid | 2009 |
Enoxaparin dosing in the elderly using adjusted body weight.
Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Drug Dosage Calculations; Enoxaparin; Factor X | 2009 |
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Aged; Aging; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Arter | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula | 2009 |
Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Drug Therapy, Combination; Endpoint Det | 2009 |
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2009 |
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; | 2010 |
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; | 2010 |
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; | 2010 |
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; | 2010 |
Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Drug Administration Schedule; Elec | 2010 |
Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Hemorrhage; Humans; Kidney; Ki | 2009 |
Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study.
Topics: Abdominal Neoplasms; Aged; Anticoagulants; Asian People; Drug Administration Schedule; Enoxaparin; F | 2010 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Australia; Canada; Enoxaparin; Europe; Female; | 2009 |
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Blood Coagulation; Dose-Response Relationship, Drug; | 2010 |
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
Topics: Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents | 2010 |
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Topics: Aged; Cause of Death; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage | 2010 |
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B | 2010 |
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B | 2010 |
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B | 2010 |
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Double-B | 2010 |
Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; B | 2010 |
Does ambulation modify venous thromboembolism risk in acutely ill medical patients?
Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Guidel | 2010 |
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Kne | 2010 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2010 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimida | 2011 |
Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cross-Over Studies; Enoxaparin; Female; Hemorrhage; H | 2011 |
Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
Topics: Adult; Aged; Blood Coagulation Factor Inhibitors; Enoxaparin; Evaluation Studies as Topic; Factor Xa | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.
Topics: Acute Disease; Administration, Oral; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Health Res | 2011 |
Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Endothelium, Vascular; Enoxap | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Drug Administrat | 2011 |
Low-molecular-weight heparin and mortality in acutely ill medical patients.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method; | 2011 |
Low-molecular-weight heparin and mortality in acutely ill medical patients.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method; | 2011 |
Low-molecular-weight heparin and mortality in acutely ill medical patients.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method; | 2011 |
Low-molecular-weight heparin and mortality in acutely ill medical patients.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Combined Modality Therapy; Double-Blind Method; | 2011 |
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspi | 2012 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazol | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up | 2012 |
Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Topics: Administration, Oral; Adult; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa | 2012 |
Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Topics: Administration, Oral; Animals; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents | 2012 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administ | 2013 |
Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Electro | 2002 |
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combin | 2002 |
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Electrocardiography; Enoxaparin; Eptifibatide; Femal | 2003 |
Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Drug Therapy, Combinati | 2003 |
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2003 |
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Failure; Hemorrhage; H | 2003 |
Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Data Collection; Dose-Response Relatio | 2003 |
Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism.
Topics: Acute Disease; Adult; Aged; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Heparin; Humans; Le | 2003 |
Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Prospective Studies; R | 2003 |
Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.
Topics: Acute Disease; Adult; Anticoagulants; Bandages; Combined Modality Therapy; Enoxaparin; Female; Hemor | 2003 |
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem | 2003 |
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem | 2003 |
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem | 2003 |
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized tr
Topics: Aged; Cohort Studies; Drug Therapy, Combination; Emergency Medical Services; Enoxaparin; Female; Hem | 2003 |
[Multicenter, prospective study comparing enoxaparin with unfractionated heparin in the treatment of submassive pulmonary thromboembolism].
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Prospectiv | 2003 |
Venous thromboembolism prophylaxis conversion in nonsurgical inpatients.
Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Hemorrhage; Heparin; Hospitalization; Humans; Ris | 2003 |
Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury.
Topics: Adolescent; Adult; Aged; Dalteparin; Enoxaparin; Female; Fibrinolytic Agents; Health Status Indicato | 2003 |
Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Angina, Unstable; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa Inhibitors; Female; Half-Lif | 2003 |
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Azetidines; Benzylamines | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2003 |
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2003 |
Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE)
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Drug Thera | 2004 |
Treatment with anticoagulants in cerebral events (TRACE).
Topics: Aged; Anticoagulants; Constriction, Pathologic; Drug Monitoring; Embolism; Enoxaparin; Female; Hemor | 2004 |
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Mo | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Angiotensin-Conve | 2004 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans | 2004 |
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Enoxaparin; Female; Fibrinolytic Agents; Hemo | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheter | 2004 |
An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
Topics: Adult; Ambulatory Care; Anticoagulants; Brazil; Causality; Comorbidity; Enoxaparin; Female; Hemorrha | 2004 |
Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Concussion; Cerebral Hemorrhage, Traumatic; Cervic | 2004 |
Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study.
Topics: Abortion, Habitual; Dose-Response Relationship, Drug; Drug Hypersensitivity; Enoxaparin; Female; Hem | 2005 |
Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
Topics: Angiography; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort | 2005 |
Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.
Topics: Adult; Aged; Ambulatory Care; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Heparin; | 2005 |
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Arthroplasty | 2005 |
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relati | 2006 |
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Topics: Administration, Oral; Anticoagulants; Arteries; Azetidines; Benzylamines; Drug Therapy, Combination; | 2006 |
Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
Topics: Aged; Anticoagulants; Coronary Disease; Device Removal; Early Ambulation; Enoxaparin; Factor Xa; Fac | 2006 |
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Fondapar | 2006 |
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
Topics: Aged; Anticoagulants; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolyt | 2006 |
Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Enoxaparin; F | 2006 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human | 2006 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human | 2006 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human | 2006 |
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Human | 2006 |
The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocard
Topics: Atrial Fibrillation; Echocardiography, Transesophageal; Electric Countershock; Enoxaparin; Feasibili | 2006 |
Bivalirudin for patients with acute coronary syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Co | 2006 |
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Transfusion; Chi-Square Distribution; Coronary Angiograp | 2007 |
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Transfusion; Coronary Dis | 2006 |
Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; In Vitro Techniques; | 2007 |
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Heparin; Humans; Male; Mi | 2007 |
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25.
Topics: Adult; Age Factors; Death, Sudden, Cardiac; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hep | 2007 |
Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
Topics: Adult; Anterior Cruciate Ligament; Anticoagulants; Arthroscopy; Double-Blind Method; Drug Administra | 2007 |
Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT).
Topics: Administration, Oral; Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Blood Loss, Surgic | 2007 |
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Clin | 2007 |
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Coronary Disease; Death, Sudden, Cardiac; | 2007 |
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Argentina; Arthroplasty, Replacement, Knee; Do | 2007 |
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Double-Blind Metho | 2007 |
Individualized compared with conventional dosing of enoxaparin.
Topics: Adult; Aged; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Enoxaparin; Female; | 2008 |
Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Enoxaparin; Female; Hemorrhage; Humans | 2007 |
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
Topics: Aged; Aspirin; Diabetes Complications; Drug Therapy, Combination; Electrocardiography; Enoxaparin; F | 2007 |
Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Knee Prosthesis; Male; Thromb | 1995 |
Prevention of postoperative thromboembolism in general surgery with enoxaparin.
Topics: Adult; Aged; Blood Loss, Surgical; Enoxaparin; Hematologic Tests; Hemorrhage; Heparin; Humans; Middl | 1994 |
Comparison of enoxaparin versus unfractionated heparin in general surgery. SURGEX-Study Group.
Topics: Blood Loss, Surgical; Double-Blind Method; Enoxaparin; Hemorrhage; Hemostasis; Heparin; Humans; Post | 1994 |
Antithromboembolic efficacy and safety of enoxaparin in general surgery. German multicentre trial.
Topics: Adult; Aged; Enoxaparin; Female; Hematologic Tests; Hemorrhage; Humans; Incidence; Male; Middle Aged | 1994 |
Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Enoxaparin; Female; Fibrin Fibrinogen De | 1994 |
Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery.
Topics: Aged; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Hip Prosthesis; H | 1993 |
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
Topics: Aged; Alanine Transaminase; Drug Administration Schedule; Enoxaparin; Female; Hemoglobins; Hemorrhag | 1994 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans | 1996 |
Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.
Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans | 1996 |
Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.
Topics: Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hip Prosthesis; Humans; M | 1996 |
Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators.
Topics: Aged; Angina, Unstable; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; M | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Ma | 1998 |
Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor | 1998 |
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Creatine Kinase; Double-Blind Method; Electro | 1999 |
Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Cross-Over Studies; Drug Costs; E | 1999 |
An equivalence study of two low-molecular-weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement.
Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Hemorrhage; Heparin, L | 2000 |
Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; He | 2000 |
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administ | 2001 |
A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Res | 2001 |
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; | 2001 |
Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
Topics: Aged; Angina, Unstable; Antifibrinolytic Agents; Double-Blind Method; Electrocardiography; Enoxapari | 2001 |
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Topics: Aged; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Hip Fr | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; F | 2001 |
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Blood Flow Velocity; Cohort Studies; Corona | 2002 |
Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
Topics: Aged; Anticoagulants; Endpoint Determination; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Hep | 2002 |
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal | 2002 |
Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticoagulants; Asp | 2002 |
Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial.
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Blood Vessel Prosthesis Implantation; Dose-Respon | 2002 |
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
Topics: Aged; Angina Pectoris, Variant; Anticoagulants; Bundle-Branch Block; Double-Blind Method; Female; He | 2005 |
An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group.
Topics: Adult; Aged; Double-Blind Method; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Inciden | 1993 |
Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early A
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Disease; Coronary Ves | 1996 |
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
Topics: Adult; Aged; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin, Low-Molecula | 1997 |
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
Topics: Anticoagulants; Death, Sudden; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; M | 1997 |
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, L | 2001 |
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Hemorrhage; Hepar | 2010 |
CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Female; Germany; Hemorrhage; Heparin; | 2011 |
Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Chemoprevention; Female; Hemorrhage; Heparin; | 2011 |
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin, | 2011 |
A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis--the membrane study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Disorders; Female; Hemorrhage; Hep | 2012 |
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
Topics: Aged; Body Weight; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin; Heparin, Low-Molec | 2003 |
Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Topics: Anticoagulants; Body Weight; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, Low | 2003 |
Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Body Weight; Cohort Studies; Female; Hemorrhage; Heparin | 2000 |
Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dose-Response Relationsh | 2001 |
Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
Topics: Aged; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; M | 2001 |
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Venous Thromboembol | 2022 |
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Topics: Aged; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pulm | 2022 |
A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer.
Topics: Adolescent; Anticoagulants; Child; Dalteparin; Hemorrhage; Humans; Neoplasms; Prospective Studies; V | 2022 |
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Topics: Administration, Oral; Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Incidence; Injec | 2020 |
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
Topics: Aged; Dalteparin; Drug-Related Side Effects and Adverse Reactions; Female; Fibrinolytic Agents; Gast | 2021 |
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Drug Therapy, Comb | 2021 |
Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasm Recurrence, Local; Neoplasms; Venous Thromb | 2021 |
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Kidney; Neoplasms; Pyrazoles; Pyridones; Venous Thro | 2022 |
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
Topics: Anticoagulants; Canada; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Neoplasm | 2017 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh | 2018 |
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Topics: Aged; Anticoagulants; Clinical Decision-Making; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage | 2018 |
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
Topics: Aged; Coumarins; Dalteparin; Disease-Free Survival; Female; Hemorrhage; Humans; Male; Middle Aged; N | 2019 |
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hem | 2019 |
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Drug Administration Sche | 2013 |
The effect of dalteparin versus unfractionated heparin on the levels of troponin I and creatine kinase isoenzyme MB in elective percutaneous coronary intervention: a multicenter study.
Topics: Aged; Anticoagulants; Biomarkers; China; Creatine Kinase, MB Form; Dalteparin; Female; Hemorrhage; H | 2014 |
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.
Topics: Adult; Dalteparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Pregnancy; Pregnancy Complicatio | 2014 |
Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
Topics: Acute Disease; Adolescent; Age Factors; Anticoagulants; Child; Child, Preschool; Dalteparin; Drug Ad | 2014 |
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
Topics: Aged; Anticoagulants; Canada; Dalteparin; Drug Administration Schedule; Europe; Female; Hemorrhage; | 2015 |
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Ne | 2015 |
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
Topics: Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Treatmen | 2017 |
Low molecular weight heparin significantly reduces embolisation after carotid endarterectomy--a randomised controlled trial.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Arachidonic Acid; Aspirin; Carotid Artery Diseases; Dal | 2009 |
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Canada; Dalteparin; Doub | 2010 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dalte | 2012 |
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
Topics: Coronary Artery Disease; Dalteparin; Double-Blind Method; Female; Fibrinolytic Agents; Hemorrhage; H | 2002 |
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Cohort Studies; Coronary Dis | 2002 |
Reporting the NAFT major bleeding rates in context: reviewers should include site investigator-classified rates.
Topics: Anticoagulants; Dalteparin; Double-Blind Method; Hemorrhage; Humans; North America; Research Design; | 2003 |
Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study.
Topics: Adolescent; Adult; Dalteparin; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Hepatic | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
Topics: Acute Disease; Aged; Coronary Disease; Dalteparin; Drug Therapy, Combination; Female; Hemorrhage; He | 2005 |
Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
Topics: Anticoagulants; Creatinine; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intensive | 2005 |
Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig | 2006 |
Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
Topics: Adult; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2007 |
Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)--a multicenter co-operative double-blind trial in comparison with heparin.
Topics: Adult; Aged; Blood Coagulation Tests; Dalteparin; Disseminated Intravascular Coagulation; Double-Bli | 1993 |
Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Topics: Adult; Aged; Aged, 80 and over; Contraindications; Coumarins; Dalteparin; Female; Fractures, Spontan | 1994 |
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
Topics: Anticoagulants; Blood Loss, Surgical; Dalteparin; Female; Hemorrhage; Hip Prosthesis; Humans; Male; | 1997 |
Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.
Topics: Aged; Anticoagulants; Dalteparin; Double-Blind Method; Embolism; Female; Heart Diseases; Heart Ventr | 1997 |
In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.
Topics: Anticoagulants; Coronary Disease; Dalteparin; Female; Femoral Artery; Hemorrhage; Heparin; Heparin A | 1997 |
A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration.
Topics: Acute Kidney Injury; Adult; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Hemofiltration; Hemog | 1999 |
Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy.
Topics: Adult; Dalteparin; Demography; Female; Fractures, Bone; Hemorrhage; Heparin; Heparin, Low-Molecular- | 1999 |
Outpatient treatment of pulmonary embolism with dalteparin.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Cohort Studies; Dalteparin; Disease-Free Survival; Fib | 2000 |
Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Feasibility Studies; Female; Hemorrhage; Hospitalization; H | 2001 |
Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
Topics: Aged; Anticoagulants; Drug Monitoring; Female; Hemorrhage; Humans; Incidence; International Normaliz | 2018 |
Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fibrinolytic Agent | 2018 |
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Norma | 2015 |
[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Combined Modality Therapy; Follow-Up Studies; He | 2011 |
A significant proportion of patients treated with citrate containing dialysate need additional anticoagulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Citric Acid; Cross-Ov | 2013 |
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
Topics: Adolescent; Adult; Aged; Antithrombin III; Biomarkers; Blood Coagulation; Cross-Over Studies; Dizzin | 2002 |
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
Topics: Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weig | 2007 |
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Female; Fibrinolyt | 2007 |
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
Topics: Acute Disease; Aged; Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Hepari | 1997 |
Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Meth | 2000 |
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Cross-Over Studies; Factor Xa Inhibitors; Femal | 2002 |
Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.
Topics: Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage; | 1996 |
Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin.
Topics: Anticoagulants; Confidence Intervals; Drug Approval; Female; Follow-Up Studies; Hemorrhage; Heparin; | 1998 |
Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angiography; Angioplasty, Balloon, Coronary; Antibodies; Coronary Disease; Double-Blind | 1999 |
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Ambulatory Care; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cause | 2000 |
[Low molecular weight heparin decreases thrombosis risk in patients receiving chemotherapy for cancer].
Topics: Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weig | 2013 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage | 2012 |
374 other studies available for dalteparin and Hemorrhage
| Article | Year |
|---|---|
The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients.
Topics: Anticoagulants; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Nadroparin; | 2023 |
Thromboembolic and bleeding complications in patients with oesophageal cancer.
Topics: Adenocarcinoma; Aged; Anticoagulants; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; E | 2020 |
[Prevention of thrombohemorrhagic postoperative complications in patients with benign prostatic hyperplasia].
Topics: Fibrinolytic Agents; Hemorrhage; Humans; Low-Level Light Therapy; Male; Nadroparin; Postoperative Co | 2017 |
Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Cohort Studies; Drug Administration Schedule; Female; He | 2017 |
Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Autopsy; Cause of Death; Chemical and Drug Ind | 2014 |
[Prophylaxis of thrombohemorrhagic complications in surgical treatment of chemoresistant pulmonary tuberculosis].
Topics: Adult; Anticoagulants; Antitubercular Agents; Female; Hemorrhage; Humans; Hydroxyethylrutoside; Indo | 2014 |
Differences in the safety profiles of two low-molecular-weight heparins.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Nadroparin; Orthopedic | 2008 |
Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Middle Aged; Nadropari | 2008 |
The individually optimized bolus dose of nadroparin is safe and effective in diabetic and nondiabetic patients with bleeding risk on hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Diabetes Mellitus; Female; Hemorr | 2011 |
Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery.
Topics: Adult; Aged; Anticoagulants; Bandages; Cohort Studies; Female; Hematoma; Hemorrhage; Humans; Laminec | 2004 |
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dose | 2007 |
Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit.
Topics: Animals; Factor Xa Inhibitors; Hemorrhage; Infusions, Intravenous; Injections, Intravenous; Injectio | 1994 |
[Comparative study of the efficacy of a low dose of antivitamin K and a preventive dose of low molecular weight heparin in the prevention of relapses of deep venous thrombosis after curative treatment in the aged subject].
Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Inde | 1994 |
Low-molecular-weight heparin and thromboembolism in pregnancy.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight; | 1999 |
Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cohort Studies; Disease-Free Survival; Female; Foll | 2001 |
Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Bandages; Combined Modality Therapy | 2001 |
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin.
Topics: Aged; Anticoagulants; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Human | 2020 |
Thromboprophylaxis with the low-molecular-weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Fibrinolytic Agents; Health Services for the Aged; | 2010 |
Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice.
Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hemorrhage; | 2008 |
Safety and Efficacy of Direct Oral Anticoagulants in Patients With Moderate to Severe Cirrhosis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Enoxaparin; Hemorrhage; H | 2022 |
Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients.
Topics: Blood Coagulation Tests; Chemoprevention; Dose-Response Relationship, Drug; Drug Dosage Calculations | 2022 |
Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
Topics: Adult; Aged; Anticoagulants; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; | 2022 |
Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice.
Topics: Animals; Anticoagulants; Blood Coagulation Tests; Drug-Related Side Effects and Adverse Reactions; E | 2021 |
A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal.
Topics: Anticoagulants; Catheters; Enoxaparin; Hemorrhage; Humans; Neoplasms; Pilot Projects; Postthrombotic | 2022 |
Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism.
Topics: Anticoagulants; Cytochrome P-450 CYP3A; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemor | 2022 |
Clinical use of low-dose parenteral anticoagulation, incidence of major bleeding and mortality: a multi-centre cohort study using the French national health data system.
Topics: Adult; Anticoagulants; Cohort Studies; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-M | 2022 |
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th | 2022 |
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th | 2022 |
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th | 2022 |
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Patient Discharge; Rivaroxaban; Venous Th | 2022 |
Outcomes of Prophylactic Enoxaparin Against Venous Thromboembolism in Hospitalized Children.
Topics: Adolescent; Anticoagulants; Child; Child, Hospitalized; Enoxaparin; Factor Xa Inhibitors; Hemorrhage | 2022 |
An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Pilot Projects; Pyraz | 2022 |
Assessing the use of Extended Venous Thromboembolism Prophylaxis on the Rates of Venous Thromboembolism and Postpancreatectomy Hemorrhage Following Pancreatectomy for Malignancy.
Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Neoplasms; Pancreatectomy; Patient Discha | 2023 |
Impact of Increased Enoxaparin Dosing on Anti-Xa Levels for Venous Thromboembolism Prophylaxis in Trauma Patients.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Retrospective Studies; Venous Thromboembolism | 2022 |
Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients.
Topics: Administration, Oral; Adult; Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Neoplasms; Venou | 2023 |
Low-molecular-weight Heparin (enoxaparin) versus unfractionated heparin for venous thromboembolism prophylaxis in patients undergoing craniotomy.
Topics: Anticoagulants; Craniotomy; Enoxaparin; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Heparin; Humans; Myocardial Infarction; Non-ST | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS- | 2022 |
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe | 2023 |
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe | 2023 |
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe | 2023 |
Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: A prospective cohort study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Prospe | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management of venous thromboembolism in morbidly obese patients: a 10-year review.
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Obesity, Morbid; Retrospective | 2023 |
Management and outcomes of calf deep vein thrombosis in patients with contraindication to full anticoagulation due to bleeding.
Topics: Anticoagulants; Contraindications; Enoxaparin; Hemorrhage; Humans; Mesenteric Ischemia; Pulmonary Em | 2023 |
Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2023 |
Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy.
Topics: Anticoagulants; Canada; Enoxaparin; Female; Genital Neoplasms, Female; Hemorrhage; Humans; Laparotom | 2023 |
Effectiveness of Body Mass Index-Based Prophylactic Enoxaparin Dosing in Bariatric Surgery Patients.
Topics: Adult; Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Female; Hemorrhage; Heparin, | 2023 |
Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report.
Topics: Anticoagulants; Enoxaparin; Extracorporeal Membrane Oxygenation; Hemorrhage; Heparin; Heparin, Low-M | 2023 |
Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Retrospective Studies; Thai | 2023 |
Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Heparin, Low-M | 2023 |
Clinical Impact of a Standardized Risk-Stratified Thromboprophylaxis Protocol for Multisystem Inflammatory Syndrome in Children.
Topics: Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Retrospective Studies; Venous Thromboembolism | 2023 |
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.
Topics: Adult; Aged; Anticoagulants; Biomarkers; Enoxaparin; Gastrointestinal Neoplasms; Hemorrhage; Humans; | 2023 |
Enoxaparin-induced bullous haemorrhagic dermatosis.
Topics: Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Middle Aged; Skin Diseases, Vesiculobullous | 2020 |
Evaluation of the Efficacy of Enoxaparin in the Neonatal Intensive Care Unit.
Topics: Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Infant, Newborn; Intensive Care U | 2021 |
New-onset seizure activity in a transplant patient on immunosuppressive therapy.
Topics: Cystic Fibrosis; Emergency Service, Hospital; Enoxaparin; Epilepsy; Female; Hemorrhage; Humans; Hype | 2020 |
Heparin hemorrhagic bullae induced by enoxaparin.
Topics: Anticoagulants; Blister; Enoxaparin; Hemorrhage; Heparin; Humans | 2021 |
Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
Topics: Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Hemorrhage; Hepar | 2020 |
Bullous hemorrhagic dermatosis.
Topics: Anticoagulants; Diagnosis, Differential; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Midd | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Cisplatin; Enoxaparin; Hemorrhage; Humans; Male; Med | 2020 |
Post-Procedural Anticoagulation After Primary Percutaneous Coronary Intervention for Anterior Acute Myocardial Infarction With Severe Left Ventricular Dysfunction.
Topics: Aged; Anterior Wall Myocardial Infarction; Anticoagulants; Dual Anti-Platelet Therapy; Echocardiogra | 2020 |
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Factor Xa In | 2020 |
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.
Topics: Aged; Anticoagulants; Antithrombins; Coronavirus Infections; COVID-19; Enoxaparin; Factor Xa Inhibit | 2020 |
Enoxaparin related spontaneous fatal retroperitoneal hemorrhage in a patient with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Drug Substitution; Enoxaparin; Fatal Outcome; Female; Hea | 2020 |
Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort.
Topics: Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Nephrotic Syndrome; Thrombosis; Venous Thromb | 2021 |
Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study.
Topics: Anticoagulants; Brazil; Enoxaparin; Hemorrhage; Humans; Orthopedic Procedures; Pharmaceutical Prepar | 2020 |
New-onset seizure activity in a transplant patient on immunosuppressive therapy.
Topics: Cystic Fibrosis; Emergency Service, Hospital; Enoxaparin; Epilepsy; Female; Hemorrhage; Humans; Hype | 2020 |
Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Costs and Cost Analysis; Enoxaparin; Fe | 2021 |
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Hemorrhage; Humans; Ma | 2021 |
Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Blood Coagulation Tests; Blood Proteins; | 2021 |
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.
Topics: Adult; Aged; Algorithms; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage; | 2021 |
Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Intensive Care Units; Renal Insufficiency; | 2021 |
Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution.
Topics: Adolescent; Anticoagulants; Enoxaparin; Heart-Assist Devices; Hemorrhage; Humans; Outpatients; Prosp | 2022 |
Comparison of Outcomes of Enoxaparin Bridge Therapy in HeartMate II versus HeartWare HVAD Recipients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heart Ventricles; Heart-Assist D | 2021 |
Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Goals; Hemorrhage; Heparin, Low-Molecular-W | 2021 |
Enoxaparin-induced distal haemorrhagic bullous dermatosis.
Topics: Enoxaparin; Hemorrhage; Humans; Skin Diseases, Vesiculobullous | 2021 |
Enoxaparin Reduces Catheter-associated Venous Thrombosis After Infant Cardiac Surgery.
Topics: Anticoagulants; Cardiac Surgical Procedures; Catheters; Child; Enoxaparin; Hemorrhage; Humans; Infan | 2022 |
Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis Following Robot-assisted Radical Cystectomy: A Retrospective Feasibility Study at a Single Academic Medical Center.
Topics: Anticoagulants; Antithrombins; Chemoprevention; Cystectomy; Enoxaparin; Female; Hemorrhage; Humans; | 2021 |
Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
Topics: Enoxaparin; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Liver Neop | 2021 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F | 2016 |
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Factor X | 2017 |
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Hepar | 2018 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Topics: Acute Disease; Anticoagulants; Benzamides; Clinical Decision-Making; Clinical Trials, Phase III as T | 2017 |
Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Coronary Thrombosis; Drug Administ | 2017 |
Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig | 2018 |
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Daltep | 2017 |
Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients.
Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; H | 2018 |
Anticoagulation prescribing patterns in patients with cancer.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle | 2018 |
A 71-year-old man with a hemorrhagic vesicular eruption.
Topics: Aged; Anticoagulants; Drug Eruptions; Enoxaparin; Hemorrhage; Humans; Male; Skin Diseases, Vesiculob | 2018 |
Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Topics: Academic Medical Centers; Adult; Aged; Anticoagulants; Drug Substitution; Enoxaparin; Factor Xa Inhi | 2019 |
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Age | 2018 |
Suboptimal use of pharmacological venous thromboembolism prophylaxis in cirrhotic patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; | 2018 |
Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Drug Administration Sched | 2018 |
Topics: Aged, 80 and over; Anesthesia, Spinal; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Intraoperativ | 2018 |
Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
Topics: Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee | 2018 |
Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Information Storage and Re | 2018 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conf | 2018 |
Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment.
Topics: Adolescent; Aged; Aged, 80 and over; Anticoagulants; Creatinine; Drug Administration Schedule; Enoxa | 2019 |
Successful angioembolization treatment in a patient with a mechanical heart valve with hemorrhagic corpus luteum.
Topics: Anticoagulants; Aortic Valve; Enoxaparin; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Ovaria | 2019 |
Fatal pulmonary embolism and pulmonary hemorrhage in lupus anticoagulant hypoprothrombinemia syndrome: a case report and review of literature.
Topics: Aged; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Fatal Outcome; Female; Gastrointestinal | 2018 |
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Data | 2019 |
Primary thromboprophylaxis in hospitalized children: A multi-center retrospective analysis.
Topics: Adolescent; Anticoagulants; Child; Enoxaparin; Female; Hemorrhage; Humans; Male; Mechanical Thrombol | 2019 |
Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.
Topics: Adult; Body Weight; Drug Dosage Calculations; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabig | 2019 |
Comparison of Venous Thromboembolism Prophylactic Measures Post Coronary Artery Bypass Graft Surgery.
Topics: Aged; Anticoagulants; Coronary Artery Bypass; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Lengt | 2019 |
[Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Female; | 2013 |
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chemopreventi | 2013 |
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
Topics: Animals; Anticoagulants; Antidotes; Benzamides; Dose-Response Relationship, Drug; Enoxaparin; Factor | 2013 |
Impact of a venous thromboembolism prophylaxis "smart order set": Improved compliance, fewer events.
Topics: Adult; Age Factors; Aged; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; Hepar | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thi | 2013 |
Hemorrhagic bullae in a 73-year-old man. Bullous hemorrhagic dermatosis related to enoxaparin use.
Topics: Aged; Anticoagulants; Drug Eruptions; Enoxaparin; Hemorrhage; Humans; Male; Skin Diseases, Vesiculob | 2013 |
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Endpoint Determination; E | 2013 |
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Blood Loss, Surgical; Coronary Artery Bypass; Enoxapa | 2013 |
Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Cesarean Section; Combined Modality T | 2014 |
Use of enoxaparin in end-stage renal disease.
Topics: Enoxaparin; Female; Hemorrhage; Heparin; Humans; Kidney Failure, Chronic; Male; Venous Thromboemboli | 2013 |
[Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?].
Topics: Adenocarcinoma; Ambulatory Care; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Enoxa | 2013 |
Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.
Topics: Aged; Anticoagulants; Body Mass Index; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle | 2014 |
Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese.
Topics: Academic Medical Centers; Adult; Anticoagulants; Enoxaparin; Female; Hemorrhage; Hospitalization; Hu | 2013 |
Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Topics: Age Factors; Anticoagulants; Antithrombin III; Critical Illness; Dose-Response Relationship, Drug; D | 2014 |
[Bullous hemorrhagic dermatosis induced by heparin: description of 2 new cases].
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Eruptions; Enoxaparin; Hemo | 2014 |
Safety of postoperative thromboprophylaxis after major hepatobiliary-pancreatic surgery in Japanese patients.
Topics: Aged; Anticoagulants; Asian People; Enoxaparin; Female; Fondaparinux; Hemorrhage; Hepatectomy; Human | 2014 |
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrh | 2014 |
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combina | 2014 |
Lower extremity hemorrhage in patients with spinal cord injury receiving enoxaparin therapy.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Lower Extremity; Male; Middle Aged; Spi | 2015 |
Early thromboembolic prophylaxis in patients with blunt solid abdominal organ injuries undergoing nonoperative management: is it safe?
Topics: Abdominal Injuries; Adult; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; H | 2015 |
Effects of enoxaparin and unfractionated heparin in prophylactic and therapeutic doses on the fertility of female Wistar rats.
Topics: Animals; Anticoagulants; Enoxaparin; Female; Fertility; Fetus; Hemorrhage; Heparin; Male; Placenta; | 2014 |
Adverse outcomes of anticoagulant use among hospitalized patients with chronic kidney disease: a comparison of the rates of major bleeding events between unfractionated heparin and enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Hepa | 2014 |
Structural and functional analyses of biosimilar enoxaparins available in Brazil.
Topics: Animals; Anticoagulants; Biosimilar Pharmaceuticals; Blood Coagulation; Blood Coagulation Tests; Bra | 2015 |
Chemoprophylaxis for venous thromboembolism in otolaryngology.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Free Tissue Flaps; Hemorrhage; Heparin; Humans; Incidence; | 2014 |
[Perioperative control of vitamin K antagonists in elective surgery].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Elective Surgical Procedures; Enoxapar | 2014 |
Role of percutaneous transcatheter embolization (PTE) in the treatment of spontaneous bleeding associated with anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Anticoagulants; Contrast Media; Embolizat | 2015 |
Bullous hemorrhagic dermatosis distant from the site of heparin injection.
Topics: Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Injections; Skin Diseases, Vesiculobull | 2014 |
The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Topics: Anticoagulants; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Enoxaparin; H | 2015 |
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; F | 2015 |
Enoxaparin-induced unilateral hemotympanum.
Topics: Anticoagulants; Ear Diseases; Enoxaparin; Female; Hemorrhage; Humans; Middle Aged | 2015 |
Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Female; Hematuria; Hemorrhage; Humans; | 2015 |
Bullous hemorrhagic dermatosis induced by enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Male; Skin; Skin Diseases, Vesiculobullous | 2016 |
Should patients with chronic liver disease receive venous thromboembolism prophylaxis?
Topics: Anticoagulants; Blood Coagulation Disorders; Enoxaparin; Hemorrhage; Heparin; Hospitalization; Human | 2015 |
[Prevention with lower bleeding risk].
Topics: Adult; Enoxaparin; Hemorrhage; Humans; Pyrazoles; Pyridones; Thromboembolism | 2015 |
Application of Adaptive DP-optimality to Design a Pilot Study for a Clotting Time Test for Enoxaparin.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Enoxaparin; Factor Xa Inhibitors; | 2015 |
Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogre | 2015 |
Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; F | 2015 |
Emergent pediatric anticoagulation reversal using a 4-factor prothrombin complex concentrate.
Topics: Anticoagulants; Blood Coagulation Factors; Child; Enoxaparin; Female; Headache; Hemorrhage; Heparin | 2016 |
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
Topics: Acute Coronary Syndrome; Anticoagulants; Canada; Cost-Benefit Analysis; Decision Support Techniques; | 2015 |
Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.
Topics: Allosteric Site; Animals; Anticoagulants; Binding Sites; Bleeding Time; Blood Coagulation; Blood Coa | 2016 |
Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Topics: Anticoagulants; Canada; Cost-Benefit Analysis; Enoxaparin; Female; Hemorrhage; Humans; International | 2016 |
Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2016 |
Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematologic Neoplasms; Hemorrhage; Heparin, Low-Molecular- | 2017 |
Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Topics: Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors | 2016 |
Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
Topics: Aged; Arthroplasty, Replacement, Knee; Australia; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrha | 2016 |
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg | 2017 |
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg | 2017 |
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg | 2017 |
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg | 2017 |
Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Clinical Protocols; Dose-Response Relationship, Drug | 2016 |
Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Erythrocyte Transfusion; Factor Xa Inhibitors; Female; Hematocrit | 2016 |
Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane | 2016 |
Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Brazil; Enoxaparin; Female; Fondaparinux; Hemorrhage; | 2016 |
Response to Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane | 2016 |
Risk of Bleeding in Patients on Full-Dose Enoxaparin With Venous Thromboembolism and Selective Serotonin Reuptake Inhibitors.
Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Interactions; Enoxaparin; Female; Hemor | 2017 |
Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Age | 2017 |
Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enoxaparin; Facto | 2017 |
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism"
Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombo | 2016 |
Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Europe; Female; Hemor | 2017 |
Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient.
Topics: Adolescent; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Pediatric Obesi | 2017 |
Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; Humans; Male; Neoplasms; | 2017 |
Safety and Effectiveness of Enoxaparin as Venous Thromboembolism Prophylaxis after Gastric Cancer Surgery in Japanese Patients.
Topics: Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Anticoagulants; Case-Control Studies; Enoxapa | 2016 |
Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.
Topics: Administration, Oral; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Humans; Kidney | 2017 |
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Enoxaparin; Female; Fibrinolytic Agen | 2008 |
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Combined Modality Therapy; C | 2009 |
Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Direct Service Costs; Drug Costs; Enoxaparin; Health Care Cos | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Human | 2008 |
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Body Mass Index; Comorbidity; Data | 2010 |
Bleeding events in patients receiving enoxaparin for the management of non-ST-elevation acute coronary syndrome (NSTEACS) at Dunedin Public Hospital, New Zealand.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Clinical Trials as Topic; Coro | 2008 |
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru | 2009 |
Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Clopidogrel; Creatinine; Dose-Response Relatio | 2009 |
Dabigatran etexilate for prevention of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2009 |
Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Case-Control Studies; Enoxaparin; Female; Follow-Up Stud | 2010 |
[Summary and perspectives. Rivaroxaban].
Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxap | 2008 |
Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Drug Monitoring; Enoxaparin; Factor VII Defi | 2009 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2009 |
The pain and the gain of treating patients with acute coronary syndromes-can the two be separated?
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Myocardial Is | 2009 |
Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Drug Therapy, Combination; Enoxaparin; Fibr | 2009 |
Enoxaparin attenuates endothelial damage with less bleeding compared with unfractionated heparin in endotoxemic rats.
Topics: Animals; Anticoagulants; CD13 Antigens; Endothelium; Endotoxemia; Enoxaparin; Fibrinogen; Hemorrhage | 2009 |
Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
Topics: Acute Coronary Syndrome; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fond | 2009 |
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Fondaparinu | 2009 |
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr | 2009 |
Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Enoxaparin; F | 2010 |
Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Enoxaparin; Eptifi | 2009 |
Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticoagulants; Body Weight; Cohort Studies; Enoxap | 2009 |
Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Creatinine; Drug Dosage Calculations; | 2009 |
Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Fi | 2009 |
Dabigatran: new drug. Continue to use heparin, a better-known option.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dab | 2009 |
The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model.
Topics: Analysis of Variance; Animals; Anticoagulants; Aspirin; Disease Models, Animal; Enoxaparin; Female; | 2009 |
[Prophylaxis of deep vein thrombosis with enoxaparin 40 mg in outpatients compared to hospitalized medically ill patients].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Cross-Sectional Studies; Enoxaparin | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Random | 2009 |
Systemic bleeding in a patient with enoxaparin-induced thrombocytopenia.
Topics: Aged, 80 and over; Anticoagulants; Enoxaparin; Fatal Outcome; Hemorrhage; Humans; Male; Thrombocytop | 2009 |
Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Topics: Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Cohort Studies; Enoxaparin; Female; Hear | 2009 |
Stroke prevention versus bleeding risk of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery.
Topics: Anticoagulants; Atrial Fibrillation; Enoxaparin; Hemorrhage; Humans; Stroke; Vitamin K | 2009 |
Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Hemorrhage; Hum | 2009 |
Antithrombin therapy for elective percutaneous coronary intervention: which agent to use? Does it matter?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin | 2009 |
Clinical and economic outcomes with appropriate or partial prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Costs and Cost Analysis; Data Collection; Enoxaparin | 2010 |
Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Contraindications; Drug Utilization; Enoxapari | 2009 |
A life threatening complication of anticoagulation prophylaxis-bilateral adrenal hemorrhage.
Topics: Adrenal Gland Diseases; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Hum | 2009 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2010 |
Don't rule out retroperitoneal bleeding just because the angiogram was done from the radial artery.
Topics: Aged; Angiography; Anticoagulants; Cardiac Catheterization; Enoxaparin; Hematoma; Hemorrhage; Humans | 2010 |
Current primary care practice in the diagnosis and management of patients with suspected venous thromboembolism and prescription of initiation dose of enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Belgium; Chi-Square Distribution; Cross-Sectional Studies; | 2010 |
Enoxaparin and fibrinolysis: ExTRACTing prognosis from bleeding complications.
Topics: Enoxaparin; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Myocardial Infarction | 2010 |
Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2010 |
Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; | 2011 |
Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Chi-Square Distribution; | 2011 |
Summaries for patients. Do the benefits of prolonged low-molecular-weight heparin treatment outweigh the harms in hospitalized patients who are bedbound?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Delayed-Action Preparations; Drug Adm | 2010 |
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.
Topics: Aged; Area Under Curve; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Com | 2010 |
Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Loss, Surgic | 2010 |
Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.
Topics: Acute Coronary Syndrome; Algorithms; Computer Simulation; Endpoint Determination; Enoxaparin; Hemorr | 2011 |
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
Topics: Animals; Anticoagulants; Clopidogrel; Drug Combinations; Enoxaparin; Factor XI; Hemorrhage; Male; Mi | 2010 |
Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Knee; Clinical Trials, Phase II as | 2010 |
How should we define major bleeding events in thromboprophylaxis?
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Bandages; Enoxaparin; Hemorrhage; Heparin, Low-Molec | 2010 |
Invited commentary.
Topics: Administration, Oral; Ambulatory Care; Anticoagulants; Blood Coagulation; Compression Bandages; Drug | 2010 |
Extended-duration venous thromboembolism prophylaxis for medical patients.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Immobilization; Risk F | 2010 |
Extended-duration venous thromboembolism prophylaxis for medical patients.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Immobilization; Risk F | 2010 |
The ATOLL trial of enoxaparin in primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Randomized Controlle | 2010 |
Unfractionated versus low-molecular-weight heparin for primary angioplasty-More data suggesting to go low.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Evidence-Based Medicine; Hemorrhage; Hep | 2011 |
Apixaban vs. enoxaparin after hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Hemorrhage; Humans; Outcome Assessment, | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Pu | 2011 |
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Blood Co | 2011 |
Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiac Surgical Procedures; Enoxaparin; Female; Heart Fail | 2011 |
Generic versions of enoxaparin available for clinical use in Brazil are similar to the original drug.
Topics: Animals; Anticoagulants; Brazil; Drugs, Generic; Enoxaparin; Hemorrhage; Magnetic Resonance Spectros | 2011 |
Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage.
Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenal Insufficiency; Aged; Anticoagulants; Arthroplasty, R | 2011 |
Razor blades, heparin and protamine--a potent mix.
Topics: Adult; Enoxaparin; Female; Hemorrhage; Heparin Antagonists; Humans; Injections; Protamines; Suicide, | 2011 |
An unusual case of massive subcutaneous chest wall haemorrhage with enoxaparin.
Topics: Aged; Anticoagulants; Diagnosis, Differential; Enoxaparin; Hemorrhage; Humans; Injections, Subcutane | 2011 |
Effectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatients.
Topics: Aged; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Emergency Medical Services; Enox | 2011 |
Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Body Mass Index; Drug Administration Schedule; Enoxaparin; | 2011 |
Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
Topics: Animals; Anticoagulants; Blood Coagulation; Brazil; Disease Models, Animal; Drugs, Generic; Enoxapar | 2012 |
Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats.
Topics: Animals; Anticoagulants; Endothelium, Vascular; Endotoxemia; Enoxaparin; Factor Xa Inhibitors; Fonda | 2012 |
Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Cohort Studies; Creatinine; | 2012 |
Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxap | 2012 |
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
Topics: Adult; Aged; Anticoagulants; Canada; Catheterization; Coumarins; Disease Management; Drug Utilizatio | 2012 |
Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Cohort Studies; Creatinine; Diet; Enoxaparin; | 2012 |
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Topics: Anticoagulants; Arthroplasty, Replacement, Ankle; Arthroplasty, Replacement, Knee; Clinical Trials, | 2012 |
Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?
Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation Tests; Drug Dosage Calculatio | 2012 |
Intentional low-molecular-weight heparin overdose: a case report and review.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Drug Overdose; Enoxaparin; Factor VIIa; Factor Xa; F | 2012 |
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast | 2013 |
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast | 2013 |
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast | 2013 |
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplast | 2013 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2012 |
Fondaparinux versus enoxaparin for prevention of venous.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery.
Topics: Arthroplasty; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Polysaccharides; Po | 2002 |
Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery.
Topics: Arthroplasty; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysacch | 2002 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
Topics: Adolescent; Aged; Aged, 80 and over; Anticoagulants; Contraindications; Drug Prescriptions; Drug Uti | 2003 |
[Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; APACHE; Enoxaparin; Female; Hemorrhage; | 2003 |
A safety analysis of thromboprophylaxis in acute medical illness.
Topics: Acute Disease; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Risk Factors; Safety; Thromb | 2003 |
Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol.
Topics: Acenocoumarol; Anticoagulants; Blood Loss, Surgical; Cohort Studies; Contraindications; Enoxaparin; | 2003 |
[Atraumatic retroperitoneal hemorrhage--interdisciplinary and differential diagnostic considerations based on a case report].
Topics: Aged; Anticoagulants; Biopsy, Needle; Diagnosis, Differential; Enoxaparin; Female; Glomerulonephriti | 2003 |
Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.
Topics: Anticoagulants; Antithrombin III; Catheters, Indwelling; Cohort Studies; Coronary Disease; Dose-Resp | 2003 |
[Spontaneous retroperitoneal hematoma induced by enoxiparin to therapeutic dose].
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematoma; Hemorrhage; Humans; Retroperitoneal Space; Tomog | 2003 |
Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Hemorrhage; Humans; Meta-Analysis as Topi | 2003 |
Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Glomerular Filtration Rate; Hemorrhage; Heparin; Hospitali | 2004 |
Life threatening haemorrhagic events associated with the administration of low-molecular-weight-heparin.
Topics: Adult; Aged; Aged, 80 and over; Critical Illness; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molec | 2004 |
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Cath | 2004 |
Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Coronary Disease; E | 2004 |
Summaries for patients. Fondaparinux or enoxaparin for deep venous thrombosis?
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Recombinant activated factor VII for treatment of enoxaparin-induced bleeding.
Topics: Aged; Enoxaparin; Factor VIIa; Fibrinolytic Agents; Hemorrhage; Humans; Male; Recombinant Proteins | 2004 |
Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Hemorrhage; Humans; Infant, Low Birth | 2004 |
Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis.
Topics: Anticoagulants; Decision Support Techniques; Enoxaparin; Hemorrhage; Heparin; Humans; Monte Carlo Me | 2004 |
Large rectus muscle hematoma with intraperitoneal bleeding and fatal abdominal compartment syndrome complicating anticoagulant therapy.
Topics: Anticoagulants; Compartment Syndromes; Enoxaparin; Fatal Outcome; Female; Hematoma; Hemorrhage; Huma | 2005 |
Fatal retroperitoneal haemorrhage associated with enoxaparin and impaired renal function.
Topics: Aged; Angina, Unstable; Anticoagulants; Creatinine; Enoxaparin; Female; Hemorrhage; Humans; Kidney T | 2005 |
The safety of low molecular weight heparin therapy during labor.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hemoglobins; Hemorrhage; He | 2005 |
Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature.
Topics: Adult; Aged; Anticoagulants; Blood Platelets; Bone Marrow Transplantation; Cohort Studies; Enoxapari | 2005 |
A protocol for the use of enoxaparin during pregnancy: results from 85 pregnancies including 13 multiple gestation pregnancies.
Topics: Adult; Aspirin; Clinical Protocols; Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; F | 2005 |
On "Current role of antithrombotic agents in the treatment of acute coronary syndromes" (Semin Thromb Hemost 2004;30:627-632).
Topics: Cerebral Hemorrhage; Confounding Factors, Epidemiologic; Enoxaparin; Fibrinolytic Agents; Hemorrhage | 2005 |
Life-threatening abdominal wall hematoma in a chronic renal failure patient after a single dose of enoxaparin.
Topics: Abdominal Injuries; Abdominal Wall; Accidents, Traffic; Adult; Anticoagulants; Enoxaparin; Epigastri | 2005 |
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum | 2005 |
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middl | 2005 |
Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Enoxaparin; Female; Heart Valve | 2005 |
Blood thinner cuts risk of bleeding in half.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Myocardial Infarction; Polysaccharides | 2006 |
Therapy for patients with acute coronary syndromes--new opportunities.
Topics: Angina, Unstable; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Fondaparinux; Hemorr | 2006 |
Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Drug Evaluation; Enoxaparin; Female; Hemorrhag | 2006 |
Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Topics: Anticoagulants; Cost-Benefit Analysis; Drug Costs; Enoxaparin; Germany; Hemorrhage; Hospitals; Human | 2006 |
Fondaparinux versus enoxaparin in acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Bypass; Drug Thera | 2006 |
Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial In | 2006 |
Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 2006 |
Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Trials, Phase III as Topic; Drug Therapy, C | 2006 |
Risk of bleeding after elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Cause of Death; Enoxaparin; Hemorrhage; Heparin; Hum | 2006 |
Bleeding complications from femoral and sciatic nerve catheters in patients receiving low molecular weight heparin.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Catheterization, Peripheral; Catheters, Indwe | 2006 |
Low-molecular-weight heparin and bleeding: how do we lower risk but maintain benefit?
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Humans; Renal Insufficiency; Risk Assessment | 2006 |
Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.
Topics: Body Weight; Costs and Cost Analysis; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-W | 2007 |
A simple venous thromboembolism prophylaxis protocol for patients undergoing bariatric surgery.
Topics: Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Hemorrhage; Heparin; Humans; Obesity | 2006 |
Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Enoxaparin; Female; Follow-Up Stu | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Protocols; Enoxaparin; Hemorrhage; Heparin; | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial | 2006 |
Enoxaparin in elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Myocardial | 2006 |
Atraumatic compartment syndrome of the dorsal compartment of the upper arm.
Topics: Acute Disease; Aged; Arm; Aspirin; Compartment Syndromes; Diagnosis, Differential; Enoxaparin; Femal | 2006 |
Summaries for patients. Safety of surgery during bridging anticoagulation therapy with low-molecular-weight heparin.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa; Female; Hemorrhage; Human | 2007 |
Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa; Female; Hemorrhage; Human | 2007 |
Fatal haemorrhage associated with enoxaparin.
Topics: Aged; Anticoagulants; Blood Transfusion; Enoxaparin; Fatal Outcome; Hemorrhage; Humans; Male; Muscul | 2007 |
Peripheral nerve block catheters and low molecular weight heparin.
Topics: Anticoagulants; Catheters, Indwelling; Device Removal; Drug Administration Schedule; Enoxaparin; Fem | 2007 |
Continuous peripheral nerve catheters in patients receiving low molecular weight heparin.
Topics: Anticoagulants; Catheters, Indwelling; Device Removal; Drug Administration Schedule; Enoxaparin; Fem | 2007 |
Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel.
Topics: Aged; Angiography; Anticoagulants; Blood Component Transfusion; Clopidogrel; Drug Interactions; Embo | 2007 |
Enoxaparin as bridging anticoagulant treatment in cardiac surgery.
Topics: Aged; Anticoagulants; Cohort Studies; Enoxaparin; Female; Hemorrhage; Humans; Intraoperative Care; M | 2008 |
Successful percutaneous retrieval of a swan-ganz catheter entrapped in an inferior vena cava filter.
Topics: Aged, 80 and over; Anticoagulants; Catheterization, Swan-Ganz; Catheters, Indwelling; Colonoscopy; D | 2007 |
Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry.
Topics: Aged; Anticoagulants; Aortic Valve; Enoxaparin; Feasibility Studies; Heart Valve Prosthesis; Heart V | 2007 |
Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes.
Topics: Aged; Coronary Disease; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Ho | 2007 |
A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Topics: Adult; Anticoagulants; Bayes Theorem; Canada; Cost-Benefit Analysis; Decision Support Techniques; De | 2007 |
Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Topics: Anticoagulants; Bone Diseases, Metabolic; Catheters, Indwelling; Dose-Response Relationship, Drug; E | 2007 |
Bleeding during enoxaparin treatment more common with age over 75 years and severe renal insufficiency.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Endpoint Determination; Enoxapa | 2007 |
[Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Sched | 2007 |
TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cause of Death; Enoxaparin; Fibrinolytic Agents; Hemorrhage; Hepa | 2007 |
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Coronary Angiography; Enoxaparin; Female; Fibrinol | 2007 |
[The safety of enoxaparine use in elderly with acute myocardial infarction].
Topics: Age Factors; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Myocardial | 2007 |
Safety of enoxaparin bridge therapy in patients with mechanical heart valves.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Heart Valve Prosthesis; Hemorrhage; Humans; Int | 2008 |
Evaluating the optimal timing of angiography: landmark or off the mark?
Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Coronary Angiography; Enoxaparin; Female; Fibrinol | 2007 |
Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Female; Germany; Hemorrhage; Hepar | 2008 |
Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Creatinine; Enoxaparin; Female; Fibrinolytic Agents; Glo | 2008 |
Bleeding effects of unfractionated heparin and low molecular weight heparins in an animal model.
Topics: Animals; Bleeding Time; Blood Pressure; Dalteparin; Dose-Response Relationship, Drug; Enoxaparin; Ga | 1994 |
Managing the risk of thrombosis in the perioperative period in patients undergoing orthopedic and trauma surgery with low-molecular-weight heparin: enoxaparin.
Topics: Anticoagulants; Bone and Bones; Enoxaparin; Hemorrhage; Hip Prosthesis; Humans; Joint Prosthesis; Kn | 1997 |
Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.
Topics: Anticoagulants; Bone Density; Cohort Studies; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Pregn | 1997 |
An unexpected complication of DVT prophylaxis.
Topics: Aged; Anticoagulants; Chemoprevention; Enoxaparin; Female; Hemorrhage; Hip Joint; Hip Prosthesis; Hu | 1997 |
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Ev | 1997 |
The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 1998 |
Enoxaparin in neurosurgical patients.
Topics: Anticoagulants; Bandages; Combined Modality Therapy; Enoxaparin; Hemorrhage; Heparin; Humans; Thromb | 1998 |
[Hemorrhagic complications of spinal and epidural analgesia].
Topics: Analgesia, Epidural; Anesthesia, Spinal; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Hemorrhage | 1999 |
Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Chemical and Drug Induced Liver Injury; Eno | 1999 |
Pursuing progress in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Enoxapa | 1999 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Placebos; Thromboembolism | 2000 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Anticoagulants; Confidence Intervals; Enoxaparin; Hemorrhage; Humans; Pulmonary Embolism; Thromboemb | 2000 |
Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Renal Dialysis; Ren | 2000 |
Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy.
Topics: Anemia; Anticoagulants; Dalteparin; Delivery, Obstetric; Dextrans; Enoxaparin; Female; Hemorrhage; H | 2000 |
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery.
Topics: Biomarkers; Double-Blind Method; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Age | 2000 |
Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.
Topics: Adult; Anticoagulants; Creatine; Drug Monitoring; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molec | 2001 |
Low-molecular-weight heparin administration in patients with end-stage renal disease--a comment.
Topics: Anticoagulants; Blood Transfusion; Enoxaparin; Hemorrhage; Humans; Kidney Diseases; Kidney Failure, | 2001 |
Low molecular weight heparin and the risk of haemorrhage following percutaneous biopsy, despite a normal standard clotting screen.
Topics: Aged; Biopsy, Needle; Carcinoma, Endometrioid; Enoxaparin; Female; Hemorrhage; Humans; Iliac Vein; I | 2001 |
Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
Topics: Anticoagulants; Coronary Stenosis; Drug Therapy, Combination; Enoxaparin; Factor VII; Hemorrhage; Hu | 2002 |
Thromboprophylaxis with reviparin in a patient with acquired hemophilia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Carcinoma, Renal Cell; Factor VIII; Hemophilia | 2005 |
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin).
Topics: Animals; Bleeding Time; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Molecular Weight; P | 1993 |
Porous balloon delivery of low molecular weight heparin in the dog coronary artery.
Topics: Angioplasty, Balloon, Coronary; Animals; Catheterization; Coronary Thrombosis; Coronary Vessels; Dog | 1996 |
[Possible effect low molecular weight heparin on survival time. New chances for cancer patients?].
Topics: Anticoagulants; Clinical Trials as Topic; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Injecti | 2003 |
[Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
Topics: Anticoagulants; Body Weight; Clinical Trials as Topic; Fibrinolytic Agents; Hemorrhage; Heparin; Hep | 2003 |
[Initial results of the PROTECT Study publicized. Stroke patients need effective thrombosis prevention].
Topics: Anticoagulants; Cerebral Infarction; Double-Blind Method; Hemorrhage; Heparin; Heparin, Low-Molecula | 2005 |
Management of intentional overdose of low-molecular-weight heparin.
Topics: Administration, Intravenous; Adult; Anterior Compartment Syndrome; Anticoagulants; Dalteparin; Drug | 2022 |
Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Neoplasms, Second Primary; Venous Thrombo | 2022 |
Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data.
Topics: Anticoagulants; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pr | 2023 |
Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers.
Topics: Aged; Dalteparin; Factor Xa Inhibitors; Female; Genital Neoplasms, Female; Hemorrhage; Humans; Middl | 2020 |
[Antithrombotic Treatment of Pulmonary Embolism].
Topics: Acute Disease; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinoly | 2020 |
[Toward the use of direct oral anticoagulants as a first line therapy in cancer-associated venous thromboembolism].
Topics: 4-Hydroxycoumarins; Administration, Oral; Anticoagulants; Clinical Trials as Topic; Dalteparin; Hemo | 2020 |
Spontaneous Retroperitoneal Hemorrhage in Dermatomyositis.
Topics: Anti-Inflammatory Agents; Anticoagulants; Dalteparin; Dermatomyositis; Female; Hemorrhage; Humans; I | 2021 |
In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Recurrence; Venous | 2020 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; H | 2018 |
Dalteparin anticoagulation in paediatric home haemodialysis.
Topics: Adolescent; Age Factors; Anticoagulants; Blood Coagulation; Child; Child, Preschool; Dalteparin; Dos | 2018 |
[Treatment of cancer-associated venous thromboembolism].
Topics: Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Practice G | 2018 |
Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Dru | 2013 |
Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.
Topics: Adult; Aged; Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Hospital Mor | 2013 |
The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment.
Topics: Adult; Anticoagulants; Biomarkers; Dalteparin; Drug Administration Schedule; Female; Fibrin Fibrinog | 2014 |
Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Glomerular Filtration Rate; Hemorrhage; | 2016 |
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Topics: Amidines; Animals; Antithrombin III; Antithrombins; Azetidines; Blood Coagulation; Chlorides; Daltep | 2010 |
Treatment of upper-extremity deep vein thrombosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Drug Therapy, Combination; F | 2011 |
Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy.
Topics: Adult; Dalteparin; Drug Evaluation; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Huma | 2002 |
Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
Topics: Anticoagulants; Cohort Studies; Dalteparin; Hemorrhage; Humans; Prospective Studies; Pulmonary Embol | 2002 |
Safety of outpatient dalteparin therapy in veterans with mechanical heart valves.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Heart Valve Prosthesis; Hemorrhage; Humans; Mal | 2005 |
The problem of risk assessment and prophylaxis of venous thromboembolism in pregnancy.
Topics: Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2007 |
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Hemorrhage; Humans; Incidence; I | 2008 |
Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit.
Topics: Acute Kidney Injury; Adult; Aged; Blood Coagulation; Critical Care; Dalteparin; Female; Fibrinopepti | 1993 |
Management of unstable coronary-artery disease.
Topics: Anticoagulants; Coronary Disease; Dalteparin; Hemorrhage; Humans; Troponin T | 2000 |
Dalteparin-induced retroperitoneal bleeding.
Topics: Animals; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Retroperitoneal Space; Ultrasonogra | 2001 |
Antithrombotic treatment in patients with unstable coronary artery disease undergoing CABG.
Topics: Angina, Unstable; Clinical Trials as Topic; Coronary Artery Bypass; Dalteparin; Drug Administration | 2001 |
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Topics: Administration, Oral; Amidines; Animals; Arginine; Azepines; Bleeding Time; Carotid Artery Thrombosi | 2001 |
Safety and Efficacy of Tinzaparin Anticoagulation during Nocturnal Hemodialysis.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Circadian Rhythm; Factor Xa; Female; Hemorrhage; Hep | 2019 |
Compliance with current VTE prophylaxis guidelines and risk factors linked to complications of VTE prophylaxis in medical inpatients: a prospective cohort study in a Spanish internal medicine department.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Guideline Adherence; Hemorrhage; Heparin, Lo | 2018 |
Utility of global hemostatic assays in the management of anticoagulation in a haemophilia patient.
Topics: Anticoagulants; Coronary Angiography; Factor VIII; Hemophilia A; Hemorrhage; Humans; International N | 2018 |
Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery.
Topics: Adult; Anticoagulants; Body Weight; Drug Administration Schedule; Drug Dosage Calculations; Female; | 2018 |
Tinzaparin safety and efficacy in pregnancy.
Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag | 2014 |
Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Topics: Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-W | 2015 |
Compartment syndrome of the thigh as a complication of anticoagulant therapy in a patient with a left ventricular assist device (Berlin Heart).
Topics: Anticoagulants; Compartment Syndromes; Heart Failure; Heart-Assist Devices; Hemorrhage; Heparin, Low | 2010 |
Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.
Topics: Aged; Anticoagulants; Drug Interactions; Female; Fibrinolytic Agents; Fluoxetine; Hemorrhage; Hepari | 2002 |
Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin.
Topics: Animals; Antidotes; Bleeding Time; Drug Evaluation; Factor VII; Factor VIIa; Hemorrhage; Hemostasis; | 2003 |
Tinzaparin in long-term treatment of deep venous thrombosis.
Topics: Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans | 2007 |
Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats.
Topics: Animals; Blood Coagulation; Drug Interactions; Factor VII; Factor VIIa; Hemorrhage; Heparin; Heparin | 2008 |
Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
Topics: Age Factors; Aged; Aged, 80 and over; Factor Xa; Female; Fibrinolytic Agents; Hemorrhage; Heparin, L | 2000 |
The outcome of ambulatory DVT management using a multidisciplinary approach.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Disease Management; Drug Evaluation; Fe | 2001 |